EUROPEAN
HEMATOLOGY
ASSOCIATION

MADRID
22ND CONGRESS
JUNE 22 - 25 | 2017
European Hematology Association

FINAL PROGRAM

Now Enrolling: **Copanlisib[a] Clinical Trials in Indolent Non-Hodgkin's Lymphoma (iNHL)**

[a]Copanlisib is an investigational agent currently in clinical trials and is not approved by the FDA, EMA, or other health authorities. The efficacy and safety of copanlisib have not been established, and this information is being provided only for the purpose of providing an overview of clinical trials for recruitment.

LEARN ABOUT THESE ONGOING STUDIES INVESTIGATING COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY iNHL

CHRONOS-3: Now enrolling[1]

A phase III, randomized study of copanlisib in combination with rituximab in patients with iNHL who have relapsed after ≥1 prior line of rituximab-containing therapy. **The primary endpoint of the study is progression-free survival (PFS).**



[b]**To see full patient inclusion and exclusion criteria, visit https://clinicaltrials.gov/ct2/show/NCT02367040.**

Selected inclusion criteria[b]: Patients ≥18 years with iNHL (FL Grade 1-3a, SLL, LPL/WM, MZL); relapsed after ≥1 prior lines of therapy, including R; ECOG performance status ≤2; ≥12 months after completion of the last R-containing treatment or be considered unfit to receive chemotherapy.

Selected exclusion criteria[b]: FL Grade 3b, disease transformation, or CLL; resistance to prior treatment with idelalisib or other PI3K inhibitors.

CHRONOS-4: Now enrolling[2]

A phase III, randomized study of copanlisib in combination with standard immunochemotherapy in patients with iNHL who have relapsed after ≥1 prior line of therapy, including rituximab and alkylating agents. **The primary endpoint of the study is PFS.**



[c]**To see full patient inclusion and exclusion criteria, visit https://clinicaltrials.gov/ct2/show/NCT02626455.**

Selected inclusion criteria[c]: Patients ≥18 years with iNHL (FL Grade 1-3a, SLL, LPL/WM, MZL); relapsed after ≥1 prior line of therapy, including R and alkylating agents; ECOG performance status ≤2.

Selected exclusion criteria[c]: FL Grade 3b, transformed disease, or CLL; R resistance at any line of therapy; type I or II diabetes mellitus with HbA1c >8.5% or fasting plasma glucose >160 mg/dL at screening; uncontrolled hypertension.

1L=first-line; 2L=second-line; C=copanlisib; CHOP=a combination of cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone; CLL=chronic lymphocytic leukemia; CR=complete response; DOR=duration of response; ECOG=the Eastern Cooperative Oncology Group; FL=follicular lymphoma; IV=intravenous; LPL=lymphoplasmacytic lymphoma; MZL=marginal zone lymphoma; ORR=objective response rate; OS=overall survival; PD=progressive disease; PI3K=phosphatidylinositol 3-kinase; QOL=quality of life; QW=once weekly; R=rituximab; RB=rituximab and bendamustine; RCHOP=rituximab and chemotherapy; SLL=small lymphocytic lymphoma; TTP=time to progression; WM=Waldenstrom macroglobulinemia.

Learn about the complete trial information at www.chronostrials.com

Copanlisib is a reversible pan-class I phosphatidylinositol 3-kinase pathway inhibitor with predominant activity against the alpha and delta isoforms.[1-3]

Contact us for more information on clinical trials 1-844-229-3710 (US and Canada only)

Bayer@emergingmed.com

References: 1. Bayer. Copanlisib and rituximab in relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) (CHRONOS-3): NCT02367040. https://clinicaltrials.gov/ct2/show/NCT02367040. Accessed October 12, 2016. **2.** Bayer. Study of copanlisib in combination with standard immunochemotherapy in relapsed indolent non-Hodgkin's lymphoma (iNHL) (CHRONOS-4): NCT02626455. https://clinicaltrials.gov/ct2/show/NCT02626455. Accessed October 12, 2016. **3.** Liu N, et al. *Mol Cancer Ther.* 2013;12(11):2319-2330.

Bayer (Schweiz) AG, Grubenstrasse 6, 8045 Zurich, Switzerland

TABLE OF CONTENTS

EUROPEAN HEMATOLOGY ASSOCIATION

HIGHLIGHTED SESSIONS

FRIDAY, JUNE 23

- **Opening Ceremony**
  13:00 – 14:15, Hall A
- **EHA-EBMT Joint Symposium**
  09:45 – 11:15, Hall E
- **EHA-JSH Joint Symposium**
  14:30 – 15:30, Hall D
- **EHA-HST Joint Symposium**
  14:30 – 15:30, Room N105
- **Presidential Symposium**
  15:45 – 17:00, Hall A

SATURDAY, JUNE 24

- **EHA-ISEH Joint Symposium**
  08:30 – 09:30, Room N104
- **EHA-ASH Joint Symposium**
  10:15 – 11:15, Hall D
- **Plenary Session I**
  13:15 – 14:30, Hall A
- **EHA-ESH Joint Symposium**
  14:45 – 15:45, Room N109
- **EHA-CSH Joint Symposium**
  14:45 – 15:45, Room N103

SUNDAY, JUNE 25

- **EHA-ISTH Joint Symposium**
  09:30 – 10:30, Room N105
- **Late Breaking Oral Session**
  11:15 – 12:45, Hall A
- **Plenary Session II**
  13:00 – 14:30, Hall A

WORDS OF WELCOME

Welcome to the 22nd Congress of the European Hematology Association (EHA) and to Madrid. This is the first congress we are organizing in the capital of Spain, a cosmopolitan city with a large cultural and artistic heritage.

This year, the Scientific Program Committee and the Advisory Board have compiled an exciting educational and scientific program, creating a testament to EHA's spirit of unity in diversity. It brings together and bridges gaps between research and clinical practice, benign and malignant disorders, and national and international societies.

A clear example are the many joint symposia in this year's program. We present you with topical symposia organized in collaboration with the European Group for Bone and Marrow Transplantation (EBMT), the European School of Haematology (ESH), the International Society of Experimental Hematology (ISEH), the International Society of Thrombosis and Haemostasis (ISTH), the International Society of Laboratory Hematology (ISLH) as well as the American Society of Hematology (ASH), the Chinese Society of Hematology (CSH), the Hematology Society of Taiwan (HST), and the Japanese Society of Hematology (JSH). Each symposium has its own merits and adds a unique perspective to a program that celebrates diversity.

Top experts are ready to share their knowledge with you during the plenary and parallel sessions. Furthermore, the quality and number of submitted abstracts clearly indicates that research and progress in laboratory diagnostics, as well as basic, translational and clinical research, are moving at high speed with many innovative findings to be presented to you here in Madrid.

A selection of interesting sessions is listed on the left page and summarized on the tab of each day in this program book. The full program is of course also available in the EHA App. With the app you can compile a personalized program that fits your particular needs and interests. EHA is also active on social media – feel free to share your congress experiences and photos with us by using our social media tags: #EHA #EHA22 #EHACongress.

We hope that by bringing together attendees from all continents the congress contributes to further uniting the hematology community. Together, let's make this congress one to remember!



Tony Green
EHA President

Shai Izraeli
Chair Scientific Program Committee

Celgene Committed to Research,

committed to improving the lives of patients

Celgene consistently invests **more than 30%** of its revenues back into Research and Development * [1]

Almost **double** of industry average [1,3]

Sponsoring >100 clinical trials [2]

Committed to support independent academic research: > 500 IIT's (Investigator Initiated Trials) [2]

Since 2010, R&D investment more than **tripled** [1]





* Data available since 2005

References

1. Celgene Annual Report 2015, 2012, 2009, 2007
2. http://www.celgene.com/research-development/clinical-trials/ consulted on April 12th 2017
3. Scrip Pharma Intelligence, https://scrip.pharmamedtechbi.com/SC097769/Scrip-100-RampD-Paths-Of-Top-50-Pharma, consulted on April 10th 2017

INT-CELG170017 – April 2017

CORPORATE SPONSORS 2017

The European Hematology Association wishes to express its gratitude to the following corporate sponsors:

PLATINUM

Celgene
Takeda Oncology
Novartis Oncology
Bristol-Myers Squibb
abbvie

GOLD

janssen Oncology
AMGEN Oncology
GILEAD
Roche

SILVER

Incyte
Jazz Pharmaceuticals

BRONZE

SeattleGenetics
ALEXION
AstraZeneca
Acerta Pharma

CONTRIBUTOR

SANOFI GENZYME
TEVA
Shire
gsk do more feel better live longer
Vifor Pharma
prothena
morphosys
pharmacyclics An AbbVie Company
agios
Karyopharm Therapeutics
ACCELERON
bluebirdbio
Otsuka Otsuka Pharmaceutical Europe Ltd.
Kite Pharma
BD
PharmaEssentia
oncopeptides

Novartis Oncology

Changing the practice of medicine

At Novartis, we use science-based innovation to address some of society's most challenging health care issues. We are passionate about discovering new ways to improve and extend people's lives.

As a leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development.

NOVARTIS

Novartis Pharma AG
CH-4002 Basel, Switzerland

1/16
G-ONC-1150235
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

SPONSORS & EXHIBITORS 22ND CONGRESS OF EHA (as of May 16)

The European Hematology Association wishes to express its gratitude to the following sponsors and exhibitors:

- Abbvie
- Adaptive Biotechnologies Corporation
- Agios Pharmaceuticals
- Alexion Pharma GmbH
- American Society of Hematology
- Amgen
- ArcherDX
- Argentinean Society of Hematology
- AROG Pharmaceuticals
- Astellas Pharma Europe
- Bayer
- BD
- Binding Site
- Bio-Rad
- Biotype Diagnostic GmbH
- Bristol-Myers Squibb
- Celgene
- Celltrion Healthcare
- Cepheid
- CLL Advocates Network
- CML Advocates Network
- Cytognos SL
- Daiichi Sankyo Europe GmbH
- Erytech Pharma
- ESLHO foundation
- EuroBloodNet
- European School of Haematology
- EWMn European Waldenstroem Network
- F. Hoffmann-La Roche Ltd
- Gilead Sciences
- Global Academy for Medical Education
- Haematology Nurses & Healthcare Professionals Group
- Harmony Alliance
- Hematology Specialist Association
- Illumina
- Incyte Biosciences International Sàrl
- Invivoscribe® Technologies, Inc.
- International Society for Laboratory Hematology
- ITP Support Association
- Janssen Pharmaceutica
- Japanese Society of Hematology
- Jazz Pharmaceuticals
- Karyopharm Therapeutics
- Leukemia Patient Advocates Foundation
- Lipomed AG
- Lymphoma Coalition
- Maco Pharma
- MDS Alliance
- MDS Foundation, Inc
- MediCom Oncology
- MorphoSys AG
- MPN Advocates Network
- MSD
- Myeloma Patients Europe
- NeoGenomics
- Nordmedica
- Novartis
- Omeros Corporation
- Otsuka Pharmaceutical Europe Ltd.
- Oxford Gene Technology
- Pfizer Oncology
- Pfizer Pharma
- Pharmacyclics, an AbbVie Company
- PIVOTAL
- prIME Oncology
- PROFILE
- Prothena Corporation
- QIAGEN
- Resonance Health
- Sandoz
- Sanofi Genzyme
- Seattle Genetics
- SEI healthcare
- SERVIER INTERNATIONAL
- Shire
- SkylineDx B.V.
- Sunesis Pharmaceuticals, Inc.
- Takeda Oncology
- Teva Pharmaceuticals Europe
- Turkish Society of Hematology
- UniQure biopharma
- Verastem, Inc.
- VIVIA BIOTECH
- Wisepress Medical Bookshop
- 37th World Congress of the International Society of Hematology (ISH 2018)

Bristol-Myers Squibb

At the Forefront of Immuno-Oncology

ADVANCING HEMATOLOGY RESEARCH

Bringing the science of Immuno-Oncology into hematologic malignancies

**FOR MORE INFORMATION,
PLEASE VISIT THE I-O SECTION OF BOOTH 930**

Bristol-Myers Squibb

Immuno-Oncology

IOES17NP01599-01-01 04/17

ABOUT EHA

EUROPEAN HEMATOLOGY ASSOCIATION

Become an EHA member

Support our mission to promote excellence in patient care, research and education in hematology.

Join your fellow EHA members worldwide and enjoy membership benefits for both professional and personal development within the field of hematology.

BECOME A MEMBER!

- Full Membership € 155/year
- Junior Membership € 20/year
- Health Care Affiliated Professional Membership € 90/year
- Emeritus Membership € 90/year

NOW 50% DISCOUNT ON MEMBERSHIP FEES FOR THE REMAINDER OF 2017

ENJOY OUR MEMBERSHIP BENEFITS ALL-YEAR ROUND

ALREADY A MEMBER? RENEW YOUR MEMBERSHIP NOW!

ehaweb.org/eha-membership

ABOUT EHA

The European Hematology Association (EHA) is a non-profit scientific association that represents European medical professionals with an active interest in hematology. The Annual Congress, organized in a major European city, offers the opportunity to learn about new data from basic, translational and clinical research and gives access to knowledge that directly impacts clinical practice. The scope of the congress has increased over the years and education and career development programs broadened.

Your educational needs are the focus of our continuing medical education program. We fulfill these needs through live events, but also through the EHA Learning Center, our online learning platform. EHA supports high quality science. We encourage research by strengthening networks and sharing knowledge.

EHA offers education, training and supports the career of hematologists in Europe through its career development program. Various research grants are available for basic, translational and clinical researchers both in their early or advanced career.

As the largest organization of hematologists in Europe, EHA has taken it upon itself to serve and further the interests of hematologists. We advocate for more research funding, improved research environment and better access to hematology care at the European level.

Information about all the initiatives of the association can be found on www.ehaweb.org.

EHA COMMITTEES AND UNITS

EXECUTIVE BOARD
AR Green, *United Kingdom* (President)
P Sonneveld, *the Netherlands* (President Elect)
C Chomienne, *France* (Past President)
M Muckenthaler, *Germany* (Secretary)
A Engert, *Germany* (Treasurer)

COUNCILORS
S Fröhling, *Germany*
G Gaidano, *Italy*
J Gribben, *United Kingdom*
S Izraeli, *Israel*
E Macintyre, *France*
MV Mateos, *Spain*
HA Papadaki, *Greece*
K Porkka, *Finland*
F Rodeghiero, *Italy*
V Sexl, *Austria*

COMMUNICATION COMMITTEE
A Hagenbeek, *the Netherlands* (Chair)
J Cools, *Belgium*
S Fröhling, *Germany*
E Macintyre, *France*
S McCann, *Ireland*
I Roberts, *United Kingdom*
M de Montalembert, *France*

CURRICULUM COMMITTEE
A Almeida, *Portugal* (Chair)
CH Toh, *United Kingdom*
M Cem Ar, *Turkey*
M Guenova, *Bulgaria*
E Hellström Lindberg, *Sweden* (ex-officio)
M Liljeholm, *Sweden*
JT Navarro Ferrando, *Spain*
G Ossenkoppele, *the Netherlands*
M Wondergem, *the Netherlands*

CRTH COMMITTEE
P Sonneveld, *the Netherlands*
A Engert, *Germany*
MV Mateos, *Spain*
A Hagenbeek, *the Netherlands*

EARLY CAREER COMMITTEE
V Gaidzik, *Germany* (Chair)
H Becker, *Germany*
AK Eisfeld, *USA*
M Gruber, *USA*
F McClanahan, *USA*
M Mraz, *Czech Republic*
C Scharenberg, *Sweden*

EDUCATION COMMITTEE
R Foà, *Italy* (Chair)
H Akan, *Turkey*
OW Bjerrum, *Denmark*
C Chomienne, *France*
J Delgado, *Spain*
C Dufour, *Italy*
A Ganser, *Germany*
AR Green, *United Kingdom*
S Modok, *Hungary*
G Ossenkoppele, *the Netherlands*
A Tichelli, *Switzerland*
A Almeida, *Portugal*
G Gaidano, *Italy*

EHA LEARNING CENTER EDITORIAL BOARD
G Ossenkoppele, *the Netherlands* (Chair)
MC Béné, *France*
D Bron, *Belgium*
S Eichinger, *Denmark*
G Gaidano, *Italy*
N Kröger, *Germany*
J Palmblad, *Sweden*
K Porkka, *Finland*
D Prati, *Italy*

EUROPEAN AFFAIRS COMMITTEE
U Jäger, *Austria* (Chair)
C Chomienne, *France*
A Hagenbeek, *the Netherlands*
P Sonneveld, *the Netherlands*
A Engert, *Germany*
E Macintyre, *France*
J Geissler, *Germany*
R Hehlmann, *Germany*

EUROPEAN BOARD FOR ACCREDITATION IN HEMATOLOGY
A Tichelli, *Switzerland* (Chair)
H Akan, *Turkey*
M Guenova, *Bulgaria*
H Schouten, *the Netherlands*
M Vilarmau, *Spain*
M Mohty, *France*
M Lozano, *Spain*
A Falanga, *Italy*

FELLOWSHIPS AND GRANTS COMMITTEE
M Muckenthaler, *Germany* (Chair)
JP Bourquin, *Switzerland*
M Alberich Jorda, *Czech Republic*
R Delwel, *the Netherlands*
J Eikenboom, *the Netherlands*
S Fröhling, *Germany*
R Handgretinger, *Germany*
T Holyoake, *United Kingdom*
K Stamatopoulos, *Greece*
C Thieblemont, *France*

FUNDRAISING & SPONSOR COMMITTEE
J Gribben, *United Kingdom* (Chair)
P Sonneveld, *the Netherlands*
R Foà, *Italy*

K Porkka, *Finland*
MV Mateos, *Spain*
G Ossenkoppele, *the Netherlands*

GOOD GOVERNANCE COMMITTEE
W Fibbe, *the Netherlands* (Chair)
T Barbui, *Italy*
L Degos, *France*
M Guenova, *Bulgaria*
L Malcovati, *Italy*

MEMBERSHIP COMMITTEE
S Fröhling, *Germany* (Chair)
J Cools, *Belgium*
V Sexl, *Austria*

NOMINATION COMMITTEE
E Hellström Lindberg, *Sweden* (Chair)
C Camaschella, *Italy*
H Döhner, *Germany*
W Fibbe, *the Netherlands*
J San Miguel, *Spain*

ONLINE & CASE UNIT
S Modok, *Hungary* (Chair)
B Bain, *United Kingdom*
J Burthem, *United Kingdom*
S McCann, *Ireland*
MF McMullin, *Ireland*
C McNamara, *United Kingdom*
M Cem Ar, *Turkey*

RESEARCH COMMITTEE
AR Green, *United Kingdom* (Chair)
W Fibbe, *the Netherlands* (Co-Chair)
C Bonini, *Italy*
J Cools, *Belgium*
R Delwel, *the Netherlands*
S Izraeli, *Israel*
U Jäger, *Austria*
MV Mateos, *Spain*
M Muckenthaler, *Germany*
B Porse, *Denmark*
I Roberts, *United Kingdom*
T Schroeder, *Switzerland*
P Sonneveld, *the Netherlands*
S Stilgenbauer, *Germany*

SCIENTIFIC PROGRAM COMMITTEE 22ND CONGRESS
S Izraeli, *Israel* (Chair)
S Eichinger, *Austria*
A Engert, *Germany*
A Fielding, *United Kingdom*
S Fröhling, *Germany*
K Grønbæk, *Denmark*
J Jansen, *the Netherlands*
JJ Kiladjian, *France*
N Kröger, *Germany*
H Ludwig, *Austria*
C Moreno, *Spain*
M Muckenthaler, *Germany*
G Ossenkoppele, *the Netherlands*
JA Pérez-Simón, *Spain*
D Rees, *United Kingdom*
A Reiter, *Germany*
F Rodeghiero, *Italy*
S Soverini, *Italy*
S Stanworth, *United Kingdom*
CH Toh, *United Kingdom*
MM van den Heuvel-Eibrink, *the Netherlands*

LOCAL REPRESENTATIVE 22ND CONGRESS
A Alegre, *Spain*

SCIENTIFIC PROGRAM COMMITTEE ADVISORY BOARD 22ND CONGRESS
I Aurer, *Croatia*
H Avet-Loiseau, *France*
C Bonini, *Italy*
JP Bourquin, *Switzerland*
M Delforge, *Belgium*
B Eichhorst, *Germany*
N Gökbuget, *Germany*
JB Hansen, *Norway*
H Hasle, *Denmark*
H Hasselbalch, *Denmark*
T Holyoake, *United Kingdom*
M Hutchings, *Denmark*
A Iolascon, *Italy*
PA Kyrle, *Austria*
T Lapidot, *Israel*
JI Martin-Subero, *Spain*
A Nagler, *Israel*
M Olsson, *Sweden*
RA Padua, *France*
D Pospíšilová, *Czech Republic*
D Prati, *Italy*
S Saußele, *Germany*
H Tamary, *Israel*
A Undas, *Poland*

SWG UNIT
P Sonneveld, *the Netherlands* (Chair)
MC Béné, *France*
M Dreyling, *Germany*
C Dufour, *Italy*
R Foà, *Italy*
S Fröhling, *Germany*
A Iolascon, *Italy*
L Malcovati, *Italy*
G Ossenkoppele, *the Netherlands*

TRTH JOINT OVERSIGHT COMMITTEE
R Delwel, *the Netherlands*
J Licht, *USA*
A Fielding, *United Kingdom*
L Kean, *USA*
M Dinauer, *USA*
S Izraeli, *Israel*
D Neuberg, *USA* (Advisor)

FUTURE EHA CONGRESSES & MEETINGS 2017 - 2018

SEPTEMBER 2017

HIGHLIGHTS OF PAST EHA (HOPE) CAIRO 2017
Dates: September 14-16, 2017
Location: Cairo, Egypt

PTHIT ANNUAL CONGRESS - EHA JOINT SYMPOSIUM
Dates: 21-23 September, 2017
Location: Warsaw, Poland

OCTOBER 2017

EHA SCIENTIFIC MEETING ON CHALLENGES IN THE DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS
Chairs: JJ Kiladjian & C Harrison
Dates: October 12-14, 2017
Location: Budapest, Hungary

LEBANESE SOCIETY OF HEMATOLOGY ANNUAL MEETING – EHA JOINT PROGRAM
Dates: October 12-14, 2017
Location: Beirut, Lebanon

EHA-AHA TUTORIAL ON BIOLOGY AND MANAGEMENT OF MYELOID MALIGNANCIES
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Dates: October 20-21, 2017
Location: Yerevan, Armenia

RUSSIAN ONCO-HEMATOLOGY SOCIETY'S CONFERENCE ON MALIGNANT LYMPHOMA - JOINT PROGRAM
Dates: October 25-26, 2017
Location: Moscow, Russian Federation

NOVEMBER 2017

TURKISH SOCIETY OF HEMATOLOGY - EHA JOINT PROGRAM
Dates: November 1-4, 2017
Location: Antalya, Turkey

INDIAN SOCIETY OF HAEMATOLOGY AND BLOOD TRANSFUSION - EHA JOINT PROGRAM
Dates: November 2-5, 2017
Location: Guwahati, Assam, India

ARGENTINIAN SOCIETY OF HEMATOLOGY - EHA JOINT EDUCATION DAY
Dates: November 17-18, 2017
Location: Mar del Plata, Argentina

EHA SCIENTIFIC MEETING ON SHAPING THE FUTURE OF MESENCHYMAL STROMAL CELLS THERAPY
Chair: W Fibbe
Dates: November 23-25, 2017
Location: Amsterdam, the Netherlands

FEBRUARY 2018

EHA SCIENTIFIC MEETING ON INTEGRATED DIAGNOSIS STRATEGIES IN ONCOHEMATOLOGY FOR THE MANAGEMENT OF CYTOPENIAS AND LEUKOCYTOSIS
Chairs: MC Béné & G Zini
Dates: February 8-10, 2018

EHA-ISHBT TUTORIAL ON LYMPHOPROLIFERATIVE AND PLASMA CELL DISORDERS
Dates: February 16-18, 2018
Location: Lucknow, India

APRIL 2018

EHA SCIENTIFIC MEETING ON NEW MOLECULAR INSIGHTS AND INNOVATIVE MANAGEMENT APPROACHES FOR ACUTE LYMPHOBLASTIC LEUKEMIA
Chair: N Gökbuget
Dates: April 12-14, 2018

RUSSIAN HEMATOLOGY SOCIETY CONGRESS - EHA JOINT PROGRAM
Dates: April 12-14, 2018
Location: Moscow, Russian Federation

JULY 2018

EHA-RHS-ROHS TUTORIAL ON REAL WORLD CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF ONCO-HEMATOLOGICAL PATIENTS TODAY
Dates: July 5-7, 2018
Location: Moscow, Russian Federation

CONGRESS ORGANIZATION

EUROPEAN HEMATOLOGY ASSOCIATION

EHA MEDICAL EDUCATION PROGRAM

Benefit directly from EHA's education opportunities

EBAH CME ACCREDITED

EHA is one of the largest international, independent providers of peer-reviewed hematological knowledge. As a knowledge platform, the association offers a comprehensive and integral curriculum which forms the basis of the Medical Education Program. This enables professionals to improve their hematology knowledge through the EHA Learning Center, the Master Class and live events.

Online opportunities

- EHA Learning Center: EHA's official learning platform.
- Master Class: online program that allows hematologists to study real patient cases, in groups, together with colleagues from all over the world.
- Curriculum Passport: online tool to monitor progress in the European Hematology Curriculum.

Live opportunities

- Educational events, including Hematology Tutorials, Highlights of Past EHA and Outreach
- Scientific events
- European Hematology Exam

CONGRESS ORGANIZATION

SCIENTIFIC PROGRAM COMMITTEE 22ND CONGRESS

S Izraeli, *Israel* (Chair)
S Eichinger, *Austria*
A Engert, *Germany*
A Fielding, *United Kingdom*
S Fröhling, *Germany*
K Grønbæk, *Denmark*
J Jansen, *the Netherlands*
JJ Kiladjian, *France*
N Kröger, *Germany*
H Ludwig, *Austria*
C Moreno, *Spain*
M Muckenthaler, *Germany*
G Ossenkoppele, *the Netherlands*
JA Pérez-Simón, *Spain*
D Rees, *United Kingdom*
A Reiter, *Germany*
F Rodeghiero, *Italy*
S Soverini, *Italy*
S Stanworth, *United Kingdom*
CH Toh, *United Kingdom*
MM van den Heuvel-Eibrink, *the Netherlands*

LOCAL REPRESENTATIVE 22ND CONGRESS

A Alegre, *Spain*

SCIENTIFIC PROGRAM COMMITTEE ADVISORY BOARD 22ND CONGRESS

I Aurer, *Croatia*
H Avet-Loiseau, *France*
C Bonini, *Italy*
JP Bourquin, *Switzerland*
M Delforge, *Belgium*
B Eichhorst, *Germany*
N Gökbuget, *Germany*
JB Hansen, *Norway*
H Hasle, *Denmark*
H Hasselbalch, *Denmark*
T Holyoake, *United Kingdom*
M Hutchings, *Denmark*
A Iolascon, *Italy*
P Kyrle, *Austria*
T Lapidot, *Israel*
JI Martin-Subero, *Spain*
A Nagler, *Israel*
M Olsson, *Sweden*
RA Padua, *France*
D Pospíšilová, *Czech Republic*
D Prati, *Italy*
S Saußele, *Germany*
H Tamary, *Israel*
A Undas, *Poland*

ABSTRACT REVIEWERS

EHA would like to thank the following experts for their time and efforts reviewing abstracts for this Congress.

Abdel-Wahab O, *USA*
Abdul-Kadir R, *United Kingdom*
Abken H, *Germany*
Adès L, *France*
Alegre A, *Spain*
Alessi MC, *France*
Almeida A, *Portugal*
Almeida J, *Spain*
Alvarez-Larrán A, *Spain*
André M, *Belgium*
Asp J, *Sweden*
Aurer I, *Croatia*
Avet-Loiseau H, *France*
Barcellini W, *Italy*
Bartels M, *the Netherlands*
Beilhack A, *Germany*
Berntorp E, *Sweden*
Bhatia R, *USA*
Bierings M, *the Netherlands*
Bocchia M, *Italy*
Bodó I, *Hungary*
Boelens JJ, *the Netherlands*
Bolli N, *Italy*
Bondanza A, *Italy*
Bonifazi F, *Italy*
Bonini C, *Italy*
Bonnet D, *United Kingdom*
Bonnetain F, *France*
Bornhauser B, *Switzerland*
Bosch F, *Spain*
Bourquin JP, *Switzerland*
Bouscary D, *France*
Brækkan SK, *Norway*
Brander DM, *United Kingdom*
Breems D, *Belgium*
Burnett A, *United Kingdom*
Caballero D, *Spain*
Calado D, *United Kingdom*
Camaschella C, *Italy*
Canaani J, *USA*
Cazzola M, *Italy*
Chakraverty R, *United Kingdom*
Chalandon Y, *Switzerland*
Chiapella A, *Italy*
Chiaretti S, *Italy*
Chng WJ, *Singapore*
Ciceri F, *Italy*
Clappier E, *France*
Colombatti R, *Italy*
Colomer D, *Spain*
Copland M, *United Kingdom*
Craddock C, *United Kingdom*
Curti A, *Italy*
Da Costa L, *France*
Damm F, *Germany*
Davies A, *United Kingdom*
De Bont E, *the Netherlands*
de Botton S, *France*
de la Fuente A, *Spain*
de la Rubia J, *Spain*
De Moerloose B, *Belgium*
de Montalembert M, *France*
Delforge M, *Belgium*
den Boer M, *the Netherlands*
Devos T, *Belgium*
Dokal I, *United Kingdom*
Dolstra H, *the Netherlands*
Dreyling M, *Germany*
Dührsen U, *Germany*
Eaves C, *Canada*
Edgren G, *Sweden*
Eichhorst B, *Germany*
Eichinger S, *Austria*
Elitzur S, *Israel*
Engelhardt M, *Germany*
Engert A, *Germany*
Facon T, *France*
Federico M, *Italy*
Fibbe W, *the Netherlands*
Fielding A, *United Kingdom*
Fröhling S, *Germany*
Ganser A, *Germany*
Garcia-Marco J, *Spain*
Ginzburg Y, *USA*
Giralt S, *USA*
Giri N, *USA*
Gisselbrecht C, *France*
Gökbuget N, *Germany*
Goldschmidt H, *Germany*
Gomes da Silva M, *Portugal*
Goudemand J, *France*
Grebien F, *Austria*
Greinix H, *Austria*
Grønbæk K, *Denmark*
Gröschel S, *Germany*
Gutierrez N, *Spain*
Hagenbeek A, *the Netherlands*
Hansen JB, *Norway*
Harrison C, *United Kingdom*
Hasle H, *Denmark*
Hasselbalch H, *Denmark*
Heemskerk JWM, *the Netherlands*
Hermans C, *Belgium*
Hermouet S, *France*
Heß G, *Germany*
Heyman M, *Sweden*
Holte H, *Norway*
Horvathova M, *Czech Republic*
Hough T, *United Kingdom*
Huls G, *the Netherlands*
Hunault-Berger M, *France*
Hutchings M, *Denmark*
Iolascon A, *Italy*
Ionova T, *Russia*
Izraeli S, *Israel*
Jansen J, *the Netherlands*
Janssen J, *the Netherlands*
Jeremias I, *Germany*
Jerkeman M, *Sweden*
Johnson P, *United Kingdom*
Jurczak W, *Poland*
Karlsson S, *Sweden*
Kaspers GJ, *the Netherlands*
Kater AP, *the Netherlands*
Kattamis A, *Greece*
Kiladjian JJ, *France*
Krause D, *Germany*
Kristinsson S, *Sweden*
Kröger N, *Germany*
Krüger W, *Germany*
Kühn M, *Germany*
Kyrle PA, *Austria*
Lamy T, *France*
Lane S, *Australia*
Laperche S, *France*
Lapidot T, *Israel*
Leblanc T, *France*
Lehmann S, *Sweden*
Lippert E, *France*
Ljungman P, *Sweden*
Lo Celso C, *United Kingdom*

Lucas C, *United Kingdom*
Ludwig H, *Austria*
Luminari S, *Italy*
Macintyre E, *France*
Maertens J, *Belgium*
Maguer-Satta V, *France*
Manz M, *Switzerland*
Martin-Subero JI, *Spain*
Mayer J, *Czech Republic*
McMahon C, *Ireland*
Medyouf H, *Germany*
Méndez-Ferrer S, *United Kingdom*
Mercher T, *France*
Mesa R, *USA*
Michallet M, *France*
Michaux L, *Belgium*
Moccia A, *Switzerland*
Montoto S, *United Kingdom*
Moreno C, *Spain*
Muckenthaler M, *Germany*
Müller-Tidow C, *Germany*
Mulligan S, *Australia*
Munshi N, *USA*
Muus P, *the Netherlands*
Nagler A, *Israel*
Nicolini F, *France*
Niemann C, *Denmark*
Nomdedéu J, *Spain*
Nurden A, *France*
Oakes C, *USA*
Olavarria E, *United Kingdom*
Oliva E, *Italy*
Olsson M, *Sweden*
Oriol A, *Spain*
Ossenkoppele G, *the Netherlands*
Padua R, *France*
Papaemmanuil E, *USA*
Pellagatti A, *United Kingdom*
Perez-Simon JA, *Spain*
Petrucci MT, *Italy*
Plesner TH, *Denmark*
Porkka K, *Finland*
Porto G, *Portugal*
Pospíšilová D, *Czech Republic*
Pott C, *Germany*
Prati D, *Italy*
Premawardhena A, *Sri Lanka*
Preudhomme C, *France*
Puissant A, *France*
Raaijmakers M, *the Netherlands*
Racil Z, *Czech Republic*
Raemaekers J, *the Netherlands*
Raje N, *USA*
Ramenghi U, *Italy*
Ravandi F, *USA*
Rees D, *United Kingdom*
Reiter A, *Germany*
Renella R, *Switzerland*
Risitano A, *Italy*
Riva N, *Italy*
Roberts I, *United Kingdom*
Rodeghiero F, *Italy*
Rosendaal FR, *the Netherlands*
Rosenquist R, *Sweden*
Rosiñol L, *Spain*
Rovó A, *Switzerland*
Rowe J, *Israel*
Ruutu T, *Finland*
Salles G, *France*
San Miguel J, *Spain*
Sanchez M, *Spain*
Sander B, *Sweden*
Santini V, *Italy*
Sanz G, *Spain*
Saußele S, *Germany*
Savage K, *Canada*
Schneider R, *the Netherlands*
Schrezenmeier H, *Germany*
Schuh A, *United Kingdom*
Sekeres M, *USA*
Selleslag D, *Belgium*
Shpilberg O, *Israel*
Skov V, *Denmark*
Socie G, *France*
Sonneveld P, *the Netherlands*
Soverini S, *Italy*
Spina M, *Italy*
Stanworth S, *United Kingdom*
Steele A, *United Kingdom*
Suttorp M, *Germany*
Tadmor T, *Israel*
Taher A, *Lebanon*
Tamary H, *Israel*
te Boekhorst P, *the Netherlands*
Teshima T, *Japan*
Thompson A, *United Kingdom*
Toh CH, *United Kingdom*
Tothova Z, *USA*
Trka J, *Czech Republic*
Trümper L, *Germany*
Ugo V, *France*
Undas A, *Poland*
Uyl-de Groot C, *the Netherlands*
Vago L, *Italy*
van den Heuvel-Eibrink MM, *the Netherlands*
van der Velden V, *the Netherlands*
van Duin M, *the Netherlands*
van Tendeloo V, *Belgium*
Venditti A, *Italy*
Verma A, *USA*
von Lilienfeld-Toal M, *Germany*
Watała C, *Poland*
Windyga J, *Poland*
Wlodarski M, *Germany*
Yacobovich J, *Israel*
Yerushalmi R, *Israel*
Zenz T, *Germany*



MyelomaHub

A medical educational resource provided by Takeda Oncology for UK healthcare professionals treating patients with multiple myeloma

EXPERT INSIGHTS

DOWNLOADABLE RESOURCES

PODCASTS

www.myelomahub.co.uk

Developed by

Takeda ONCOLOGY

UK/NP/1603/0027(6)c April 2017

REVIEWERS EDUCATIONAL UPDATES IN HEMATOLOGY BOOK

EHA would like to thank the following experts for their time and efforts reviewing the articles for the Educational Updates in Hematology Book of this Congress.

Anderson R, *United Kingdom*
Ariens R, *United Kingdom*
Armand PA, *USA*
Baruchel A, *France*
Becattini C, *Italy*
Besses C, *Spain*
Blaise D, *France*
Brousse V, *France*
Bueren J, *Spain*
Cosmi B, *Italy*
Cymbalista F, *France*
Döhner K, *Germany*
Enblad G, *Sweden*
Fielding A, *United Kingdom*
Gribben J, *United Kingdom*
Grønbæk K, *Denmark*
Hellström-Lindberg E, *Sweden*
Jacoby E, *Israel*
Jilma B, *Austria*
Kaiser M, *United Kingdom*
Koschmieder S, *Germany*
Ludwig H, *Austria*
Makris M, *United Kingdom*
Malcovati L, *Italy*
Massey E, *United Kingdom*
Moreau P, *France*
Müller M, *Germany*
Muller-Tidow C, *Germany*
Nemeth E, *USA*
Niemann C, *Denmark*
Pane F, *Italy*
Pasqualucci L, *USA*
Platzbecker U, *Germany*
Porter J, *United Kingdom*
Rachmilewitz E, *Israel*
Rambaldi A, *Italy*
Rosenwald A, *Germany*
Saglio G, *Italy*
Salles G, *France*
Schlatt S, *Germany*
Schlenk R, *Germany*
Stanworth S, *United Kingdom*
Stevenson F, *United Kingdom*
Tamary H, *Israel*
Tausch E, *Germany*
Valk P, *the Netherlands*
Weiss G, *Austria*
Zucca E, *Switzerland*

The Educational Updates in Hematology are freely available on the EHA Learning Center, learningcenter.ehaweb.org.

ORGANIZERS

European Hematology Association
EHA Executive Office
Koninginnegracht 12b
2514 AA The Hague
The Netherlands
Tel: +31 (0)70 3455 563
Fax: +31 (0)70 3923 663
E-mail: info@ehaweb.org

Congress Logistics
MCI Amsterdam
Schipluidenlaan 4
1062 HE Amsterdam
The Netherlands
Tel: +31 (0)20 570 96 00
E-mail: eha@mci-group.com

Hotel Accommodation
MCI Amsterdam
Schipluidenlaan 4
1062 HE Amsterdam
The Netherlands
Tel: +31 (0)20 570 96 00
E-mail:
ehagroups@mci-group.com



Hall C

Chaired by Francesc Bosch, who will be joined by Florence Cymbalista, Paolo Ghia, and Peter Hillmen

RELAPSED/ REFRACTORY CLL:

HOW FAR HAVE WE COME, AND WHERE WILL WE GO NEXT

AbbVie-sponsored symposia at the 22nd Congress of the European Hematology Association

THURSDAY JUNE 22 2017
16:15-18:15



EMERGING NOVEL AGENTS FOR AML:

ARE WE ON THE THRESHOLD OF A TRANSFORMATION IN THERAPY?

Room N103

Chaired by Hagop Kantarjian, who will be joined by Lionel Adès, Hartmut Döhner, and Gail Roboz

Date of Preparation: April 2017
ES/VEN/0417/0524

abbvie

AWARDS

PeerCME

Visit us online at **www.peercme.com/biosimilars-update**

CME Certified

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care

Friday, 23 June 2017

Room: N103 (first floor)
IFEMA – Feria de Madrid

17:15 – 18:45 U-i-H Symposium

Expert perspectives from:

Moderator
Paul Cornes, BA, BM BCH, MA, MRCP, FRCR
Comparative Outcomes Group
Bristol, United Kingdom

Faculty
Arnold G. Vulto, PharmD, PhD, FCP
Erasmus University Medical Center
Rotterdam, The Netherlands

Faculty
Wojciech Jurczak, MD, PhD
Jagiellonian University
Krakow, Poland

AGENDA

Welcome & Introduction
- Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

The role of biosimilars in promoting sustainability of care
- Presentation by Paul Cornes, BA, BM BCH, MA, MRCP, FRCR, and panel discussion

A look at biosimilars development
- Presentation by Arnold G. Vulto, PharmD, PhD, FCP, and panel discussion led by Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

The role of new molecule innovation in the sustainability of treatment for haematologic malignancies
- Presentation by Wojciech Jurczak, MD, PhD, and panel discussion led by Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

"Ask the Faculty" and Take-Home Messages
- Entire panel

www.peercme.com/biosimilars-update

Official Sponsored Update-in-Hematology Session at the 22nd Congress of the European Hematology Association.
This educational activity is supported by Sandoz.
This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.
Please contact webmaster@peercme.com for more information.

TRAVEL GRANT WINNERS

For this Congress 140 travel grants have been awarded to junior members of EHA, based on the mean score of their abstracts.

EHA congratulates the following persons with their travel grants:

Agrawal M, *Germany*
Anagnostou T, *USA*
Arriazu E, *Spain*
Barcia Duran JG, *USA*
Beekman R, *Spain*
Bhoi S, *Sweden*
Binder M, *USA*
Birgisdóttir AM, *Iceland*
Blunt M, *United Kingdom*
Botthof J, *United Kingdom*
Bouillon AS, *Belgium*
Bröckelmann P, *Germany*
Buffiere A, *France*
Burney C, *United Kingdom*
Cabal-Hierro L, *USA*
Caraffini V, *Austria*
Casado Izquierdo P, *United Kingdom*
Cerchione C, *Italy*
Chaudhry G, *India*
Chitre S, *United Kingdom*
Cleyrat C, *USA*
De Bie J, *Belgium*
de la Morena-Barrio ME, *Spain*
De Paepe K, *United Kingdom*
De Rosa G, *Italy*
Di Marcantonio D, *USA*
Dinmohamed A, *the Netherlands*
Dominguez Rodriguez M, *Spain*
Duran-Ferrer M, *Spain*
Eisfeld AK, *USA*
Escribà Garcia L, *Spain*
Eskelund C, *Denmark*
Fancello L, *Belgium*
Farina F, *Italy*
Fattizzo B, *Italy*
Fernandez MC, *Spain*
Ferrero S, *Italy*
Figueroa R, *Spain*
Flasinski M, *Germany*
Gabelli M, *Italy*
Ganuza Fernandez M, *USA*
García Ramírez P, *Spain*
Geelen I, *the Netherlands*
Giannoni L, *Italy*
Gugliotta G, *Italy*
Hansen J, *Denmark*
Hasibeder A, *Germany*
Healey M, *United Kingdom*
Hermetet F, *France*
Herrmann O, *Germany*
Hu B, *USA*
Iskander D, *United Kingdom*
Jaafar S, *United Kingdom*
Jentzsch M, *Germany*
Jetani H, *Germany*
Kampen K, *Belgium*
Karamitros D, *United Kingdom*
Kardosova M, *Czech Republic*
Karjalainen R, *Finland*
Karsa M, *Australia*
Kim JC, *Republic of Korea*
Kim T, *Canada*
Koning MT, *the Netherlands*
Larrea de Orte E, *Spain*
Li X, *China*
Lippert L, *Germany*
Machnicki MM, *Poland*
Maekawa T, *Japan*
Manier S, *France*
Mannion N, *United Kingdom*
Manta L, *Germany*
Marchesini M, *Italy*
McKerrell T, *United Kingdom*
McPherson S, *United Kingdom*
Medrano Domínguez M, *Spain*
Meyer-Pannwitt, V, *Germany*
Milani P, *Italy*
Miller K, *USA*
Mitchell RJ, *United Kingdom*
Mora B, *Italy*
Morales Hernandez A, *USA*
Morita K, *Japan*
Nadeu F, *Spain*
Nasso D, *Italy*
Norfo R, *United Kingdom*
O'Byrne S, *United Kingdom*
Okasha D, *Egypt*
Ordoñez R, *Spain*
Papaioannou D, *USA*
Passaro D, *United Kingdom*
Pawlyn C, *United Kingdom*
Pei X, *China*
Peric Z, *Croatia*
Plevova K, *Czech Republic*
Pozzo F, *Italy*
Prassek VV, *Germany*
Pugliese N, *Italy*
Rencz F, *Hungary*
Ribeiro D, *Portugal*
Rotolo A, *United Kingdom*
Saeed BRM, *Germany*
Sala E, *Italy*
Schmidt L, *Austria*
Schwartzman O, *Israel*
Seyfried F, *Germany*
Short N, *USA*
Smith J, *United Kingdom*
Song Y, *China*
Stamatopoulos B, *Belgium*
Stege C, *the Netherlands*
Stieglitz E, *USA*
Sud A, *United Kingdom*
Suksangpleng T, *Thailand*
Sulima S, *Belgium*
Suzuki K, *Japan*
Svaton M, *Czech Republic*
Sverrisdottir IS, *Iceland*
Talati C, *USA*
Theis F, *Germany*
Thivakaran A, *Germany*
Thompson P, *USA*
Thorsteinsdottir S, *Iceland*
Tissino E, *Italy*
Toda J, *Japan*
Unnikrishnan A, *Australia*
Uras I, *Austria*

Van de Wyngaert Z, *France*
Van den Bergh M, *USA*
van Dooijeweert B, *the Netherlands*
van Straaten S, *the Netherlands*
Vermaat J, *the Netherlands*
Versluis J, *the Netherlands*
Vinas I, *Spain*
Vinchi F, *Germany*
Viswanathan GK, *India*
Wannez A, *Belgium*
Weigl A, *Germany*
Wiggers C, *the Netherlands*
Zaninetti C, *Italy*

Travel Grant Supported By
Giuseppe Bigi Association
Salvatore D, *Italy*

YOUNGEHA BEST ABSTRACT AWARDS

One of the primary missions of the European Hematology Association is to support young hematology clinicians and researchers. This year we are proud to announce the launching of the YoungEHA Best Abstract Awards. These will be awarded to the highest ranking abstracts in the following four categories: Clinicians or medical students training for a PhD degree, PhD research students, postdoctoral fellows and clinical hematology trainees. We are honored these outstanding YoungEHA trainees will be presenting during the EHA congress – they are the future of Hematology!

CLINICAL TRAINEE AWARD

- C Pawlyn, United Kingdom

MD-PHD AWARD

- O Schwartzman, Israel

PHD RESEARCH STUDENT AWARD

- JG Barcia Duran, USA

POSTDOCTORAL RESEARCH TRAINEE AWARD

- F Vinchi, Italy

JOSÉ CARRERAS LECTURE & AWARD

The José Carreras Award was established by EHA in order to honor leaders in hematological research and is presented each year to an established and active investigator who has made an important contribution to hematology. This honor has been bestowed on internationally recognized specialists for their invaluable contribution to the field of hematology.

EHA congratulates the winner of the 2017 José Carreras Lecture and Award, Professor Ruud Delwel (Erasmus MC, Rotterdam, the Netherlands), for his outstanding contributions to the research of acute myeloid leukemia. Professor Delwel was one of the first to describe the heterogeneity of acute myeloid leukemias. Utilizing modern genomic and gene editing tools he recently uncovered the regulatory mechanisms modulating the expression of leukemia causing genes.

During the Opening Ceremony, Professor Delwel will present the José Carreras Honorary Lecture. This lecture takes place on Friday, June 23 at 13:30 – 14:15 in Hall A.

The previous winners are:

2016	E Hellström Lindberg, *Sweden*
2015	H de Thé, *France*
2014	H Döhner, *Germany*
2013	K Rajewsky *Germany*
2012	J San Miguel, *Spain*
2011	D Higgs, *United Kingdom*
2010	B Falini, *Italy*
2009	W Vainchenker, *France*
2008	J Goldman, *United Kingdom*
2007	R Bertina, *the Netherlands*
2006	E Gluckman, *France*
2005	H Waldmann, *United Kingdom*
2004	V Diehl, *Germany*
2003	C Verfaillie, *Belgium*
2002	L Luzzatto, *Italy*
2001	M Greaves, *United Kingdom*
2000	D Collen, *Belgium*
1999	C Rozman, *Spain*

JEAN BERNARD LIFETIME ACHIEVEMENT AWARD

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology. EHA is proud to posthumously grant the 2017 Jean Bernard Lifetime Achievement Award to Professor David Grimwade (King's College London School of Medicine, London, United Kingdom), for his significant contribution to the translational research to improve therapy of acute myeloid leukemia. His major contributions were in studying the molecular interactions between leukemia genetics and response to therapy. The molecular tools that he developed for determining minimal residual disease have been widely adopted for personalized adjustment of therapy of acute myeloid leukemia. In addition to his research achievements Professor Grimwade had a specific passion for educating innumerable hematologists around the world.

The award will be presented to Frances Hildreth, David Grimwade's wife, during Plenary Session I on Saturday, June 24 at 13:15 – 14:30 in Hall A.

The previous winners of the award are:

2016 C Camaschella, *Italy*
2015 V Diehl, *Germany*
2014 F Stevenson, *United Kingdom*
2013 T Barbui, *Italy*
2012 L Degos, France
2011 B Löwenberg, *the Netherlands*
2010 E Montserrat, *Spain*
2009 P Mannuccio Mannuci, *Italy*
2008 D Hoelzer, *Germany*

TALENT ACCELERATOR PROGRAMS

By investing in promising early careers, EHA fosters the next generation of leaders in hematology research. Talented researchers can apply for either funding or research training programs.

RESEARCH GRANTS

The winners of the 2016 and 2017 rounds will be acknowledged during the Opening Ceremony on Friday, June 23.

2016 WINNERS:

JOHN GOLDMAN CLINICAL RESEARCH GRANT

- R Schneider, Erasmus Medical Center, Rotterdam, the Netherlands

CLINICAL RESEARCH GRANT

- E Gavriilaki, George Papanicolaou Hospital, Thessaloniki, Greece

NON-CLINICAL ADVANCED RESEARCH GRANTS

- A Puissant, IUH - St Louis Hospital – Paris, France
- J Nangalia, Wellcome Trust Sanger Institute, United Kingdom

JOSÉ CARRERAS NON-CLINICAL JUNIOR RESEARCH GRANT

- S Sulima, KU Leuven, Belgium

NON-CLINICAL JUNIOR RESEARCH GRANT

- S Dertschnig, University College London, United Kingdom

SHORT TERM COLLABORATION AWARD

- J Thaler, University of Vienna, Austria

2017 WINNERS:

The winners were announced after the book was printed. Please check the EHA website for the list of winners.

If you are interested in applying for a research grant, please check the EHA website or drop by the EHA booth.

RESEARCH TRAINING IN HEMATOLOGY

By learning from the best in your field and getting in-depth comprehensive feedback, translational and clinical researchers are improving their skills and knowledge. Both training programs are intense and customized to fit each participant's professional development.

EHA CRTH
CLINICAL RESEARCH TRAINING IN HEMATOLOGY

EHA CLINICAL RESEARCH TRAINING IN HEMATOLOGY (CRTH)

CRTH 2016-2017 WINNERS:

A Brioli, *Germany*
A Broijl, *the Netherlands*
A Bukauskas, *Lithuania*
M Cabrero, *Spain*
V Gaidzik, *Germany*
K van Galen, *the Netherlands*
M Griffin, *United Kingdom*
E Hatzimichael, *Greece*
L López-Anglada Fernández, *Spain*
J Krawczyk, *Ireland*
C McNamara, *Canada*
K Metzeler, *Germany*
L Scarfò, *Italy*
F Thol, *Germany*
M Tobiasson, *Sweden*
C Tomuleasa, *Romania*
C Vitale, *Italy*

TRANSLATIONAL RESEARCH
TRAINING IN HEMATOLOGY

EHA-ASH TRANSLATIONAL RESEARCH TRAINING IN HEMATOLOGY (TRTH)

TRTH 2017 WINNERS:

F Asmar, *Denmark*
G Bianchi, *USA*
L Brunetti, *USA*
D Duarte, *United Kingdom*
P Gallipoli, *United Kingdom*
A Giustacchini, *United Kingdom*
D Herranz, *USA*
T Itkin, *USA*
G Lee, *USA*
A Mottok, *Canada*
S Ng, *USA*
A Pastore, *USA*
F Pastore, *USA*
L Quek, *United Kingdom*
N Rao Tata, *Switzerland*
K Rouault-Pierre, *United Kingdom*
L Smeenk, *the Netherlands*
C Thirant, *France*
D Wiseman, *United Kingdom*
K-R Yu, *USA*

If you are interested in applying for TRTH or CRTH, please attend the bite-size CRTH or TRTH on Saturday, June 24 at 16:00 – 17:15 or drop by the EHA booth.

KEY INFORMATION

EUROPEAN HEMATOLOGY ASSOCIATION

OPENING HOURS

Please find below all opening hours of the different areas and information desks:

	Wednesday, June 21	Thursday, June 22	Friday, June 23	Saturday, June 24	Sunday, June 25
Cloakroom Registration area, Hall 5	x	07:00-21:30	07:00-19:30	07:00-19:30	07:00-16:00
CME Booth Hall 9	x	07:30-19:30	07:30-17:30	07:30-17:30	07:30-14:30
EHA Booth Hall 9	x	07:30-19:30	07:30-17:30	07:30-17:30	07:30-14:30
Congress Run Registration Desk Hall 5	x	x	09:00-17:00	x	x
Exhibition Hall 7	x	09:00-16:30	09:00-16:30	09:00-16:30	09:00 -13:30
Poster Desk Hall 7	x	x	09:30-19:00	09:30-19:30	09:30-11:00
Press Center First floor, above Hall 5	x	07:30-18:00	07:30-18:00	07:30-18:00	07:30-14:00
Business center First floor, above Hall 5	x	07:30-18:00	07:30-18:00	07:30-18:00	07:30-14:00
Registration Area Hall 5	13:30-17:30	07:00-19:30	07:00-17:30	07:30-17:30	07:30-15:00
Speaker Service Center Hall 9	13:30-17:30	07:00-19:30	07:00-17:30	07:30-17:30	07:30-13:00
Madrid & Public Transport Information Hall 5	13:30-17:30	07:00-21:30	07:00-19:15	07:30-19:30	07:30-15:00

SERVICES PROVIDED DURING CONGRESS

Service	Name	Location
Abstract Book	Book Desk	Registration Area
Cash withdrawal	Cash dispenser	Outside Hall 5
City and excursion information	Madrid Information Desk	Registration Area
Cloakroom and luggage	Cloakroom	Registration Area
Email and internet	Internet Corners	Hall 7 and 9
Exhibition information	Exhibitor desk	Registration Area
First Aid	First Aid	First floor, between Hall 7 and 9
Hotel Information	Hotel Information Desk	Registration Area
Lost and found	Registration Services Desk	Registration Area
EHA Congress Run registration	EHA Congress Run desk	Registration Area
EHA Grooves Tickets	EHA Grooves Desk	Registration Area
Poster Information	Poster Desk	Poster Area, Hall 7
Restaurant Information	Madrid Information Desk	Registration Area
Presentation check-in	Speaker Service Center	Hall 9
WiFi	Wireless Internet	Throughout the venue

CONGRESS INFORMATION

VENUE
IFEMA – Feria de Madrid, South Entrance, Av. Partenón, 5, 28042 Madrid, Spain.

REGISTRATION HOURS
The registration area is located in Hall 5 and will be open during the following hours:

Wednesday, June 21	13:30-17:30
Thursday, June 22	07:00-19:30
Friday, June 23	07:00-17:30
Saturday, June 24	07:30-17:30
Sunday, June 25	07:30-15:00

EXHIBITION
The exhibition will be open during the following hours:

Thursday, June 22	09:00-16:30
Friday, June 23	09:00-16:30
Saturday, June 24	09:00-16:30
Sunday, June 25	09:00-13:30

EHA BOOTH
The EHA Booth is located in Hall 9. Please come and visit us to collect your EBAH Credit Points, get information on membership, the EHA Learning Center and to find out what more EHA can do for you!

BADGES
All participants will receive a personal badge upon registration. You are kindly requested to wear this badge when attending any scientific session or congress related event. Only participants who are wearing their name badge will be admitted to the meeting rooms, the exhibition area, satellite symposia and updates-in-hematology.

Name badges have been color-coded as follows:

RED	EHA members
ORANGE	EHA junior members
GREEN	delegates
YELLOW	junior delegates
BLUE	exhibitors
PURPLE	press

The charge for replacement of lost badges will be € 30 per badge.

SOCIAL MEDIA
EHA is active on various social media platforms. Follow us on the networks below and get real-time hematology updates:
Facebook: European Hematology Association
Linkedin: EHA
Twitter: @EHA_hematology
#EHA #EHA22 #YoungEHA #EHACongress

PRESS CENTER
The Press Center is located on the first floor, above hall 5. Press inquiries prior to and after the annual congress should be directed to communication@ehaweb.org or +31 (0)70 3020 099.

The Press Center will be open during the following hours:

Thursday, June 22	07:30 – 18:00
Friday, June 23	07:30 – 18:00
Saturday, June 24	07:30 – 18:00
Sunday, June 25	07:30 – 14:00

CERTIFICATES OF ATTENDANCE
See page 37.

BUSINESS CENTER
General printing services as well as photocopying will be available at the Business Center managed by the IFEMA. A minimum payment will be required per page.

INTERNET
WiFi is available in all areas. The network name is: EHA. There is no password required. A number of internet corners with computers can be found in the Exhibition Hall and in the seating area of Hall 9, see the floor plan on page 318.

CLOAKROOM AND LUGGAGE
In the cloakroom you can leave your belongings free of charge. The cloakroom is located at the Registration area in Hall 5 (see floor plan, page 318) and will be open during the following hours:

Thursday, June 22	07:00 – 21:30
Friday, June 23	07:00 – 19:30
Saturday, June 24	07:00 – 19:30
Sunday, June 25	07:00 – 16:00

LOST AND FOUND
Items that are found by the IFEMA and EHA staff will be brought to the Registration Services Desk (Registration area). Should you have lost any of your personal belongings, we kindly ask you to visit this desk to report it or to pick up items.

INSURANCE
In registering for the 22nd Congress of EHA, participants agree that neither EHA, the organizing committee nor the congress organizers assume any liability whatsoever. Participants are requested to make their own arrangements with respect to health and travel insurance.

PRAYING ROOM
A praying room is available on the first floor, room A10.09 (see floor plan, page 319)

LUNCH & REFRESHMENTS
Lunch is included in the registration fee from Friday until Sunday. Lunch tickets are attached to the participants' badge sheet. These tickets are valid on Friday, June 23, Saturday, June 24 and Sunday, June 25. Lunch and coffee (Thursday 22nd only) will be provided in the Catering Area (located next to the Exhibition in Hall 7).

EHA CONGRESS RUN
The congress run (5km) will take place on Saturday, June 24, 06:45 – 08:00 at Juan Carlos I Park - Hamburgo roundabout, close to Partenon Avenue, and 12c Pavillion at IFEMA Madrid. The start is located at the corner of Av Partenon/ Calle via Dublin. Based on availability you can register on-site on Friday, June 23, 09:00 - 17:00. Join this healthy start of the day!

SCIENTIFIC INFORMATION

CONGRESS MATERIALS ON THE EHA LEARNING CENTER
Find all congress materials on the EHA Learning Center - EHA's official learning platform. Materials become available prior, during and shortly after the congress. Watch, download, read and browse through the abstracts, webcasts of congress sessions, E-posters, interviews with leading experts and the Educational Updates in Hematology Book and articles. Visit the EHA Learning Center online via learningcenter.ehaweb.org or come by the EHA Booth to find out more about how to get access!

HARD COPY ABSTRACT BOOK
If you have pre-registered for the hard copy of the Abstract Book, a voucher will be attached to your badge sheet. With this voucher you can pick up your book at the Book Desk. If you would like to buy a hard copy on-site, please go to the Book Desk in the Registration Area.

EDUCATIONAL UPDATES IN HEMATOLOGY BOOK

This year, the "Educational Updates in Hematology" book is available online via the EHA Learning Center. The book will not be available in hard copy.

EHA CONGRESS RECORDINGS AND BROADCASTS – COME AND VISIT THE LIVE RECORDINGS IN THE EHA STUDIO

A selection of semi-live reports and interviews with the leaders in the field of this moment, are recorded and broadcast during the congress. Recordings take place every day during the congress in the EHA Studio in Hall 9.
ON DEMAND; watch the materials after the congress via the mobile app, the EHA website and EHA's official learning platform, the EHA Learning Center.
The materials are available for everyone, including those not attending the congress.

SPEAKER SERVICE CENTER

Equipment to enable a final check of your PowerPoint presentation is available in the Speaker Service Center located in Hall 9 (see floor plan, page 318).
The Speaker Service Center will be open during the following hours::

Wednesday, June 21	13:30 - 17:30
Thursday, June 22	07:00 - 19:30
Friday, June 23	07:00 - 17:30
Saturday, June 24	07:30 - 17:30
Sunday, June 25	07:30 - 13:00

Only PowerPoint presentations will be accepted. To ensure that the presentations are well prepared, we strongly advise you to bring your presentation AT LEAST 3 HOURS before the start of your presentation to the Speaker Service Center.
You can bring your presentation on a USB memory stick. You may bring your own laptop (exclusively for copying your presentation onto the network). The use of your own laptop during your presentation is strictly prohibited.

EHA MOBILE APP

A special mobile app has been developed for this congress in which you can find the entire program in detail. Use the app to find sessions of interest, create your own program, find and read all the abstracts and locate the meeting rooms. Download the app from the Apple App store or Google Play.

MEET-THE-EXPERT SESSIONS – FIRST COME FIRST SERVE

In total 12 small scale Meet-the-Expert sessions are organized on Friday and Saturday, during the following timeslots:

Friday, June 23	11:30 - 12:30 & 14:30 - 15:30
Saturday, June 24	11:30 - 12:30 & 14:45 - 15:45

The number of participants is limited to 50 persons per session in order to guarantee the opportunity of intensive interaction with leading experts in the field. The session details can be found in the program pages.

WEBSITE

Up-to-date information regarding the congress program, including all abstracts, is available at the congress section of www.ehaweb.org.

POSTER SESSION

The main goal of the Poster Session is to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators (senior experts in the field) and interested congress participants. The Poster Session consists of two parts: the Poster Walk and Poster Browsing Time. This setup guarantees sufficient time for all posters that have been selected for a presentation. The first hour of the Poster Walk is moderated and then followed by the Poster Browsing Time, where the rest of the posters can be browsed on the e-poster screens available in the poster area.
Poster walks will be organized during the poster sessions on Friday, June 23 at 17:15 – 18:45 and Saturday, June 24 at 17:30 - 19:00. Poster authors and moderators are requested to be present at the first poster in their poster session, at the beginning of the presentation time (Friday at 17:15 and Saturday at 17:30).
Poster Browsing Time will be organized after the Poster Walk, on Friday, June 23, 18:15 – 18:45 and Saturday, June 24, 18:30 – 19:00.

POSTER PITCHES

Poster pitches are an exciting new opportunity to promote basic science and research, and to attract delegates to the poster walks. During selected oral sessions, 5-8 presenters will have the opportunity to pitch their abstract/poster to the attendees of the session. The following simultaneous sessions contain a poster pitch:

- **AML Biology I: Towards molecular therapies**
  Friday, June 23, 11:30 - 12:45, Room N103
- **Hematopoiesis, stem cells and microenvironment**
  Friday, June 23, 11:30 - 12:45, Room N104
- **Lymphoma biology**
  Friday, June 23, 11:30 - 12:45, Room N101
- **New insights into chronic lymphocytic leukemia biology**
  Friday, June 23, 11:30 - 12:45, Hall D
- **AML Biology II: Epigenetic targets**
  Saturday, June 24, 11:30 - 12:45, Hall E

POSTER AREA AND (E-)POSTER DESK

Poster sessions will take place in the Poster Area (Hall 7).
The Poster Area and (E-)Poster Desk will be open on:

Friday, June 23	09:30 – 19:00
Saturday, June 24	09:30 – 19:30
Sunday, June 25	09:30 – 11:00

FREE POSTER PRINTING SERVICE

Poster presenters that have submitted their posters online (before May 25) to the poster printing service offered by Pfizer, can collect their posters at the Poster Desk in the Poster Area (Hall 7).

POSTER MOUNTING

Posters should be mounted during the indicated set-up time (see below), using double sided tape or Velcro tape. Assistance will be available at the Poster Desk.

POSTER VIEWING AND PRESENTATION

Posters will be on display in the Poster Area for two days and will be open for viewing on Friday and Saturday during registration hours. Poster authors are requested to be present at their poster during the entire presentation time (see below) to attend the Poster walks. During these walks, an expert in the field will discuss posters in the same poster session, together with interested congress participants.

REMOVING YOUR POSTER MATERIAL

All posters should be removed after Poster Session II (Saturday, June 24 as of 19:00).
If posters are not removed before 11:00 on Sunday, June 25, they will be removed and disposed of.

DISCLOSURES

As part of the European Board for Accreditation in Hematology (EBAH) accreditation procedures, all speakers and chairs are obliged to provide disclosures of relevant financial relations. The disclosures of all invited speakers and chairs of the 22nd Congress have been included in the disclosure index on page 235. On the first slide of every presentation the disclosure must be presented for at least 10 seconds.

PROGRAM CHANGES

Program updates will be available through the mobile app as well as on a printed flyer available at the registration desk.

Poster Session I - Friday, June 23	
Set-up	Friday, June 23, 09:30 - 12:00
Viewing	Friday, June 23, 09:30 - Saturday, June 24, 19:00
Presentation during Poster Walk	Friday, June 23, 17:15 - 18:15
Poster Browsing time	Friday, June 23, 18:15 - 18:45
Dismantling	Saturday, June 24, 19:00 - Sunday, June 25, 11:00

Poster Session II - Saturday, June 24	
Set-up	Friday, June 23, 09:30 - 12:00
Viewing	Friday, June 23, 09:30 - Saturday, June 24, 19:00
Presentation during Poster Walk	Saturday, June 24, 17:30 - 19:00
Poster Browsing time	Saturday, June 24, 18:30 - 19:00
Dismantling	Saturday, June 24, 19:00 - Sunday, June 25, 11:00

The Poster Area is open during the above mentioned hours. Unauthorized access outside these opening hours is in violation of the registration terms and conditions and can result in permanent expulsion from the congress and the congress grounds.

A GREENER EHA CONGRESS

CERTIFICATE OF ATTENDANCE: THIS YEAR DIGITAL ONLY

The EHA Certificate of Attendance will be sent to your personal e-mail address after the congress, saving a large amount of paper. Please pass by the designated stations in the Registration Area in order to make sure we have correct e-mail address in our database. You can do this from Friday, June 23 (12:00) to Sunday, June 25 (15:00).

FSC CERTIFIED PAPER

All paper used for our congress badges, final program books, pocket programs and related congress materials is fully FSC certified. The Forest Stewardship Council (FSC) is an international non-profit, multi-stakeholder organization established in 1993 to promote responsible management of the world's forests. The FSC does this by setting standards on forest products, along with certifying and labeling them as eco-friendly.

CONGRESS BAGS FROM RECYCLED PET MATERIAL

Recycled PET is the most common practice of saving energy when producing plastic and reducing pollution in mass production. That's why the congress bags this year are made of this eco-friendly material.

TAILOR MADE CONGRESS LUNCH

Food and paper waste are reduced by allowing each participant to assemble his or her own lunch. Help us reduce waste, think twice and pick your favorite items only. Enjoy your lunch!

PUBLIC TRANSPORT TICKETS OFFERED

Madrid public transportation is clean, fast, safe, extensive and efficient. EHA offers each delegate a public transport ticket in order to reduce CO2 emissions on their daily commute to the congress center.

GENERAL INFORMATION

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 25-30 degrees. June is the beginning of summer and from this month on Madrid sees much more sun and you can enjoy the warm weather. Make sure you protect yourself against the sun and keep hydrated.

ELECTRICITY SUPPLY

In Madrid the alternating current is 220 volt. Plugs and sockets follow European standard with two round pins.

BANKING SERVICE

The official currency in Madrid is the Euro (€). Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 10:00 to 16:00. ATM Cash dispensers (Cajero automático) are located throughout the congress venue, at the airport and railway stations.

CURRENCY FOR CONGRESS RELATED PAYMENTS

All payments related to your congress registration should be made in Euro (€).

INFORMATION

For practical information about the city please visit the Madrid & Public Transport Information Desk. This desk is located in Hall 5 and will be open during the following hours:

Wednesday, June 21	13:30 - 17:30
Thursday, June 22	07:00 - 21:30
Friday, June 23	07:00 - 19:15
Saturday, June 24	07:30 - 19:30
Sunday, June 25	07:30 - 15:00

HOTEL INFORMATION DESK

For hotel information and reservations please visit the Hotel Information Desk. This desk is located in the Registration Area and will be open during the following hours:

Wednesday, June 21	13:30 - 17:30
Thursday, June 22	07:00 - 19:30
Friday, June 23	07:00 - 17:30
Saturday, June 24	07:30 - 17:30
Sunday, June 25	07:30 - 15:00

DINING OUT IN MADRID & TIPPING

Restaurants in Madrid usually serve lunch from 13:30 until 15:00. Dinner service usually starts at 20:30 with busiest hours between 20:30 - 22:30. Dinner bookings are recommended.

It is also recommended to leave a gratuity of 10% of the bill if the service was satisfying.

PUBLIC TRANSPORT

TRANSPORTATION IN MADRID

PUBLIC TRANSPORT IS INCLUDED
IN YOUR REGISTRATION!

Every delegate will receive a Public Transport Ticket voucher attached to their congress badge. This voucher can be exchanged for the physical ticket at the Public Transport desk at the Registration Area, Hall 5.

The public transport ticket is valid for 5 consecutive days on Madrid's extensive travel network.
The ticket covers all Metro lines, metropolitan bus lines and the light rail system (Cercanías) within the metropolitan area, which covers downtown Madrid, the financial district, the shopping areas, the IFEMA area and the airport – Metro line 8 (pink) and light rail connection to terminal T4. It also covers the airport supplement, which is usually added to one-way metro or Cercanías tickets.

Please follow strictly the instructions on the ticket itself in order to avoid any fines around the city.

HOW TO REACH THE IFEMA CONGRESS VENUE

FROM THE AIRPORT

The IFEMA congress venue is only a few kilometres away from Madrid Barajas International Airport (MAD) and can be reached by using one of the following means of transport.

BY METRO

From Madrid Barajas International Airport (MAD) it is only a short metro ride to IFEMA. Take metro line 8 from Aeropuerto T1-T2-T3-T4 (direction to Nuevos Ministerios) to Campo de las Naciones. From Campo de las Naciones station it is a 5 minute walk to the entrance of IFEMA.

BY BUS

A number of bus lines including number 112 and 122 stop outside the IFEMA congress
venue. Bus timetables can be found on the following website: www.crtm.es

BY TAXI

A taxi from Madrid Barajas International Airport (MAD) to IFEMA costs around € 20. All terminals have clearly marked taxi ranks outside the arrivals area. Official taxis are white with a red stripe and have the Madrid City Council coat-of-arms on their doors.

To call a taxi please dial:

+34 911 76 00 81
+34 622 465 365

Address: IFEMA – Feria de Madrid, Avda. del Partenón, 5

Please advise your taxi driver to take you to the South entrance.

prIME Oncology satellite symposia to be held at the 22nd Congress of the European Hematology Association

prIME ONCOLOGY | Aptitude Health Company

Growing Today's Clinical Expertise Improving Tomorrow's Clinical Decisions

THURSDAY, JUNE 22

08.00 – 10.00 Hall D

Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma

This educational activity is supported by Celgene, Karyopharm Therapeutics, and PharmaMar.

Webcast available July 2017

08.00 – 10.00 Room N103

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia

Chair: Miguel Sanz, MD, Valencia, Spain

This educational activity is supported by a grant from Celgene and Helsinn Healthcare SA.

Webcast available July 2017



19.00 – 21.00 Room N103

Current State-of-the-Art and Future Strategies in Acute Lymphoblastic Leukemia

Chair: Dieter Hoelzer, MD, PhD, Frankfurt, Germany

This educational activity is supported by a grant from Shire.

Webcast available July 2017



FOR MORE INFO AND ACCESS TO WEBCASTS:
www.prIMEoncology.org/madrid-2017-heme-symposia

Find the insights you need...

Join our program today!

www.prIMEoncology.org

ACCME ACCREDITED WITH COMMENDATION

PROGRAM OVERVIEW

PROGRAM-AT-A-GLANCE



ABOUT THE CONGRESS PROGRAM

OBJECTIVES OF THE EHA CONGRESS

The EHA Annual Congress provides a forum for presenting new data from clinical trials and basic research and sharing ideas for hematological innovation as well as disseminating evidence-based knowledge of primary clinical relevance.

Hematologists and affiliated professionals attending the EHA Congress will be able to:

- Enhance their knowledge of evidence-based approaches on diagnosis and treatment of hematologic diseases.
- Access the latest results on clinical and translational research in hematologic disorders.
- Be updated on emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties.
- Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.

These general goals for the Congress will be further refined with learning goals for all presentations of the invited speaker program.

On the following pages you will find information about the congress program, new sessions and program changes.

WHAT'S NEW THIS YEAR?

The congress program is in constant development to meet the needs of attendees and to keep up with developments in the field. This year, the Thursday program has been expanded with an extra timeslot for satellite symposia, to provide pharmaceutical companies with a platform to share their research results. The programs are available in this program book and in the EHA App.

The well-appreciated Meet-the-Expert sessions have now been divided over four timeslots, two on Friday and two on Saturday. This means you have more opportunities to meet and interact with experts in the field.

Another important change is related to the Laboratory Diagnosis Workshop, which is organized on Saturday morning and constitutes a full morning program focused on a variety of topics related to diagnosis and the 2016 WHO classification. The workshop is now co-organized by EHA and the International Society of Laboratory Hematology.

Like every year, EHA has sought the collaboration of a number of societies to bring different views and expertises to the program via the joint symposia. The following societies are contributing to the program with a joint session:

- **European Group for Bone and Marrow Transplantation (EBMT)**
  60 years of allogeneic stem cell transplantation
  Friday, June 23, 09:45 - 10:45
- **Hematology Society of Taiwan (HST)**
  Acute myeloid leukemia
  Friday, June 23, 14:30 - 15:30
- **International Society of Experimental Research (ISEH)**
  Hematopoietic stem cells and their niche
  Saturday, June 24, 08:30 - 09:30
- **Chinese Society of Hematology (CSH)**
  Stem cell transplantation for relapsed leukemia
  Saturday, June 24, 14:45 - 15:45
- **International Society of Thrombosis and Haemostasis (ISTH)**
  Anticoagulation in difficult patients
  Sunday, June 25, 09:30 - 10:30

HOW TO NAVIGATE THE CONGRESS PROGRAM?

1 DOWNLOAD THE EHA APP

The EHA app is your high-tech gateway to access all the content of the congress all from the palm of your hand. You can view the program by day, track or session type.

2 SELECT SESSIONS OF INTEREST BY USING THE TRACKS AND THE SESSION DESCRIPTIONS

Tracks in Hematology

The sections of the Hematology Curriculum form the basis for the 'tracks of hematology' that make navigating the congress program a bit easier. Please find below an overview of the tracks and their subdivisions:

- 1 Clinical hematology: Benign
- 2 Clinical hematology: Myeloid malignancies
- 3 Clinical hematology: Lymphoid malignancies and plasma cell disorders
- 4 Clinical hematology: Stem cell transplantation and special therapy
- 5 Laboratory diagnosis
- 6 Thrombosis and hemostasis
- 7 Transfusion medicine
- 8 General skills
- 9 Pediatric hematology
- 10 Personalized medicine
- B Biology
- T Translational
- C Clinical

SESSION DESCRIPTIONS

Below you can find descriptions of the various session types offered in the congress program.

PLENARY SESSIONS

Focus: Outstanding speakers within basic science or clinical hematology on a topic of general interest.
Format: Plenary lectures by 2 or 3 speakers and 2 chairs.

EDUCATION SESSIONS

Format: Education sessions concentrate on one topic and follow a common principle. The first speaker gives information on basic principles and mechanisms, the second speaker on translational research and the third on clinical aspects. This format has been chosen with the hope to attract both basic researchers and clinicians to the same session.
Format: 90 minutes, 3 speakers and 1 chair, sessions are repeated once.

HEMATOLOGY-IN-FOCUS

Focus: The Hematology-in-Focus sessions concentrate on a hot scientific or clinical topic in any field of hematology. These sessions are designed to look at one topic in-depth, rather than the broader overview provided in Education sessions.
Format: 60 minutes, 2 or 3 speakers and 1 chair.

BASIC-SCIENCE-IN-FOCUS

Focus: Basic-Science-in-Focus sessions zoom in on very specific topics in basic research and are intended mainly for basic and translational researchers.
Format: 60 minutes, 2 or 3 speakers and 1 chair.

MEET-THE-EXPERTS

Focus: Meet-the-Expert sessions focus on one topic in depth with an expert in the field.
Format: The session is hosted by one speaker who will discuss questions from the audience. In some cases the speaker presents a few slides to introduce the topic.

CLINICAL DEBATES

Focus: These clinical or diagnostic debates all relate to a controversial topic in the field of hematology.
Format: 60 minutes, 2 debaters and 1 chair.

EARLY CAREER SESSIONS

Focus: The Early Career Sessions address topics of interest for scientists and clinicians in the early stages of their careers.
Format: 60 minutes, 2 or 3 speakers and 1 or 2 chairs.

JOINT SYMPOSIA

Focus: The joint symposia demonstrate EHA's connections with well-known societies in- and outside of Europe. The topic of the symposium can be scientific or educational, but also political or any other aspect important to the professional and medical development of hematologists.
Format: 60 minutes, number of speakers and chairs varies.

SCIENTIFIC WORKING GROUP SESSIONS

Focus: The SWG Sessions are organized by the EHA Scientific Working Groups, which are active networks of researchers and clinicians. The sessions highlight research coming out of each working group.
Format: 60 minutes, number of speakers varies.

SIMULTANEOUS SESSIONS

Focus: The simultaneous sessions are the core of the abstract program compiled from the abstracts submitted for presentation at the congress.
Format: 75 minutes, abstract-based presentations by 5 speakers and 2 chairs.

POSTER SESSIONS

Focus: The poster session is a collection of poster walks, each poster walk includes up to 10 poster presentations selected from the abstracts submitted for presentation at the congress.
Format: 90 minutes, abstract-based posters by a maximum of 10 speakers and 1 Poster Walk moderator.

EBAH CME ACCREDITATION

Participants of the 22nd Congress of EHA are eligible to receive Continuing Medical Education (CME) Credit Points from the European Board for Accreditation in Hematology (EBAH). CME is widely accepted as a means to encourage individual practitioners to maintain and develop professional knowledge and skills. This accreditation system has been implemented as a service to hematologists in response to this need. It facilitates identification and registration of CME activities, which have been submitted to a peer-review process and respond to pre-established quality standards. Attendants of the 22nd Congress of EHA are eligible to receive one Credit Point for every hour of accredited activity.

CME Credit Points will be awarded for the scientific and educational sessions including Plenary Sessions, Education Sessions, Meet-the-Experts, Clinical Debates, Hematology-in-Focus, Basic-Science-in-Focus, EHA-ISLH Laboratory Diagnosis Workshop, Simultaneous Sessions, the workshops, EHA Scientific Working Groups Meetings and the Joint Symposia with ASH, ESH, ISEH, ISTH, EBMT, JSH, CSH and HST.

HOW TO CLAIM YOUR CREDIT POINTS

You need to have an account on the EBAH platform so the Credit Points can be added to your online CME portfolio, this is free of charge. In case you have already provided the email connected to your EBAH account upon your registration for the Congress, this will be used to add your Credit Points. If you failed to do so or do not have an account yet, you are welcome to create one, and then we kindly invite you to visit the EBAH CME booth, where staff will be happy to assist you to make sure your points are added. At the booth you can also check the status of your current EBAH account and update your contact details. A sufficient number of computers are made available to register an account with the EBAH system.

STEPS TO FOLLOW FOR YOUR CME CREDIT POINTS

Step 1: Visit the EBAH website: www.ebah.org
Step 2: If you have an account in this system which you already submitted upon your registration for Congress, you may log in.
In case you do not have an account yet, you may create an account by clicking "Create CME account" and let us know you did so at the EBAH CME booth.
Step 3: Your EBAH CME Credit Points Certificate will be available in your personal account in PDF format for downloading, saving and printing.

For further assistance or more information on CME accreditation we kindly invite you to visit the EBAH booth or contact: info@ebah.org T +31 (0)70 302 00 99.

EUROPEAN HEMATOLOGY ASSOCIATION

PROGRAM OVERVIEW PER DAY

	Hall A	Hall B	Hall C	Hall D	Hall E
08:00 →			**MSD** Anti-PD1 in Lymphomas and Multiple Myeloma	**prIME Oncology** Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma	**Invivoscribe** NGS-based Clinical Assessment of B- and T-Cell Clonality and MRD Determination
10:00 →			P.59	P.59	P.60
10:45 →	**Celgene** The evolving art of treating multiple myeloma	**Janssen** The when, why and how of managing your CLL patients: clarity in a changing environment	**Novartis** Recent Advances in MPNs	**Bristol-Myers Squibb** A look ahead: the next chapter of immuno-oncology research in hematologic malignancies	
12:45 →	P.62	P.63	P.63	P.64	
13:30 →		**Janssen** Multiple Myeloma: Changing the present, creating the future	**Novartis** Emerging Trends in Chronic Myeloid Leukemia and Acute Myeloid Leukemia	**Celgene** Innovation today, treatments tomorrow: tailoring treatment strategies for myeloid malignancies	
15:30 →		P.66	P.66	P.67	
16:15 →			**Abbvie** Relapsed/refractory CLL: How far have we come, and where will we go next	**Celgene** Shifting treatment paradigms in non-Hodgkin lymphoma	**Amgen** Navigating the treatment continuum in multiple myeloma
18:15 →			P.69	P.70	P.70
19:00 →				**AROG Pharmaceuticals** Targeting the FLT-3 pathway in AML: Evolution of next generation tyrosine kinase inhibitors	**Global Academy for Medical Education** New Horizons in the Treatment of Acute Myeloid Leukemia
21:00 →				P.73	P.73

THURSDAY, JUNE 22

Room N101	Room N105	Room N103	Room N104	
Pfizer Targeting AML: recent advances and clinical perspectives	**Sanofi Genzyme** The Sherlock Holmes approach to diagnosis and treatment: Thrombocytopenia in rare haematological diseases	**prIME Oncology** Fine tuning therapeutic strategies in acute myeloid leukemia in 2017 and beyond	**MorphoSys AG** Diffuse large b-cell lymphoma management: exploring novel treatment strategies	← 08:00
P.60	P.61	P.61	P.62	← 10:00
Novartis Managing safety of investigational CAR T-cell therapies in leukemias and lymphomas	**Takeda Oncology** Continuous therapy in multiple myeloma: on target with proteasome inhibition	**Jazz Pharmaceuticals** Raising the bar: New management and treatment in Acute Leukemias		← 10:45
P.64	P.65	P.65		← 12:45
Novartis Leading towards optimizing the treatment of ITP and new treatment strategies in SAA and MDS	**Takeda Oncology** Unmet need in the management of advanced-stage hodgkin lymphoma: where do we go from here?	**Amgen** Aiming higher in adult ALL: novel therapies and treatment strategies	**Gilead** Defining treatment strategies for CLL and FL in the era of targeted therapies: evidence and experience	← 13:30
P.67	P.68	P.68	P.69	← 15:30
Gilead Expert Guides in AML: Exploring Current Challenges and Future Directions to Optimise Patient Outcomes	**Incyte** Patients in focus: What´s relevant for CML and PH+ALL?	**Abbvie** Emerging novel agents for AML: Are we on the threshold of a transformation in therapy?	**Alexion** Thrombosis in complement-mediated diseases	← 16:15
P.71	P.71	P.72	P.72	← 18:15
Pfizer GETTING PERSONAL; Individualising Therapy in CML	**Shire** A new practical tool to help identify Gaucher disease: Accelerating diagnosis and improving long-term outcomes for patients	**prIME Oncology** Current state-of-the-art and future strategies in acute lymphoblastic leukemia	**Celltrion** The 1st biosimilar rituximab based on clinical evidence	← 19:00
P.74	P.74	P.75	P.75	← 21:00

EUROPEAN HEMATOLOGY ASSOCIATION

PROGRAM OVERVIEW PER DAY

	Hall A	Hall B	Hall C	Hall D	Hall E	Room N101	Room N105	Room N103
08:00 →								
08:30 →	**Education Session** Indolent lymphoma **T C** P.79	**Education Session** Myeloproliferative neoplasms **T C** P.79	**SWG Session** Novel developments in myeloma and related diseases **T C** P.79	**Education Session** Acute lymphoblastic leukemia: The worst and the best **T C** P.80	**Education Session** Stem cell transplantation - GvHD **B T C** P.80	**Molecular Hemopoiesis Workshop** **B T** P.81	**Education Session** Thrombosis **B T C** P.82	**Education Session** Hereditary hematological disorders **T C** P.82
09:30 →								
09:45 →	**Education Session** Immunotherapy lymphoma **B T C** P.85	**Education Session** Myeloproliferative neoplasms **T C** P.85	**Education Session** Chronic myeloid leukemia **T C** P.86	**Education Session** Acute lymphoblastic leukemia: The worst and the best **T C** P.86	**EHA-EBMT Joint Symposium** 60 years of allogeneic stem cell transplantation **T C** P.86		**Education Session** Bleeding disorders **B T C** P.87	**Education Session** Hereditary hematological disorders **T C** P.87
10:45 →								
11:15 →								
11:30 →	**Simultaneous Session** New advances in plasma cell disorders and implications for therapy **T C** P.90	**Simultaneous Session** Aggressive Non-Hodgkin lymphoma - 1st line **C** P.90	**Simultaneous Session** MRD directed treatment in AML **B T C** P.90	**Simultaneous Session** New insights into chronic lymphocytic leukemia biology **B T** P.91	**Simultaneous Session** Pathogenesis of MDS **B T** P.92	**Simultaneous Session** Lymphoma biology **B T** P.92	**Simultaneous Session** Thalassemia **B T C** P.93	**Simultaneous Session** AML Biology I: Towards molecular therapies **B T** P.93
12:45 →								
13:00 →	**Opening Ceremony Research Grant Winners José Carreras Lecture** P.96							
14:15 →								
14:30 →	**Hematology-in-Focus** News in WHO 2016 classification of hematopoietic malignancies **C** P.96	**Clinical Debate** Should low risk MDS be transplanted? **C** P.96	**Hematology-in-Focus** Waldenström's disease **B T C** P.96	**EHA-JSH Joint Symposium** Next generation sequencing **B T** P.97	**Clinical Debate** Reversal of direct oral anticoagulants (DOAC): Do we really need an antidote? **C** P.97	**Hematology-in-Focus** Leukemias with mixed phenotypes **T C** P.97	**EHA-HST Joint Symposium** Acute myeloid leukemia **T C** P.98	**Clinical Debate** Do new studies support a preferential indication of plasma-derived vs. recombinant concentrates for the treatment of new patients with severe hemophilia A? **C** P.98
15:30 →								
15:45 →	**Presidential Symposium** **B T C** P.100							
17:00 →								
17:15 →	**POSTER SESSION I - Hall 7**						**Updates-in-Hematology Celgene** CAR-T cell therapy: Progress and Prospects P.100	**Updates-in-Hematology PeerVoice** Biosimilars for Hematologic Malignancies: The Path to Sustainable Care P.101
18:45 →								

FRIDAY, JUNE 23

Room N104	Room N109	Room N111	Room N113	Room N115	Room N107	Room N108	Room N117	
								← 08:00
								← 08:30
SWG Session New insights in neutropenias **B T C** P.83	**SWG Session** Minimal residual disease in leukemia **C** P.83	**Basic-Science-in-Focus** Myeloid derived suppressor cells **B T** P.84	**Basic-Science-in-Focus** Microbiome **B T C** P.84	**Basic-Science-in-Focus** Focus on iron **B** P.84				← 09:30
								← 09:45
SWG Session Aging and hematology: New challenges **C** P.88	**SWG Session** Present and future of quality of life and symptom assessment in daily clinical practice in hematological malignancies **C** P.88	**Basic-Science-in-Focus** Role of NK cells in myeloid malignancies and SCT **B T C** P.88	**Basic-Science-in-Focus** Aging and hematopoiesis **B T** P.89	**SWG Session** Red cell & iron: RBC hydration defects **B T C** P.89				← 10:45
								← 11:15
Simultaneous Session Hematopoiesis, stem cells and microenvironment **B T** P.94	**Simultaneous Session** Gene therapy, cellular immunotherapy and vaccination 1 **B T C** P.95				**Meet-the-Expert** Approach to iron overload in MDS and after BMT **C** P.96	**Meet-the-Expert** ALL in adolescence and young adults case studies **C** P.96	**Meet-the-Expert** Amylodoisis treatment **C** P.96	← 11:30
								← 12:30
								← 12:45
								← 13:00
								← 14:15
Hematology-in-Focus Chronic myelomonocytic leukemia (CMML) **B T C** P.98	**Early Career Session** EHA Fellowship and TRTH Awardees **B T C** P.98	**Hematology-in-Focus** Erythropoiesis and rare anemias **T C** P.99	**Hematology-in-Focus** How to diagnose and manage cytopenias in children and young adults? **T C** P.99		**Meet-the-Expert** Management of Von Willebrand disease **C** P.99	**Meet-the-Expert** CLL in the era in targeted therapies **C** P.99	**Meet-the-Expert** Treatment of GvHD **C** P.99	← 14:30
								← 15:30
								← 15:45
								← 17:00
								← 17:15
Updates-in-Hematology Prothena AL amyloidosis, don't miss it! P.102								← 18:45

TRACKS

1. Clinical hematology: Benign
2. Clinical hematology: Myeloid malignancies
3. Clinical hematology: Lymphoid malignancies and plasma cell disorders
4. Clinical hematology: Stem cell transplantation and special therapy
5. Laboratory diagnosis
6. Thrombosis and hemostasis
7. Transfusion medicine
8. General skills
9. Pediatric hematology
10. Personalized medicine

SUBDIVISIONS/TRACKS

- B Biology
- T Translational
- C Clinical
- Early Career Hematologist
- Early Career Scientist

EUROPEAN HEMATOLOGY ASSOCIATION

PROGRAM OVERVIEW PER DAY

	Hall A	Hall B	Hall C	Hall D	Hall E	Room N101	Room N105	Room N103
08:00 →								
08:30 →	**Education Session** Immunotherapy in lymphoma B T C	**Education Session** Multiple myeloma T C	**SWG Session** Lymphomas: Diagnosis and follow-up of lymphoma T C	**Education Session** Chronic myeloid leukemia T C	**EHA-ISLH Laboratory Diagnosis Workshop** B T C	**Education Session** Stem cell transplantation - GVHD B T C	**Basic-Science-in-Focus** Genomics and epigenomics of CLL B T	**SWG Session** MDS and the role of the immune system in pathophysiology and therapy T C
09:30 →	P.123	P.123	P.123	P.124	P.124	P.125	P.126	P.126
09:45 →								
10:15 →	**Education Session** Indolent lymphoma T C	**Education Session** Chronic lymphocytic leukemia B T C	**Education Session** Acute myeloid leukemia T C	**EHA-ASH Joint Symposium** The future of genome editing for hematology/ CRISPR B T C		**Education Session** Fertility preservation in patients with hematological malignancies T C	**SWG Session** Adult ALL first line therapy: Major results and future approaches of national ALL study groups C	**SWG Session** Mantle cell lymphoma: The PROs and CONs in the treatment of MCL patients C
10:45 →								
11:15 →	P.128	P.128	P.129	P.129	P.124	P.130	P.130	P.130
11:30 →	**Simultaneous Session** Front-line combinations in multiple myeloma and amyloidosis C	**Simultaneous Session** Hodgkin and indolent lymphoma - Clinical C	**Simultaneous Session** Biology of MPN: JAK2 and beyond B T	**Simultaneous Session** Clinical trials including treatment discontinuation in CML C	**Simultaneous Session** AML Biology II: Epigenetic targets B T	**Simultaneous Session** Acquired and inherited platelet disorders T C	**Simultaneous Session** Acute lymphoblastic leukemia - Biology B T	**Simultaneous Session** Thrombotic disorders T C
12:45 →	P.133	P.133	P.133	P.134	P.134	P.135	P.136	P.136
13:15 →	**Jean Bernard Lifetime Achievement Award**							
13:30 →	**Plenary Session 1** B T							
14:30 →	P.138							
14:45 →	**Clinical Debate** News in WHO 2016 Treatment should be started in every patient with high risk smoldering multiple myeloma C	**Hematology-in-Focus** Richter transformation in CLL T C	**Hematology-in-Focus** Rare lymphoma subtypes C	**Hematology-in-Focus** New strategies in cellular therapy to prevent relapse of acute leukemia B T C	**Clinical Debate** All children with sickle cell anemia and an HLA identical sibling should be offered hematopoietic stem cell transplantation C	**Hematology-in-Focus** Novel approaches for treatment of hemophilia C	**Hematology-in-Focus** Pediatric hematology: New drugs for children C	**EHA-CSH Joint Symposium** Stem cell transplantation for relapsed leukemia C
15:45 →	P.138	P.138	P.138	P.139	P.139	P.139	P.139	P.140
16:00 →	**Simultaneous Session** New drugs for rescue in relapsed/ refractory multiple myeloma T C	**Simultaneous Session** Improving prognostication and front-line therapy in chronic lymphocytic leukemia T C	**Simultaneous Session** Aggressive Non-Hodgkin lymphoma-Relapsed/refractory C	**Simultaneous Session** Targeted treatment of AML T C	**Simultaneous Session** Immunotherapy in ALL T C	**Simultaneous Session** Biology and disease monitoring in CML T C	**Simultaneous Session** Prognostic markers and new treatment in MDS T C	**Simultaneous Session** Stem cell transplantation - Clinical 1 C
17:15 →	P.141	P.142	P.142	P.142	P.143	P.143	P.144	P.144
17:30 →	POSTER SESSION II - Hall 7						**Updates-in-Hematology Pfizer** Broadening our horizons in relapsed/ refractory ALL	
19:00 →							P.146	

SATURDAY, JUNE 24

Room N104	Room N109	Room N111	Room N113	Room N115	Room N107	Room N108	Room N117	
EHA-ISEH Joint Symposium Hematopoietic stem cells and their niche **B** P.126	**Education Session** Update on hemoglobinopathies **B T C** P.127	**Education Session** Bleeding disorders **B T C** P.127	**SWG Session** Treatment of difficult to treat thrombocytopenias **C** P.127	**Patient Advocacy Session** Innovative clinical trial designs, adaptive pathways (MAPPs) and patient involvement in R&D **C** P.128				08:00 / 08:30
SWG Session New tools for MPN patients management **C** P.131	**Education Session** Update on hemoglobinopathies **B T C** P.131	**Education Session** Thrombosis **B T C** P.132	**SWG Session** Stem cells: Metabolic regulation of stem cell **B T** P.132	**SWG Session** Mesenchymal stem cells: The immunology of tissue repair **B T** P.132				09:30 / 09:45
Simultaneous Session Stem cell transplantation - Experimental **B T C** P.136	**Simultaneous Session** Sickle cell disease, enzymes **B T** P.137			**Patient Advocacy Session** Pregnancy during and after treatment: Myths and reality **C** P.137	**Meet-the-Expert** How I treat elderly AML **C** P.138	**Meet-the-Expert** Aplastic anemia or MDS in a child - How to distinguish? **C** P.138	**Meet-the-Expert** Treatment of advanced systemic mastocytosis **C** P.138	10:45 / 11:15 / 11:30 / 12:30 / 12:45 / 13:15
	EHA-ESH Joint Symposium Doctor-patient communication regarding bad news and future prospects **C** P.140	**Early Career Session** Biologic, translational and clinical hematology: What is beyond? **B T C** P.140		**EU Funded Projects in Hematology** HARMONY P.141	**Meet-the-Expert** Stop of TKI in CML **C** P.141	**Meet-the-Expert** Eosinophilia **C** P.141	**Meet-the-Expert** How I plan and run a hospital patient blood management programme? **C** P.141	14:30 / 14:45 / 15:45
Simultaneous Session Bone marrow failure and PNH **B T C** P.144	**Simultaneous Session** Quality of life, palliative care, ethics and health economics **C** P.145	**Early Career Session** Bite-size CRTH **C** P.145	**Early Career Session** Bite-size TRTH **T** P.146	**EHA Advocacy Session** New drugs in hematology: Fair pricing & access **C** P.146				16:00 / 17:15 / 17:30 / 19:00

TRACKS

1. Clinical hematology: Benign
2. Clinical hematology: Myeloid malignancies
3. Clinical hematology: Lymphoid malignancies and plasma cell disorders
4. Clinical hematology: Stem cell transplantation and special therapy
5. Laboratory diagnosis
6. Thrombosis and hemostasis
7. Transfusion medicine
8. General skills
9. Pediatric hematology
10. Personalized medicine

SUBDIVISIONS/TRACKS

- B Biology
- T Translational
- C Clinical
- Early Career Hematologist
- Early Career Scientist

EUROPEAN HEMATOLOGY ASSOCIATION

PROGRAM OVERVIEW PER DAY

	Hall A	Hall C	Hall D	Hall E	Room N101	Room N105
08:00 →	**Simultaneous Session** Targeted therapies in relapsed in chronic lymphocytic leukemia **T C**	**Simultaneous Session** Follicular lymphoma - Clinical **C**	**Simultaneous Session** Changing the strategy of therapy in multiple myeloma **C**	**Simultaneous Session** Old and new drugs in MPN **T C**	**Simultaneous Session** Childhood and more intensive treatment of AML **T C**	**Simultaneous Session** Stem cell transplantation - Clinical 2 **C**
09:15 →	P.167	P.167	P.167	P.168	P.168	P.169
09:30 →	**Education Session** Chronic lymphocytic leukemia **B T C**	**Education Session** Aggressive lymphoma **B T C**	**SWG Session** ELN-EHA-SWG on CML **B T C**	**Education Session** Myelodysplastic syndromes **B T C**	**Education Session** Acute myeloid leukemia **T C**	**EHA-ISTH Joint Symposium** Anticoagulation in difficult patients **T C**
10:30 →	P.171	P.171	P.172	P.172	P.173	P.173
11:00 →						
11:15 →	**Late Breaking Oral Session**	**Education Session** Aggressive lymphoma **B T C**	**Education Session** Multiple myeloma **T C**	**Education Session** Myelodysplastic syndromes **B T C**	**Education Session** Fertility preservation in patients with hematological malignancies **T C**	**SWG Session** A roadmap for CLL treatment: What to choose and why **C**
11:45 →						
12:45 →	P.175	P.176	P.176	P.176	P.177	P.177
13:00 →	**Plenary Session 2** **B T C**					
14:30 →	P.180					
14:30 →	Business Meeting					
15:00 →	P.180					

SUNDAY, JUNE 25

Room N103	Room N104	Room N109	Room N111	Room N113	Room N115	
Simultaneous Session Biomarkers in ALL **B T C** P.169	**Simultaneous Session** Infectious diseases, supportive care **C** P.170	**Simultaneous Session** Iron: Deficiency and overload **B T C** P.170	**Simultaneous Session** Gene therapy, cellular immunotherapy and vaccination 2 **B T** P.170			← 08:00
						← 09:15
Basic-Science-in-Focus Hematopoietic stem cells and the microenvironment **B T** P.173	**Basic-Science-in-Focus** Vaccines & antibodies **B T C** P.174	**Education Session** Blood transfusion **B T C** P.174	**Education Session** Acquired problems in red cells **B T C** P.174	**SWG Session** EuroFlow: High throughput flowcytometry in Hemato-Oncology **C** P.175	**Basic-Science-in-Focus** Metabolomics and leukemia **B T** P.175	← 09:30 ← 10:30 ← 11:00
SWG Session Acute myeloid leukemia **B T C** P.178	**SWG Session** Bleeding and thrombosis: Acquired bleeding disorder emergencies **C** P.178	**Education Session** Blood transfusion **B T C** P.178	**Education Session** Acquired problems in red cells **B T C** P.179	**Basic-Science-in-Focus** Methylation and epigenetics **B T** P.179	**Basic-Science-in-Focus** Mouse models of acute leukemia **B T** P.179	← 11:15 ← 11:45 ← 12:45
						← 13:00

TRACKS

1. Clinical hematology: Benign
2. Clinical hematology: Myeloid malignancies
3. Clinical hematology: Lymphoid malignancies and plasma cell disorders
4. Clinical hematology: Stem cell transplantation and special therapy
5. Laboratory diagnosis
6. Thrombosis and hemostasis
7. Transfusion medicine
8. General skills
9. Pediatric hematology
10. Personalized medicine

SUBDIVISIONS/TRACKS

- **B** Biology
- **T** Translational
- **C** Clinical
- Early Career Hematologist
- Early Career Scientist

VISIT EHA'S ADVOCACY TRACK!

EHA's advocacy track puts the spotlight on high-impact patient and policy issues.

Two of the advocacy track's main sessions are organized by patient advocates. The first Patient Advocacy Session will focus on the cumulative impact of new clinical trial designs, the EMA's new 'Adaptive Pathways' (MAPPS) licensing scheme and the new EU Clinical Trials Regulation. What opportunities do they offer to patients and clinicians? Will they help accelerate research and access to new therapies in areas of high unmet medical need, without compromising the gathering of solid evidence?

The second Patient Advocacy Session will focus on fertility and pregnancy during and after treatment, a major concern for many cancer patients. The speakers will discuss existing hurdles and potential approaches and address some persisting myths about what is and should be possible or even allowed, from various viewpoints – patient, clinical, research, legal and bioethical.

The third major element of this track is the EHA Advocacy Session, which will highlight an issue of great importance to hematologists and patients: the pricing of innovative medicines. At a time when rising prices increasingly threaten the availability and affordability of innovative pharmaceutical care, there is an urgent need for a new, more transparent economic model that will deliver innovative medicines at fair prices. Speakers will present the economic, public health and patient perspectives, followed by discussion with an industry panel.

EARLY CAREER TRACK

As a young researcher or hematologist, it's important to enlarge your network and to stay up-to-date in order to enrich your professional life.

Sessions that are marked 'Early Career' will help you accomplish these goals.

Talk to recipients and reviewers of EHA Career Development programs to learn how to apply successfully at the Early Career Reception on Thursday, June 22, 18:00.

Learn the interesting results from research supported by EHA Research Grants at the Early Career session on Friday, June 23, 14:30 – 15:30.

Get a head start on becoming an independent researcher in clinical or translational research at the mini-CRTH or mini-TRTH sessions on Saturday, June 24, 16:00 – 17:15.

Get Groovy with EHA on Saturday, June 24, 19:30.

Learn which EHA programs will help your professional development at the EHA Booth

INSIDER TIPS ON NAVIGATING THE CONGRESS PROGRAM

To successfully approach the massive conference program of the 22nd Congress, it is certainly good to get a first feeling for the different session types: What is offered, and how can I get the best balance out of everything? Regardless of whether you are an early career hematologist at the beginning of your clinical training, or a basic scientist, some of the sessions are a "must see" for every attendee. These include the "Big 3" (the Presidential Symposium on Friday featuring the highest scoring abstracts, the Plenary Sessions on Saturday and Sunday, and the block of Late breaking Abstracts on Sunday morning), the two consecutive blocks of Education sessions at the start of every day, and of course the oral and poster sessions of the presented abstracts. The latter are not only important from a scientific perspective, but even more for the goal of a successful EHA attendance: meeting people and exchanging ideas in an open, collaborative environment. In addition, this year features a new exciting addition to the program: The Early Career sessions on Saturday afternoon. While the first session is lead by "rising stars" of hematology who are presenting their research, the second and third sessions provide insights into the EHA-ASH TRTH and CRTH classes.

In addition to those sessions which are of interest for all early career hematologists, there are several program items which may be more important for either clinicians or others with a more basic science focus. As a clinician, the Hematology-in-Focus and Meet-the-Expert sessions contain a multitude of exciting presentations and make it hard to choose what to attend. The Meet-the-Expert session on clinical trial design may be of special importance for clinicians who are already more advanced in their clinical training. The SWG sessions at the start of every day provide a great overview of broad topics, and are also highly recommended.

For early career translational researchers and PhDs, Sessions in the morning on Friday, Saturday and Sunday should be considered: The Basic Science-in-Focus sessions on Saturday and Sunday, as well as some of the SWG sessions and the EHA-ASH symposium provide great insight into advancing topics with high yield.

For certain patients with chronic ITP and other cytopenias

MAKE REVOLADE (eltrombopag) YOUR **FIRST CHOICE**[1]

Step inside **Booth #940 at the 22nd Congress of the European Hematology Association** to learn more

- Paediatric Chronic ITP
- Adult Chronic ITP
- Severe Aplastic Anaemia
- Chronic Hepatitis C Virus–Associated Thrombocytopenia

REVOLADE (eltrombopag) is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year and above who are refractory to other treatments (e.g. corticosteroids, immunoglobulins); in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation; and in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.[1]*

*The information on indication has been abbreviated and reworded compared with the SmPC.

Reference: 1. REVOLADE Summary of Product Characteristics. November 2016.

Please see Important Safety Information for REVOLADE in the back of the publication.

NOVARTIS

Once daily oral therapy

REVOLADE™ (eltrombopag olamine)

Novartis Pharma AG
CH-4002 Basel Switzerland

April 2017

G-REV-1160583

IMPORTANT SAFETY INFORMATION

REVOLADE® / PROMACTA™

Important note: Before prescribing, consult full prescribing information.

Presentation: • Film-coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg, or 100 mg of eltrombopag free acid. • Powder for oral suspension containing eltrombopag olamine equivalent to 25 mg of eltrombopag free acid per sachet.

Indications: • Eltrombopag is indicated for the treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura (ITP) to increase platelet counts and reduce or prevent bleeding. • Eltrombopag is indicated in patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia to enable the initiation of interferon based therapy/ to optimize interferon based therapy. • Eltrombopag is indicated for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy.

Dosage and administration: • Dosing regimens must be individualized based on the patient's platelet counts. • Dose regimen: Starting dose between 25 to 50 mg once daily. Monitoring and individual dose adjustment. Maintenance doses with maximum daily doses between 75 to 150 mg depending on patient population and indication.

Special populations: • Pediatric age group: safety and efficacy not established in patients with chronic HCV or SAA. • Elderly: No clinically significant differences in safety. • Renal impairment: Caution and close monitoring recommended. • Hepatic impairment: Caution and close monitoring, starting dose 25 mg once daily.

Contraindications: • None.

Warnings and precautions: • Hepatotoxicity: Eltrombopag administration can cause hepatobiliary laboratory abnormalities, severe hepatotoxicity and potentially fatal liver injury. • Hepatic decompensation (use with interferon): Chronic HCV patients with cirrhosis may be at risk for hepatic decompensation, some with fatal outcomes, when receiving alpha interferon therapy. Close monitoring for signs and symptoms of hepatic decompensation. • Thrombotic/thromboembolic complications: Use with caution in patients with known risk factors for thromboembolism. Monitoring of platelet counts and potentially dose reduction or discontinuation. • Increased risk for bleeding after discontinuation of treatment. Monitoring weekly for 4 weeks following discontinuation. • Risk for malignancies and progression of malignancies. • Patient with cataracts: Routine monitoring.

Women of child-bearing potential, pregnancy: • Should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.

Breast-feeding: • Not recommended unless the expected benefit justifies the potential risk to the infant.

Adverse drug reactions (by highest reporting frequency):

ITP study population: • Very common (≥10%): Nausea, diarrhoea. • **Common (1 to 10%):** Pharyngitis, urinary tract infection, dry mouth, vomiting, increased aspartate aminotransferase, increased alanine aminotransferase, alopecia, rash, back pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, cataract.

Uncommon (0.1 to 1%): Drug-induced liver injury.

ITP pediatric study population (1 to 17 years of age) – Additional ADRs: • Very common (≥10%): Nasopharyngitis, upper respiratory tract infection. • **Common (1 to 10%):** Rhinitis, abdominal pain, toothache, cough, oropharyngeal pain, rhinorrhoea, pyrexia.

HCV study population: • Very common (≥10%): Anaemia, decreased appetite, insomnia, headache, cough, nausea, diarrhoea, pruritus, alopecia, myalgia, fatigue, pyrexia, chills, asthenia, oedema peripheral, influenza like illness. • **Common (1 to 10%):** Hyperbilirubinaemia, drug-induced liver injury, rash, cataract.

SAA study population: • Very common (≥10%): Headache, cough, dyspnoea, oropharyngeal pain, rhinorrhoea, abdominal pain, diarrhoea, nausea, transaminases increased, ecchymosis, arthralgia, muscle spasms, pain in extremity, dizziness, fatigue, febrile neutropenia, pyrexia. • **Common (1 to 10%):** Rash, cataract.

Adverse reaction from spontaneous reports: Rare (0.01 to 0.1%): Thrombotic microangiopathy with acute renal failure. • **Not known:** skin discolouration.

For a complete list of ADRs, consult full prescribing information.

Interactions: • Rosuvastatin: Dose reduction and monitoring. Other OATP1B1 and BCRP substrates to be used with caution. • Cyclosporine (BCRP inhibitor): monitoring weekly for 2 to 3 weeks, eltrombopag dose may need to be increased: • Polyvalent cations (chelation): staggered administration. • Food interactions. • Lopinavir/ritonavir: Caution and monitoring of platelet count weekly for 2 to 3 weeks.

Packs and prices: Country-specific.

Legal classification: Country-specific.

THURSDAY, JUNE 22

SPECIAL SESSIONS OF THE DAY

We would like to draw your attention to the following sessions:

SATELLITE SYMPOSIA → Page 59 - Page 75

EXHIBITION

DON'T FORGET TO VISIT THE EXHIBITION IN HALL 7

The exhibition will be open on the following days and times:

Thursday, June 22	09:00-16:30
Friday, June 23	09:00-16:30
Saturday, June 24	09:00-16:30
Sunday, June 25	09:00-13:30

→ SATELLITE SYMPOSIUM
08:00 – 10:00, Hall C

ANTI-PD1 IN LYMPHOMAS AND MULTIPLE MYELOMA

Chair: PL Zinzani, Bologna University, Department of Hematology, A.O.U. Policlinico Sant'Orsola Malpighi, Italy

PROGRAM

- **Introduction and welcome**
  PL Zinzani, Bologna University, Department of Hematology, A.O.U. Policlinico Sant'Orsola Malpighi, Italy
- **Understanding the Rationale For Immunotherapy in Hematologic Malignancies**
  PL Zinzani, Bologna University, Department of Hematology, A.O.U. Policlinico Sant'Orsola Malpighi, Italy
- **Clinical Updates for Hodgkin Lymphoma**
  R Chen, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, United States
- **Q&A**
  Faculty
- **Pursuing Immunotherapy in Non-Hodgkin Lymphoma**
  S Neelapu, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
- **Navigating the Multiple Myeloma Landscape**
  SZ Usmani, Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, United States
- **Q&A / Closing Remarks**
  Faculty
  PL Zinzani, Bologna University, Department of Hematology, A.O.U. Policlinico Sant'Orsola Malpighi, Italy

→ SATELLITE SYMPOSIUM
08:00 - 10:00, Hall D
This independent educational activity is industry supported.

NAVIGATING THE COMPLEX WATERS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA

Chair: M Dimopoulos, University of Athens, Athens, Greece

PROGRAM

- **Welcome, introduction, and pop quiz**
  M Dimopoulos, University of Athens, Athens, Greece
- **Looking back to shore: How did we get to relapsed/refractory (RR) multiple myeloma (MM)?**
  P Moreau, University of Nantes, Nantes, France
- **Wind in our sails: Next generation therapeutic options in R/R MM**
  M Dimopoulos, University of Athens, Athens, Greece
- **What's on the near horizon? New targets in R/R MM**
  S Lonial, Emory University, Atlanta, United States
- **Avoiding treacherous waters: Balancing efficacy with adversity**
  E Ocio, University of Salamanca, Salamanca, Spain
- **Conclusion and key points**
  M Dimopoulos, University of Athens, Athens, Greece

→ SATELLITE SYMPOSIUM
08:00 - 10:00, Hall E

NGS-BASED CLINICAL ASSESSMENT OF B- AND T-CELL CLONALITY AND MRD DETERMINATION

Chair: M Arcila, Memorial Sloan Kettering Cancer Center, Molecular Diagnostic Service, New York, United States

PROGRAM

- **Minimal Residual Disease in Multiple Myeloma by NGS: A Comparison with Flow Cytometry and ASO-PCR**
  R Garcia Sanz, University Hospital of Salamanca, Hematology Department, Salamanca, Spain
- **IGHV Somatic Hypermutation Analysis by NGS in CLL Routine Diagnostics**
  R Bomben, Oncology Reference Center (CRO) Aviano - Clinical and Experimental Onco-Hematology Unit, Aviano, Italy
- **Minimal Residual Disease Detection of Lymphoid and Plasma Cell Neoplasms Using a Next-Generation Sequencing (NGS)-Based Assay**
  M Arcila, Memorial Sloan Kettering Cancer Center, Molecular Diagnostic Service, New York, United States
- **Deep sequencing reveals clinically relevant subclonal IGHV rearrangements in CLL**
  B. Stamatopoulos, University of Brussels (ULB), Laboratory of Clinical Cell Therapy, Brussels, Belgium

→ SATELLITE SYMPOSIUM
08:00 - 10:00, Room N101

TARGETING AML: RECENT ADVANCES AND CLINICAL PERSPECTIVES

Chair: O Ottmann, Cardiff University, Cardiff, United Kingdom

PROGRAM

- **Welcome and introduction**
  O Ottmann, Cardiff University, Cardiff, United Kingdom
- **Advances in the molecular characterisation of AML**
  P Paschka, University Hospital Ulm, Ulm Germany
- **Challenges and emerging opportunities for elderly unfit patients with AML**
  J Cortes, Md Anderson cancer center, Houston, United States
- **Innovative therapeutic approaches for fit patients with AML**
  O Ottmann, Cardiff University, Cardiff, United Kingdom
- **Debate: The relevance of MRD in AML clinical practice - For MRD**
  A Venditti, University of Rome tor Vergata, Rome, Italy
- **Debate: The relevance of MRD in AML clinical practice - Against MRD**
  R Schlenk, National Center for Tumor Diseases, Heidelberg, Germany
- **Closing remarks**
  O Ottmann, Cardiff University, Cardiff, United Kingdom

SANOFI GENZYME

→ SATELLITE SYMPOSIUM
08:00 - 10:00, Room N105

THE SHERLOCK HOLMES APPROACH TO DIAGNOSIS AND TREATMENT: THROMBOCYTOPENIA IN RARE HAEMATOLOGICAL DISEASES

Chair: MD Cappellini, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

PROGRAM

- **Welcome and introduction**
  MD Cappellini, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- **Holmes unmasks an accidental villain**
  M Machaczka, Karolinska University Hospital Huddinge, Stockholm, Sweden
- **Watson is lured by a seductive melody**
  G Massenkeil, Klinikum Gütersloh gGmbH, Gütersloh, Germany
- **The curious case of Ludwig the tailor**
  J Villarubia, Hospital Universitario Ramón y Cajal, Madrid, Spain
- **Holmes and Watson are baffled by a blinding blizzard**
  M Machaczka, Karolinska University Hospital Huddinge, Stockholm, Sweden
- **Holmes turns as white as a ghost**
  G Massenkeil, Klinikum Gütersloh gGmbH, Gütersloh, Germany
- **Suspicious circumstances make trouble for Holmes**
  J Villarubia, Hospital Universitario Ramón y Cajal, Madrid, Spain
- **Concluding remarks**
  MD Cappellini, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

prIME ONCOLOGY Aptitude Health Company

→ SATELLITE SYMPOSIUM
08:00 - 10:00, Room N103
This educational activity is supported by a grant from Celgene and Helsinn Healthcare SA.

FINE TUNING THERAPEUTIC STRATEGIES IN ACUTE MYELOID LEUKEMIA IN 2017 AND BEYOND

Chair: M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain

PROGRAM

- **Welcome, introduction, and quiz questions**
  M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain
- **Examining genetics and genomics in acute myeloid leukemia (AML) in 2017**
  E Papaemmanuil, Memorial Sloan Kettering Cancer Center, New York, United States
- **Personalizing initial therapy in AML**
  F Lo Coco, University Tor Vergata Rome, Italy
- **What's on the horizon for relapsed/refractory AML?**
  L Pleyer, Salzberg Cancer Research Institute, Salzburg, Germany
- **A deeper dive into AML subgroups**
  M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain
- **Key points**
  M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain

→ SATELLITE SYMPOSIUM
08:00 - 10:00, Room N104

DIFFUSE LARGE B-CELL LYMPHOMA MANAGEMENT: EXPLORING NOVEL TREATMENT STRATEGIES

Chair: B Coiffier, Centre Hospitalier Lyon Sud, Pierre-Benite, France

PROGRAM

- **Welcome and Introduction**
  B Coiffier, Centre Hospitalier Lyon Sud, Pierre-Benite, France
- **DLBCL upfront treatments – What have we learned from recent trials**
  G Nowakowski, Mayo Clinic, Rochester, United States
- **Progressive disease - Treatment standards and goals**
  G Hess, Johannes Gutenberg University, Mainz, Germany
- **Changing treatment landscape in R/R DLBCL – Novel targets and new strategies**
  W Jurczak, Jagiellonian University, Krakow, Poland

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Hall A

THE EVOLVING ART OF TREATING MULTIPLE MYELOMA

Chair 1: M Attal, L'Université Toulouse Capitole, Toulouse, France
Chair 2: F Davies, UAMS Myeloma Institute, Little Rock, United States

PROGRAM

- **Welcome and introduction**
  M Attal, L'Université Toulouse Capitole, Toulouse, France
  F Davies, UAMS Myeloma Institute, Little Rock, United States
- **Depicting the nature of long remissions**
  B Paiva, Universidad de Navarra, Pamplona, Spain
- **The renaissance of maintenance after transplant**
  M Attal, L'Université Toulouse Capitole, Toulouse, France
- **The modern art of treating patients when transplant is not an option**
  G Jackson, Newcastle University, Newcastle, United Kingdom
- **"But is it art?" A post-modern approach to managing relapse**
  F Davies, UAMS Myeloma Institute, Little Rock, United States
- **Closing remarks**
  M Attal, L'Université Toulouse Capitole, Toulouse, France
  F Davies, UAMS Myeloma Institute, Little Rock, United States

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Hall B

THE WHEN, WHY AND HOW OF MANAGING YOUR CLL PATIENTS: CLARITY IN A CHANGING ENVIRONMENT

Chair: F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

PROGRAM

- **Welcome & Introduction**
  F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain
- **Patient assessment: Optimising the stratification of patients with CLL**
  P Ghia, Università Vita-Salute San Raffaele, Milano, Italy
- **Optimizing outcomes: Options for previously untreated CLL**
  S Coutre, Stanford University School of Medicine, Stanford, CA, United States
- **Optimizing outcomes: Selecting our strategy for patients with relapsed CLL**
  P Hillmen, St James's University Hospital, Leeds, United Kingdom
- **Practical management considerations in the era of novel agents**
  G Follows, Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
- **Summary and Close**
  F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Hall C

RECENT ADVANCES IN MPNS

Chair: F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain

PROGRAM

- **Welcome**
  F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain
- **Recent Updates in the Diagnosis and Prognosis of MPNs**
  H Kvasnicka, Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, Germany
- **Current Treatment Landscape in Myelofibrosis**
  F Passamonti, University of Insubria, Varese, Italy
- **Recent Updates in the Treatment of Polycythemia Vera**
  S Verstovsek, The University of Texas MD Anderson Cancer Center, Houston, United States
- **JAK Inhibitors in the Transplant Setting**
  P Laneuville, McGill University Health Centre and Research Institute, Montreal, Canada
- **Summary and Q&A**
  F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain
- **Closing Remarks**
  F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain

Bristol-Myers Squibb

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Hall D

A LOOK AHEAD: THE NEXT CHAPTER OF IMMUNO-ONCOLOGY RESEARCH IN HEMATOLOGIC MALIGNANCIES

Chair: I Borrello, Johns Hopkins School of Medicine, Baltimore, Maryland, United States

PROGRAM

- **Welcoming Remarks**
  I Borrello, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- **Behind the Science: A Primer on Immuno-Oncology in Hematology**
  I Borrello, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- **Current Perspectives and Future Possibilities of Immuno-Oncology in Multiple Myeloma**
  N Van De Donk, VU University Medical Center, Amsterdam, the Netherlands
- **Immuno-Oncology as a Treatment Option for Lymphoma**
  P Borchmann, University Hospital of Cologne, Cologne, Germany
- **Making Headway with Immuno-Oncology Research in Acute Myeloid Leukemia**
  N Daver, MD Anderson Cancer Center, Houston, Texas, United States
- **Open Discussion with the Experts and Closing Remarks**
  I Borrello, Johns Hopkins School of Medicine, Baltimore, MD, United States

NOVARTIS

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Room N101

MANAGING SAFETY OF INVESTIGATIONAL CAR T-CELL THERAPIES IN LEUKEMIAS AND LYMPHOMAS

Chair: U Jäger, Medical University of Vienna, Vienna, Austria

PROGRAM

- **Opening remarks**
  U Jäger, Medical University of Vienna, Vienna, Austria
- **Safety and efficacy of anti-CD19 therapies: Acute lymphoblastic leukemia**
  S Rives, Hospital Sant Joan de Déu, Madrid, Spain
- **Safety and efficacy of anti-CD19 therapies: Non-Hodgkin lymphoma**
  P Corradini, University of Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- **Differences in safety management algorithms**
  S Maude, Children's Hospital of Philadelphia, Philadelphia, United States
- **Biomarkers for the prediction of safety profiles**
  S Maude, Children's Hospital of Philadelphia, Philadelphia, United States
- **Long term patient management after investigational CAR therapy**
  U Jäger, Medical University of Vienna, Vienna, Austria
- **Panel discussion**
- **Closing remarks**
  U Jäger, Medical University of Vienna, Vienna, Austria

Takeda ONCOLOGY

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Room N105

CONTINUOUS THERAPY IN MULTIPLE MYELOMA: ON TARGET WITH PROTEASOME INHIBITION

Chair: P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States

PROGRAM

- **Chair's Welcome and Introduction**
  P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States
- **Targeting the plasma cell: rationale for proteasome inhibition in multiple myeloma**
  S Lonial, Winship Cancer Institute, Atlanta, GA, United States
- **Continuous therapy as a treatment paradigm**
  E Terpos, University of Athens School of Medicine, Athens, Greece
- **TOURMALINE-MM1: the role of ixazomib in relapsed/refractory multiple myeloma**
  P Moreau, University Hospital Hôtel Dieu, Nantes, France
- **Clinical decision making in relapsed/refractory multiple myeloma**
  P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States
- **Panel discussion and Q&A**
  All
- **Summary and close**
  P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States

Jazz Pharmaceuticals®

→ SATELLITE SYMPOSIUM
10:45 - 12:45, Room N103

RAISING THE BAR: NEW MANAGEMENT AND TREATMENT IN ACUTE LEUKEMIAS

Chair: H Döhner, University Hospital Ulm, Ulm, Germany

PROGRAM

- **Welcome**
  H Döhner, University Hospital Ulm, Ulm, Germany
- **The latest movement: What's new in the management and treatment of Acute Lymphoblastic Leukemia?**
  N Boissel, Assitance Publique – Hôpitaux de Paris, France
- **New players in the treatment of Acute Myeloid Leukemia: Are we improving treatment?**
  N Russell, University of Nottingham, Nottingham, United Kingdom
- **Setting the tone: Managing challenging patients with Acute Myeloid Leukemia – case study overview**
  G Roboz, Weill Medical College of Cornell University, New York, United States
  H Döhner, University Hospital Ulm, Ulm, Germany
- **Close**
  H Döhner, University Hospital Ulm, Ulm, Germany

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Hall B

MULTIPLE MYELOMA: CHANGING THE PRESENT, CREATING THE FUTURE

Chair 1: P Moreau, University Hospital of Nantes, Nantes, France
Chair 2: X De La Rubia, University Hospital Doctor Peset, Valencia, Spain

PROGRAM

- **Welcome & Introduction**
  X De La Rubia, University Hospital Doctor Peset, Valencia, Spain
- **Current considerations for transplant eligible patients and possible impact of immunotherapy in patient management**
  M Cavo, University School of Medicine, Bologna, Italy
- **Current and future considerations for transplant ineligible newly-diagnosed myeloma**
  S Zweegman, VU University Medical Center, Amsterdam, the Netherlands
- **A revolution in therapy for patients with relapsed refractory MM ? A focus on CD38 monoclonal antibodies**
  M Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
- **When advancements in science meet patients**
  A Aguarón, Madrid, Spain
- **Translating evidence into tomorrow´s practice**
  P Moreau, University Hospital of Nantes, Nantes, France

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Hall C

EMERGING TRENDS IN CHRONIC MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA

Chair 1: H Döhner, Universitätsklinikum Ulm, Ulm, Germany
Chair 2: G Saglio, University of Turin, Orbassano, Italy

PROGRAM

- **Welcome and Opening Remarks**
  G Saglio, University of Turin, Orbassano, Italy
- **TFR and the Future of CML Treatment**
  G Saglio, University of Turin, Orbassano, Italy
- **Molecular Monitoring in the Setting of Deep Molecular Response and TFR**
  S Branford, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia
- **From Diagnosis to Remission: The Patient Journey**
  R Christensen, Lyle – Patientorganization for lymphoma, leukemia and MDS, Zealand, Denmark
- **CML Panel Discussion & Audience Questions**
  G Saglio, University of Turin, Orbassano, Italy
- **Current Recommendations for Genetic Testing in AML**
  H Döhner, Universitätsklinikum Ulm, Ulm, Germany
- **The Role of Genomics and Identifying Co-Mutations in Predicting Outcomes in AML**
  E Papaemmanuil, Memorial Sloan Kettering Cancer Center, New York, United States
- **AML Panel Discussion & Audience Questions**
  H Döhner, Universitätsklinikum Ulm, Ulm, Germany
- **Closing Remarks**
  H Döhner, Universitätsklinikum Ulm, Ulm, Germany

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Hall D
This scientific symposium has been organised and funded by Celgene

INNOVATION TODAY, TREATMENTS TOMORROW: TAILORING TREATMENT STRATEGIES FOR MYELOID MALIGNANCIES

Chair: G Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

PROGRAM

- **Welcome and introduction**
  G Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
- **A genomic portrait of lower-risk MDS by the European MDS Registry**
  A de Graaf, Radboud University Medical Centre, Nijmegen, the Netherlands
- **Linking progress in our understanding of MDS to an innovative treatment approach**
  A Giagounidis, Marien Hospital Düsseldorf, Düsseldorf, Germany
- **Can the mutational landscape of AML inform targeted treatment?**
  C Craddock, Queen Elizabeth Hospital, Birmingham, United Kingdom
- **A review of existing and emerging treatments for older patients with AML**
  A Schuh, Princess Margaret Cancer Centre, Toronto, Canada
- **Closing remarks**
  G Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Job Bag: UK-CELG170059j
Job Bag: INT-CELG170027
Date of preparation: April 2017

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Room N101

LEADING TOWARDS OPTIMIZING THE TREATMENT OF ITP AND NEW TREATMENT STRATEGIES IN SAA AND MDS

Chair: J Bussel, Weill Cornell Medical College, New York, United States

PROGRAM

- **Welcome and introduction from the Chair**
  J Bussel, Weill Cornell Medical College, New York, United States
- **Where we are now: Current treatment strategies for patients with ITP**
  J Bussel, Weill Cornell Medical College, New York, United States
- **The road ahead: Considerations for long-term treatment of ITP patients with TPO-R agonists**
  J Bussel, Weill Cornell Medical College, New York, United States
- **Striding towards the future: Recent advances in the treatment of patients with SAA**
  P Scheinberg, Division of Clinical Hematology, Antônio Ermírio de Moraes Cancer Center, Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
- **Stop, start, continue? Practical guidance on the use of TPO-R agonists in patients with SAA**
  P Scheinberg, Division of Clinical Hematology, Antônio Ermírio de Moraes Cancer Center, Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
- **Taking the next step: Addressing unmet supportive care needs in patients with MDS**
  M Mittelman, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- **Panel discussion/Q&A**
  J Bussel, Weill Cornell Medical College, New York, United States
- **Summary and close from Chair**
  J Bussel, Weill Cornell Medical College, New York, United States

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Room N105

UNMET NEED IN THE MANAGEMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA: WHERE DO WE GO FROM HERE?

Chair: J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

PROGRAM

- **Welcome and introductions**
  Problem statement: What are the key issues in treating advanced-stage Hodgkin lymphoma?
  J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
- **Current treatment landscape: A focus on ABVD**
  P Brice, Hôpital Saint-Louis, Paris, France
- **Current treatment landscape: A focus on BEACOPP**
  P Borchmann, University Hospital of Cologne, Cologne, Germany
- **Managing risk in advanced-stage Hodgkin lymphoma**
  C Moskowitz, Memorial Sloan-Kettering Cancer Center, New York, United States
- **Future prospects: Where do we go from here?**
  J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
- **Panel discussion and Q&A session:**
  Beyond the current treatment paradigm: What does the future hold for advanced-stage Hodgkin lymphoma?
  All
- **Conclusions and meeting close**
  J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Room N103

AIMING HIGHER IN ADULT ALL: NOVEL THERAPIES AND TREATMENT STRATEGIES

Chair: J M Hernández, Universidad de Salamanca-CSIC, Salamanca, Spain

PROGRAM

- **Welcome and introduction**
  J M Hernández, Universidad de Salamanca-CSIC, Salamanca, Spain
- **Modern approaches to frontline management of adult ALL**
  N Boissel, Saint-Louis Hospital, Paris, France
- **Novel therapies for the treatment of adult patients with relapsed/refractory B-ALL**
  A Rambaldi, University of Milan, Bergamo, Italy
- **Improving survival and quality of life in adult relapsed/refractory B-ALL**
  M Topp, University of Wurzburg, Wurzburg, Germany
- **Ongoing challenges and future perspectives**
  D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany

→ SATELLITE SYMPOSIUM
13:30 - 15:30, Room N104

DEFINING TREATMENT STRATEGIES FOR CLL AND FL IN THE ERA OF TARGETED THERAPIES: EVIDENCE AND EXPERIENCE

Chair 1: U Jäger, Medical University of Vienna, Vienna, Austria
Chair 2: F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

PROGRAM

- **Welcome, introduction and overview of agenda**
  U Jäger, Medical University of Vienna, Vienna, Austria
  F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain
- **Treatment choice in CLL: What does the evidence tell us?**
  F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain
- **Treatment choice in FL: What does the evidence tell us?**
  W Hiddemann, Ludwig-Maximilians University, Munich, Germany
- **How do we achieve optimal sequencing of therapies in CLL?**
  L Ysebaert, The Cancer University Institute of Toulouse, Toulouse, France
- **How does our understanding of signaling pathways inform treatment decisions?**
  P Ghia, San Raffaele Scientific Institute, Milan, Italy
- **Real-world patient management: Case studies in double-refractory FL**
  A Isidori, Marche Nord Hospital, Pesaro, Italy
- **Real-world patient management: Case studies in CLL**
  T Munir, St. James's University Hospital, Leeds, United Kingdom
- **How I manage patients in my practice**
  U Jäger, Medical University of Vienna, Vienna, Austria
- **Conclusions and close**
  U Jäger, Medical University of Vienna, Vienna, Austria
  F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

→ SATELLITE SYMPOSIUM
16:15 - 18:15, Hall C

RELAPSED/REFRACTORY CLL: HOW FAR HAVE WE COME, AND WHERE WILL WE GO NEXT

Chair: F Bosch, University hospital Vall d'Hebron, Barcelona, Spain

PROGRAM

- **Welcome and introduction**
  F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Here and now: Current approaches with targeted agents in relapsed/refractory CLL**
  F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Treatment in practice: Sequencing of targeted therapy**
  F Cymbalista, Hôpital Avicenne, Bobigny, France
- **Roundtable discussion: Implementing the new targeted treatment paradigm**
  F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Evolution of therapy for relapsed/refractory CLL: Emerging regimens and agents**
  P Hillmen, St James's University Hospital, Leeds, United Kingdom
- **Future goals of treatment: Finite duration as a desirable goal**
  P Ghia, Università Vita, Milan, Italy
- **Roundtable discussion: What does the future hold for patients with relapsed/refractory CLL?**
  F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Q&A**
- **Closing comments**
  F Bosch, University hospital Vall d'Hebron, Barcelona, Spain

→ SATELLITE SYMPOSIUM
16:15 - 18:15, Hall D

SHIFTING TREATMENT PARADIGMS IN NON-HODGKIN LYMPHOMA

Chair: D Caballero, University Hospital, Salamanca, Spain

PROGRAM

- **Welcome and introduction**
  D Caballero, University Hospital, Salamanca, Spain
- **Follicular lymphoma: strategies in the era of new targeted therapies**
  D Caballero, University Hospital, Salamanca, Spain
- **Shaping treatment approaches in DLBCL using molecular subtyping**
  U Vitolo, University Hospital, Turin, Italy
- **Mantle cell lymphoma: evolving treatment strategies**
  M Dreyling, University Hospital Grosshadern, Munich, Germany
- **The emerging role of checkpoint inhibitors in NHL**
  R Houot, University Hospital, Rennes, France
- **Closing remarks**
  D Caballero, University Hospital, Salamanca, Spain

→ SATELLITE SYMPOSIUM
16:15 - 18:15, Hall E

NAVIGATING THE TREATMENT CONTINUUM IN MULTIPLE MYELOMA

Chair: A Oriol, Hospital German Trias i Pujol, Barcelona, Spain

PROGRAM

- **Putting the patient first – Optimised treatment strategies**
  N Raje, Massachusetts General Hospital, Boston, United States
- **Facing disease relapse – Tailored treatment options**
  K Yong, University College London, London, United Kingdom
- **Holistic patient care with impact on treatment outcome**
  E Terpos, University of Athens, Athens, Greece
- **Interactive panel discussion**
  All faculty
- **Conclusion and closing**
  A Oriol, Hospital German Trias i Pujol, Barcelona, Spain

→ SATELLITE SYMPOSIUM
16:15 - 18:15, Room N101

EXPERT GUIDES IN AML: EXPLORING CURRENT CHALLENGES AND FUTURE DIRECTIONS TO OPTIMISE PATIENT OUTCOMES

Chair: W Hiddemann, Ludwig-Maximilians University, Munich, Germany

PROGRAM

- **Welcome and introduction**
  W Hiddemann, Ludwig-Maximilians University, Munich, Germany
- **The Journey So Far: The Research Pathway to Our Current Standard of Care**
  W Hiddemann, Ludwig-Maximilians University, Munich, Germany
- **Challenges in Our Way: Novel Prognostic Markers in AML**
  J Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- **Choosing a Path: How to Guide Treatment in AML**
  A Venditti, Tor Vergata University, Rome, Italy
- **Identifying New Routes: Molecular Characterisation of AML to Inform Future Research**
  H Serve, University Hospital Frankfurt, Germany
- **Panel discussion and close**
  W Hiddemann, Ludwig-Maximilians University, Munich, Germany
  All

→ SATELLITE SYMPOSIUM
16:15 - 18:15, Room N105

PATIENTS IN FOCUS: WHAT´S RELEVANT FOR CML AND PH+ALL?

Chair 1: MB Baccarani, University of Bologna, Bologna, Italy
Chair 2: EO Olavarria, Imperial College, London, United Kingdom

PROGRAM

- **The evolving role of molecular monitoring**
  HDL De Lavallade, King's College Hospital, London, United Kingdom
- **Factors affecting clinical decision making in refractory and relapsed CP-CML patients**
  DR Rea, Hôpital Saint-Louis, Paris, France
- **Current Challenges, New Insights and Future Directions in Ph+ALL**
  GM Martinelli, University of Bologna, Bologna, Italy
- **Closure**
  EO Olavarria, Imperial College London, London, United Kingdom

abbvie

→ SATELLITE SYMPOSIUM
16:15 – 18:15, Room N103

EMERGING NOVEL AGENTS FOR AML: ARE WE ON THE THRESHOLD OF A TRANSFORMATION IN THERAPY?

Chair: H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

PROGRAM

- **Chair's welcome**
  H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- **Improving the efficacy and safety of AML therapy**
  H Döhner, University Hospital of Ulm, Ulm, Germany
- **Molecular biology of AML and implications for therapy**
  G Roboz, Weill Medical College of Cornell University, New York, New York, United States
- **Emerging novel agents for AML therapy**
  H Kantarjian,The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- **Treating the AML patient with less intensive therapy – evolving options**
  L Adès, St Louis Hospital, University of Paris, Paris, France
- **Panel discussion and Q&A**
  All
- **Chair's summary and close**
  H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

ALEXION

→ SATELLITE SYMPOSIUM
16:15 - 18:15, Room N104

THROMBOSIS IN COMPLEMENT-MEDIATED DISEASES

Chair: B Kemkes-Matthes, University of Giessen, Giessen, Germany

PROGRAM

- **Welcome and Introduction: Overview of Thrombosis in complement-mediated disease**
  B Kemkes-Matthes, University of Giessen, Giessen, Germany
- **The Path to Thrombosis through Complement**
  C Schmidt, University of Ulm, Ulm, Germany
- **Complement-Mediated Diseases in Hematology**
  S Zeerleder, University of Amsterdam, Amsterdam, the Netherlands
- **Paroxysmal Nocturnal Hemoglobinuria: – "The Most Vicious Thrombophilic State*"**
  A Hill, University of Leeds, Leeds, United Kingdom
- **Conclusion and Q&A**
  B Kemkes-Matthes, University of Giessen, Giessen, Germany

(*Luzzatto L, et al. Haematologica 2010)

→ SATELLITE SYMPOSIUM
19:00 – 21:00, Hall D

TARGETING THE FLT-3 PATHWAY IN AML: EVOLUTION OF NEXT GENERATION TYROSINE KINASE INHIBITORS

Chair: H Döhner, University Hospital of Ulm, Germany

PROGRAM

- **Welcome**
  H Döhner, University Hospital of Ulm, Ulm, Germany
- **Biology of FLT-3, FLT-3 mutations and the mutational spectrum**
  S Meshinchi, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
- **Clinical spectrum of FLT-3 positive AML**
  R Schlenk, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany
- **Activity of single-agent crenolanib in FLT-3 positive AML**
  J Cortes, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- **Activity of crenolanib with induction chemotherapy in FLT-3 positive AML**
  E Wang, Roswell Park Cancer Institute, Buffalo, New York, United States
- **Activity of crenolanib with salvage chemotherapy in relapsed/refractory FLT-3 positive AML**
  R Stone, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- **Conclusion and wrap up**
  H Döhner, University Hospital of Ulm, Ulm, Germany

→ SATELLITE SYMPOSIUM
19:00 - 21:00, Hall E

NEW HORIZONS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA

JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel

PROGRAM

- **Welcome**
  JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel
- **Introduction: Recent Developments in the Treatment of AML**
  JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel
- **Q&A**
- **Defining key targets for therapy in AML: Lessons from gene expression and molecular pathway activation patterns**
  F Lo Coco, University Tor Vergata Rome, Italy
- **Q&A**
- **How tyrosine kinase inhibitors may affect primary AML blasts: outcomes in R/R AML**
  M Sanz, Universitario y Politécnico La Fe Valencia, Valencia, Spain
- **Q&A**
- **Panel discussion**
  Moderator: JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel
- **Wrap-up & Adjourn**
  JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel

→ SATELLITE SYMPOSIUM
19:00 - 21:00, Room N101

GETTING PERSONAL; INDIVIDUALISING THERAPY IN CML

Chair: G Rosti, Department of Hematology and Oncology. St Orsola University Hospital, Bologna, Italy

PROGRAM

- **Improving long-term outcomes; Maximizing efficacy in second line and beyond**
  G Rosti, Department of Hematology and Oncology. St Orsola University Hospital, Bologna, Italy
- **Choosing the right TKI for patients; Treatment options focusing on an optimal QOL**
  T Brümmendorf, Euregionales Comprehensive Cancer Center Aachen, Aachen, Germany
- **Treatment outcomes; Data from the real world**
  J Apperley, Hammersmith Hospital, London, United Kingdom
- **Future perspectives; Is there an unmet need in CML?**
  LF Casado, Hospital Virgen De La Salud, Toledo, Spain

→ SATELLITE SYMPOSIUM
19:00 - 21:00, Room N105

A NEW PRACTICAL TOOL TO HELP IDENTIFY GAUCHER DISEASE: ACCELERATING DIAGNOSIS AND IMPROVING LONG-TERM OUTCOMES FOR PATIENTS

Chair 1: A Mehta, Royal Free Hospital, London, United Kingdom
Chair 2: D Kuter, Center for Hematology, Massachusetts General Hospital, Boston, United States

PROGRAM

- **A rare heterogeneous disease: What do I need to know?**
  A Mehta, Royal Free Hospital, London, United Kingdom
- **The many faces of Gaucher: Challenging case studies**
  A Mehta, Royal Free Hospital, London, United Kingdom
  D Kuter, Center for Hematology, Massachusetts General Hospital, Boston, United States
- **A new diagnostic tool for clinical practice**
  A Mehta, Royal Free Hospital, London, United Kingdom
  D Kuter, Center for Hematology, Massachusetts General Hospital, Boston, United States

→ SATELLITE SYMPOSIUM
19:00 - 21:00, Room N103
This educational activity is supported by a grant from Shire.

CURRENT STATE-OF-THE-ART AND FUTURE STRATEGIES IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany

PROGRAM

- **Welcome, introduction, and quiz questions**
  D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany
- **Diagnosis and risk assessment of acute lymphoblastic leukemia in 2017**
  D I Marks, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
- **Making the most of induction therapy in ALL**
  D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany
- **MRD and risk-adapted post-remission therapy**
  R Foà, University of Rome, Rome, Italy
- **New strategies for relapsed/refractory ALL**
  M Topp, University of Würzburg, Würzburg, Germany
- **Conclusion and key points**
  D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany

→ SATELLITE SYMPOSIUM
19:00 - 21:00, Room N104

THE 1ST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE

Chair: B Coiffier, University of Lyon-1, Hospicos Civils de Lyon, Lyon, France

PROGRAM

- **Welcome and introduction: perceptual evolution on biosimilar**
  B Coiffier, University of Lyon-1, Hospicos Civils de Lyon, Lyon, France
- **Reducing budgets, increasing access**
  L Gulácsi, Corvinus University of Budapest, Budapest, Hungary
- **The rationale of biosimilarity**
  J Gonçalves, University of Lisboa, Lisboa, Portugal
- **Clinical evidence of biosimilar rituximab**
  C Buske, University of Ulm, Ulm, Germany
- **Biosimilar in oncology: yesterday, today and a look ahead**
  Moderator: B Coiffier, University of Lyon-1, Hospicos Civils de Lyon, Lyon, France

At **TAKEDA ONCOLOGY,** we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

We've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we've made great strides in our fight against cancer, we are determined to do more – to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.

We know that our mission is not a quick or simple one, but we are up for the task:
we aspire to cure cancer.

JOIN US IN BOOTH #630
Make a wish to make a difference for cancer patients.

Takeda
ONCOLOGY

To learn more, visit us at ***takedaoncology.com.***
@TakedaOncology

FRIDAY, JUNE 23

SPECIAL SESSIONS OF THE DAY

Next to the high quality scientific and education sessions of the day we would like to draw your attention to the following interesting sessions:

→ EDUCATION SESSION 3 5 T C
08:00 - 09:30, Hall A
Repeat Session:
Saturday, June 24, 09:45 - 11:15, Hall A

NEW APPROACHES TO INDOLENT LYMPHOMA

Chair: P Brice (Hopital Saint Louis, Paris, France)

- **Molecular profiling of indolent lymphoma**
  S Pileri (European Institute of Oncology, Milan, Italy)
- **Update on follicular lymphoma: Time beyond chemotherapy?**
  K Hübel (University of Cologne, Germany)
- **Treatment of extranodal marginal zone B-cell lymphomas**
  M Raderer (Medical University Vienna, Austria)

LEARNING GOALS

S Pileri

After attending this lecture, the participant will be able to

– Describe the molecular characteristics of the main varieties of indolent lymphoma.
– Discuss how they can impact on the prognosis and therapy in the present era of precision medicine.

K Hübel

After attending this lecture, the participant will be able to

– Understand requirements for a chemotherapy-free approach in Follicular Lymphoma.
– Recognize the potential of existing and emerging therapeutics in the management of Follicular Lymphoma.
– Assess critically the benefits and risks of common cytotoxic regimens versus targeted therapies in different lines of treatment.

M Raderer

After attending this lecture, the participant will be able to

– Eradication of Helicobacter pylori remains the preferred first-line therapy in patients with gastric MALT lymphoma.
– Also patients with HP-negative gastric MALT lymphoma may also be managed with (clarithromycin-based) antibiotic therapy.
– Antibiotic therapy can also be given in patients with ocular adnexal MALT-lymphomas as sole initial management.
– Both systemic treatment as well as radiotherapy appear to have curative potential in localised disease.

→ EDUCATION SESSION 2 5 T C
08:00 - 09:30, Hall B
Repeat Session:
Friday, June 23, 09:45 - 11:15, Hall B

MYELOPROLIFERATIVE NEOPLASMS

Chair: J Samuelsson (Karolinska Institute, Stockholm, Sweden)

- **Molecular genetics in MPN**
  AM Vannucchi (University of Florence, Italy)
- **Targeting specific mutations in MPN**
  A Mullally (Brigham and Women's Hospital, Boston, USA)
- **Emerging treatments for classical myeloproliferative neoplasms**
  C Harrison (Guys and St Thomas' NHS Foundation Trust, London, United Kingdom)

LEARNING GOALS

AM Vannucchi

After attending this lecture, the participant will be able to

– Describe current status of mutation landscape in patients with myeloproliferative neoplasms (MPN).
– Describe the key role of driver mutations in the revised 2016 WHO diagnostic criteria of MPN.
– Discuss the prognostic relevance of driver and non-driver mutations for patients with myelofibrosis.

A Mullally

After attending this lecture, the participant will be able to

– Summarize the key molecular driver mutations in MPN.
– Describe the development and use of JAK2 inhibitors in MPN.
– Describe investigational approaches focused on enhancing the clonal selectivity of MPN therapies.

C Harrison

After attending this lecture, the participant will be able to

– Appreciate the importance of an accurate diagnosis of specific MPN.
– Select an appropriate prognostic score for their patient and understand how these may be changing during the coming years.
– Discuss pros and cons of conventional treatment options for MPN patients in particular the emerging story with regard to HU and IFN.
– Understand the different efficacies of JAK inhibitors and the potential other emerging therapies for MPN patients.

→ SCIENTIFIC WORKING GROUPS 3 5 10 T C
08:30 - 09:30, Hall C

MULTIPLE MYELOMA: NOVEL DEVELOPMENTS IN MYELOMA AND RELATED DISEASES

Chair: M Kaiser (The Institute of Cancer Research & Royal Marsden Hospital, London, United Kingdom)

- **Treatment and sequence in relapsed and refractory multiple myeloma**
  X Leleu (CHU La Milétrie, Poitiers, France)
- **Should imaging be part of MRD?**
  E Zamagni (Seragnoli Institute of Hematology, Bologna, Italy)
- **Novel approaches in AL-Amyloidosis**
  G Palladini (University of Pavia, Italy)
- **Is NGS of value for clinical practice?**
  KM Kortüm (University Hospital, Würzburg, Germany)

LEARNING GOALS

X Leleu

After attending this lecture, the participant will be able to

– Describe current and emerging therapies for RRMM.

- Describe objectives and concepts of treatment in the RRMM setting.
- Understand early versus late relapse.
- Understand relapsed versus relapsed refractory, versus primary refractory.
- Understand high risk versus standard risk.

E Zamagni
After attending this lecture, the participant will be able to
- Be aware of the new response criteria for multiple myeloma as stated by the international myeloma working group.
- Understand the different methods for minimal residual disease evaluation after treatment, both inside and outside the bone marrow, with a particular focus on imaging techniques.
- Discuss pros and cons of each methods, timing and availability.

G Palladini
After attending this lecture, the participant will be able to
- Describe current and emerging therapy for patients with AL amyloidosis.
- Select appropriate upfront therapy based upon risk stratification.
- Monitor response to treatment with clonal and organ markers.

KM Kortüm
After attending this lecture, the participant will be able to
- Identify patients that might benefit from NGS testing.
- Understand the limits and chances of current clinically oriented NGS testing in MM.

→ EDUCATION SESSION 3 9 10 **T C**
08:00 - 09:30, Hall D
Repeat Session:
Friday, June 23, 09:45 - 11:15, Hall D

ACUTE LYMPHOBLASTIC LEUKEMIA: THE WORST AND THE BEST

Chair: R Pieters (Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands)

- **Balancing efficacy and toxicity in the treatment of childhood ALL**
  A Vora (Great Ormond Street Hospital, London, United Kingdom)
- **Immunotherapy for ALL: From biology to the clinic and back**
  T Fry (Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, USA)
- **Novel approaches with recently licensed drugs or recently studied in relapsed ALL**
  JM Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

LEARNING GOALS

A Vora
After attending this lecture, the participant will be able to
- Describe the burden of toxicity of treatment for childhood ALL.
- Discuss risk stratification for childhood ALL.
- Select treatment that provides optimal efficacy with minimal toxicity based on leukaemia phenotype, genotype and treatment response.

T Fry
After attending this lecture, the participant will be able to
- Describe the clinical activity and limitations of CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in pediatric malignancies.
- Differentiate between and explain the patterns of failure following CD19 CAR T cells.
- List possible approaches to improve durability of remission following CAR T cell therapy for acute lymphoblastic leukemia.

JM Ribera
After attending this lecture, the participant will be able to
- Although ALL is highly curable with conventional chemotherapy, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL, especially in adults.
- Immunotherapeutic approaches have significantly improved the outcome of R/R ALL patients and are currently tested in early phases of the disease.
- Targeted therapy combined with conventional chemotherapy and/or immunotherapy can provide promising results in some specific subtypes of ALL.

→ EDUCATION SESSION 4 **B T C**
08:00 - 09:30, Hall E
Repeat Session:
Saturday, June 24, 08:00 - 09:30, Room N101

STEM CELL TRANSPLANTATION - GVHD

Chair: N Kröger (University Medical Center Hamburg-Eppendorf, Germany)

- **The role of the intestinal microbiota in graft-versus-host disease**
  R Zeiser (Freiburg University Medical Center, Germany)
- **The role of intestinal flora in patients undergoing allogeneic hematopoietic stem cell transplantation**
  M van den Brink (Memorial Sloan Kettering Cancer Center, New York, USA)
- **Balancing Graft versus Leukemia and Graft versus Host responses**
  JHF Falkenburg (Leiden University Medical Center, the Netherlands)

LEARNING GOALS

R Zeiser
After attending this lecture, the participant will be able to
- Describe emerging molecular therapies for steroid refractory GVHD.
- Discuss novel concepts on the role of neutrophils in GVHD.
- Understand the basic principles of GVHD biology.

M van den Brink
After attending this lecture, the participant will be able to
- Describe the major changes observed in the intestinal microbiota of patients undergoing that are associated with graft-vs-host disease and transplant-related mortality.
- Recapitulate the impact of antibiotic therapy, broad- vs narrow-spectrum antibiotic, on clinical outcomes in allogeneic

hematopoietic stem cell transplantation (allo-HSCT) patients.
– Discuss current and putative future options for gut microbiota interventions to increase survival and gastrointestinal health in patients undergoing allo-HSCT.

JHF Falkenburg
After attending this lecture, the participant will be able to
– Understand the different nature of allo-immune T cell responses following HLA matched and HLA mismatched stem cell transplantation.
– Estimate the likelihood of developing selective GVL responses after allogeneic stem cell transplantation.
– Understand how post-transplant circumstances and interventions influence the balance between GVL and GVHD.

→ MOLECULAR HEMOPOIESIS WORKSHOP
08:00 - 11:15, Room N101
Organizer: S Fröhling (National Center for Tumor Diseases, Heidelberg, Germany)

PART 1: SIGNALLING
2 B

Chair: V Sexl (Pharmacology and Toxicology, Vienna, Austria)
- **JAK-STAT signaling in myeloproliferative neoplasms**
  A Mullally (Brigham and Women's Hospital, Boston, USA)
- **Inflammatory cell death in AML**
  P Jost (TU München, Germany)
- **Molecular signaling in CLL**
  M Hallek (University Hospital of Cologne, Germany)
- **Exploring and exploiting aberrant cell fate programs in leukemia**
  J Zuber (Research Institute of Molecular Pathology (IMP), Vienna, Austria)

LEARNING GOALS

A Mullally
After attending this lecture, the participant will be able to
– Understand the mechanism by which mutant calreticulin is oncogenic.
– Understand the aberrant signal transduction pathway activation that occurs as a result of mutations in calreticulin in MPN.

P Jost
After attending this lecture, the participant will be able to
– Understand the relevance of inflammatory cell death for AML blast cell survival.
– Describe the role of TNF signaling in FLT3-ITD AML.
– Define the expression levels of RIPK3 in primary de novo FLT3-ITD AML.

M Hallek
An up-to-date program is available via the mobile app.

J Zuber
After attending this lecture, the participant will have learned
– How genetically engineered AML mouse models, in-vivo transcriptomics and focused genetic screens can aid drug target discovery.
– How common gene regulatory programs maintain aberrant LSC self-renewal downstream of disease-defining mutations in AML.
– How genome-wide CRISPR/Cas9-screens can be used to decipher synthetic-lethal dependencies.

PART 2: HEMATOPOIETIC STEM CELLS & THEIR NICHE
2 3 5 B T

Chair: J Schwaller (University Children's Hospital Basel, Switzerland)
- **Single cell functional and transcriptional analysis of normal primary human lympho-myeloid progenitors**
  P Vyas (Weatherall Institute of Molecular Medicine, Oxford, United Kingdom)
- **DNMT3A mutations enhance CpG ,utagenesis through deregulation of the active DNA demethylation pathway**
  M Sanders (Erasmus Medical Center, Rotterdam, the Netherlands)
- **Maintenance of tissue resident macrophages during tissue repair and aging**
  E Gomez Perdiguero (Institut Pasteur, Paris, France)
- **Multicolor quantitative imaging cytometry of bone and marrow**
  T Schroeder (ETH Zurich, Basel, Switzerland)

LEARNING GOALS

P Vyas
After attending this lecture, the participant will be able to
– How are normal haemopoietic progenitors purified?
– What are the assays of haemopoietic progenitor function?
– How are transcriptional signatures identified and how do they correlate with function?

M Sanders
After attending this lecture, the participant will be able to
– Describe the elements involved in active DNA demethylation and understand their dynamic interplay.
– Describe which genetic lesions, commonly observed in clonal hematopoiesis and myeloid malignancies, impact this pathway and their repercussion on DNA methylation dynamics.
– Discuss the etiology of these preleukemic mutations and their significance for leukemic development.

E Gomez Perdiguero
After attending this lecture, the participant will be able to
– Understand current challenges when studying tissue macrophages
– Understand different methods available for characterising the developmental origin of myeloid cells.
– Discuss potential implication of ontogeny into macrophage functions.

T Schroeder
After attending this lecture, the participant will be able to
– Current state of the art and remaining challenges in quantitative 3D bone marrow imaging.
– Update on latest insights into hematopoietic stem and progenitor cell bone marrow niche.

PART 3: TRANSCRIPTIONAL AND EPIGENETIC REGULATION

1 2 3 5 10 **B** **T**

Chair: O Abdel-Wahab (Memorial Sloan Kettering Cancer Center, New York, USA)

- **Discovery and functional characterization of long non-coding RNAs in acute myeloid leukemia**
  C Lobry (Institut Gustave Roussy / INSERM, Villejuif, France)
- **Hedgehog-Gli signaling in bone marrow fibrosis**
  R Schneider (Erasmus MC, Rotterdam, the Netherlands)
- **Insights into hematopoiesis using single-cell transcriptomics**
  O Kilpivaara (University of Helsinki, Finland)
- **Delineating and targeting cancer-specific chromatin vulnerabilities in T cell leukemia**
  P Ntziachristos (Feinberg School of Medicine, Northwestern University, Chicago, USA)

LEARNING GOALS

C Lobry

After attending this lecture, the participant will be able to
- Understand basic biology of long non-coding RNA.
- Understand usage of CRISPRi and CRISPRa technologies to modulate lncRNA expression.
- Understand how lncRNA can regulate oncogenes in acute leukemia.
- Discuss potential usage of targeting lncRNA for leukemia treatment.

R Schneider

After attending this lecture, the participant will be able to
- Describe the contribution of Gli1+ cells in bone marrow fibrosis.
- Describe the cellular and molecular mechanisms in the fibrotic transformation of stromal cells in bone marrow fibrosis.
- Discuss the therapeutic strategy of targeting Gli proteins in bone marrow fibrosis.

O Kilpivaara

After attending this lecture, the participant will be able to
- Describe the single-cell transcriptome analysis principle.
- Discuss the value of using single-cell vs. “bulk” RNA-sequencing.

P Ntziachristos

After attending this lecture, the participant will be able to
- Describe major clinical and molecular characteristics of T cell acute lymphoblastic leukemia (ALL).
- Describe the roles of ubiquitin specific peptidases (USPs) in sustaining oncogenic activity and transcriptional response.
- Discuss the molecular and phenotypic effect of therapeutic inhibition of USPs in preclinical models of T-ALL using small molecule inhibitors.
- Discuss how information gained from recent molecular studies could lend rationale towards targeted therapies, exploiting cancer vulnerabilities.

→ EDUCATION SESSION

5 6 **B** **T** **C**

08:00 - 09:30, Room N105
Repeat Session:
Saturday, June 24, 09:45 - 11:15, Room N111

THROMBOSIS

Chair: W Ageno (University of Insubria, Varese, Italy)

- **Cross-talk between coagulation and inflammation**
  T Renné (University Medical Center Hamburg, Germany & Karolinska Institutet, Stockholm, Sweden)
- **Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism**
  M Huisman (Leiden University Medical Center, the Netherlands)
- **Controversies in treating small clots in the leg and in the lung**
  S Schellong (Städtisches Klinikum Dresden, Germany)

LEARNING GOALS

T Renné

After attending this lecture, the participant will be able to
- Understand the novel concept of Safe Anticoagulants that do not increase bleedings.
- Get insight in the crosstalk of coagulation and inflammation.
- Learn about the plasma contact system.

M Huisman

After attending this lecture, the participant will be able to
- Describe current and emerging diagnostic algorithms for patients with clinically suspected venous thromboembolism.
- Select appropriate diagnostic algorithms for selected populations including older patients, pregnant patients, and patients with suspected recurrent venous thromboembolism.

S Schellong

After attending this lecture, the participant will be able to
- Acknowledge the new situation that for DVT as well as for PE the current standard diagnostic imaging detects clots in the leg and the lung which might be clinically insignificant and do not require standard treatment.
- Define a subgroup of patients with isolated distal DVT which represents a very low risk group for proximal extension and PE.
- Discuss the risk difference of two different patient groups with subsegmental PE: cancer patients with incidental PE versus symptomatic patients without cancer.

→ EDUCATION SESSION

1 2 3 6 9 **T** **C**

08:00 - 09:30, Room N103
Repeat Session:
Friday, June 23, 09:45 - 11:15, Room N103

HEREDITARY HEMATOLOGICAL DISORDERS

Chair: J Sevilla (Hospital Infantil Universitario Niño Jesús, Madrid, Spain)

- **Syndromes predisposing to hematological malignancies**
  C Kratz (Hannover Medical School, Germany)

- **Diagnosis of inherited bone marrow failure and myelodysplastic syndromes**
  A Shimamura (Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA)
- **The 100.000 genomes project**
  WH Ouwehand (Wellcome Trust Sanger Institute, University of Cambridge, NHS Blood & Transplant, United Kingdom)

LEARNING GOALS

C Kratz

After attending this lecture, the participant will be able to
- Know the genetic syndromes associated with a range of hematologic neoplasms.
- Know the different clinical features and cancer risks associated with these conditions.
- Know why the identification of such syndromes is highly relevant clinically.

A Shimamura

After attending this lecture, the participant will be able to
- Diagnosis of inherited bone marrow failure (BMF) and inherited myelodysplastic syndromes (MDS) informs surveillance strategies and treatment decisions.
- Classical clinical stigmata of these inherited syndromes may be absent.
- Understand the indications and caveats of genetic screening strategies for the diagnosis of patients with bone marrow failure.

WH Ouwehand

After attending this lecture, the participant will be able to
- New approaches to gene discovery for inherited haematological diseases of unknown molecular aetiology by whole genome sequencing.
- Review of newly identified inherited haematological disorders since the introduction of high throughput sequencing in 2009.
- The application of high throughput sequencing platforms for the comprehensive molecular diagnosis of inherited haematological diseases caused by DNA variants in known genes.
- The need for sharing of genotype and phenotype data via 'safe-haven' models.

→ SCIENTIFIC WORKING GROUPS 1 2 9 **B** **T** **C**
08:30 - 09:30, Room N104

GRANULOCYTE AND MONOCYTE DISORDERS: NEW INSIGHTS IN NEUTROPENIAS

Chair: C Dufour (G Gaslini Children's Hospital, Genova, Italy)
- **Drivers of leukemogenesis in congenital neutropenias**
  K Welte (University Children's Hospital, Tuebingen, Germany)
- **Neutrophil extra cellular traps (NET)**
  J Donadieu (Hôpital Trousseau, Paris, France)
- **PEG Filgrastim in SCN**
  F Fioredda (Istituto Giannina Gaslini, Genoa, Italy)

LEARNING GOALS

K Welte

After attending this lecture, the participant will be able to
- Have an overview on the germ-line mutations causing congenital neutropenias.
- Have and overview on the available treatment for congenital neutropenias.
- Be more aware about the leukemia risk of patients with congenital neutropenias.
- Know that acquired mutations in the CSF3R and RUNX1 are major drivers of leukemogenesis.

J Donadieu

After attending this lecture, the participant will be able to
- What is NET?
- How to study NET and what is a pertinent to understand pathology?
- Do NET and the pathophysiology of diseases?

F Fioredda

After attending this lecture, the participant will be able to
- Have an overview on the available treatments for severe congenital neutropenia.
- Be more aware about the use of Pegfilgrastim in severe congenital neutropenia.

→ SCIENTIFIC WORKING GROUPS 2 3 5 9 **C**
08:30 - 09:30, Room N109

LEUKEMIA DIAGNOSIS: MORPHOLOGY AND FLOW CYTOMETRY: MINIMAL RESIDUAL DISEASE IN LEUKEMIA

Chair: MC Bene (Nantes University Hospital, France)
- **The challenge of morphological remission**
  A Tichelli (University Hospital, Basel, Switzerland)
- **Flow cytometry for MRD detection in ALL**
  G Basso (University of Padova, Italy)
- **Flow cytometry for MRD detection in AML**
  GJ Schuurhuis (VU University Medical Center, Amsterdam, the Netherlands)

LEARNING GOALS

A Tichelli

After attending this lecture, the participant will be able to
- Know the criteria of morphological response and morphological remission in AML, MDS, CML and BCR-ABL1 negative MPN.
- Recognize possible pitfalls in morphological interpretation of remission.
- Understand the clinical relevance of morphology in monitoring response to treatment.

G Basso

After attending this lecture, the participant will be able to
- Discuss the main strenghts and pitfalls of Flow Cytometry in Minimal Residual Disease detection in children affected by Acute Lymphoblastic Leukemia (ALL).

– Describe the clinical impact of Flow Cytometry Minimal Residual Disease in childhood ALL in patients stratification and in follow-up.

GJ Schuurhuis

After attending this lecture, the participant will be able to

– MRD is extra prognostic factor to be used for risk stratification and adaptation of consolidation therapy.
– Incorporation of post-diagnosis stem cell load improves MRD based prognostic impact and with that may lead to further adaptation of therapy.
– Prognostic impact, and with that the clinical consequences, of incorporation of MRD and stem cells mean different things in different classically-defined cytogenetic sub-groups.
– MRD urgently needs further standardization to enable further implementation in clinical studies.

→ BASIC-SCIENCE-IN-FOCUS 1 2 **B T**
08:30 - 09:30, Room N111

MYELOID DERIVED SUPPRESSOR CELLS

Chair: AA van de Loosdrecht (VU University Medical Center, Amsterdam, the Netherlands)

- **A clinical and biological perspective of human myeloid-derived suppressor cells in cancer**
  G Pawelec (University of Tuebingen, Germany)
- **Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment**
  S Ostrand-Rosenberg (University of Maryland Baltimore County, United States)

LEARNING GOALS

G Pawelec

After attending this lecture, the participant will be able to

– Consolidate their knowledge about human myeloid-derived suppressor cells and distinguish their characteristics from murine MDSCs.
– Recognize that MDSC levels are altered in cancer patients in association with patient survival.
– Be aware of the different mechanisms employed by MDSCs to exert immune suppression.
– Acquire knowledge of possible therapeutic agents that can be used to target MDSCs and reduce immune suppression.

S Ostrand-Rosenberg

After attending this lecture, the participant will be able to

– Appreciate the immune suppressive role that myeloid cells play in promoting the progression of primary and metastatic cancer.
– Describe how the low grade pro-inflammatory environment prevalent in obesity mechanistically leads to immune suppression and tumor growth.
– Explain how high fat diet-induced immune suppressive myeloid cells protect against the metabolic dysfunction associated with obesity.

→ BASIC-SCIENCE-IN-FOCUS 2 3 4 **B T C**
08:30 - 09:30, Room N113

MICROBIOME

Chair: M van den Brink (Memorial Sloan Kettering Cancer Center, New York, USA)

- **Modifying the microbiome in allogeneic stem cell transplantation**
  A Bhatt (Stanford University, Palo Alto, USA)
- **Role of molecular tools for discrimination of fungal infections in cancer**
  T Lion (Children´s Cancer Research Institute, Vienna, Austria)

LEARNING GOALS

A Bhatt

After attending this lecture, the participant will be able to

– Provide a basis to select candidate patients based on both disease and patient-related factors.
– Provide a basis to define optimal timing of transplantation in individual patient.
– Discuss the use of hypomethylating agents as part of a comprehensive strategy to prevent relapse after transplantation in high risk patients.
– Discuss the clinical utility of somatic mutations in MDS transplantation decision-making.

T Lion

After attending this lecture, the participant will be able to

– Describe the current place of molecular diagnostic approaches in the detection of invasive fungal infections.
– Discuss the advantages and limitations of molecular diagnostics in relation to established standards.
– Discuss future directions in optimized fungal diagnostics in immunocompromised patients.

→ BASIC-SCIENCE-IN-FOCUS 1 **B**
08:30 - 09:30, Room N115

FOCUS ON IRON

Chair: M Muckenthaler (University of Heidelberg, Germany)

- **Iron and macrophages**
  I Theurl (Medical University of Innsbruck, Austria)
- **Iron storage and release**
  F Carlomagno (DMMBM, University Federico II, Naples, Italy)
- **Role of TFR2 in erythropoiesis**
  A Nai (Ospedale San Raffaele - San Raffaele Scientific Institute, Milan, Italy)

LEARNING GOALS

I Theurl

After attending this lecture, the participant will be able to

– Understand the basics of macrophage iron metabolism.
– Discuss the interaction of innate immunity and iron metabolism.

– Conceive treatment options for diseases in which an altered macrophage iron metabolism plays a central role in disease pathology.

F Carlomagno

After attending this lecture, the participant will be able to

– Understand the role of ferritinophagy in maintaining iron homeostasis.
– Know how NCOA4 functions in controlling ferritinophagy.
– Envisage how ferritinophagy is connected to cell cycle control.

A Nai

After attending this lecture, the participant will be able to

– Dissect the hepatic and erythroid functions of Transferrin Receptor 2.
– Understand the beneficial effect of deleting erythroid Transferrin Receptor 2 in ineffective erythropoiesis.

→ EDUCATION SESSION 3 4 **B T C**
09:45 - 11:15, Hall A
Repeat Session:
Saturday, June 24, 08:00 - 09:30, Hall A

IMMUNOTHERAPY IN LYMPHOMA

Chair: A Engert (University Hospital of Cologne, Germany)

- **The role of the microenvironment in the pathogenesis of B-cell lymphomas**
  G Lenz (Translational Oncology, Münster, Germany)
- **Immune checkpoint inhibitors**
  A Younes (Memorial Sloan Kettering Cancer Center, New York, USA)
- **Is transplantation in lymphoma still needed in the era of immunotherapy?**
  A Sureda (Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain)

LEARNING GOALS

G Lenz

After attending this lecture, the participant will be able to

– Describe the role of the microenvironment in the biology of different B-cell lymphomas.
– Discuss important components of the microenvironment of different B-cell malignancies.
– Appreciate the interaction between bystander and malignant cells in B-cell lymphomas.

A Younes

An up-to-date program is available via the mobile app.

A Sureda

After attending this lecture, the participant will be able to

– Understand how the introduction of check point inhibitors will potentially modify the profile of Hodgkin's lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation.
– Describe transplant related toxicities and long term outcome of patients with Hodgkin's lymphoma that have been previously treated with check point inhibitors.
– Learn how to use check point inhibitors in those patients that relapse after the allogeneic procedure.

→ EDUCATION SESSION 2 5 **T C**
09:45 - 11:15, Hall B
Repeated from:
Friday, June 23, 08:00 - 09:30, Hall B

MYELOPROLIFERATIVE NEOPLASMS

Chair: J Samuelsson (Karolinska Institute, Stockholm, Sweden)

- **Molecular genetics in MPN**
  AM Vannucchi (University of Florence, Italy)
- **Targeting specific mutations in MPN**
  A Mullally (Brigham and Women's Hospital, Boston, USA)
- **Emerging treatments for classical myeloproliferative neoplasms**
  C Harrison (Guys and St Thomas' NHS Foundation Trust, London, United Kingdom)

LEARNING GOALS

AM Vannucchi

After attending this lecture, the participant will be able to

– Describe current status of mutation landscape in patients with myeloproliferative neoplasms (MPN).
– Describe the key role of driver mutations in the revised 2016 WHO diagnostic criteria of MPN.
– Discuss the prognostic relevance of driver and non-driver mutations for patients with myelofibrosis.

A Mullally

After attending this lecture, the participant will be able to

– Summarize the key molecular driver mutations in MPN.
– Describe the development and use of JAK2 inhibitors in MPN.
– Describe investigational approaches focused on enhancing the clonal selectivity of MPN therapies.

C Harrison

After attending this lecture, the participant will be able to

– Appreciate the importance of an accurate diagnosis of specific MPN.
– Select an appropriate prognostic score for their patient and understand how these may be changing during the coming years.
– Discuss pros and cons of conventional treatment options for MPN patients in particular the emerging story with regard to HU and IFN.
– Understand the different efficacies of JAK inhibitors and the potential other emerging therapies for MPN patients.

→ EDUCATION SESSION 2 5 10 T C
09:45 - 11:15, Hall C
Repeat Session:
Saturday, June 24, 08:00 - 09:30, Hall D

CHRONIC MYELOID LEUKEMIA

Chair: S Soverini (University of Bologna, Italy)

- **Novel approaches to eradicate CML stem cells**
  M Copland (University of Glasgow, United Kingdom)
- **Molecular work up and monitoring of CML patients**
  N Cross (University of Southampton, United Kingdom)
- **How to treat CML in 2017**
  A Hochhaus (UK Jena, Germany)

LEARNING GOALS

M Copland

After attending this lecture, the participant will be able to

– Describe the different potential mechanisms of CML stem cell resistance to tyrosine kinase inhibitors.
– Discuss potential therapeutic strategies, in preclinical development or early phase clinical trials, which may improve eradication of CML stem cells.

N Cross

After attending this lecture, the participant will be able to

– Describe the essential elements for the diagnostic work of CML patients.
– Discuss factors associated with heterogeneous response to TKI therapy.
– Understand the role of molecular monitoring for personalised treatment, and how this process is standardised.

A Hochhaus

After attending this lecture, the participant will be able to

– Describe current and emerging therapies for newly diagnosed patients with CML.
– Select appropriate upfront therapy based upon patients treatment goals and preferences, considering efficacy, safety and costs of various options.
– Describe recommended monitoring strategies and clinical consequences from monitoring.
– Describe the selection of second line therapies according to biological and clinical parameters.
– Understand which patients may be eligible for treatment free remission.

→ EDUCATION SESSION 3 9 10 T C
09:45 - 11:15, Hall D
Repeated from:
Friday, June 23, 08:00 - 09:30, Hall D

ACUTE LYMPHOBLASTIC LEUKEMIA: THE WORST AND THE BEST

Chair: R Pieters (Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands)

- **Balancing efficacy and toxicity in the treatment of childhood ALL**
  A Vora (Great Ormond Street Hospital, London, United Kingdom)
- **Immunotherapy for ALL: From biology to the clinic and back**
  T Fry (Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, USA)
- **Novel approaches with recently licensed drugs or recently studied in relapsed ALL**
  JM Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

LEARNING GOALS

A Vora

After attending this lecture, the participant will be able to

– Describe the burden of toxicity of treatment for childhood ALL.
– Discuss risk stratification for childhood ALL.
– Select treatment that provides optimal efficacy with minimal toxicity based on leukaemia phenotype, genotype and treatment response.

T Fry

After attending this lecture, the participant will be able to

– Describe the clinical activity and limitations of CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in pediatric malignancies.
– Differentiate between and explain the patterns of failure following CD19 CAR T cells.
– List possible approaches to improve durability of remission following CAR T cell therapy for acute lymphoblastic leukemia.

JM Ribera

After attending this lecture, the participant will be able to

– Although ALL is highly curable with conventional chemotherapy, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL, especially in adults.
– Immunotherapeutic approaches have significantly improved the outcome of R/R ALL patients and are currently tested in early phases of the disease.
– Targeted therapy combined with conventional chemotherapy and/or immunotherapy can provide promising results in some specific subtypes of ALL.

→ EHA - EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION JOINT SYMPOSIUM 4 T C
09:45 - 10:45, Hall E

60 YEARS OF ALLOGENEIC STEM CELL TRANSPLANTATION

Chairs: M Mohty (Hôpital Saint-Antoine, Paris, France)
AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

- **From dogs to humans... The 60 year long road of allogeneic stem cell transplantation**
  R Storb (Fred Hutchinson Cancer Research Center, Seattle, USA)
- **The long journey of donor search: From sibling to MUD to cord and haplo transplantation**
  E Gluckman (Hôpital Saint Louis, Paris, France)

- **Harnessing T-cell mediated anti-leukemic effect: From unmanipulated donor T-cells to tumor-specific and genetically modified T-cells**
  HJ Kolb (Kolb Consulting UG, Munich, Germany)

LEARNING GOALS

R Storb

After attending this lecture, the participant will be able to
- The history and underlying principles of blood and marrow stem cell transplantation.
- The sources of stem cell grafts.
- The importance of tissue antigens.
- Graft-vs.-host disease and graft-vs.-tumor effects.
- The diseases for which transplantation can be curative.
- The concept of "minimal intensity" transplantation for older patients and those with comorbid conditions.
- Targeted radioimmunotherapy.
- Myeloablative vs. nonmyeloablative conditioning regimens.

E Gluckman

After attending this lecture, the participant will be able to
- Development of bone marrow registries.
- Development of cord blood banks.
- Interaction between donor registries and patients outcome data.
- Role of HLA for donor choice.
- Criteria of donor choice.
- Outcome of alternative donor transplants.

HJ Kolb

After attending this lecture, the participant will be able to
- The efficacy of donor lymphocytes in different diseases.
- The pathophysiology of the sustained GVL effect in chronic myeloid leukemia.
- The different effects of prophylactic/preemptive and therapeutic donor lymphocyte transfusions.
- The stimulation of GVL by leukemia derived dendritic cells and direct antigen presentation.

→ EDUCATION SESSION 5 6 9 **B T C**
09:45 - 11:15, Room N105
Repeat Session:
Saturday, June 24, 08:00 - 09:30, Room N111

BLEEDING DISORDERS

Chair: F Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

- **Biological and clinical relevance of fibrin clot structure**
  N Mutch (University of Aberdeen, United Kingdom)
- **Diagnosis and management of DIC and primary hyperfibrinolysis**
  A Squizzato (Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy)
- **Diagnosis and management of rare bleeding disorders**
  G Kenet (Sheba Medical Center, Tel Hashomer, Israel)

LEARNING GOALS

N Mutch

After attending this lecture, the participant will be able to
- Discuss conditions in which abnormal clot structure is observed and the downstream impact on clot stability.
- Describe how the fibrin network is degraded by the fibrinolytic system and how this can be monitored.
- Explain the factors that may influence clot structure in different areas of the vasculature.

A Squizzato

After attending this lecture, the participant will be able to
- Describe four main clinical phenotypes of patients with DIC.
- Promptly diagnose DIC and rapidly identify underlying disorders of DIC.
- Provide the best supportive therapy to prevent or treat main clinical manifestations of DIC.

G Kenet

After attending this lecture, the participant will be able to
- Describe the epidemiology, symptoms and diagnosis of patients with rare bleeding disorders.
- Discuss current and emerging treatment options, including non- replacement therapy.

→ EDUCATION SESSION 1 2 3 6 9 **T C**
09:45 - 11:15, Room N103
Repeated from:
Friday, June 23, 08:00 - 09:30, Room N103

HEREDITARY HEMATOLOGICAL DISORDERS

Chair: J Sevilla (Hospital Infantil Universitario Niño Jesús, Madrid, Spain)

- **Syndromes predisposing to hematological malignancies**
  C Kratz (Hannover Medical School, Germany)
- **Diagnosis of inherited bone marrow failure and myelodysplastic syndromes**
  A Shimamura (Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA)
- **The 100.000 genomes project**
  WH Ouwehand (Wellcome Trust Sanger Institute, University of Cambridge, NHS Blood & Transplant, United Kingdom)

LEARNING GOALS

C Kratz

After attending this lecture, the participant will be able to
- Know the genetic syndromes associated with a range of hematologic neoplasms.
- Know the different clinical features and cancer risks associated with these conditions.
- Know why the identification of such syndromes is highly relevant clinically.

A Shimamura
After attending this lecture, the participant will be able to
– Diagnosis of inherited bone marrow failure (BMF) and inherited myelodysplastic syndromes (MDS) informs surveillance strategies and treatment decisions.
– Classical clinical stigmata of these inherited syndromes may be absent.
– Understand the indications and caveats of genetic screening strategies for the diagnosis of patients with bone marrow failure.

WH Ouwehand
After attending this lecture, the participant will be able to
– New approaches to gene discovery for inherited haematological diseases of unknown molecular aetiology by whole genome sequencing.
– Review of newly identified inherited haematological disorders since the introduction of high throughput sequencing in 2009.
– The application of high throughput sequencing platforms for the comprehensive molecular diagnosis of inherited haematological diseases caused by DNA variants in known genes.
– The need for sharing of genotype and phenotype data via 'safe-haven' models.

→ SCIENTIFIC WORKING GROUPS 2 3 8 **C**
09:45 - 10:45, Room N104

ELDERLY TASK FORCE IN HEMATOLOGY: AGING AND HEMATOLOGY: NEW CHALLENGES

Chair: D Bron (Institut Jules Bordet, Brussels, Belgium)
- **Introduction: Unmet needs in the supportive care of older patients with malignant hemopathies?**
  D Bron (Institut Jules Bordet, Brussels, Belgium)
- **Immunosenescence or why are older patients more sensitive to malignancies?**
  T Fulop (Université de Sherbrooke, Research Center on Aging, Canada)
- **Immunosenescence: When and how to vaccinate older patients with malignant hemopathies?**
  R Solana (IMIBIC, Cordoba, Spain)

LEARNING GOALS

T Fulop
After attending this lecture, the participant will be able to
– Understand immune changes with aging: Immunosenescence.
– Assess the specific alterations contributing to the increased sensitivity to malignancies.
– Discuss the eventual impact of immunosenescence on the treatment of malignancies in the elderly.

R Solana
After attending this lecture, the participant will be able to
– Understand the basis of age-associated alterations of the immune response.
– Discuss the possible use and limitations of vaccination therapies in elderly AML patients.

→ SCIENTIFIC WORKING GROUPS 2 3 8 **C**
09:45 - 10:45, Room N109

QUALITY OF LIFE AND SYMPTOMS: PRESENT AND FUTURE OF QUALITY OF LIFE AND SYMPTOM ASSESSMENT IN DAILY CLINICAL PRACTICE IN HAEMATOLOGICAL MALIGNANCIES

Chair: T Ionova (Multinational Center for QoL Research, St Petersburg, Russia)
- **The value of PRO measures in clinical trials versus daily practice**
  E Oliva (Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy)
- **Barriers and solutions in assessing PROs in daily practice**
  A Fielding (UCL, London, United Kingdom)
- **Hematological malignancies: The patient's voice**
  A Waldmann (LHRM e.V., Ruesselsheim, Germany)
- **A novel PRO tool for patients with hematological malignancies in clinical practice**
  S Salek (University of Hertfordshire, Hatfield, United Kingdom)

LEARNING GOALS

E Oliva
After attending this lecture, the participant will be able to
– Discuss advantages of PRO measures in clinical practice.
– Describe current PRO measures for patients with haematological malignancies and their applicability in clinical trials and in daily practice.
– Select available PRO measures based upon patient and disease characteristics.

A Fielding
An up-to-date program is available via the mobile app.

A Waldmann
An up-to-date program is available via the mobile app.

S Salek
After attending this lecture, the participant will be able to
– List the disease and treatment related Quality of life issues important to patients with haematological malignancy.
– Discuss the need for a new measure of HRQoL and Symptoms for the management of patients with HM in routine clinical practice
- Describe the new haematological malignancy specific patient-reported outcome measure, the HM-PRO.

→ BASIC-SCIENCE-IN-FOCUS 2 4 **B T C**
09:45 - 10:45, Room N111

ROLE OF NK CELLS IN MYELOID MALIGNANCIES AND SCT

Chair: U Koehl (Institute of Cellular Therapeutics, Hannover Medical School, Germany)
- **Functional diversification of human NK cells**
  K Malmberg (University of Oslo, Norway)

- **Engineering NK cells for the treatment of hematologic malignancies**
  K Rezvani (The University of Texas MD Anderson Cancer Center, Houston, USA)

LEARNING GOALS

K Malmberg

After attending this lecture, the participant will be able to

– Understand the basic principle behind the functional regulation of natural killer cells.
– Appreciate the phenotypic and functional diversity within the NK cell repertoire.
– Discuss the use of NK cells in cancer immunotherapy across HLA-barriers.

K Rezvani

After attending this lecture, the participant will be able to

– Describe current and emerging strategies for the next generation of cell immunotherapies using natural killer cells.
– Discuss strategies for the manufacture of effective cancer immunotherapies by redirecting NK cell specificity using chimeric antigen receptors (CAR) and by making them less susceptible to the tumor microenvironment.

→ BASIC-SCIENCE-IN-FOCUS 1 2 **B T**
09:45 - 10:45, Room N113

AGING AND HEMATOPOIESIS

Chair: G Vassiliou (Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

- **Limited regenerative capacity of the HSC compartment as a cause of aged hematopoiesis**
  M Milsom (HI-STEM & DKFZ, Heidelberg, Germany)
- **Aging, clonal hematopoiesis and pre-leukemia**
  L Shlush (The Weizmann Institute of Science, Rehovot, Israel)

LEARNING GOALS

M Milsom

After attending this lecture, the participant will be able to

– Understand the likely role of hematopoietic stem cell (HSC) attrition in driving age-associated pathologies of the hematopoietic system.
– Appreciate key differences between animal models of hematopoietic ageing and aged human hematopoiesis, along with the likely reasons for these differences.
– Recognise the link between environmental stress agonists, HSC division history and hematologic ageing.

L Shlush

An up-to-date program is available via the mobile app.

→ SCIENTIFIC WORKING GROUPS 1 **B T C**
09:45 - 10:45, Room N115

RED CELL AND IRON: RBC HYDRATION DEFECTS

Chair: A Iolascon (University Federico II Naples, Italy)

- **RBC membrane transport in health and disease**
  G Bosman (Radboud University Medical Center, Nijmegen, the Netherlands)
- **Stomatocytosis and allied disorders**
  I Andolfo (University of Naples, Italy)
- **RBC hydration defects**
  C Brugnara (Boston Children's Hospital, USA)

LEARNING GOALS

G Bosman

After attending this lecture, the participant will be able to

– Interpret pathological red blood cell shape and function based on disturbed membrane transport characteristics.
– Apply the most informative diagnostic tools to identify the most likely molecular pathophysiological mechanism underlying disturbed red blood cell homeostasis.
– Identify putative connections between biomarkers of disturbed systemic metabolism and red blood cell structure and function.

I Andolfo

After attending this lecture, the participant will be able to

– Identify clinical parameters to suspect an hereditary anemias due to altered permeability of red blood cell membrane.
– Explain differential diagnosis of the patients with altered permeability of red blood cell membrane.
– Understand the molecular genetics of hereditary anemias associated with altered permeability of red blood cell membrane comprising targeted-NGS approach.

C Brugnara

After attending this lecture, the participant will be able to

– Describe the major pathways capable of producing erythrocyte dehydration in hemoglobinopathies.
– Be familiar with diagnostic and clinical implication of the presence of dense, dehydrated cells.
– Discuss potential therapeutic strategies aimed at reducing red cell dehydration in hemoglobinopathies.

→ SIMULTANEOUS SESSIONS 3 **T** **C**
11:30 – 12:45, Hall A

NEW ADVANCES IN PLASMA CELL DISORDERS AND IMPLICATIONS FOR THERAPY

Chairs: H Avet-Loiseau (IUC-Oncopole, Toulouse, France)
H Goldschmidt (Medizinische Klinik V, Universitätsklinikum Heidelberg, Germany)

11:30 – 11:45
S100 **NEXT GENERATION SEQUENCING (NGS) METHODOLOGY FOR DETERMINING CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)**
C Chiu[1] ([1]Janssen Research & Development, LLC, Spring House, PA, United States)

11:45 – 12:00
S101 **EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA**
J San-Miguel[1] ([1]Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain)

12:00 – 12:15
S102 **MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL**
S Oliva[1] ([1]Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

12:15 – 12:30
S103 **PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**
W Zhang[1] ([1]Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China)

12:30 – 12:45
S104 **PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF PREVIOUS PLASMA CELL–DIRECTED THERAPIES**
MA Gertz[1] ([1]Mayo Clinic, Rochester, United States)

→ SIMULTANEOUS SESSIONS 3 **C**
11:30 – 12:45, Hall B

AGGRESSIVE NON-HODGKIN LYMPHOMA - 1ST LINE

Chairs: M Dreyling (Klinikum der Universitaet Muenchen, Germany)
A la Fuente Burguera (MD Anderson Cancer Center, Madrid, Spain)

11:30 – 11:45
S105 **RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL TRANSPLANTATION PROLONGS SURVIVAL IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE LYMA TRIAL OF THE LYSA/GOELAMS GROUP**
S Le Gouill[1] ([1]Nantes Medical University, nantes, France)

11:45 – 12:00
S106 **POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA**
H Tilly[1] ([1]University of Rouen, Rouen, France)

12:00 – 12:15
S107 **RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND SAFETY IN THE RANDOMIZED MABEASE STUDY IN FIRST-LINE DLBCL**
P Lugtenburg[1] ([1]Erasmus MC Cancer Institute, Rotterdam, the Netherlands)

12:15 – 12:30
S108 **ANALYSIS AND CHARACTERIZATION OF HEMATOLOGIC CANCERS USING A COMPREHENSIVE NGS PANEL COMPRISED OF DNA AND RNA BAITS TARGETING 704 GENES**
AR Carson[1] ([1]Invivoscribe, San Diego, United States)

12:30 – 12:45
S109 **TP53 MUTATIONS, BUT NOT DELETION OF TP53 AND CDKN2A, HAVE INDEPENDENT PROGNOSTIC VALUE IN MANTLE CELL LYMPHOMA TREATED BY THE NORDIC (MCL2 AND MCL3) REGIMEN**
CW Eskelund[1] ([1]University Hospital of Copenhagen, Copenhagen, Denmark)

→ SIMULTANEOUS SESSIONS 2 5 9 10 **B** **T** **C**
11:30 – 12:45, Hall C

MRD DIRECTED TREATMENT IN AML

Chairs: G Ossenkoppele (VU University Medical Center, Amsterdam, the Netherlands)
A Venditti (Università di Roma "Tor Vergata", Italy)

11:30 – 11:45
S110 **DEEP MOLECULAR RESPONSE TO GILTERITINIB IMPROVES SURVIVAL IN FLT3 MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA**
A Jessica[1] ([1]Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States)

11:45 – 12:00
S111 **RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP**
A Venditti[1] ([1]Hematology, University Tor Vergata, Roma, Italy)

12:00 – 12:15

S112 **GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION.**
J Versluis[1] ([1]Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands)

12:15 – 12:30

S113 **LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY**
W Zeijlemaker[1] ([1]VU University Medical Center, Amsterdam, the Netherlands)

12:30 – 12:45

S114 **DEFINITION OF PARTIAL RESPONSE IN YOUNGER AML PATIENTS AFTER FIRST INDUCTION COURSE MAY BE EXTENDED BY INCLUSION OF IMMUNOPHENOTYPIC DETECTION OF MEASURABLE RESIDUAL DISEASE IN CR**
S Freeman[1] ([1]University of Birmingham , Birmingham , United Kingdom)

→ SIMULTANEOUS SESSIONS 3 5 B T
11:30 – 12:45, Hall D

NEW INSIGHTS INTO CHRONIC LYMPHOCYTIC LEUKEMIA BIOLOGY

Chairs: A Steele (Leukemia and Lymphoma Molecular Mechanisms and Therapy Group, Southampton, United Kingdom)
JI Martin-Subero (IDIBAPS, Barcelona, Spain)

11:30 – 11:45

S115 **CLINICAL IMPACT OF THE SUBCLONAL ARCHITECTURE AND MUTATIONAL COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA**
F Nadeu[1, 2] (1IDIBAPS, Barcelona, Spain, [2]CIBERONC, Madrid, Spain)

11:45 – 12:00

S116 **FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ÐLPHA AND C-MYC IN CLL CELLS**
V Meyer-Pannwitt[1, 2] ([1]Department of Molecular Genetics (B061), Cooperation Unit "Mechanisms of Leukemogenesis", DKFZ, Heidelberg, Germany, [2]Internal Medicine III, Ulm University, Ulm, Germany)

12:00 – 12:15

Poster Pitches

P236 **GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA**
J Brown
Full Poster presentation: Friday, June 23 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 1". More information on page 109

P244 **DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?**
S Bhoi
Full Poster presentation: Friday, June 23 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 1". More information on page 109

P583 **NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS**
F Pozzo
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

P588 **INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE**
E Tissino
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

P586 **MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
F Morabito
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

P589 **IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY**
F Yates
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

12:15 – 12:30

S117 **INTEGRATIVE ANALYSIS OF THE GENOME, EPIGENOME, TRANSCRIPTOME AND THREE-DIMENSIONAL CHROMATIN STRUCTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA**
R Beekman[1] ([1]IDIBAPS, Barcelona, Spain)

12:30 – 12:45

S118 **THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR (BCR) CROSS-TALK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS**
A Danilov[1] ([1]Oregon Health and Science University, Portland, United States)

→ SIMULTANEOUS SESSIONS 2 5 B T
11:30 – 12:45, Hall E

PATHOGENESIS OF MDS

Chairs: M Cazzola (University of Pavia, Italy)
D Nowak (University Hospital Mannheim, Germany)

11:30 – 11:45
S119 **LOW MYBL2 EXPRESSION OBSERVED IN MYELODYSPLASTIC SYNDROME PATIENTS WITH WORSE PROGNOSIS IS ASSOCIATED WITH ALTERED DNA REPAIR MECHANISMS IN HAEMATOPOETIC STEM CELLS**
P Garcia[1] ([1]University of Birmingham, Birmingham, United Kingdom)

11:45 – 12:00
S120 **A NOVEL GENETIC AND MORPHOLOGIC PHENOTYPE OF ARID2-MEDIATED MYELODYSPLASTIC SYNDROMES.**
H Makishima[1], [5] ([1]Cleveland Clinic, Cleveland, United States, [5]Kyoto University, Kyoto, Japan)

12:00 – 12:15
S121 **THE VALUE OF NGS PANEL SEQUENCING TO MOLECULARLY DEFINE MYELOID MALIGNANCIES AND CLARIFY BORDERLINE CASES: A STUDY ON 39 GENES IN 1143 PATIENTS**
C Baer1 (1MLL Munich Leukemia Laboratory, Munich, Germany)

12:15 – 12:30
S122 **IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS**
A Pellagatti[1] ([1]University of Oxford, Oxford, United Kingdom)

12:30 – 12:45
S123 **TRANSCRIPTOME SEQUENCING REVEALS DISTINCT SUBTYPES OF MYELODYSPLASIA WITH PROGNOSTIC SIGNIFICANCE**
S Ogawa[1] ([1]Kyoto University, Kyoto, Japan)

→ SIMULTANEOUS SESSIONS 3 5 B T
11:30 – 12:45, Room N101

LYMPHOMA BIOLOGY

Chairs: E Macintyre (Université Sorbonne Paris Cité (Descartes) / Hôpital Necker Enfants Malades, Paris, France)
K Grønbæk (Rigshospitalet, Copenhagen Ø, Denmark)

11:30 – 11:45
S124 **GENETIC ALTERATIONS INVOLVING PROGRAMMED DEATH LIGANDS IN EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS**
K Kataoka[1] ([1]Kyoto University, Kyoto, Japan)

11:45 – 12:00
S125 **FOXO1 CONTROL CD20 EXPRESSION AND INFLUENCE B-CELL LYMPHOMA RESPONSE TO RITUXIMAB-BASED IMMUNOTHERAPY**
M Dwojak[1] ([1]Medical University of Warsaw, Warsaw, Poland)

12:00 – 12:15
Poster Pitches

P295 **GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY**
A Sud
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 112

P296 **SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA**
P Balsas
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 112

P297 **AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS**
M Dominguez Rodriguez
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 112

P298 **XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA**
M Crespo
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 112

P299 **MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.**
Y Watatani
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 112

P300 **A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS**
M Duran-Ferrer
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 113

P301 **ACTIVATION OF RHOA-VAV1 SIGNALING AXIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA**
M Fujisawa
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 113

P302 **STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION**
A Arai
Full Poster presentation: Friday, June 23 – Poster Walk: "Lymphoma biology". More information on page 113

12:15 – 12:30
S126 **ALPHA-KETOGLUTURATE EXPOSES METABOLIC VULNERABILITIES IN B-CELL LYMPHOMAS**
R Aguiar[1] ([1]University of Texas Health Science Center, San Antonio, United States)

12:30 – 12:45
S127 **DELETION OF THE F-BOX PROTEIN NIPA (NUCLEAR INTERACTION PARTNER OF ALK) IMPAIRS NPM-ALK DRIVEN TRANSFORMATION**
LJ Lippert[1] ([1]University of Freiburg Medical Center, Freiburg, Germany)

→ SIMULTANEOUS SESSIONS 1 4 5 9 B T
11:30 – 12:45, Room N105

THALASSEMIA

Chairs: GL Forni (European Reference Networks for Rare Diseases ERN-EuroBloodNet / Ospedale Galliera, Genova, Italy)
C McMahon (Our Lady's Children's Hospital, Crumlin, Dublin, Ireland)

11:30 – 11:45
S128 **GENE THERAPY FOR BETA THALASSEMIA: INITIAL RESULTS FROM THE PHASE I/II TIGET-BTHAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS GENETICALLY MODIFIED WITH GLOBE LENTIVIRAL VECTOR**
S Marktel[1] ([1]San Raffaele Scientific Institute, Milano, Italy)

11:45 – 12:00
S129 **LUSPATERCEPT INCREASES HEMOGLOBIN AND DECREASES TRANSFUSION BURDEN IN ADULTS WITH Ð-THALASSEMIA**
A Piga[1] ([1]Turin University, Turin, Italy)

12:00 – 12:15
S130 **DENOSUMAB INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA MAJOR AND OSTEOPOROSIS: RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, PHASE 2B CLINICAL TRIAL**
E Voskaridou[1] ([1] "Laiko" General Hospital, Athens, Greece)

12:15 – 12:30
S131 **LONG-TERM HEALTH STATUS AFTER HSC TRANSPLANTATION FOR THALASSEMIA: THE FRENCH EXPERIENCE**
I Thuret[1] ([1]Hopital de la Timone, Assistance publique-hôpitaux de Marseille, Marseille, France)

12:30 – 12:45
S132 **CD34+ AND HUMAN INDUCED PLURIPOTENT STEM CELL (IPSC) DIFFERENTIATION TO TRANSFUSION READY RED BLOOD CELLS**
MJ Claessen[1], [2] ([1]AMC Amsterdam, Amsterdam, the Netherlands, [2]Sanquin Research, Amsterdam, the Netherlands)

→ SIMULTANEOUS SESSIONS 2 5 9 10 B T
11:30 – 12:45, Room N103

AML BIOLOGY I: TOWARDS MOLECULAR THERAPIES

Chairs: A Thompson (Centre for Biomolecular Sciences, Nottingham, United Kingdom)
M Kühn (University Medical Center, Johannes Gutenberg-Universität Mainz, Germany)

11:30 – 11:45
S133 **FUNCTIONAL PROTEOMICS IDENTIFIES SETD2 AS A CRITICAL EFFECTOR OF MLL FUSION PROTEINS TO SAFEGUARD GENOMIC INTEGRITY.**
A Skucha[1] ([1]CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria)

11:45 – 12:00
S134 **CEBPA-MUTANT ACUTE MYELOID LEUKEMIA IS SENSITIVE TO SMALL-MOLECULE-MEDIATED INHIBITION OF THE MEN-IN-MLL INTERACTION**
L Schmidt[1] ([1]Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria)

12:00 – 12:15
Poster Pitches

P171 **RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**
K Suzuki
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

P172 **BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML**
S Raffel
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

P173 **NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST**
L Brunetti
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

P174 **THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA**
D Papaioannou
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

P175 **A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA**
D Moujalled
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

P176 **THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA**
E Voisset
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

P177 **DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENISIS**
D Heckl
Full Poster presentation: Friday, June 23 – Poster Walk: "Acute myeloid leukemia - Biology 1". More information on page 105

12:15 – 12:30
S135 **INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA**
I Antony-Debre[1], [2] ([1]Gustave Roussy, Villejuif, France, [2]Albert Einstein College of Medicine, New York, United States)

12:30 – 12:45
S136 **METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA (AML)**
P Gallipoli[1] ([1]UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

→ SIMULTANEOUS SESSIONS 1 4 5 9 B T
11:30 – 12:45, Room N104

HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT

Chairs: W Fibbe (Leiden University Medical Center, the Netherlands)
S Karlsson (Lund University, Sweden)

11:30 – 11:45
S137 **STEP-WISE REPROGRAMMING OF ENDOTHELIAL CELLS INTO IMMUNE-COMPETENT HEMATOPOIETIC STEM CELLS**
JG Barcia Duran[1] ([1]Weill Cornell Graduate School of Medical Sciences, New York, United States)

11:45 – 12:00
S138 **MARROW MESENCHYMAL STEM CELLS RESCUE BONE MARROW ENDOTHELIAL CELLS SUFFERING CHEMOTHERAPY STRESS BY TRANSFERRING MITOCHONDRIA THROUGH NANOTUBES**
Y Feng[1] ([1]Institute of Hematology, Beijing, China)

12:00 – 12:15
Poster Pitches

P268 **TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION**
S Solier
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 111

P264 **ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE**
D Passaro
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 110

P265 **BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS**
R Groen
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 110

P266 **MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS**
C Nombela Arrieta
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 111

P267 **TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION**
M Koning
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 111

P269 **MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13**
K Beider
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 111

P270 **RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR**
S OByrne
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 111

P271 **HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS**
M Ganuza Fernandez
Full Poster presentation: Friday, June 23 – Poster Walk: "Hematopoiesis, stem cells and microenvironment". More information on page 111

12:15 – 12:30
S139 **SHORT-TERM FEEDING OF A HIGH-FAT DIET DISTURBS LIPID RAFT/TGF-ÐETA SIGNALING-MEDIATED QUIESCENCE OF HEMATOPOIETIC STEM CELLS IN C57BL/6J MOUSE BONE MARROW**
F Hermetet[1], [2] ([1]UMR1231 Inserm / Université Bourgogne Franche-Comté / AgroSup, Dijon, France, [2]LabEx LipSTIC, Dijon, France)

12:30 – 12:45
S140 **A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS**
D Karamitros[1], [2] ([1]Oxford Biomedical Research Centre, Oxford, United Kingdom, [2]WIMM/NDCLS University of Oxford, Oxford, United Kingdom)

→ SIMULTANEOUS SESSIONS 1 4 5 9 10 B T C
11:30 – 12:45, Room N109

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION 1

Chairs: Z Berneman (Antwerp University Hospital, Edegem, Belgium)
T Haas (III. Medizinische Klinik, Technische Universität München, Germany)

11:30 – 11:45
S141 **WILMS' TUMOR 1 (WT1) RNA-ELECTROPORATED DENDRITIC CELL VACCINATION AS POST-REMISSION TREATMENT TO PREVENT OR DELAY RELAPSE IN ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A PHASE II STUDY IN 30 PATIENTS**
Z Berneman[1] ([1]ANTWERP UNIVERSITY HOSPITAL, Edegem, Belgium)

11:45 – 12:00
S142 **FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS**
Y Lin[1] ([1]Mayo Clinic, Rochester, MN, United States)

12:00 – 12:15
S143 **BASELINE AND EARLY POST-TREATMENT CLINICAL AND LABORATORY FACTORS ASSOCIATED WITH SEVERE NEUROTOXICITY FOLLOWING 19-28Z CAR T CELLS IN ADULT PATIENTS WITH RELAPSED B-ALL**
J Park[1] ([1]MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, United States)

12:15 – 12:30
S144 **FIRST EVIDENCE DEMONSTRATING ENGRAFTMENT AND REPOPULATION ADVANTAGE OF GENE-CORRECTED HEMATOPOIETIC REPOPULATING CELLS IN NON-CONDITIONED FANCONI ANEMIA PATIENTS**
J Sevilla[1] ([1]Hospital Infantil Universitario Niño Jesús. FIB HIUNJ. CIBERER, Madrid, Spain)

12:30 – 12:45
S145 **TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS CONFERS POTENT REACTIVITY AGAINST ACUTE MYELOID LEUKEMIA (AML)**
H Jetani[1] ([1]University Hospital Würzburg, Würzburg, Germany)

→ MEET-THE EXPERT 1 2 4 C
11:30 - 12:30, Room N107
Availability on first come first serve basis

AN APPROACH TO IRON OVERLOAD IN MDS AND EITHER IN BMT OR BEFORE, DURING AND AFTER BMT

Speaker: E Rachmilewitz (Edith Wolfson Medical center, Holon, Israel)

→ MEET-THE EXPERT 3 9 C
11:30 - 12:30, Room N108
Availability on first come first serve basis

ALL IN ADOLESCENCE AND YOUNG ADULTS CASE STUDIES

Speaker: JM Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

→ MEET-THE EXPERT 3 C
11:30 - 12:30, Room N117
Availability on first come first serve basis

AMYLODOISIS TREATMENT

Speaker: GP Merlini (Scientific Institute Policlinico San Matteo and University of Pavia, Italy)

→ SPECIAL SESSION
13:00 – 14:15, Hall A

OPENING CEREMONY

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)

- **Opening address**
  AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
- **Presentation EHA – José Carreras young investigator award & EHA research grants**
  M Muckenthaler, Chair Fellowships & Grants Committee (University of Heidelberg, Germany)
- **Introduction José Carreras Award & Lecture**
  S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)
- **José Carreras Lecture:**
  AML: The Evil side of gene regulation
  R Delwel (Erasmus MC, Rotterdam, the Netherlands)

→ HEMATOLOGY-IN-FOCUS 2 3 5 C
14:30 - 15:30, Hall A

NEWS IN WHO 2016 CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES

Chair: U Jäger (Medical University of Vienna, Austria)

- **Lymphoid malignancies**
  SH Swerdlow (University of Pittsburgh School of Medicine, USA)
- **Myeloid malignancies**
  M Cazzola (University of Pavia, Italy)

LEARNING GOALS

SH Swerdlow

After attending this lecture, the participant will be able to

– Explain the process by which the WHO lymphoma classification was developed.
– Discuss the major changes introduced in the 2016 revised WHO lymphoma classification & upcoming monograph.
– Apply the practice-changing elements of the revised classification & diagnostic criteria in their clinical work.

M Cazzola

After attending this lecture, the participant will be able to

– Describe the most important modifications of the 2016 revision of the WHO classification of myeloid malignancies.
– Describe the many novel molecular findings with diagnostic and/or prognostic importance that have been incorporated into the 2016 revision.
– Discuss the different levels of integration of genetic data into the clinicopathological classification of myeloid malignancies.

→ CLINICAL DEBATE 2 4 C
14:30 - 15:30, Hall B

SHOULD LOW RISK MDS BE TRANSPLANTED?

Chair: JA Pérez Simón (University Hospital Virgen del Rocío, Seville, Spain)

- **Yes**
  N Kröger (University Medical Center Hamburg-Eppendorf, Germany)
- **No**
  P Fenaux (Hôpital St Louis, Paris, France)

→ HEMATOLOGY-IN-FOCUS 3 B T C
14:30 - 15:30, Hall C

WALDENSTRÖM'S DISEASE

Chair: MV Mateos (University Hospital of Salamanca, Spain)

- **Molecular biology of Waldenström's disease**
  S Treon (Harvard Medical School, Boston, USA)
- **Novel treatment strategies in Waldenström's macroglobulinemia**
  E Kastritis (National and Kapodistrian University of Athens, Greece)

LEARNING GOALS

S Treon

After attending this lecture, the participant will be able to

– Understand current and novel therapeutic options for WM.
– Understand the role of MYD88 and CXCR4 mutations in treatment choices in WM.
– Role of maintenance therapy in WM.

E Kastritis

After attending this lecture, the participant will be able to

- Indications for treatment in patients with Waldenström's Macroglobulinemia and definitions of symptomatic disease.
- Available treatment options for patients with symptomatic Waldenström's Macroglobulinemia.
– Risk assessment in patients with WM and risk adapted/ symptom oriented choice of therapy.
– Management of special populations of patients with WM (elderly, transplant candidates, IgM-related complications, IgM amyloidosis).
– Management of rare complications of WM.
– Management of relapsed / refractory disease.

→ **EHA - JAPANESE SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM** 2 3 5 **B T**
14:30 - 15:30, Hall D

NEXT GENERATION SEQUENCING OF HEMATOLOGICAL MALIGNANCIES

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
K Akashi, President of JSH (Kyushu University, Fukuoka, Japan)

- **NGS discovering cancer immune evasion through disruption of PD-L1 3'-UTR sequence**
  S Ogawa (Kyoto University, Japan)
- **Interrogating the architecture of cancer genomes**
  P Campbell (The Wellcome Trust Sanger Inst, Hinxton, United Kingdom)

LEARNING GOALS

S Ogawa

After attending this lecture, the participant will be able to

– Describe how cancer cells evade host immune system using checkpoints.
– Describe how PD-L1 expression is regulated via its 3'-UTR sequences.
– Describe how the mechanism is deregulated in cancer cells via disruption of the 3'-UTR sequences, leading to abnormally high expression of PD-L1 and promoting cancer immune evasion.
– Describe how PD-L1 3'-UTR disruption could be exploited as a potential biomarkers to predict the response to anti-PD-1/PD-L1 antibodies.

P Campbell

After attending this lecture, the participant will be able to

- Understand patterns of somatic mutation in normal blood cells.
- Use somatic mutations as read-outs of clonal structure.

→ **CLINICAL DEBATE** 6 **C**
14:30 - 15:30, Hall E

REVERSAL OF DIRECT ORAL ANTICOAGULANTS (DOAC): DO WE REALLY NEED AN ANTIDOTE?

Chair: PA Kyrle (Medical University of Vienna, Austria)

- **Yes**
  M Levi (Academic Medical Center, University of Amsterdam, the Netherlands)
- **No**
  W Ageno (University of Insubria, Varese, Italy)

→ **HEMATOLOGY-IN-FOCUS** 2 3 5 9 **T C**
14:30 - 15:30, Room N101

LEUKEMIAS WITH MIXED PHENOTYPES

Chair: J Martinez-Lopez (Hospital Universitario 12 de Octubre, Madrid, Spain)

- **What is ambiguous: Shrinking the zone of uncertainty between ALL and AML**
  O Hrusak (CLIP Childhood Leukaemia Investigation Prague, Czech Republic)
- **Genomics and clinical characteristics of mixed phenotype acute leukemia**
  H Inaba (St. Jude Children's Research Hospital, Memphis, USA)

LEARNING GOALS

O Hrusak

After attending this lecture, the participant will be able to

– Distinguish 4 categories of ambiguous lineage leukemias while being aware of overlaps among them.
– Relate current knowledge and history of the ambiguous lineage leukemia definitions.
– Describe the molecular genetic heterogeneity of ambiguous lineage leukemias.
– Understand the criteria for selecting the upfront ALL or AML type of therapy.
– Know the options in treatment failure including transplant and change of treatment type.
– Describe the nature of on-treatment lineage switches, and when to react to them therapeutically.

H Inaba

After attending this lecture, the participant will be able to

– Describe the results of an international collaborative genomic study of pediatric mixed-phenotype acute leukemia.
– Discuss the possible pathophysiology of pediatric mixed-phenotype acute leukemia.
– Discuss the treatment options for pediatric mixed-phenotype acute leukemia based on genetic findings.

→ EHA - HEMATOLOGY SOCIETY OF TAIWAN JOINT SYMPOSIUM 2 5 T C
14:30 - 15:30, Room N105

ACUTE MYELOID LEUKEMIA

Chairs: DT Lin (The Hematology Society of Taiwan, Taipei, Taiwan)
C Chomienne (Hôpital Saint-Louis, Paris, France)

- **Clinical implications of gene alterations in risk-adapted treatment of AML**
  HF Tien (National Taiwan University Hospital, Taipei, Taiwan)
- **Emerging therapeutic strategies in AML**
  S Knapper (Cardiff University, United Kingdom)

LEARNING GOALS

HF Tien

After attending this lecture, the participant will be able to

– Understand the landscape of gene mutations in AML.
– Know the implications of gene mutations in classification, risk stratification, and personalized treatment of AML.

S Knapper

After attending this lecture, the participant will be able to

– Describe emerging treatment strategies for adults with newly diagnosed and relapsed / refractory AML.
– Understand the expanding options for targeted intervention in different genetic sub-groups and disease scenarios.
– Appreciate some of the challenges in designing and coordinating clinical trials in this rapidly expanding field.

→ CLINICAL DEBATE 6 9 C
14:30 - 15:30, Room N103

DO NEW STUDIES SUPPORT A PREFERENTIAL INDICATION OF PLASMA-DERIVED VS. RECOMBINANT CONCENTRATES FOR THE TREATMENT OF NEW PATIENTS WITH SEVERE HEMOPHILIA A?

Chairs: D Di Michele (National Institutes of Health, USA)
F Rodeghiero (Hematology Project Foundation / Fondazione Progetto Ematologia, Vicenza, Italy)

- **Yes**
  PM Mannucci (IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan, Italy)
- **No**
  F Pignatti (European Medicines Agency, London, United Kingdom}

→ HEMATOLOGY-IN-FOCUS 2 10 B T C
14:30 - 15:30, Room N104

CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

Chair: F Onida (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Italy)

- **From genetics to epigenetics in CMML**
  E Solary (Gustave Roussy, Inserm, Villejuif, France)
- **Risk adapted treatment of CMML**
  E Padron (H. Lee Moffitt Cancer Center, Tampa, USA)

LEARNING GOALS

E Solary

After attending this lecture, the participant will be able to

– Combine appropriate tools to rapidly distinguish a chronic myelomonocytic leukemia from a reactive monocytosis.
– Summarize current understanding of chronic myelomonocytic leukemia pathogenesis.
– Identify the main prognostic factors identified so far in this disease.
– Discuss current therapeutic options and emerging therapeutic strategies.

E Padron

After attending this lecture, the participant will be able to

– Describe state of the art diagnostic criteria for Chronic Myelomonocytic Leukemia (CMML).
– Describe current standard of care and emerging therapies in CMML.
– Describe preclinical challenges and opportunities for future translational research in CMML.

→ EARLY CAREER SESSION 1 2 3 B T C
14:30 - 15:30, Room N109

EHA FELLOWSHIP AND TRTH AWARDEES

Chair: AK Eisfeld (The Ohio State University, Columbus, USA)

- **Clonal heterogeneity and clonal evolution in AML during chemotherapy-understanding a dynamic disease**
  K Metzeler (Laboratory for Leukemia Diagnostics, University of Munich, Germany)
- **Molecular regulation of exit from quiescence in human hematopoietic stem cells**
  E Laurenti (Wellcome Trust MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom)
- **Macrophage iron recycling or dietary iron uptake: What causes iron overload in hemochromatosis?**
  S Altamura (University of Heidelberg, Germany)

LEARNING GOALS

K Metzeler

After attending this lecture, the participant will be able to

– Describe the spectrum of conditions characterized by somatic mutations in hematopoietic stem/precursor cell clones, from clonal hematopoiesis of indeterminate potential (CHIP) to myeloid neoplasms.
– Discuss the relevance of clonal hematopoiesis as a risk factor for spontaneous and therapy-induced myeloid neoplasia.
– Summarize our current knowledge on pre-leukemic clones in AML, their persistence after induction chemotherapy, and their clinical relevance.

E Laurenti
After attending this lecture, the participant will be able to
– The human hematopoietic stem cell (HSC) compartment contains functionally and molecularly distinct HSC subsets.
– The transcriptional status of HSC subsets is highly dependent on the cell cycle state.
- The quiescent state (G0) masks transcriptional differences between human HSC subsets.

S Altamura
An up-to-date program is available via the mobile app.

→ HEMATOLOGY-IN-FOCUS 1 5 9 **T** **C**
14:30 - 15:30, Room N111

ERYTHROPOIESIS AND RARE ANEMIAS

Chair: A Iolascon (University Federico II Naples, Italy)
- **Genetic studies of human erythropoiesis**
  V Sankaran (Boston Children's Hospital/ Broad Institute, USA)
- **Gene targeted NGS to improve diagnosis of rare anemia**
  B Clark (King's College Hospital, London, United Kingdom)

LEARNING GOALS

V Sankaran
After attending this lecture, the participant will be able to
– Describe our current understanding of human erythropoiesis and hemoglobin gene regulation
– Discuss the current understanding of how rare and common genetic variation can influence human erythropoiesis.
– Describe how genetic insight is suggesting new treatments for sickle cell disease, thalassemia, and Diamond-Blackfan anemia.

B Clark
After attending this lecture, the participant will be able to
– Understand what targeted next generation sequencing is.
– Understand the diagnostic utility of next generation sequencing for red cell disorders.

→ HEMATOLOGY-IN-FOCUS 1 2 9 **T** **C**
14:30 - 15:30, Room N113

HOW TO DIAGNOSE AND MANAGE CYTOPENIAS IN CHILDREN AND YOUNG ADULTS?

Chair: A Shimamura (Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA)
- **Immune mediated cytopenia**
  D Teachey (Children's Hospital of Philadelphia, USA)
- **Myelodysplastic syndrome**
  C Niemeyer (University Children's Hospital, Freiburg, Germany)

LEARNING GOALS

D Teachey
After attending this lecture, the participant will be able to
– Describe current treatment approaches and targeted therapeutic options for patients with autoimmune cytopenias.
– Discuss recently described syndromes that can present with chronic or multi-lineage autoimmune cytopenias and define populations who should undergo additional diagnostic testing.

C Niemeyer
After attending this lecture, the participant will be able to
– Recognize the genetic disorders presenting with cytopenia in young individuals.
– Plan diagnostic procedures for each patient in a rational and cost-effective manner.
– Critically discuss therapy options including immunosuppressive therapy and stem cell transplantation.

→ MEET-THE EXPERT 6 **C**
14:30 - 15:30, Room N107
Availability on first come first serve basis

MANAGEMENT OF VON WILLEBRAND DISEASE

Speaker: G Castaman (Center for Bleeding Disorders, Careggi University Hospital, Florence, Italy)

→ MEET-THE EXPERT 3 10 **C**
14:30 - 15:30, Room N108
Availability on first come first serve basis

CLL IN THE ERA IN TARGETED THERAPIES

Speaker: C Moreno (Hospital Santa Creu I Sant Pau, Barcelona, Spain)

→ MEET-THE EXPERT 4 **C**
14:30 - 15:30, Room N117
Availability on first come first serve basis

TREATMENT OF GVHD

Speaker: T Ruutu (Clinical Research Institute, Helsinki University Hospital, Finland)

→SPECIAL SESSION 1 2 3 4 6 7 8 9 10 **B T C**
15:45 – 17:00, Hall A

PRESIDENTIAL SYMPOSIUM

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)

YOUNG EHA AWARDS

- **Introduction**
  S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)

15:45 – 16:00

S146 **BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS**
M Algeri[1] ([1]Ospedale Pediatrico Bambino Gesu, Rome, Italy)

16:00 – 16:15

S147 **RE-CREATING HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN (HPFH) WITH CRISPR/CAS9 TO TREAT SICKLE CELL DISEASE (SCD) AND BETA-THALASSEMIA (BETA-THAL)**
A Lundberg[1] ([1]CRISPR Therapeutics, Cambridge, United States)

16:15 – 16:30

S148 **EXPOSURE TO INFECTION TRIGGERS PAX5 AND ETV6-RUNX1 CHILDHOOD BCP-ALL**
J Hauer[2] ([2]Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany)

16:30 – 16:45

S149 **REVERSIBLE PHARMACOLOGICAL TARGETING OF RHOA ALLOWS IMPROVED STORAGE, SURVIVAL AND HEMOSTATIC ACTIVITY OF PLATELETS IN VITRO AND IN VIVO, IN MICE AND IN PRIMATES.**
S Hegde[1], [2] ([1]Cincinnati Children's Hospital Medical Center, Cincinnati, United States, [2]University of Cincinnati College of Medicine, Cincinnati, United States)

16:45 – 17:00

S150 **TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP**
P Borchmann[1] ([1]University Hospital of Cologne, Cologne, Germany)

→UPDATES-IN-HEMATOLOGY
17:15 - 18:45, Room N105

CAR-T CELL THERAPY: PROGRESS AND PROSPECTS

Chair: M Hudecek, Universitätsklinikum Würzburg, Würzburg, Germany

This Update in Hematology session features experts in the field of CAR-T cell therapy and will cover three topics. The session will be introduced by the meeting chair and then begin with a review of the efficacy data available to date across different indications and target antigens. Results of combinations of CAR-T cells with other agents will be discussed and assessed in the context of designing future clinical trials. Particular attention will be paid to the CAR-T production processes that may impact efficacy and safety.
The next topic of the session will cover the discussion on safety aspects focusing on cytokine release syndrome and CNS toxicity. Efforts aimed at the use of predictive clinical features and biomarkers for these adverse events will be reviewed. Practical approaches to patient management for minimizing the risks and impact of adverse events will be discussed. The session will be concluded with a look into the future of adoptive T-cell therapies. Novel constructs for the next generation of CARs will be described, as well as new antigen targets and the characteristics which make them appealing and discuss rational CAR-T combination approaches to improve safety and outcomes.

- Understand the current efficacy of CAR-T cell therapy and approaches for optimisation
- Understand the safety aspects of CAR-T cell therapy and approaches to minimize the incidence and impact of adverse events
- Gain insights into the future of CAR-T cell technology and novel approaches to improve safety and outcomes

PROGRAM

- **Introduction**
  M Hudecek, Universitätsklinikum Würzburg, Würzburg, Germany
- **Data update: efficacy review across indications and antigen targets**
  J Abramson, Massachusetts General Hospital, Boston, MA, United States
- **Data update: safety and patient management**
  S Grupp, Abramson Cancer Center, Philadelphia, United States
- **Scientific developments: targets, constructs, combinations**
  M Sadelain, Memorial Sloan Kettering Cancer Center, New York, United States

→ UPDATES-IN-HEMATOLOGY
17:15 - 18:45, Room N103

BIOSIMILARS FOR HEMATOLOGIC MALIGNANCIES: THE PATH TO SUSTAINABLE CARE

Chair: P Cornes, Comparative Outcomes Group, Bristol, United Kingdom

Biologic therapies for hematologic malignancies represent a much needed treatment advance; however, the associated financial burden and potentially long duration of therapy present a challenge to the sustainability of care. During this interactive Update in Haematology session, the expert faculty will explore how the advent of biosimilar agents may impact the sustainability of treatment for hematologic malignancies. In the first presentation, Dr. Paul Cornes will review the current economic burden of cancer care, and the panel will discuss how biosimilars may alleviate this financial burden and expand access to care. Panellists will evaluate the critical role of both physicians and pharmacists in driving sustainability of care, and explore how to overcome perceived obstacles to incorporating biosimilars into treatment plans. In the second presentation, Dr. Arnold Vulto will review the development process for biosimilars, and the panel will evaluate biosimilars as alternative options to originator molecules in light of the current regulatory environment. In the final presentation, Dr. Wojciech Jurczak will review how monoclonal antibodies have changed the landscape of treatment for hematologic malignancies and evaluate opportunities for these agents to further advance treatment strategies. The panel will go on to discuss the potential role of biosimilars and where these may fit into future treatment paradigms for the management of hematologic malignancies. The audience will have the opportunity to ask questions of the expert faculty and participate in this interactive programme through an audience response system.

- Recognise the similarities and differences between biosimilars and originators
- Discuss the role of biosimilars in sustainability of treatment for hematologic malignancies
- Evaluate the data on monoclonal antibodies for the treatment of hematologic malignancies and the role of biosimilar monoclonal antibodies to address some lingering gaps in care

PROGRAM

- **Introduction and welcome**
  P Cornes, Comparative Outcomes Group, Bristol, United Kingdom
- **The role of biosimilars in promoting sustainability of care [presentation and panel discussion]**
  P Cornes, Comparative Outcomes Group, Bristol, United Kingdom
- **A look at biosimilars development [presentation and panel discussion]**
  AG Vulto, Erasmus University Medical Center, Rotterdam, the Netherlands
- **The role of new molecule innovation in the sustainability of treatment for hematologic malignancies [presentation and panel discussion]**
  W Jurczak, Jagiellonian University, Kopernika, Poland
- **Ask the faculty**
  P Cornes, Comparative Outcomes Group, Bristol, United Kingdom

→ UPDATES-IN-HEMATOLOGY
17:15 - 18:45, Room N104

AL AMYLOIDOSIS, DON'T MISS IT!

Chair: M Gertz, Mayo Clinic College of Medicine, Rochester, United States

Amyloid light chain (AL) amyloidosis is a rare and often fatal disease caused by clonal plasma cells that create misfolded light chains, which form soluble toxic aggregates and deposited fibrils (amyloid). Amyloid can lead to progressive failure of critical organs and systems (eg, heart, kidneys, nervous system) causing significant morbidity and mortality. The most common presenting symptoms such as fatigue, edema, dyspnea are nonspecific and are often confused with those of other more common diseases; heterogeneous symptoms cause delays in suspicion and diagnosis, or missed diagnoses. AL amyloidosis is associated with a high disease burden, which negatively impacts patients' physical and mental well-being. There is a substantial need to increase disease awareness and early diagnosis to improve outcomes. At this symposium we will discuss the key to making a diagnosis, the use of biomarkers to manage patients' disease and the importance of organ response in patients' quality of life and survival.

1. To educate on the diagnosis of AL amyloidosis and increase clinical suspicion
2. To inform on the importance of biomarkers for diagnosis and prognosis
3. To discuss disease management and the importance of organ responses

PROGRAM

- **Welcome and introduction**
  M Gertz, Mayo Clinic College of Medicine, Rochester, United States
- **Early diagnosis can change the outcomes: clinical case (part I)**
  M Liedtke, Stanford University School of Medicine, Stanford, United States
- **Early diagnosis can change the outcomes: presentation**
  A Wechalekar, National Amyloidosis Centre, University College London (Royal Free Campus), London, United Kingdom
- **Incorporating biomarkers in the management of patients' disease: case study (part II)**
  M Liedtke, Stanford University School of Medicine, Stanford, United States
- **Incorporating biomarkers in the management of patients' disease: presentation**
  D Mohty, National Amyloidosis Center and Hematology unit, CHU Limoges, Limoges, France
- **Organ response: the ultimate goal of therapy: case study (part III)**
  M Liedtke, Stanford University School of Medicine, Stanford, United States
- **Organ response: the ultimate goal of therapy: presentation**
  S Schoenland, Universitätsklinikum Heidelberg, Heidelberg, Germany
- **Closing and remarks**
  M Gertz, Mayo Clinic College of Medicine, Rochester, United States

POSTER SESSION I

The main goal of the Poster Session is to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators (senior experts in the field) and interested congress participants. The Poster Session consists of two parts: the Poster Walk and Poster Browsing Time. This setup guarantees sufficient time for all posters that have been selected for a presentation. The first hour of the Poster Walk is moderated and then followed by the Poster Browsing Time, where the rest of the posters can be browsed on the e-poster screens available in the poster area.

Poster walks will be organized during the poster sessions on Friday, June 23 at 17:15 – 18:45 and Saturday, June 24 at 17:30 - 19:00. Poster authors and moderators are requested to be present at the first poster in their poster session, at the beginning of the presentation time (Friday at 17:15 and Saturday at 17:30).
Poster Browsing Time will be organized after the Poster Walk, on Friday, June 23 18:15 – 18:45 and Saturday, June 24 at 18:30 – 19:00.

17:15 – 18:45, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY 1

Moderator: J Soulier (INSERM U944/CNRS UMR7212 Hôpital Saint-Louis & University Paris Diderot UP7, France)

P151 **TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
J De Bie[1] ([1]KU Leuven, Leuven, Belgium)

P152 **BCL-2 INHIBITION AS NEW THERAPEUTIC OPPORTUNITY FOR RPL10 R98S MUTANT PEDIATRIC T-ALL**
K Kampen[1] ([1]KU Leuven, LKI Leuven Cancer Institute, Leuven, Belgium)

P153 **TRANSLATOME ANALYSIS OF THE T-ALL ASSOCIATED RIBOSOMAL PROTEIN L10 R98S MUTATION REVEALS ALTERED SERINE METABOLISM**
L Fancello[1] ([1]KU Leuven - University of Leuven, Leuven, Belgium)

P154 **REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN**
M Karsa[1] ([1]Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia)

P155 **TP53 MUTATIONS DISRUPTING DNA BINDING LEAD TO CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA**
M Pogodzinski[1] ([1]Charité - Universitaetsmedizin Berlin, Berlin, Germany)

P156 **GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA**
R De Smedt[1] ([1]Ghent University, Gent, Belgium)

P157 **IL-7 FLEXIBLY REGULATES AUTOPHAGY-DEPENDENT VIABILITY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS**
D Ribeiro[1] ([1]Instituto de Medicina Molecular, Lisbon, Portugal)

P158 **PRECLINICAL ACTIVITY OF ENTOSPLETINIB IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
S Tasian[2, 3] ([2]Children's Hospital of Philadelphia, Philadelphia, United States, [3]Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States)

P159 **PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION**
R Lehal[1] ([1]Cellestia Biotech AG, Basel, Switzerland)

17:15 – 18:45, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL 1

Moderator: S Chiaretti (Sapienza University of Rome, Italy)

P160 **IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL.**
R Mitchell[1] ([1]UCL Cancer Institute, London, United Kingdom)

P161 **PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY**
G Tsaur[1] ([1]Regional Children Hospital #1, Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation)

P162 **PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY**
B Ostrowska[1] ([1]The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland, Warszawa, Poland)

P163 **CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE**
R Bassan[1] ([1]Ospedale dell'Angelo, Mestre Venezia, Italy)

P164 **RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA**
N Morley[1] ([1]Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom)

P165 **CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA – A SINGLE INSTITUTION EXPERIENCE**
K Miller[1] ([1]Mayo Clinic, Rochester, United States)

P166 **MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE "SAPIENZA" UNIVERSITY BETWEEN 1996 AND 2016**
S Chiaretti[1] ([1]Sapienza University of Rome, Rome, Italy)

P167 **THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA**
K Leung[1] ([1]The Chinese University of Hong Kong, Shatin, Hong Kong)

P168 **PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL HDAC EXPRESSION**
N Vega-Garcia[1] ([1]Institut de Recerca Pediàtrica Hospital Sant Joan de Deu, Barcelona, Spain)

P169 **MINIMAL DISSEMINATED DISEASE DETECTION BY FLOW-CYTOMETRIC IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA**
G Viswanathan[1] ([1]Advanced Centre for Treatment, Research and Education in Cancer (Actrec) - Tata Memorial Centre (TMC), MUMBAI, India)

P170 **INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL**
N Short[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - BIOLOGY 1

Moderator: S Gröschel (DKFZ Heidelberg / University Hospital Heidelberg, Germany)

P171 **RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**
K Suzuki[1] ([1]Nagoya University Graduate School of Medicine, Nagoya, Japan)

P172 **BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML**
S Raffel[1, 2, 3] ([1]German Cancer Research Center, Heidelberg, Germany, [2]Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany, [3]Heidelberg University, Heidelberg, Germany)

P173 **NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST**
L Brunetti[1] ([1]Baylor College of Medicine, Houston, United States)

P174 **THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA**
D Papaioannou[1] ([1]The Ohio State University, Columbus, United States)

P175 **A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA**
D Moujalled[1, 2] ([1]Monash University, Melbourne, Australia, [2]The Alfred Hospital, Melbourne, Australia)

P176 **THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA**
E Voisset[1] ([1]King's College London, London, United Kingdom)

P177 **DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENISIS**
D Heckl[1] ([1]Hannover Medical School, Hannover, Germany)

P179 **ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTI-LINEAGE ENGRAFTED MICE**
B Saeed[1] ([1]Heidelberg University Hospital, Heidelberg, Germany)

P180 **THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A 'COMPLEX' STORY**
N Mannion[1] ([1]Institute of Cancer Sciences, MVLS, University of Glasgow, Glasgow, United Kingdom)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - BIOLOGY 2

Moderator: A Puissant (INSERM U944, Institute of Hematology, St Louis Hospital, Paris, France)

P181 **STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX**
R Karjalainen[1] ([1]Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland)

P182 **IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING**
F Rücker[1] ([1]University Hospital of Ulm, Ulm, Germany)

P183 **H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE**
S Garciaz[1, 2, 3] ([1]Paoli-Calmettes Institute, Marseille, France, [2]Cancer research center, Marseille, France, [3]Aix-Marseille University, Marseille, France)

P184 **FUNCTIONAL ASSESSMENT OF NOVEL DIAGNOSTIC FLT3 MUTATIONS AND INHIBITION BY KINASE INHIBITORS**
K Tarlock[1, 2] ([1]Seattle Children's Hospital, Seattle, United States, [2]Fred Hutchinson Cancer Research Center, Seattle, United States)

P186 **THE BCL-2 INHIBITOR VENETOCLAX INHIBITS NRF2 ANTIOXIDANT PATHWAY ACTIVATION INDUCED BY HYPOMETHYLATING AGENTS IN ACUTE MYELOID LEUKEMIA**
L Nguyen[1] ([1]City of Hope Medical Center, Duarte, United States)

P187 **UNRAVELING EPIGENOMIC REGULATION IN THE EVOLUTION OF RELAPSING PEDIATRIC AML**
C Wiggers[1, 2] ([1]University Medical Center Utrecht, Utrecht, the Netherlands, [2]Hubrecht Institute, Utrecht, the Netherlands)

P188 **MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RARĐ AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS**
M Mckeown[1] ([1]Syros Pharmaceuticals, Cambridge, United States)

P189 **FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS**
D Sampath[1] ([1]Genentech, South San Francisco, United States)

P190 **SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7**
L Smit[1] ([1]VU University Medical Center, Amsterdam, the Netherlands)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 1

Moderator: S Freeman (University of Birmingham, United Kingdom)

P191 **ONGOING PHASE 2 CLINICAL TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): STAGE 1 AND STAGE 2 RESULTS**
N Pemmaraju[1] ([1]MD Anderson Cancer Center, Houston, TX, United States)

P192 **PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
K Takahashi[1] ([1]UT MD ANDERSON CANCER CENTER, Houston, United States)

P193 **DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY**
L Østgård[1], [2] ([1]Aarhus University Hospital, Aarhus, Denmark, [2]Aarhus University Hospital, Aarhus, Denmark)

P194 **IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS**
U Borate[1] ([1]Oregon Health & Science University, Portland, United States)

P195 **MUTATIONAL LOAD OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE – IMPACT OF AZACITIDINE TREATMENT LINE**
L Pleyer[1], [2], [3] ([1]Paracelsus Medical University, Salzburg, Austria, [2]Center for Clinical Cancer and Immunology Trials, Salzburg, Austria, [3]Cancer Cluster, Salzburg, Austria)

P196 **MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA**
T Yabushita[1] ([1]Kobe City Medical Center General Hospital, Kobe City, Japan)

P197 **NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA**
V Mcclain[1] ([1]Invivoscribe, San Diego, United States)

P198 **IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?**
M Fernandez-Mercado[1], [2], [3] ([1]School of Engineering, University of Navarra, San Sebastian, Spain, [2]Biodonostia HRI, Donostia University Hospital, San Sebastian, Spain, [3]CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain)

P199 **EXPERIENCE WITH MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN AML WITH RUNX1-RUNX1T1: A STUDY ON 186 PATIENTS**
A Hoellein[1] ([1]Munich Leukemia Laboratory, Munich, Germany)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 2

Moderator: D Breems (Ziekenhuis Netwerk Antwerpen, Belgium)

P200 **NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**
G Montalban-Bravo[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

P201 **VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)**
F Ravandi[1] ([1]MD Anderson, Houston, United States)

P202 **ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS.**
J Sierra[1] ([1]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

P203 **GMI-1271, A POTENT E-SELECTIN ANTAGONIST, COMBINED WITH INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS WITH UNTREATED AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE**
D DeAngelo[1] ([1]Dana-Farber Cancer Institute, Boston, United States)

P204 **A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)**
J Cortes[1] ([1]University of Texas, MD Anderson Cancer Center, Houston, TX, United States)

P205 **CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKEMIA CELLS**
P García-Ramírez[1] ([1]Complejo Hospitalario de Navarra, Pamplona, Spain)

P206 **CLONAL HETEROGENEITY IN LEUKEMIC STEM CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA**
L Manta[1] ([1]University of Heidelberg, Heidelberg, Germany)

P207 **TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE**
K Takahashi1 (1University of Texas MD Anderson Cancer Center, Houston, United States)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 3

Moderator: C Muller-Tidow (University Hospital Heidelberg, Germany)

P208 **STABLE DISEASE WITH HEMATOLOGIC IMPROVEMENT IS CLINICALLY MEANINGFUL FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE**
A Schuh[1] ([1]Princess Margaret Cancer Centre/University Health Network, Toronto, Canada)

P209 **A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA**
N Short[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

P210 **OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA**
B Medeiros[1] ([1]Stanford University School of Medicine, Stanford, CA, United States)

P211 **NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION**
T Kadia[1] ([1]MD Anderson Cancer Center, Houston, United States)

P212 **HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA**
SY Hung[1] ([1]National Taiwan University Hospital, Taipei City, Taiwan, Republic of China)

P213 **LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR**
O Pérez-López[1] ([1]Virgen del Rocío University Hospital, Sevilla, Spain)

P214 **POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY**
C Frairia[1] ([1]University-Hospital Città della Salute e della Scienza, Torino, Italy, Torino, Italy)

P215 **DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB (AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (MIDH2)**
A Fathi[1, 2] ([1]Massachusetts General Hospital Cancer Center, Boston, United States, [2]Harvard Medical School, Boston, United States)

17:15 – 18:45, Poster area

AGGRESSIVE NON-HODGKIN LYMPHOMA - 1ST LINE

Moderator: To be announced

P216 **RADIOTHERAPY TO PET-NEGATIVE BULKY DISEASE CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF 187 PATIENTS WITH BULKY DISEASE OF THE OPTIMAL→60 STUDY OF THE DSH-NHL**
M Pfreundschuh[1] ([1]Saarland University Medical School, Homburg, Germany)

P217 **OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP**
A Bonnet[1] ([1]University Hospital Hôtel-Dieu, Nantes, France)

P218 **OUTCOME OF ELDERLY DLBCL PATIENTS (↗ 80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY**
M Trněný[1] ([1]Charles University General Hospital, Prague, Czech Republic)

P219 **IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015**
A Dinmohamed[1], [2], [3] ([1]Erasmus MC Cancer Institute, Rotterdam, the Netherlands, [2]Erasmus Univeristy Medical Center, Rotterdam, the Netherlands, [3]the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands)

P220 **CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE HEPATITIS C - ASSOCIATED NON-HODGKIN LYMPHOMA (DLBCL + C).**
S Lepkov[1] ([1]Russian National Research Medical University named after N.I. Pirogov, Moscow, Russian Federation)

P221 **MAGNETIC RESONANCE IMAGING FOR EARLY DETECTION OF ANTHRACYCLINE CARDIOTOXICITY IN MALIGNANT LYMPHOMA**
A Laursen[1] ([1]Rigshospitalet, Copenhagen, Denmark)

P222 **ANTI-INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY-ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH R-CHOP**
M Pfreundschuh[1] ([1]Saarland University Medical School, Homburg, Germany)

P223 **RELAPSE CHARACTERISTICS AND THE ROLE OF SURVEILLANCE COMPUTED TOMOGRAPHY IN AGGRESSIVE NON-HODGKIN LYMPHOMA**
KW Kang[1] ([1]Korea University School of Medicine, Seoul, Korea, Republic Of)

P224 **A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS**
J Ji[1] ([1]West China Hospital of Sichuan University, Chengdu, China)

P225 **LONG TERM FOLLOW-UP OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS TREATED WITH IFOSFAMIDE, ETOPOSIDE, EPIRUBICIN / INTERMEDIATE METHOTREXATE AND AUTOLOGOUS STEM CELL TRANSPLANTATION**
M Sieniawski[1] ([1]Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom)

17:15 – 18:45, Poster area

BONE MARROW FAILURE SYNDROMES INCL. PNH - BIOLOGY

Moderator: M Bartels (Wilhelmina Kinderziekenhuis, Utrecht, the Netherlands)

P226 **IDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY**
T Ripperger[1] ([1]Hannover Medical School, Hannover, Germany)

P227 **LOSS OF THE HOMOLOGOUS RECOMBINATION GENE RAD51 LEADS TO FANCONI ANEMIA-LIKE SYMPTOMS IN ZEBRAFISH**
J Botthof[1], [2], [3] ([1]University of Cambridge, Cambridge, United Kingdom, [2]Wellcome Trust Sanger Institute, Cambridge, United Kingdom, [3]University of Cambridge, Cambridge, United Kingdom)

P228 **A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS**
C Burney[1] ([1]University Hospitals Bristol NHS Trust, Bristol, United Kingdom)

P229 **GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS**
G Guenechea[1], [2] ([1]Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, Spain, [2]Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain)

P230 **STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY**
A Wannez[1], [2] ([1]University of Namur, Namur, Belgium, [2]Université catholique de Louvain, Yvoir, Belgium)

P231 **TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA –PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY**
F Beier[1] ([1]Medical Faculty, RWTH Aachen University, Aachen, Germany)

P232 **TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015.**
S Giammarco[1] ([1]Università Cattolica del Sacro Cuore, Rome, Italy)

P233 **CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM**
D Iskander[1] ([1]Imperial College London, London, United Kingdom)

P234 **BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS**
M Miano[1] ([1]IRCCS Istituto Giannina Gaslini, Genova, Italy)

P235 **COVERSIN, A NOVEL C5 COMPLEMENT INHIBITOR, FOR THE TREATMENT OF PNH: RESULTS OF A PHASE 2 CLINICAL TRIAL**
A Hill[1] ([1]Leeds Teaching Hospitals, LEEDS, United Kingdom)

17:15 – 18:45, Poster area

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY 1

Moderator: D Colomer (Unitat d'Hematopatologia, Barcelona, Spain)

P236 **GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA**
J Brown[1], [2], [3] ([1]Broad Institute of MIT and Harvard, Cambridge, United States, [2]Dana-Farber Cancer Institute, Boston, United States, [3]Brigham and Women's Hospital, Boston, United States)

P237 **DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK ALLELE GENOTYPE IN CLL**
J Brown[1], [2] ([1]Dana Farber Cancer Institute, Boston, United States, [2]Harvard Medical School, Boston, United States)

P238 **BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY**
K Plevova[1], [2] ([1]University Hospital Brno, Brno, Czech Republic, 2Masaryk University, Brno, Czech Republic)

P239 **INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P STATUS IN CLL PATIENTS**
M Stevens-Kroef[1] ([1]Radboud university medical center, Nijmegen, the Netherlands)

P240 **CYTOGENETIC CLONAL EVOLUTION OCCURS AT THE TIME OF DISEASE PROGRESSION DURING IBRUTINIB THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL.**
P Thompson[1] ([1]MD Anderson Cancer Center, Houston, United States)

P241 **LANDSCAPE OF SOMATIC MUTATIONS AND THEIR IMPACT ON RESPONSE AND OUTCOMES FROM LENALIDOMIDE-BASED THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
B Hu[1] ([1]MD Anderson Cancer Center, Houston, Texas, United States)

P242 **HIGH THROUGHPUT IMMUNOPROFILING OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS ASSIGNED TO STEREOTYPED SUBSET #4: NOVEL INSIGHTS INTO THE DEPTH, DIVERSITY AND TEMPORAL DYNAMICS OF CLONAL EVOLUTION**
L Sutton[3], [4] ([3]Uppsala University, Uppsala, Sweden, [4]Karolinska Institutet, Stockholm, Sweden)

P243 **FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC LYMPHOCYTIC LEUKEMIA SPECIFIC EPIGENOTYPE**
K Szarc Vel Szic[1] ([1]University Freiburg Medical Center, Freiburg, Germany)

P244 **DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?**
S Bhoi[1] ([1]Uppsala University, Uppsala, Sweden)

17:15 – 18:45, Poster area

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL

Moderator: To be announced

P245 **ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY**
A Rawstron[1] ([1]HMDS, St. James's Institute of Oncology, Leeds, United Kingdom)

P246 **CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS**
B Stamatopoulos[1] ([1]J. Bordet Institute, University of Brussels, Brussels, Belgium)

P247 **DURABILITY OF RESPONSES ON CONTINUOUS THERAPY AND FOLLOWING DRUG CESSATION IN DEEP RESPONDERS WITH VENETOCLAX AND RITUXIMAB**
M Anderson[1] ([1]Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Cancer and Hematology Division, Melbourne, Australia)

P248 **PREDICTIVE AND PROGNOSTIC IMPACT OF GENE MUTATIONS IN THE CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) WITH OR WITHOUT OFATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL**
E Tausch[1] ([1]Ulm University, Ulm, Germany)

P249 **RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
A Danilov[1] ([1]Oregon Health and Science University, Portland, United States)

P250 **RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014**
A Dinmohamed[1], [2], [3] ([1]the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands, [2]Erasmus University Medical Center, Utrecht, the Netherlands, [3]Erasmus MC Cancer Institute, Rotterdam, the Netherlands)

P251 **CUMULATIVE ILLNESS RATING SCALE (CIRS) PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI): AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG**
V Goede[1], [2] ([1]University Hospital Cologne, Cologne, Germany, [2]St. Marien Hospital, Cologne, Germany)

P252 **A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA**
D Allsup[1], [2] ([1]Hull and East Yorkshire NHS Trust, Hull, United Kingdom, 2Hull York Medical School, Hull, United Kingdom)

P253 **FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): DURABLE REMISSIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B)**
J Brown[1] ([1]Dana-Farber Cancer Institute (CLL Research Consortium), Boston, United States)

P254 **THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANT IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE**
T Anagnostou[1] ([1]Mayo Clinic, Rochester, United States)

17:15 – 18:45, Poster area

CHRONIC MYELOID LEUKEMIA - CLINICAL 1

Moderator: J Mayer (Masaryk University Hospital, Brno, Czech Republic)

P255 **IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL**
S Rinaldetti[1] ([1]Universitätsmedizin Mannheim, Mannheim, Germany)

P256 **HLA-G MOLECULES AND CLINICAL OUTCOME IN CHRONIC MYELOID LEUKEMIA**
G Caocci[1] ([1]University of Cagliari, Cagliari, Italy)

P257 **DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE**
T Hughes[1] ([1]SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia)

P258 **NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS**
S Pushpakom[1] ([1]University of Liverpool, Liverpool, United Kingdom)

P259 **EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA**
S Jung[3], [4] ([3]Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea, Republic Of, [4]College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of)

P261 **A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL**
GN Franke[1] ([1]Universitätsklinikum Leipzig AöR, Leipzig, Germany)

P262 **VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS**
I Geelen[1] ([1]Albert Schweitzer Hospital, Dordrecht, the Netherlands)

P263 **FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP**
H Nakamae[1] ([1]Graduate School of Medicine, Osaka City University, Osaka, Japan)

17:15 – 18:45, Poster area

HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT

Moderator: T Itkin (Weill Cornell Medicine, New York)

P264 **ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE**
D Passaro[1] ([1]The Francis Crick Institute, London, United Kingdom)

P265 **BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS**
R Groen[1] ([1]VU University Medical Center, Amsterdam, the Netherlands)

P266 **MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS**
C Nombela Arrieta[1] ([1]University and Universit Hospital Zurich, Zurich, Switzerland)

P267 **TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION**
M Koning[1] ([1]Leiden University Medical Center, Leiden, the Netherlands)

P268 **TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION**
S Solier[1] ([1]Gustave Roussy, VILLEJUIF, France)

P269 **MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13**
K Beider[1] ([1]SHEBA MEDICAL CENTER, Ramat-Gan, Israel)

P270 **RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR**
S O'Byrne[1] ([1]University of Oxford, Oxford, United Kingdom)

P271 **HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS**
M Ganuza Fernandez[1] ([1]St. Jude Children's Research Hospital, Memphis, United States)

P272 **A20 RESTRAINS THYMIC REGULATORY T CELL DEVELOPMENT**
T Haas[1] ([1]Klinikum rechts der Isar, TU München, München, Germany)

P273 **THE TRANSCRIPTION FACTOR C/EBPG REGULATES MAST CELL DEVELOPMENT AND FUNCTION**
M Kardosova[1] ([1]Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic)

P274 **TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR BARCODING AND TRANSCRIPTOME-WIDE PROFILING**
D Tronik-Le Roux[1] ([1]CEA, Paris, France)

17:15 – 18:45, Poster area

HODGKIN LYMPHOMA

Moderator: A Sureda (Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain)

P275 **LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL) TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP (GHSG)**
D Eichenauer[1] ([1]University Hospital Cologne, Cologne, Germany)

P276 **ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16–59**
J Russell[1] ([1]Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom)

P277 **IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION**
N Pugliese[1] ([1]University of Naples Federico II, Naples, Italy)

P278 **LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN'S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM**
K Byrne[1] ([1]Adelphi Real World, Bollington, United Kingdom)

P279 **CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.**
H Saeed[1] ([1]University of Kentucky- Markey Cancer Center, Lexington, United States)

P280 **THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS**
P Tsirigotis[1] ([1]National and Kapodistrian University of Athens, Athens, Greece)

P281 **NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY**
B Ferhanoglu[1, 2] ([1]Koc University School of Medicine, Istanbul, Turkey, [2]V.K.V. American Hospital, Istanbul, Turkey)

P282 **GENOTYPING OF HODGKIN LYMPHOMA ON THE LIQUID BIOPSY**
V Spina[1] ([1]Institute of Oncology Research, Bellinzona, Switzerland)

P283 **FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA**
G Sambuceti[1] ([1]IRCCS San Martino - IST, Genova, Italy)

17:15 – 18:45, Poster area

IRON METABOLISM, DEFICIENCY AND OVERLOAD

Moderator: A Kattamis (University of Athens, 'Aghia Sofia' Children's Hospital, Greece)

P284 **ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM B-THALASSEMIA AND HEMOCHROMATOSIS COHORT STUDIES**
F Vinchi[1] ([1]University of Heidelberg & EMBL, Heidelberg, Germany)

P285 **REAL-WORLD ADHERENCE TO IRON CHELATION THERAPY: COMPARING A FILM-COATED TABLET VERSUS DISPERSIBLE TABLET OF DEFERASIROX**
Q Said[3] ([3]Novartis Pharmaceuticals, East Hanover, United States)

P286 **MEDIATION BY PATIENT-REPORTED OUTCOMES ON THE ASSOCIATION BETWEEN FILM-COATED VERSUS DISPERSIBLE FORMULATIONS OF DEFERASIROX AND SERUM FERRITIN REDUCTION: A POST HOC ANALYSIS OF THE ECLIPSE TRIAL**
A Taher[1] ([1]American University of Beirut Medical Center, Beirut, Lebanon)

P287 **ASSESSMENT OF THE PERFORMANCE OF A WIDELY AVAILABLE T2*/R2* LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE IN A POPULATION OF THALASSEMIA PATIENTS**
T St Pierre[4] ([4]The University of Western Australia, Crawley, Australia)

P288 **SIMILAR TRENDS IN RENAL FUNCTION AS MEASURED BY SERUM CREATININE DURING LONG-TERM IRON CHELATION TREATMENT WITH OR WITHOUT DEFERASIROX IN PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS**
R Origa[1] ([1]Ospedale Pediatrico Microcitemico 'A Cao', University of Cagliari, Cagliari, Italy)

P289 **WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR THE DIAGNOSIS OF RED CELL AND IRON DISORDERS**
P Aguilar Martinez[1] ([1]HOPITAL SAINT ELOI, MONTPELLIER CEDEX 5, France)

P290 **CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET**
A Maggio[1] ([1]Campus of Hematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo, Italy)

P291 **IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA**
R El-Farrash[1] ([1]Faculty of Medicine-Ain Shams University, Cairo, Egypt)

P292 **THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PEDIATRIC CANCER SURVIVORS**
T St. Pierre[1, 2] ([1]Resonance Health, Claremont, Australia, [2]The University of Western Australia, Crawley, Australia)

P293 **DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY**
G Porto[1] ([1] I3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal)

P294 **FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE COMPLEX IN WOMEN WITH IRON DEFICIENCY ANEMIA – A RANDOMISED CONTROLLED TRIAL**
G Chaudhry[1] ([1]SBAMI, New Delhi, India)

17:15 – 18:45, Poster area

LYMPHOMA BIOLOGY

Moderator: F Asmar (Rigshospitalet, Copenhagen, Denmark)

P295 **GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY**
A Sud[1] ([1]The Institute of Cancer Research, London, United Kingdom)

P296 **SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA**
P Balsas[1] ([1]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain)

P297 **AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS**
P Dominguez [1] ([1]Weill Cornell Medicine, New York, United States)

P298 **XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA**
M Crespo[1] ([1]Vall d'Hebron Institute of Oncology, Barcelona, Spain)

P299 **MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.**
Y Watatani[1] ([1]Kyoto university, Kyoto, Japan)

P300 **A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS**
M Duran-Ferrer[1] ([1]UB, Barcelona, Spain)

P301 **ACTIVATION OF RHOA-VAV1 SIGNALING AXIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA**
M Fujisawa[1] ([1]University of Tsukuba, Tsukuba city, Japan)

P302 **STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION**
E Onozawa[1], [2] ([1]Tokyo Medical and Dental University, Tokyo, Japan, [2]Tokyo Medical and Dental University, Tokyo, Japan)

P303 **RECURRENT MUTATIONS IN MICRO-RNA BINDING SITES MAY BE POTENTIALLY RELEVANT IN FOLLICULAR LYMPHOMA**
E Larrea[1] ([1]Biodonostia, Donostia/San Sebastian, Spain)

P304 **CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL**
S Ferrero[1] ([1]Università di Torino, Torino, Italy)

17:15 – 18:45, Poster area

MULTIFACED ASPECTS OF BLEEDING DISORDERS

Moderator: I Bodó (Emory University School of Medicine, Atlanta, USA)

P305 **A LOOKBACK AT VWD TYPE 2A AND 2M CLASSIFICATION IN A LARGE COMPREHENSIVE HAEMOPHILIA CENTRE.**
S Jaafar[1], [2] ([1]Royal Free Hospital /NHS, london, United Kingdom, [2]katharine dormandy haemophilia centre/royal free hospital, london, United Kingdom)

P306 **RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS.**
C Santoro[1] ([1]HEMATOLOGY SAPIENZA UNIVERSITY, Rome, Italy)

P307 **OSTEOPOROSIS IN PATIENTS WITH HEMOPHILIA**
V Zorenko[1] ([1]National Research Center for Hematology, Moscow, Russian Federation)

P308 **PREVALENCE OF GENETIC MARKERS OF OXIDATIVE STRESS IN PATIENTS WITH SEVERE HEMOPHILIA FROM NORTH-WESTERN RUSSIA**
S Kapustin[1] ([1]Russian Research Institute Of Haematology And Transfusiology, Saint-Petersburg, Russian Federation)

P309 **THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN CONGENITAL FACTOR XIII DEFICIENCY**
A Noroozi-Aghideh[1] ([1]AJA UNIVERSITY OF MEDICAL SCIENCES, Tehran, Iran, Islamic Republic Of)

P310 **GENETIC CONFIRMATION AND FINDING NOVEL MUTATIONS IN GLANZMANN THROMBASTHENIA AND VON WILLEBRAND DISEASE FAMILIES BY DIAGNOSTIC EXOME SEQUENCING**
Y Shim[1] ([1]Keimyung University School of Medicine and Dongsan Medical Center, Daegu, Korea, Republic Of)

P311 **HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA**
Z Irina[1] ([1]Russian Research Institute of hematology, Saint-Petersburg, Russian Federation)

P312 **AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA**
A Kreuger[1], [2] ([1]Sanquin Research, Leiden, the Netherlands, [2]LUMC, Leiden, the Netherlands)

17:15 – 18:45, Poster area

MYELODYSPLASTIC SYNDROMES – CLINICAL 1

Moderator: L Pleyer (Paracelsus Medical University, Salzburg, Austria)

P313 **MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES**
M Shiseki[1] ([1]Tokyo Women's Medical University, Tokyo, Japan)

P314 **MOLECULAR MARKERS PREDICTING RESPONSE TO AZACITIDINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES.**
Y Nannya[1] ([1]Kyoto University, Kyoto, Japan)

P315 **UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA**
G Montalban-Bravo[1] ([1]MD Anderson Cancer Center, Houston, United States)

P316 **AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES.**
M Díez Campelo[1] ([1]GESMD, Valencia, Spain)

P317 **UN UPDATE OF A PHASE II EXPLORATORY STUDY OF OPN-305, A TOLL-LIKE RECEPTOR 2 (TLR-2) ANTIBODY, IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH PRIOR HYPOMETHYLATING AGENT (HMA) THERAPY**
G Garcia-Manero[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

P318 **IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS**
J Caballero Berrocal[1] ([1]University Hospital of Salamanca, Salamanca, Spain)

P319 **VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS): A PHASE 1/ COHORT EXPANSION STUDY**
M Jacoby[1] ([1]Washington University Medical School, St. Louis, United States)

17:15 – 18:45, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY

Moderator: WJ Chng (National University Cancer Institute, Singapore)

P320 **ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE**
S Barrio[1] ([1]Würzburg University Hospital, Würzburg, Germany)

P321 **ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA**
M Marchesini[1] ([1]MDAnderson Cancer Center, Houston, United States)

P322 **PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.**
M D'agostino[1] ([1]Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

P323 **TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA**
S Manier[1], [2] ([1]Dana-Farber Cancer Institute, Boston, United States, [2]Lille Hospital, Lille, France)

P324 **DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMIDS**
K Dimopoulos[1] ([1]Rigshospitalet, Copenhagen, Denmark)

P325 **MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA**
R Ordoñez[1] ([1]Center for Applied Medical Research (CIMA), Pamplona, Spain)

P326 **CLINICAL IMPLICATIONS OF CLONAL CD34+ CELLS IN STEM CELL HARVEST FROM PATIENTS WITH PLASMA CELL DYSCRASIAS**
S Chitre[1] ([1]KINGS COLLEGE LONDON, London, United Kingdom)

P327 **PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA**
M Ishibashi[1] ([1]Nippon Medical School, Tokyo, Japan)

P328 **TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001**
A Molina[1] ([1]Sutro Biopharma, South San Francisco, United States)

P329 **GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING**
I Cuenca[1] ([1]Hospital 12 de Octubre, Madrid, Spain)

17:15 – 18:45, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 1

Moderator: N Bolli (Università degli Studi di Milano, Italy)

P330 **IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY**
S Thorsteinsdottir[1] ([1]Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland)

P331 **PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA**
M Binder[1] ([1]Mayo Clinic, Rochester, United States)

P332 **LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB**
P McCarthy[1] ([1]Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, United States)

P333 **UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)**
D Siegel[1] ([1]Hackensack University Medical Center, Hackensack, United States)

P334 **EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX**
M Dimopoulos[1] ([1]National and Kapodistrian University of Athen, Athens, Greece)

P335 **DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (↗75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES**
MV Mateos[1] ([1]University Hospital of Salamanca/IBSAL, Salamanca, Spain)

P336 **ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL**
H Ludwig[1] ([1]Wilhelminen Cancer Research Institute, Vienna, Austria)

P337 **EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS**
E Kastritis[1] ([1]National and Kapodistrian University of Athens, Athens, Greece)

P338 **AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)**
M Dimopoulos[1] ([1]National and Kapodistrian University of Athens School of Medicine, Athens, Greece)

P339 **THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)**
J San Miguel[1] ([1]Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA) Hospital Universitario Virgen del Rocio, Pamplona, Spain)

17:15 – 18:45, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 2

Moderator: J de la Rubia (University Hospital Dr. Peset, Valencia, Spain)

P340 **FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN – PREDNISONE – BORTEZOMIB (MPV) IN PATIENTS ↗ 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY**
S Zweegman[1] ([1]VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands)

P341 **THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB, BENDAMUSTINE, AND DEXAMETHASONE (CBD) IS EFFICIENT AND SAFE IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA**
M Gramatzki[1] ([1]Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Kiel, Germany)

P342 **CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP**
U Hegenbart[1] ([1]University Hospital, Heidelberg, Germany)

P343 **MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)**
P Sonneveld[1] ([1]Erasmus MC Cancer Institute, Rotterdam, the Netherlands)

P344 **PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B KEYNOTE-013 STUDY**
V Ribrag[1] ([1]Institut Gustave Roussy, Villejuif, France)

P345 **ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM.**
Z Van De Wyngaert[1] ([1]CHRU Lille, Lille, France)

P346 **SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS**
JC Kim[1] ([1]Inha University Hospital, Incheon, Korea, Republic Of)

P347 **A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK**
O gamage[1] ([1]Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom)

P348 **SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES**
T Dejoie[1] ([1]Centre Hospitalier Universitaire-Nantes, Nantes, France)

P349 **THE CONNECT MM REGISTRY: IMPACT OF THE CYTOGENETIC ABNORMALITY T(11;14) ON SURVIVAL OUTCOMES IN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA**
C Gasparetto[1] ([1]Duke University Medical Center, Durham, United States)

17:15 – 18:45, Poster area

MYELOPROLIFERATIVE NEOPLASMS - CLINICAL 1

Moderator: A Almeida (Instituto Português de Oncologia de Lisboa (IPO Lisboa), Portugal)

P350 **RAS-PATHWAY MUTATION PATTERNS DEFINE EPIGENETIC SUBCLASSES IN JUVENILE MYELOMONOCYTIC LEUKEMIA**
D Lipka[1], [2] ([1]German Cancer Research Center (DKFZ), Heidelberg, Germany, [2]German Cancer Research Center (DKFZ), Heidelberg, Germany)

P351 **CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY**
B Mora[1] ([1]Ospedale di Circolo, ASST Sette Laghi, Varese, Italy)

P352 **MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE (MDS/MPN-U)**
P Bose[1] ([1]University of Texas MD Anderson Cancer Center, Houston, United States)

P353 **GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA**
E Stieglitz[1, 2] ([1]UCSF Benioff Children's Hospital, San Francisco, United States, [2]University of California, San Francisco, San Francisco, United States)

P354 **LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER?**
V Geoffroy[1] ([1]Institut Paoli Calmettes, Marseille, France)

P355 **INCIDENCE AND OUTCOME OF SECONDARY NON HEMATOLOGICAL CANCERS IN ADULT PATIENTS WITH MASTOCYTOSIS**
M Bonifacio[1, 2] ([1]University of Verona, Verona, Italy, [2]Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy)

P356 **HIGH WBC COUNT WAS THE RISK FACTOR FOR SURVIVAL IN PATIENTS WITH CSF3R- MUTATED CHRONIC NEUTROPHILIC LEUKEMIA**
Q Jiang[1] ([1]Peking University Institute of Hematology, Beijing, China)

P357 **CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA**
E Rumi[1, 2] ([1]Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [2]Department of Molecular Medicine, University of Pavia, Pavia, Italy)

P358 **VALIDATION OF THE REVISED IPSET-THROMBOSIS SCORE IN 734 PATIENTS WITH WHO 2016-DEFINED ESSENTIAL THROMBOCYTHEMIA. REPORT OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)**
L Gugliotta[1] ([1]Policlinico S.Orsola-Malpighi, Bologna, Italy)

P359 **CORRELATIONS BETWEEN INFLAMMATORY BIOMARKERS AND INDIVIDUAL SYMPTOMS EXPRESSED BY MYELOFIBROSIS PATIENTS IN THE COMFORT-I TRIAL: ANALYSIS OF BASELINE ASSOCIATIONS AND CHANGES OVER TIME**
H Geyer[1] ([1]Mayo Clinic, Phoenix, AZ, United States)

17:15 – 18:45, Poster area

PLATELET DISORDERS: BASIC

Moderator: To be announced

P360 **NOVEL HETEROZYGOUS ITGB3 P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN ĐIIBĐ3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL ĐIIBĐ3 LOCALIZATION**
N Miyashita[1] ([1]Hokkaido University Graduate School of Medicine, Sapporo, Japan)

P361 **CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG**
J Bastida[1] ([1]Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain)

P362 **DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRESPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA**
S Wang[1] ([1]State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin, China)

P363 **A DECREASED INTRACELLULAR S1P LEVEL AND S1P RECEPTORS EXPRESSED ON MEGAKARYOCYTES POSSIBLY CONTRIBUTE TO DEFECTIVE PROPLATELETS FORMATION IN IMMUNE THROMBOCYTOPENIA**
X Zhang[1] ([1]Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)

P364 **ANTIBODY MEDIATED GLYCAN MODIFICATION: A POTENTIAL ROLE IN PLATELET DESTRUCTION IN AUTOIMMUNE THROMBOCYTOPENIA**
I Marini[1] ([1]University Hospital of Tübingen , Tübingen, Germany)

P365 **NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA**
P Noris[1] ([1]IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy)

P366 **TNF-Đ BLOCKADE CORRECTED THE IMPAIRED BALANCE OF MONOYCTE/MACROPHAGE SUBSETS IN PRIMARY IMMUNE THROMBOCYTOPENIA**
Y Zhao[1] ([1]Qilu Hosipital, Jinan, China)

P367 **A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)**
J Grainger[1] ([1]University of Manchester, Manchester, United Kingdom)

P368 **NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS?**
N Binsaleh[1] ([1]Manchester Metropolitan University, Manchester, United Kingdom)

17:15 – 18:45, Poster area

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS 1

Moderator: K Weisel (University Hospital of Tuebingen, Germany)

P369 **PATIENT-REPORTED OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION BEFORE AND DURING TREATMENT WITH ECULIZUMAB: RESULTS FROM THE INTERNATIONAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REGISTRY**
P Muus[1] ([1]Radboud University Medical Center, Nijmegen, the Netherlands)

P370 **ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS THROMBOEMBOLISM**
P Toulon[1] ([1]Pasteur University Hospital, Nice, France)

P371 **IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME.**
S Lachance[1] ([1]Université de Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada)

P372 **ACUTE MYELOID LEUKEMIA (AML) TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALLY-INSURED POPULATION**
M Hagiwara[1] ([1]Policy Analysis Inc., Brookline, MA, United States)

P373 **HEALTH-RELATED QUALITY OF LIFE IN AL AMYLOIDOSIS PATIENTS WITH NERVOUS SYSTEM INVOLVEMENT**
K McCausland[1] ([1]Optum, Lincoln, United States)

P374 **ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE**
R Iredale[1] ([1]University of South Wales, Pontypridd, United Kingdom)

P375 **THE BUDGET IMPACT OF TREATMENT-FREE REMISSION FOR FIRST-LINE NILOTINIB OR GENERIC IMATINIB IN TREATING CHRONIC PHASE PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA**
P Brandt[2] ([2]Novartis Pharmaceuticals Corporation, East Hanover, United States)

P376 **GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (→65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES**
J de la Rubia[17] ([17]H.U. Doctor Peset , Valencia, Spain)

P377 **NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY**
R Scherber[1], [2] ([1]Mayo Clinic, Scottsdale, United States, [2]Oregon Health and Science University, Portland, United States)

P378 **DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE**
C Karamanidou[1] ([1]CERTH, Thessaloniki, Greece)

17:15 – 18:45, Poster area

STEM CELL TRANSPLANTATION - CLINICAL 1

Moderator: C Solano (Hospital Clínico Universitario-INCLIVA Institute of Research, University of Valencia, Spain)

P379 **OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**
A Nagler[5] ([5]Chaim Sheba Medical Center, , Tel-Hashomer, Israel)

P380 **BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS**
M Jentzsch[1] ([1]UNIVERSITÄTSKLINIKUM LEIPZIG, Leipzig, Germany)

P381 **THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS**
A Bertaina[1] ([1]Ospedale Pediatrico Bambino Gesu, Rome, Italy)

P382 **EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM POOLED BM-MNCS OF MULTIPLE DONORS**
S Kuci[1] ([1]Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany)

P383 **HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL DAMAGE COMPLICATIONS**
T Morishita[1] ([1]Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan)

P384 **IMPACT OF CONDITIONING REGIMEN ON OUTCOMES OF T-REPLETE HAPLO-IDENTICAL TRANSPLANTATION FOR PATIENTS OVER 45 YEARS-OLD WITH AML: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**
D Nasso[1], [2] ([1]"Tor Vergata¨ University of Rome, Rome, Italy, [2]Hôpital Saint Antoine, Paris, France)

P385 **ROLE OF UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A DECISION ANALYSIS**
S Fuji[1] ([1]National Cancer Center Hospital, Tokyo, Japan)

P386 **OUTCOMES OF THIOTEPA BASED REDUCED-INTENSITY CONDITIONING VERSUS STANDARD REDUCED-INTENSITY CONDITIONING IN ADULT PATIENTS UNDERGOING DOUBLE-UNIT CORD-BLOOD HEMATOPOIETIC STEM CELL TRANSPLANT.**
P Sharma[1] ([1]University of Colorado, Denver, United States)

P387 **INTERFERON-Ð IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
XD Mo[1] ([1]Institute of Hematology, Beijing, China)

P388 **COMPARABLE LONG-TERM OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR OLDER PATIENTS (AGE ↗50 YEARS) WITH AML FROM SIBLING AND MATCHED UNRELATED DONORS. A REPORT ON BEHALF OF THE ALWP OF EBMT.**
A Shimoni[1] ([1]CHAIM SHEBA MEDICAL CENTER, Tel-Hashomer, Israel)

P389 **IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME**
J Aoki[1] ([1]Kanagawa Cancer Center, Yokohama, Japan)

P390 **LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT**
Y Han[1], [2] ([1]Soochow University, Suzhou, China, 2The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology, Suzhou, China)

17:15 – 18:45, Poster area

THALASSEMIA

Moderator: A Taher (American University of Beirut Medical Center (AUBMC), Lebanon)

P391 **QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR HBE/Ð-THALASSEMIC PATIENTS**
J Kittivorapart[1], [2], [3] ([1]NHS Blood and Transplant, Bristol, United Kingdom, [2]University of Bristol, Bristol, United Kingdom, [3]Faculty of Medicine Siriraj Hospital, Bangkok, Thailand)

P392 **A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA**
L De Franceschi[1] ([1]University of Verona, Verona, Italy)

P393 **MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE?**
M Grosso[1] ([1]University of Naples Federico II, Naples, Italy)

P394 **SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR**
A Meloni[1] ([1]Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy)

P395 **VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES**
T Suksangpleng[1] ([1]Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand)

P396 **TRANSIENT ELASTOGRAPHY IN NON TRANSFUSION DEPENDENT THALASSEMIA: A SUCCESSFUL TOOL TO ASSESS AND MONITORING LIVER FIBROSIS**
A Marcon[1] ([1]Foundation IRCCS "Ca' Granda" Ospedale Maggiore Policlinico, Milan, Italy)

P397 **INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC PATIENTS: A SINGLE INSTITUTION'S LONGITUDINAL EXPERIENCE**
E Repousi[1] ([1]National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece)

P398 **SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL**
M Elalfy[1] ([1]AinShams university, Cairo, Egypt)

P399 **LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS WITH THALASSEMIA MAJOR**
M Casale[1] ([1]AORN A. Cardarelli, Napoli, Italy)

P400 **LONG TERM FOLLOW-UP OF A COHORT OF WELL TREATED Ð-THALASSEMIA MAJOR PATIENTS BY MULTI-ORGAN R2* MAGNETIC RESONANCE IMAGING**
G Forni[1] ([1]Ospedale Galliera Genova, Genova, Italy)

17:15 – 18:45, Poster area

TRANSFUSION MEDICINE

Moderators: S Stanworth (NHS Blood and Transplant / Oxford University Hospitals NHS Trust, United Kingdom)
D Prati (Ospedale Alessandro Manzoni, Lecco, Italy)

P401 **DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST HTLV-1 INFECTION**
T Mizukami[1] ([1]National Institute of Infectious Diseases, Tokyo, Japan)

P402 **THE CONTAMINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA PATIENTS TO AUTOLOGOUS TRANSPLANTATION**
M Lozano[1] ([1]IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, Spain)

P403 **EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY LONDON HOSPITAL**
R Moll[1] ([1]Royal Free Hospital, London, United Kingdom)

P404 **A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MIRASOL PATHOGEN REDUCTION TECHNOLOGY**
L Gutierrez[4] ([4]IdISSC, Madrid, Spain)

P405 **USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING**
D Warcel[1] ([1]Royal Free Hospital, London, United Kingdom)

P406 **SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING**
M Healey[1] ([1]Loughborough University, Loughborough, United Kingdom)

EUROPEAN HEMATOLOGY ASSOCIATION

EHA-SWG SCIENTIFIC MEETING

Challenges in the diagnosis and management of myeloproliferative neoplasms

EBAH CME ACCREDITED

Dates: October 12-14, 2017
Location: Budapest, Hungary

Organized by:
EHA Scientific Working Group on Myeloproliferative Neoplasms

Chairs:
C Harrison, JJ Kiladjian

EHASWG SCIENTIFIC WORKING GROUPS

Topics:

- Molecular pathogenesis and diagnosis
- State of the art: Novel therapies for MPNs
- Indolent MPN
- What's new in myelofibrosis?
- Use of interferon in MPN
- Mechanisms of resistance to JAK inhibitors
- Patient advocacy in EU
- Prognostic scores in MPN
- Advances in systemic mastocytosis
- Advances in diagnosis and management of CMML
- State of the art: investigation and management of erythrocytosis

SATURDAY, JUNE 24

SPECIAL SESSIONS OF THE DAY

Next to the high quality scientific and education sessions of the day we would like to draw your attention to the following interesting sessions:

ADVOCACY TRACK

INTERESTED IN ADVOCACY & LOBBYING?

EHA Advocacy Track offers interesting sessions for you on Saturday:

→ EDUCATION SESSION 3 4 **B T C**
08:00 - 09:30, Hall A
Repeated from:
Friday, June 23, 09:45 - 11:15, Hall A

IMMUNOTHERAPY IN LYMPHOMA

Chair: A Engert (University Hospital of Cologne, Germany)

- **The role of the microenvironment in the pathogenesis of B-cell lymphomas**
  G Lenz (Translational Oncology, Münster, Germany)
- **Immune checkpoint inhibitors**
  A Younes (Memorial Sloan Kettering Cancer Center, New York, USA)
- **Is transplantation in lymphoma still needed in the era of immunotherapy?**
  A Sureda (Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain)

LEARNING GOALS

G Lenz

After attending this lecture, the participant will be able to

– Describe the role of the microenvironment in the biology of different B-cell lymphomas.
– Discuss important components of the microenvironment of different B-cell malignancies.
– Appreciate the interaction between bystander and malignant cells in B-cell lymphomas.

A Younes

An up-to-date program is available via the mobile app.

A Sureda

After attending this lecture, the participant will be able to

– Understand how the introduction of check point inhibitors will potentially modify the profile of Hodgkin's lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation.
– Describe transplant related toxicities and long term outcome of patients with Hodgkin's lymphoma that have been previously treated with check point inhibitors.
– Learn how to use check point inhibitors in those patients that relapse after the allogeneic procedure.

→ EDUCATION SESSION 3 5 10 **T C**
08:00 - 09:30, Hall B
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Hall D

MULTIPLE MYELOMA

Chair: A Alegre (Hospital Universitario de La Princesa, Madrid, Spain)

- **Immunopathology of MM**
  N Munshi (Dana-Farber Cancer Institute, Boston, USA)
- **Genetic classification of myeloma for prognostication and treatment selection**
  H Avet-Loiseau (IUC-Oncopole, Toulouse, France)
- **New treatment approaches in myeloma in 2017**
  JF San-Miguel (Universidad de Navarra, Pamplona, Spain)

LEARNING GOALS

N Munshi

After attending this lecture, the participant will be able to

– Describe the immune status in multiple myeloma.
– Discuss the impact of immune dysfunction on myeloma cell growth and survival.
– Elucidate various methods and mechanisms to augment immune function for potential therapeutic application.

H Avet-Loiseau

After attending this lecture, the participant will be able to

– Understand the genetic heterogeneity in myeloma.
– Know what main prognostic parameters are.
– Understand how these factors may influence treatment choices.

JF San-Miguel

After attending this lecture, the participant will be able to

– Better tools for diagnosis and monitoring treatment efficacy are being implemented.
– Early treatment and the use of more efficient drugs upfront prolong survival.
– The treatment goal is to find the best possible balance between efficacy, toxicity and cost, particularly at the time of relapse.

→ SCIENTIFIC WORKING GROUPS 3 5 **T C**
08:30 - 09:30, Hall C

LYMPHOMAS: DIAGNOSIS AND FOLLOW-UP OF LYMPHOMA

Chair: MJ Kersten (Academic Medical Center, Amsterdam, the Netherlands)

- **Introduction EHA LyG**
  MJ Kersten (Academic Medical Center, Amsterdam, the Netherlands)
- **Do we still need bone marrow biopsies?**
  TC El-Galaly (Aalborg University Hospital, Denmark)
- **Interim-PET as a valid biomarker for early response in malignant lymphoma; when to perform and how to assess**
  J Zijlstra (VU University medical center, Amsterdam, the Netherlands)
- **Circulating tumor DNA in Non-Hodgkin lymphoma: Clinical and future research applications**
  M Roschewski (National Cancer Institute, NIH, Bethesda, USA)

LEARNING GOALS

TC El-Galaly

After attending this lecture, the participant will be able to

– Learn about the diagnostic value of routine bone marrow biopsy in different lymphoma subtypes.
– Be informed about the Lugano Classification recommendations for routine bone marrow biopsy.
– Be informed about the controversies related to prognostic value of imaging-ascertained bone marrow involve.

J Zijlstra
After attending this lecture, the participant will be able to
– Describe the role of interim-PET in Hodgkin lymphoma.
– Discuss the assessment of PET-CT and the aetiology of false-positive/ false-negative PET-CT.
– Describe the difficulties in using interim-PET in DLBCL trials.

M Roschewski
After attending this lecture, the participant will be able to
– Describe how circulating tumor DNA assays compare to medical imaging as a surveillance tool in diffuse large B-cell lymphoma.
– Understand the potential advantages of circulating tumor DNA assays over tissue biopies.
– Discuss future potential applications of circulating tumor DNA assays across the spectrum of non-Hodgkin lymphomas.

→ EDUCATION SESSION 2 5 10 **T** **C**
08:00 - 09:30, Hall D
Repeated from:
Friday, June 23, 09:45 - 11:15, Hall C

CHRONIC MYELOID LEUKEMIA

Chair: S Soverini (University of Bologna, Italy)
- **Novel approaches to eradicate CML stem cells**
  M Copland (University of Glasgow, United Kingdom)
- **Molecular work up and monitoring of CML patients**
  N Cross (University of Southampton, United Kingdom)
- **How to treat CML in 2017**
  A Hochhaus (UK Jena, Germany)

LEARNING GOALS

M Copland
After attending this lecture, the participant will be able to
– Describe the different potential mechanisms of CML stem cell resistance to tyrosine kinase inhibitors.
– Discuss potential therapeutic strategies, in preclinical development or early phase clinical trials, which may improve eradication of CML stem cells.

N Cross
After attending this lecture, the participant will be able to
– Describe the essential elements for the diagnostic work of CML patients.
– Discuss factors associated with heterogeneous response to TKI therapy.
– Understand the role of molecular monitoring for personalised treatment, and how this process is standardised.

A Hochhaus
After attending this lecture, the participant will be able to
– Describe current and emerging therapies for newly diagnosed patients with CML.
– Select appropriate upfront therapy based upon patients treatment goals and preferences, considering efficacy, safety and costs of various options.
– Describe recommended monitoring strategies and clinical consequences from monitoring.
– Describe the selection of second line therapies according to biological and clinical parameters.
– Understand which patients may be eligible for treatment free remission.

→ EHA - INTERNATIONAL SOCIETY OF LABORATORY HEMATOLOGY (ISLH) - LABORATORY DIAGNOSIS WORKSHOP
08:00 - 11:15, Hall E

Organizers: JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)
A Orfao (University of Salamanca, Spain)

B-CELL MALIGNANCIES 3 5 9 10 **T** **C**

Chairs: JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)
G Zini (Catholic University Fondazione Policlinico Gemelli, Rome, Italy)
- **Pathogenic mechanisms in mantle cell lymphoma: Impact on the heterogeneity and WHO-2016 subclassification of the disease**
  P Jares (Hospital Clinic Barcelona, University of Barcelona, Spain)
- **How many subtypes of diffuse large B-cell lymphoma can be defined?**
  J Cabeçadas (Instituto Português de Oncologia, Lisbon, Portugal)
- **Is the WHO-2016 sufficient for the diagnosis and classification of plasma cell neoplasias?**
  B Durie (Cedars Sinai Medical Center, USA)

LEARNING GOALS

P Jares
After attending this lecture, the participant will be able to
– Understand the molecular pathogenesis in the development and progression of major subtypes of MCL.
– Recognize the different MCL variants, including the two indolent variants: Leukemic nonnodal MCL and in situ mantle cell neoplasia (ISMCN).

J Cabeçadas
After attending this lecture, the participant will be able to
– Identify the most important subtypes of DLBC according to the new (2017) WHO classification of lymphoid tumors.
– Understand the strategies for subtyping of DLBCL, NOS.
– Use the information in the pathology report to stratify patients and select possible therapeutic options.

B Durie
An up-to-date program is available via the mobile app.

T-CELL AND NK-CELL MALIGNANCIES

3 5 **T C**

Chairs: T George (University of New Mexico, Albuquerque, USA)
J Cabeçadas (Instituto Português de Oncologia, Lisbon, Portugal)

- **Current classification of T/NK cell lymphomas: Controversies and questions**
  S Pileri (European Institute of Oncology, Milan, Italy)
- **T-cell malignancies of the skin: Separate disease entities?**
  J Goodlad ((HMDS, Leeds, United Kingdom))
- **The role of molecular genetics in the classification of peripheral T cell malignancies?**
  P Gaulard (Hôpital Henri Mondor, Créteil, France)

LEARNING GOALS

S Pileri

After attending this lecture, the participant will be able to

- Discussion of the main changes introduced by the revised WHO Classification.
- Identification of the new diagnostic and prognostic algorithms applied to peripheral T/NK-cell lymphomas.
- Difficulties encountered by peripheral Hospitals in the application of such algorithms and need for inter-institutional networks.

J Goodlad

An up-to-date program is available via the mobile app.

P Gaulard

After attending this lecture, the participant will be able to

- Describe recurrent gene mutations in epigenetic modifiers (TET2, IDH2, DNMT3) in T-cell lymphomas of Follicular Helper T-cells (TFH) origin and their potential clinical implications.
- Recognize the genetic heterogeneity of anaplastic large cell lymphomas and the diagnostic importance and clinical relevance of the genetic alterations.
- Recognize that activating mutations in genes of the JAK-STAT pathway are common to several cytotoxic PTCL entities.

MYELOID MALIGNANCIES

2 5 **C**

Chairs: A Orfao (University of Salamanca, Spain)
MC Bene (Nantes University Hospital, France)

- **The WHO 2016 classification of myelodysplastic/myeloproliferative neoplasms**
  A Orazi (Weill Cornell Medical College, New York, USA)
- **What is new in the WHO-2016 classification of MDS**
  L Malcovati (University of Pavia, Italy)

LEARNING GOALS

A Orazi

After attending this lecture, the participant will be able to

- Update the participants on the WHO 2016 diagnostic criteria for myelodysplastic/myeloproliferative neoplasms.
- Describe how a proper diagnosis can be achieved by careful integration of clinical, morphologic and biologic data (e.g. cytogenetics and molecular genetics).
- Discuss strategies useful to achieve a reproducible differential diagnosis with other myeloid neoplasms.

L Malcovati

After attending this lecture, the participant will be able to

- Describe definitions and diagnostic criteria introduced by the 2016 revision of the WHO classification of Myelodysplastic Syndromes/Neoplasms.
- Discuss the role of cytogenetic abnormalities and somatic mutations in the diagnosis and classification of Myelodysplastic Syndromes/Neoplasms.
- Discuss the limitations of current classification of Myelodysplastic Syndromes/Neoplasms and identify the areas of diagnostic uncertainty.

→ EDUCATION SESSION

4 **B T C**

08:00 - 09:30, Room N101
Repeated from:
Friday, June 23, 08:00 - 09:30, Hall E

STEM CELL TRANSPLANTATION - GVHD

Chair: N Kröger (University Medical Center Hamburg-Eppendorf, Germany)

- **GvHD prophylaxis and treatment, new modalities**
  R Zeiser (Freiburg University Medical Center, Germany)
- **The role of the intestinal microbiota in graft-versus-host disease**
  M van den Brink (Memorial Sloan Kettering Cancer Center, New York, USA)
- **Balancing Graft versus Leukemia and Graft versus Host responses**
  JHF Falkenburg (Leiden University Medical Center, the Netherlands)

LEARNING GOALS

R Zeiser

After attending this lecture, the participant will be able to

- Describe emerging molecular therapies for steroid refractory GVHD.
- Discuss novel concepts on the role of neutrophils in GVHD.
- Understand the basic principles of GVHD biology.

M van den Brink

After attending this lecture, the participant will be able to

- Describe the major changes observed in the intestinal microbiota of patients undergoing that are associated with graft-vs-host disease and transplant-related mortality.
- Recapitulate the impact of antibiotic therapy, broad- vs narrow-spectrum antibiotic, on clinical outcomes in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients.
- Discuss current and putative future options for gut microbiota interventions to increase survival and gastrointestinal health in patients undergoing allo-HSCT.

JHF Falkenburg

After attending this lecture, the participant will be able to

- Understand the different nature of allo-immune T cell responses

following HLA matched and HLA mismatched stem cell transplantation.
– Estimate the likelihood of developing selective GVL responses after allogeneic stem cell transplantation.
– Understand how post-transplant circumstances and interventions influence the balance between GVL and GVHD.

→ BASIC-SCIENCE-IN-FOCUS 3 **B T**
08:30 - 09:30, Room N105

GENOMICS AND EPIGENOMICS OF CLL

Chair: D Rossi (Oncology Institute of Southern Switzerland, Bellinzona, Italy)

- **Genetics and epigenetics of CLL evolution**
  D Landau (Weill Cornell Medicine, New York, USA)
- **Epigenetics of CLL - The Blueprint project**
  JI Martin-Subero (IDIBAPS, Barcelona, Spain)

LEARNING GOALS

D Landau

After attending this lecture, the participant will be able to
– Describe current and emerging concepts in CLL genomics.
– Describe epigenetic contribution to CLL evolution.
– Describe the relationship between CLL therapy and CLL evolution.

JI Martin-Subero

After attending this lecture, the participant will be able to
– Describe different epigenetic marks and their impact on genome function.
– Be aware that the DNA methylation profile is widely modulated during B-cell differentiation and that epigenetic imprints from normal B cells at different maturation stages are useful to classify CLLs into 3 different clinico-biological groups.
– Know that an integrative analysis of different epigenetic marks is important to understand oncogenic deregulation in CLL.

→ SCIENTIFIC WORKING GROUPS 2 **T C**
08:30 - 09:30, Room N103

MYELODYSPLASTIC SYNDROMES (MDS): MDS AND THE ROLE OF THE IMMUNE SYSTEM IN PATHOPHYSIOLOGY AND THERAPY

Chair: U Platzbecker (Uni Dresden, Germany)

- **Coexistance of MDS and immune disorders**
  O Fain (Hôpital Saint Antoine (AP-HP), Paris, France)
- **Modification of immune signalling by epigenetic therapy in MDS**
  K Gronbaek (Rigshospitalet, Copenhagen Ø, Denmark)
- **Immunotherapeutic approaches in MDS and overlap diseases**
  A Ganser (Medizinische Hochschule Hannover, Germany)

LEARNING GOALS

O Fain

After attending this lecture, the participant will be able to
– Describe the autoimmune and autoinflammatory disorders associated with MDS.
– Discuss the links between immune disorders and MDS.
– Discuss treatment of these associated manifestations in MDS patients according to the type of immune disorders and the type of MDS.

K Gronbaek

After attending this lecture, the participant will be able to
– How epigenetic therapy modulate the innate and adaptive immune system in MDS.
– How epigenetic therapy may have “side effects” on healthy immune cells in MDS.
– Why combinations of hypomethylating agents, vitamin C and immune check point inhibitors may improve the outcome of treatment in MDS.

A Ganser

After attending this lecture, the participant will be able to
– Understand the pathopysiological basis for immunotherapy in patients with MDS.
– Use the selection criteria for immunosuppressive therapy with special emphasis on ATG/cyclosporin A.
– Understand the rational for the clinical studies with checkpoint inhibitors in MDS.

→ EHA - INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY JOINT SYMPOSIUM 1 4 9 **B**
08:30 - 09:30, Room N104

HEMATOPOIETIC STEM CELLS AND THEIR NICHE

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom
D Traver, Past President ISEH (UCSD, La Jolla, USA)

- **Developmental specification of hematopoietic stem cells**
  D Traver (UCSD, La Jolla, USA)
- **Long-term single cell quantification: New tools for old questions in hematopoiesis research**
  T Schroeder (ETH Zurich, Basel, Switzerland)

LEARNING GOALS

D Traver

After attending this lecture, the participant will be able to
– Describe the current understanding of HSC emergence during embryogenesis.
– Understand the importance of the Notch pathway in HSC specification.
– Discuss how study of HSC generation in vivo informs the instruction of HSC fate in vitro from human pluripotent precursors.

T Schroeder

After attending this lecture, the participant will be able to
– Understand the importance of quantifying single-cell dynamics.
– Current state of the art and remaining challenges in long-term bioimaging.
– Latest approaches and conclusions in analyzing molecular mechanisms of hematopoietic stem and progenitor cell fate control.

→ EDUCATION SESSION 1 9 B T C
08:00 - 09:30, Room N109
Repeat Session:
Saturday, June 24, 09:45 - 11:15, Room N109

UPDATE ON HEMOGLOBINOPATHIES

Chair: MD Cappellini (University of Milan-Foundation IRCCS Policlinico Hospital, Italy)

- **Genome editing in hemoglobinopathies**
  M Weiss (St Jude Children's Research Hospital, Memphis, USA)
- **Iron chelation in hemoglobinopathies**
  V Viprakasit (Siriraj Hospital, Mahidol University, Bangkok, Thailand)
- **Neurological complications of sickle cell disease**
  F Kirkham (UCL Great Ormond Street Institute of Child health, London, United Kingdom)

LEARNING GOALS

M Weiss

After attending this lecture, the participant will be able to

- Understand the genetics of common hemoglobinopathies: sickle cell disease and beta thalassemia.
- Understand the tools of genome editing and how they can be applied to treating hemoglobinopathies.
- Understand potential barriers for using genome editing to treat hemoglobinopathies.

V Viprakasit

After attending this lecture, the participant will be able to

- Describe current and latest mechanism of iron overload and its clinical significance in thalassemia and hemoglobinopathies.
- Select appropriate iron overload monitoring based upon availability and accessibility.
- Discuss iron chelation options for thalassemia patients with iron overload as a monotherapy or a combination of different iron chelators.

F Kirkham

After attending this lecture, the participant will be able to

- Understand the causes of acute neurological events, including stroke, in sickle cell disease.
- Manage acute stroke in sickle cell disease in collaboration with emergency, intensive care and stroke unit physicians and neurologists.
- Follow the guidelines for primary and secondary prevention of stroke in children and adults with sickle cell disease.

→ EDUCATION SESSION 5 6 9 B T C
08:00 - 09:30, Room N111
Repeated from:
Friday, June 23, 09:45 - 11:15, Room N105

BLEEDING DISORDERS

Chair: F Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

- **Biological and clinical relevance of fibrin clot structure**
  N Mutch (University of Aberdeen, United Kingdom)
- **Diagnosis and management of DIC and primary hyperfibrinolysis**
  A Squizzato (Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy)
- **Diagnosis and management of rare bleeding disorders**
  G Kenet (Sheba Medical Center, Tel Hashomer, Israel)

LEARNING GOALS

N Mutch

After attending this lecture, the participant will be able to

- Discuss conditions in which abnormal clot structure is observed and the downstream impact on clot stability.
- Describe how the fibrin network is degraded by the fibrinolytic system and how this can be monitored.
- Explain the factors that may influence clot structure in different areas of the vasculature.

A Squizzato

After attending this lecture, the participant will be able to

- Describe four main clinical phenotypes of patients with DIC.
- Promptly diagnose DIC and rapidly identify underlying disorders of DIC.
- Provide the best supportive therapy to prevent or treat main clinical manifestations of DIC.

G Kenet

After attending this lecture, the participant will be able to

- Describe the epidemiology, symptoms and diagnosis of patients with rare bleeding disorders.
- Discuss current and emerging treatment options, including non- replacement therapy.

→ SCIENTIFIC WORKING GROUPS 6 9 C
08:30 - 09:30, Room N113

THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS: TREATMENT OF DIFFICULT TO TREAT THROMBOCYTOPENIAS

Chair: CL Balduini (University of Pavia-IRCCS Policlinico San Matteo Foundation, Italy)

- **Thrombocytopenia in the critically ill**
  NP Juffermans (Academic Medical Center, Amsterdam, the Netherlands)
- **Acute management of thrombotic microangiopathies**
  JA Kremer Hovinga (Inselspital, Bern University Hospital, Switzerland)
- **Is it possible to increase platelet count in inherited thrombocytopenias without giving platelet transfusions?**
  A Pecci (IRCCS Policlinico San Matteo Foundation - University of Pavia, Italy)

LEARNING GOALS

NP Juffermans

After attending this lecture, the participant will be able to

– Describe mechanisms and effects of thrombocytopenia in the critically ill.
– Select indications for prophylactic platelet transfusion (prior to invasive procedures).
– Management of platelet transfusions not resulting in platelet count increment.

JA Kremer Hovinga
An up-to-date program is available via the mobile app.

A Pecci
After attending this lecture, the participant will be able to
– Critically evaluate the current and emerging therapeutic options to increase platelet count in patients with inherited thrombocytopenias.

→PATIENT ADVOCACY SESSION 1 1 2 3 8 10 **C**
08:00 - 09:30, Room N115

INNOVATIVE CLINICAL TRIAL DESIGNS, ADAPTIVE PATHWAYS (MAPPS) AND PATIENT INVOLVEMENT IN R&D

Chairs: S Wintrich (MDS UK Patient Support Group, London, United Kingdom)
S Liptrott (European Institute of Oncology, Milan, Italy)

- **Patient perspective on new trial design, regulation and patient involvement**
  G Spurrier-Bernard (Melanoma Patients Network Europe & MelanomeFrance, Teilhet, France)
- **Adaptive pathways and other approaches to promote timely access to medicines**
  F Pignatti (European Medicines Agency, London, United Kingdom)
- **Designing innovative clinical trials: Methodology and practice**
  EH Estey (University of Washington, Seattle, USA)
- **How will the new EU Clinical Trials Regulation foster innovation in clinical trials?**
  B Woermann (Charité University Medicine, Berlin, Germany)

LEARNING GOALS

G Spurrier-Bernard
An up-to-date program is available via the mobile app.

F Pignatti
An up-to-date program is available via the mobile app.

EH Estey
After attending this lecture, the participant will be able to
– Appreciate the conflict between the scientific need to randomize patients between a new and an older, often unsatisfactory, therapy and the wish of patients not to be randomized to the older therapy.
– Become familiar with “adaptive” randomization as a means to address this dilemma.
– Understand the value of designs that adaptively monitor several outcomes (e.g. response and toxicity) rather than only a single outcome (toxicity in phase 1 and response in phase 2).
– Understand the importance of any design’s “operating characteristics”.

B Woermann
An up-to-date program is available via the mobile app.

→EDUCATION SESSION 3 5 **T C**
09:45 - 11:15, Hall A
Repeated from:
Friday, June 23, 08:00 - 09:30, Hall A

NEW APPROACHES TO INDOLENT LYMPHOMA

Chair: P Brice (Hôpital Saint Louis, Paris, France)

- **Molecular profiling of indolent lymphoma**
  S Pileri (European Institute of Oncology, Milan, Italy)
- **Update on follicular lymphoma: Time beyond chemotherapy?**
  K Hübel (University of Cologne, Germany)
- **Treatment of extranodal marginal zone B-cell lymphomas**
  M Raderer (Medical University Vienna, Austria)

LEARNING GOALS

S Pileri
After attending this lecture, the participant will be able to
– Describe the molecular characteristics of the main varieties of indolent lymphoma.
– Discuss how they can impact on the prognosis and therapy in the present era of precision medicine.

K Hübel
After attending this lecture, the participant will be able to
– Understand requirements for a chemotherapy-free approach in Follicular Lymphoma.
– Recognize the potential of existing and emerging therapeutics in the management of Follicular Lymphoma.
– Assess critically the benefits and risks of common cytotoxic regimens versus targeted therapies in different lines of treatment.

M Raderer
After attending this lecture, the participant will be able to
– Eradication of Helicobacter pylori remains the preferred first-line therapy in patients with gastric MALT lymphoma.
– Also patients with HP-negative gastric MALT lymphoma may also be managed with (clarithromycin-based) antibiotic therapy.
– Antibiotic therapy can also be given in patients with ocular adnexal MALT-lymphomas as sole initial management.
– Both systemic treatment as well as radiotherapy appear to have curative potential in localised disease.

→EDUCATION SESSION 3 10 **B T C**
09:45 - 11:15, Hall B
Repeat Session:
Sunday, June 25, 09:30 - 11:00, Hall A

CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: B Eichhorst (University Clinic of Cologne, Germany)

- **Relevance of microenvironment in CLL**
  F Caligaris-Cappio (Italian Association for Cancer Research, Milan, Italy)

- **Prognostic factors in CLL: When, which and how?**
  S Pospisilova (Masaryk University and University Hospital Brno, Czech Republic)
- **Prioritisation therapies in CLL**
  C Wendtner (Klinikum Schwabing, Munich, Germany)

LEARNING GOALS

F Caligaris-Cappio

After attending this lecture, the participant will be able to
- Describe how malignant CLL cells entail a bi-directional dialogue with a host of non-malignant elements within the microenvironment.
- Describe the key cellular elements in the microenvironment.
- Describe how cell-cell interactions favour malignant cell growth, survival and prevent anti-tumour response.

S Pospisilova

After attending this lecture, the participant will be able to
- Describe the biological and clinical factors applicable in CLL prognostication.
- Define the predictive markers currently used for therapy response assessment in CLL patients.
- Indicate the timepoints when the prognostic and predictive factors should be analyzed during the disease course.

C Wendtner

After attending this lecture, the participant will be able to
- For CLL patients we have to prioritize treatment options based on clinical and novel molecular markers.
- Chemoimmunotherapy remains the standard-of-care for the majority of CLL patients in the frontline setting.
- Novels drugs like ibrutinib, idelalisib and venetoclax are nowadays treatment standards for CLL patients with relapsed/refractory disease.

→ EDUCATION SESSION 2 5 9 10 **T C**
09:45 - 11:15, Hall C
Repeat Session:
Sunday, June 25, 09:30 - 11:00, Room N101

ACUTE MYELOID LEUKEMIA

Chair: G Ossenkoppele (VU University Medical Center, Amsterdam, the Netherlands)
- **Molecular diagnostics in AML**
  L Bullinger (University Hospital of Ulm, Germany)
- **Targeting mutated FLT3 in AML**
  M Levis (Johns Hopkins University, Phoenix, USA)
- **3+7 and beyond**
  N Vey (Institut Paoli Calmettes, Marseille, France)

LEARNING GOALS

L Bullinger

After attending this lecture, the participant will be able to
- There is a growing need to implement novel next-generation-sequencing (NGS) based gene panel diagnostic tools to rapidly capture inter- and intra-individual disease heterogeneity.
- Future technological developments will enable genome-wide comprehensive genomic, epigenomic and transcriptomic characterization of the disease (at single cell level), but for now these approaches are reserved for research questions.
- Molecular genomics have started to inform patient care with regard to improved disease classification and risk prediction (knowledge databases), MRD monitoring and guiding targeted therapeutic approaches.

M Levis

After attending this lecture, the participant will be able to
- Identify the subsets of AML patients that might benefit from FLT3 inhibition
- Describe the different points in AML therapy where FLT3 inhibitors are likely to be incorporated.
- Discuss the different potential roles for selective versus non-selective FLT3 inhibitors.

N Vey

After attending this lecture, the participant will be able to
- Describe current and emerging therapies for patients with AML.
- Describe the main mechanisms of action of current new drugs and the rationale for their combination.
- Discuss how emerging therapies might be combined to or replace 3+7.

→ EHA - AMERICAN SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM 1 4 9 10 **B T C**
10:15 - 11:15, Hall D

THE FUTURE OF HEMATOLOGY: GENOME EDITING/CRISPR

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
K Anderson, President of ASH (Dana-Farber /Harvard Cancer Center, Boston, USA)
- **CRISPR/Cas9 Genome Editing, from Mechanism to Therapy**
  J Corn (Innovative Genomics Institute, Berkeley, USA)
- **Towards clinical translation of targeted gene editing in human hematopoietic stem cells**
  L Naldini (San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy)

LEARNING GOALS

J Corn

After attending this lecture, the participant will be able to
- Describe how CRISPR-Cas9 gene editing works.
- Determine whether gene editing may be appropriate to address a given patient disease.
- Develop a rough timeline for clinical application of gene editing.

L Naldini

After attending this lecture, the participant will be able to understand the:
- Advanced stage of clinical testing reached by HSC gene therapy using conventional gene replacement with lentiviral vectors.
- Potential advantages and current limitations of targeted gene

editing vs. gene replacement strategies for the correction of genetic deficiencies in HSC.
– Solutions being developed to overcome the constrains to safe and successful gene editing of HSC.

→ EDUCATION SESSION 2 3 4 8 9 **T** **C**
09:45 - 11:15, Room N101
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Room N101

FERTILITY PRESERVATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Chair: D Meirow (Sheba Medical Center, Tel Hashomer, Israel)

- **The effects of chemotherapy and radiotherapy on reproduction**
  WH Wallace (University of Edinburgh, United Kingdom)
- **What patients expect from hematologists**
  A Plate (Myeloma Patients Europe, Munich, Germany)
- **Fertility preservation in female patients**
  MM Dolmans (Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Gynécologie, Brussels, Belgium)
- **Fertility preservation in pre-pubertal and adult males**
  R Mitchell (University of Edinburgh, United Kingdom)

LEARNING GOALS

WH Wallace

After attending this lecture, the participant will be able to
– More high quality research is required to provide the evidence for impaired testicular and ovarian function after chemotherapy and radiation.
– Conditioning treatments for BMT that include chemotherapy and or radiotherapy are likely to impair gonadal function irrespective of the age of the patient at treatment.
– Radiotherapy to a field that includes the pelvis in females may impair uterine function with increased risk of miscarriage and preterm delivery.

MM Dolmans

After attending this lecture, the participant will be able to
– Cite and outline currently available fertility preservation options.
– Select the most appropriate course of action according to disease type and treatment, as well as patient age.
– Describe recent advances and successes in oocyte and ovarian tissue cryopreservation.

R Mitchell

After attending this lecture, the participant will be able to
– Understand the key differences between the prepubertal and adult testis.
– Describe how cancer treatments can damage the prepubertal testis.
– Discuss the options available for fertility preservation in prepubertal and adolescent males.
– Describe the experimental approaches that are currently under investigation for young males at risk of infertility.

→ SCIENTIFIC WORKING GROUPS 2 **C**
09:45 - 10:45, Room N105

EUROPEAN WORKING GROUP ON ALL (EWALL): ADULT ALL FIRST LINE THERAPY: MAJOR RESULTS AND FUTURE APPROACHES OF NATIONAL ALL STUDY GROUPS

Chair: N Gökbuget (University Hospital, Goethe University, Frankfurt, Germany)

- **Major results and future approaches of Italian ALL study groups**
  S Chiaretti (Sapienza University of Rome, Italy)
- **France-Belgium-Switzerland: The GRAALL Intergroup**
  H Dombret (University Hospital Saint-Louis, Paris, France)
- **The role of allogeneic transplant in U.K. trials for adult ALL**
  A Fielding (UCL, London, United Kingdom)
- **Strategies of the GMALL Group**
  N Gökbuget (University Hospital, Goethe University, Frankfurt, Germany)

LEARNING GOALS

S Chiaretti

After attending this lecture, the participant will be able to
– Describe the gold standard management of adults and adolescents with Ph-negative ALL in first-line treatment.
– Describe the gold standard management of Ph-positive ALL in first-line treatment.
– Describe the introduction of novel compounds in the current/forth coming trials for both Ph-negative and Ph-positive in first-line treatment.

H Dombret

An up-to-date program is available via the mobile app.

A Fielding

An up-to-date program is available via the mobile app.

N Gökbuget

After attending this lecture, the participant will be able to
– Describe the major strategies of the German Multicenter ALL Study Group.
– Discuss options for MRD based treatment intensification.
– Explain different strategies for younger and older patients.

→ SCIENTIFIC WORKING GROUPS 3 **C**
09:45 - 10:45, Room N103

EUROPEAN MANTLE CELL LYMPHOMA NETWORK: THE PROS AND CONS IN THE TREATMENT OF MCL PATIENTS

Chair: M Dreyling (Klinikum der Universitaet Muenchen, Germany)

- **Pro: Uniform standard treatment in all elderly patients**
  S Rule (Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom)
- **Con: Standard treatment has to be individual in elderly patients**
  C Visco (San Bortolo Hospital, Vicenza, Italy)

- **Immunological approaches in MCL**
  S Ansell (Mayo Clinic, Rochester, USA)

LEARNING GOALS

S Rule

After attending this lecture, the participant will be able to
- Understand the current treatment algorithms for elderly patients with mantle cell lymphoma.
- Understand risk stratification for this group of patients.
- The difficulties in individualising therapy based on the limited treatment options and lack of targeted therapy.

C Visco

After attending this lecture, the participant will be able to
- Describe current and emerging therapies for older patients with Mantle Cell Lymphoma.
- Select appropriate upfront therapy based upon patient and disease characteristics.
- Discuss treatment options for older patients who may or may not be candidates for standard chemotherapy.

S Ansell

After attending this lecture, the participant will be able to
- Describe the immunological barriers to an effective anti-tumor response in mantle cell lymphoma (MCL).
- Discuss immunological treatment approaches to MCL.

→ SCIENTIFIC WORKING GROUPS 2 8 **C**
09:45 - 10:45, Room N104

EUROPEAN WORKING GROUP FOR PHILADELPHIA-NEGATIVE MPN: NEW TOOLS FOR MPN PATIENTS MANAGEMENT

Chair: JJ Kiladjian (Hôpital Saint-Louis, Paris, France)
- **Social media: Impact on research and management of MPNs**
  R Mesa (Mayo Clinic, Phoenix, USA)
- **Are MPN patients and doctors ready for e-medicine?**
  P Jourdain (CH R Dubos, Pontoise, France)
- **What have we learned from MPN registries**
  M Hultcrantz (Karolinska Institute, Stockholm, Sweden)

LEARNING GOALS

R Mesa

After attending this lecture, the participant will be able to
- Understand the functionality and parameters of the most common social media platforms and how they can be used in academic hematology.
- Understand the role of social media for patient engagement in research, increasing clinical trial accrual and survey research.
- Understand use of social media to assist in clinical management of myeloproliferative neoplasms.

P Jourdain

After attending this lecture, the participant will be able to
- Characterize a telemedicine or E health project.
- Analyze the main component of a telemedicine project from definition to evaluation.

M Hultcrantz

After attending this lecture, the participant will be able to
- Describe the epidemiology, prognosis and survival of MPN patients in relation to the general population estimated using various statistical methods.
- Have knowledge of the spectrum of complications as well as treatment-related effects associated with MPNs.
- Understand the benefits, possibilities, and limitations of population-based register research.

→ EDUCATION SESSION 1 9 **B T C**
09:45 - 11:15, Room N109
Repeated from:
Saturday, June 24, 08:00 - 09:30, Room N109

UPDATE ON HEMOGLOBINOPATHIES

Chair: MD Cappellini (University of Milan-Foundation IRCCS Policlinico Hospital, Italy)
- **Genome editing in hemoglobinopathies**
  M Weiss (St Jude Children's Research Hospital, Memphis, USA)
- **Iron chelation in hemoglobinopathies**
  V Viprakasit (Siriraj Hospital, Mahidol University, Bangkok, Thailand)
- **Neurological complications of sickle cell disease**
  F Kirkham (UCL Great Ormond Street Institute of Child health, London, United Kingdom)

LEARNING GOALS

M Weiss

After attending this lecture, the participant will be able to
- Understand the genetics of common hemoglobinopathies: sickle cell disease and beta thalassemia.
- Understand the tools of genome editing and how they can be applied to treating hemoglobinopathies.
- Understand potential barriers for using genome editing to treat hemoglobinopathies.

V Viprakasit

After attending this lecture, the participant will be able to
- Describe current and latest mechanism of iron overload and its clinical significance in thalassemia and hemoglobinopathies.
- Select appropriate iron overload monitoring based upon availability and accessibility.
- Discuss iron chelation options for thalassemia patients with iron overload as a monotherapy or a combination of different iron chelators.

F Kirkham

After attending this lecture, the participant will be able to
- Understand the causes of acute neurological events, including stroke, in sickle cell disease.
- Manage acute stroke in sickle cell disease in collaboration with emergency, intensive care and stroke unit physicians and neurologists.
- Follow the guidelines for primary and secondary prevention of stroke in children and adults with sickle cell disease.

→ EDUCATION SESSION 5 6 B T C
09:45 - 11:15, Room N111
Repeated from:
Friday, June 23, 08:00 - 09:30, Room N105

THROMBOSIS

Chair: W Ageno (University of Insubria, Varese, Italy)

- **Cross-talk between coagulation and inflammation**
  T Renné (University Medical Center Hamburg, Germany & Karolinska Institutet, Stockholm, Sweden)
- **Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism**
  M Huisman (Leiden University Medical Center, the Netherlands)
- **Controversies in treating small clots in the leg and in the lung**
  S Schellong (Städtisches Klinikum Dresden, Germany)

LEARNING GOALS

T Renné

After attending this lecture, the participant will be able to

– Understand the novel concept of Safe Anticoagulants that do not increase bleedings.
– Get insight in the crosstalk of coagulation and inflammation.
– Learn about the plasma contact system.

M Huisman

After attending this lecture, the participant will be able to

– Describe current and emerging diagnostic algorithms for patients with clinically suspected venous thromboembolism.
– Select appropriate diagnostic algorithms for selected populations including older patients, pregnant patients, and patients with suspected recurrent venous thromboembolism.

S Schellong

After attending this lecture, the participant will be able to

– Acknowledge the new situation that for DVT as well as for PE the current standard diagnostic imaging detects clots in the leg and the lung which might be clinically insignificant and do not require standard treatment.
– Define a subgroup of patients with isolated distal DVT which represents a very low risk group for proximal extension and PE.
– Discuss the risk difference of two different patient groups with subsegmental PE: cancer patients with incidental PE versus symptomatic patients without cancer.

→ SCIENTIFIC WORKING GROUPS 1 4 B T
09:45 - 10:45, Room N113

EUROPEAN WORKING GROUP FOR STEM CELLS: METABOLIC REGULATION OF STEM CELL

Chair: D Bonnet (The Francis Crick Institute, London, United Kingdom)

- **Mitochondrial regulation of hematopoietic stem cells**
  HW Snoeck (Columbia University, New York, USA)
- **Nutrient fueling of hematopoietic stem cell lineage specification**
  N Taylor (Institut de Genetique Moleculaire de Montpellier, France)
- **P38α protects hematopoietic stem/progenitor cells in acute and aging stresses**
  K Takubo (National Center for Global Health and Medicine, Tokyo, Japan)

LEARNING GOALS

HW Snoeck

After attending this lecture, the participant will be able to

– Understand mitochondrial biology and its relation to stem cell function.
– Understand approaches to investigate mitochondrial function and calcium homeostasis in hematopoietic stem cells function.

N Taylor

After attending this lecture, the participant will be able to

– Recount the different nutrients that are used to fuel hematopoietic stem cell maintenance and differentiation.
– Discuss alterations in metabolite utilization during hematopoietic stem cell differentiation.
– Describe nutrient pathway utilization that may result in pathological HSC differentiation.

K Takubo

After attending this lecture, the participant will be able to

– Describe functional roles of metabolic programs in hematopoietic stem cell homeostasis.
– Describe molecules that govern metabolic programs in hematopoietic stem/progenitor cells.

→ SCIENTIFIC WORKING GROUPS 1 4 B T
09:45 - 10:45, Room N115

MESENCHYMAL STEM CELLS: THE IMMUNOLOGY OF TISSUE REPAIR

Chair: W Fibbe (Leiden University Medical Center, the Netherlands)

- **The immune challenges of pluripotent stem cell based therapy**
  Y Xu (University of California, San Diego, La Jolla, USA)
- **Neural stem cell-mediated immune regulation and brain repair**
  S Pluchino (Wellcome Trust-Medical Research Council Stem Cell Institute, Cambridge, United Kingdom)

LEARNING GOALS

Y Xu

After attending this lecture, the participant will be able to

– Understand the mechanism underlying the immunogenicity of pluripotent stem cells and their derivatives.
– Learn new strategies to induce immune tolerance of pluripotent stem cell derived cells.
– Learn new technologies to study human immune responses in model system.

S Pluchino

After attending this lecture, the participant will be able to

– Understand the state of the art non-hematopoietic stem cell treatments for inflammatory neurological diseases.
– Understand the main immune regulatory effects of neural stem cell-based therapeutics.

→ SIMULTANEOUS SESSIONS 3 C
11:30 – 12:45, Hall A

FRONT-LINE COMBINATIONS IN MULTIPLE MYELOMA AND AMYLOIDOSIS

Chairs: P Sonneveld (Erasmus MC, Rotterdam, the Netherlands)
P Moreau (University Hospital, Nantes, France)

11:30 – 11:45
S407 **QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY.**
C Pawlyn[1] ([1]The Institute of Cancer Research, London, United Kingdom)

11:45 – 12:00
S408 **DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT**
S Kumar[1] ([1]Mayo Clinic, Rochester, United States)

12:00 – 12:15
S409 **DEPTH OF RESPONSE AS SURROGATE MARKER FOR PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH VMP AND RD: GEM2010MAS65**
MV Mateos[1] ([1]University Hospital of Salamanca, Salamanca, Spain)

12:15 – 12:30
S410 **CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA**
F Gay[1] ([1]Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

12:30 – 12:45
S411 **HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS**
M Minnema[1] ([1]1UMC UTRECHT, Utrecht, the Netherlands)

→ SIMULTANEOUS SESSIONS 3 9 C
11:30 – 12:45, Hall B

HODGKIN AND INDOLENT LYMPHOMA – CLINICAL

Chairs: A Engert (University Hospital of Cologne, Germany)
A Hagenbeek (University of Amsterdam, the Netherlands)

11:30 – 11:45
S412 **NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL**
A Engert[1] ([1]University Hospital of Cologne, Cologne, Germany)

11:45 – 12:00
S413 **EARLY CHEMOTHERAPY INTENSIFICATION WITH ESCALATED BEACOPP IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A POSITIVE INTERIM PET-CT AFTER 2 ABVD CYCLES: LONG-TERM RESULTS OF THE GITIL/FIL HD 0607 TRIAL**
A Gallamini[1] ([1]Centre A. Lacassagne, Nice, France)

12:00 – 12:15
S414 **DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP**
PJ Bröckelmann[1] ([1]University Hospital of Cologne, Cologne, Germany)

12:15 – 12:30
S415 **A REVISED STAGING SYSTEM FOR WALDENSTRÖM'S MACROGLOBULINEMIA**
E Kastritis[1] ([1]Greek Myeloma Study Group, Athens, Greece)

12:30 – 12:45
S416 **SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) TREATED WITH RITUXIMAB (R) MONOTHERAPY: A LONG TERM FOLLOW-UP STUDY ON 104 PATIENTS**
C Kalpadakis[1] ([1]University Hospital, University of Crete, Heraklion, Greece)

→ SIMULTANEOUS SESSIONS 2 5 B T
11:30 – 12:45, Hall C

BIOLOGY OF MPN: JAK2 AND BEYOND

Chairs: H Hasselbalch (Zealand University Hospital, Roskilde, Denmark)
S Hermouet (Inserm U1232 - CRCINA, Université de Nantes, France)

11:30 – 11:45
S417 **YOU DON'T KNOW JAK: A PROGRAMMED RIBOSOMAL FRAMESHIFTING DEFECT POTENTIATES THE TRANSFORMING ACTIVITY OF THE JAK2-V617F MUTATION**
S Sulima[1] ([1]KU Leuven, Leuven, Belgium)

11:45 – 12:00
S418 **EFFECTIVENESS OF LSD1 INHIBITION FOR THE TREATMENT OF MPN**
JS Jutzi[1] ([1]University Medical Center, Freiburg, Germany)

12:00 – 12:15
S419 **LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL**
V Caraffini[1] ([1]Medical University of Graz, Graz, Austria)

12:15 – 12:30
S420 **JAK2 V617F HAEMATOPOIETIC CLONES WITH DIFFERENT EXPANSION KINETICS ARE DETECTABLE SEVERAL YEARS PRIOR TO MPN DIAGNOSIS**
T Mckerrell[1], [2] ([1]University of Cambridge, Cambridge, United Kingdom, 2Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

12:30 – 12:45
S421 **DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM**
R Norfo[1] ([1]MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom)

→ SIMULTANEOUS SESSIONS 2 **C**
11:30 – 12:45, Hall D

CLINICAL TRIALS INCLUDING TREATMENT DISCONTINUATION IN CML

Chairs: M Suttorp (Univ. Hospital "Carl Gustav Carus", Dresden, Germany)
M Bocchia (Azienda Ospedaliera Universitaria Senese, Siena, Italy)

11:30 – 11:45
S422 **DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL**
CM Zwaan[1] ([1]Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands)

11:45 – 12:00
S423 **INITIAL REDUCTION OF THERAPY BEFORE COMPLETE WITHDRAWAL IMPROVES THE CHANCE OF SUCCESSFUL TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKAEMIA (CML): YEAR 2 RESULTS IN THE BRITISH DESTINY STUDY**
R Clark[1] ([1]Royal Liverpool University Hospital, Liverpool, United Kingdom)

12:00 – 12:15
S424 **ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 –YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV**
R Hehlmann[1] ([1]Ruprecht Karls University Heidelberg, Mannheim, Germany)

12:15 – 12:30
S425 **BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL**
TH Brümmendorf[1] ([1]Universitätsklinikum der RWTH Aachen, Aachen, Germany)

12:30 – 12:45
S426 **CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS**
M Pfirrmann[1] ([1]LMU München, München, Germany)

→ SIMULTANEOUS SESSIONS 2 5 9 10 **B** **T**
11:30 – 12:45, Hall E

AML BIOLOGY II: EPIGENETIC TARGETS

Chairs: R Schneider (Erasmus MC, Rotterdam, the Netherlands)
F Grebien (Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria)

11:30 – 11:45
S427 **ETO2-GLIS2 RECRUITS ETO2/ERG COMPLEX AT SUPER-ENHANCERS TO CONTROL TRANSCRIPTION AND DRIVE LEUKEMIC PROPERTIES IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA**
C Thirant[1], [2] ([1]INSERM U1170, Villejuif, France, [2]Gustave Roussy, Villejuif, France)

11:45 – 12:00
S428 **NUCLEOSOME BINDING PROTEIN HMGN1 BLOCKS MYELOID DIFFERENTIATION AND PROMOTES CLONAL DOMINANCE VIA ABERRANT HISTONE ACETYLATION**
L Cabal-Hierro[1], [2] ([1]Broad Institute, Cambridge, United States, [2]Dana Farber Cancer Insitute/ Harvard Medical School, Boston, United States)

Poster Pitches

P526 **DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS**
S Adams
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 3". More information on page 149

P527 **THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION**
R Slany
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 3". More information on page 149

P528 **PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.**
D Di Marcantonio
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 3". More information on page 149

P537 **GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA**
J Takeda
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 4". More information on page 149

P538 **THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES**
A Al Hinai
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 4". More information on page 149

P539 **EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML**
J Smith
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 4". More information on page 149

P540 **NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA**
IJ Lau
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 4". More information on page 150

12:15 – 12:30
S429 **PIWIL4 ACTS AS A PIRNA BINDING, EPIGENETICALLY ACTIVE AND GROWTH REGULATORY PROTEIN IN HUMAN ACUTE MYELOID LEUKEMIA**
S Bamezai[1] ([1]Institute for Experimental Cancer Research, Ulm, Germany)

12:30 – 12:45
S430 **METTL3 CONTROLS TRANSLATION OF TARGET MRNAS BY N6 METHYLATION OF ADENOSINE RESIDUES IN THEIR CODING SEQUENCE AND CONSTITUTES A NOVEL THERAPEUTIC VULNERABILITY OF ACUTE MYELOID LEUKAEMIA**
K Tzelepis[1] ([1]Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

→ SIMULTANEOUS SESSIONS **6 9 T C**
11:30 – 12:45, Room N101

ACQUIRED AND INHERITED PLATELET DISORDERS

Chairs: CH Toh (University of Liverpool, United Kingdom)
To be announced

11:30 – 11:45
S431 **THE COMBINATION OF ORAL ALL-TRANS RETINOIC ACID AND DANAZOL VS DANAZOL AS SECOND-LINE TREATMENT IN ADULT IMMUNE THROMBOCYTOPENIA: A MULTICENTRE, RANDOMIZED, OPEN-LABEL TRIAL**
XH Zhang[1, 2, 3] ([1]Collaborative Innovation Center of Hematology, Peking University, Beijing, China, [2]Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, [3]Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)

11:45 – 12:00
S432 **NOVEL PERSPECTIVES IN GENOTYPE-PHENOTYPE CORRELATIONS IN MYH9-RELATED DISEASE: NO LONGER JUST A MATTER OF HEAD OR TAIL**
C Zaninetti[1] ([1]IRCCS Policlinico San Matteo Foundation, and University of Pavia, Pavia, Italy)

12:00 – 12:15
S433 **A MONOALLELIC LOSS-OF-FUNCTION MUTATION IN THE THROMBOPOIETIN (THPO) GENE IS RESPONSIBLE FOR A NEW FORM OF INHERITED THROMBOCYTOPENIA (IT)**
P Noris[1] ([1]IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy)

12:15 – 12:30
S434 **POSITION OF THE GFI1B ZINC FINGER MUTATION DECOUPLES CD34 EXPRESSION FROM ALPHA-GRANULE DEFICIENCY IN GFI1B-RELATED PLATELET DISORDERS**
W Stevenson[1] ([1]UNIVERSITY OF SYDNEY, Sydney, Australia)

12:30 – 12:45
S435 **TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES**
J Bussel[1] ([1]Weill Cornell Medicine, New York, NY , United States)

→ SIMULTANEOUS SESSIONS 3 5 9 **T C**
11:30 – 12:45, Room N105

ACUTE LYMPHOBLASTIC LEUKEMIA – BIOLOGY

Chairs: E Clappier (Saint-Louis Hospital, Paris, France)
B Bornhauser (University Children's Hospital Zurich, Switzerland)

11:30 – 11:45
S436 **THE YING AND YANG OF JAK SIGNALING : LOSS OF USP9X BUFFERS JAK SIGNALING AND ENHANCES SURVIVAL OF CRLF2-JAK-STAT EXPRESSING B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.**
O Schwartzman[1], [2] ([1]Sackler medical school,Tel Aviv University, Tel Aviv, Israel, [2]The Gene Development and Environment Pediatric Research Institute, Pediatric Hemato-Oncology, Edmond and Lily Safra Children Hospital, Sheba Medical Center, Ramat Gan , Israel)

11:45 – 12:00
S437 **TNF RECEPTOR 2 IS REQUIRED FOR RIP1-DEPENDENT CELL DEATH IN LEUKEMIA**
J Aguadé-Gorgorió[1] ([1]University Children's Hospital Zurich, Zurich, Switzerland)

12:00 – 12:15
S438 **THERAPEUTIC TARGETING OF ONCOGENIC MYB ACTIVITY IN T-ALL**
T Pieters[1] ([1]Center for Medical Genetics, Ghent University, Ghent, Belgium)

12:15 – 12:30
S439 **THE T-CELL LEUKEMIA ASSOCIATED RIBOSOMAL RPL10 R98S MUTATION ENHANCES JAK-STAT SIGNALING**
S Vereecke[1] ([1]Department of Oncology, LKI, KU Leuven, Leuven, Belgium)

12:30 – 12:45
S440 **NFATC3-PLA2G15 IS A NOVEL INTERGENICALLY SPLICED CHIMERA THAT IS ASSOCIATED WITH AGGRESSIVE T-ACUTE LYMPHOBLASTIC LEUKAEMIA BIOLOGY.**
J Bond[1], [2] ([1]Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France, [2]Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, Paris, France)

→ SIMULTANEOUS SESSIONS 6 **T C**
11:30 – 12:45, Room N103

THROMBOTIC DISORDERS

Chairs: S Eichinger (Medical University of Vienna, Austria)
To be announced

11:30 – 11:45
S441 **ASSESSING THE RISK-BENEFIT OF ANTICOAGULANTS IN ELDERLY PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: A POPULATION BASED STUDY**
A Lazo-Langner[1], [2] ([1]Western University, London, Canada, [2]Western University, London, Canada)

11:45 – 12:00
S442 **RISK OF THROMBOSIS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA: A POPULATION-BASED COHORT STUDY**
AM Birgisdóttir[1] ([1]Faculty of Medicine, University of Iceland and Landspitali University Hospital, Reykjavik, Iceland)

12:00 – 12:15
S443 **COMPARATIVE ANALYSIS OF PREDICTIVE MODELS FOR THROMBOEMBOLIC EVENTS IN LYMPHOMA PATIENTS**
D Antic[1] ([1]Clinical Center of Serbia, Belgrade, Serbia)

12:15 – 12:30
S444 **IMPACT OF A NEW ELECTRONIC ALERT SYSTEM (V2.0) FOR VENOUS THROMBOEMBOLISM PREVENTION IN HOSPITALISED CANCER PATIENTS.**
R Figueroa[1] ([1]Clínica universidad de Navarra, Pamplona (Navarra), Spain)

12:30 – 12:45
S445 **IDENTIFICATION OF A NEW AND RELATIVELY FREQUENT SERPINC1 GENE DEFECT CAUSING ANTITHROMBIN DEFICIENCY HARDLY DETECTED BY CURRENT MOLECULAR METHODS: DUPLICATION OF EXON 6.**
ME De La Morena-Barrio[1], [2] ([1]Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Murcia, Spain, [2]Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)

→ SIMULTANEOUS SESSIONS 1 2 3 4 9 10 **B T C**
11:30 – 12:45, Room N104

STEM CELL TRANSPLANTATION – EXPERIMENTAL

Chairs: C Bonini (Fondazione San Raffaele Del Monte Tabor, Milan, Italy)
N Kröger (University Medical Center Hamburg-Eppendorf, Germany)

11:30 – 11:45
S446 **CYTOSOLIC NUCLEIC ACID SENSORS PROMOTE INTESTINAL EPITHELIAL INTEGRITY DURING ACUTE TISSUE DAMAGE AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE**
H Poeck[1] ([1]Technische Universität München, München, Germany)

11:45 – 12:00
S447 **CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES**
P van Balen[1] ([1]LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, the Netherlands)

12:00 – 12:15
S448 **MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS**
V Van Hoeven[1, 2] ([1]Academic Medical Center Amsterdam, Amsterdam, the Netherlands, [2]Academic Medical Center Amsterdam, Amsterdam, the Netherlands)

12:15 – 12:30
S449 **ABERRANT T CELL RESPONSES IN THE BONE MARROW MICROENVIRONMENT OF PATIENTS WITH POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
Y Kong[1] ([1]Peking University Institute of Hematology, Beijing, China)

12:30 – 12:45
S450 **HIGHER FREQUENCY OF SWITCHED MEMORY B CELLS PREDICTS THE INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**
RM Saliba[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

→ SIMULTANEOUS SESSIONS 1 9 **B T**
11:30 – 12:45, Room N109

SICKLE CELL DISEASE, ENZYMES

Chairs: R Colombatti (Azienda Ospedaliera-Università di Padova, Italy)
V Brousse (Hopital Necker Enfants Malades, APHP & Inserm S -1134, Institut National de Tranfusion Sanguine, Paris, France)

11:30 – 11:45
S451 **EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE DRIVE PK STUDY**
RF Grace[1] ([1]Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, United States)

11:45 – 12:00
S452 **STEM CELL TRANSPLANTATION IN PYRUVATE KINASE DEFICIENCY**
S Van Straaten[1, 2] ([1]UMC Utrecht, Utrecht, the Netherlands, [2]UMC Utrecht, Utrecht, the Netherlands)

12:00 – 12:15
S453 **HEREDITARY XEROCYTOSIS: CLINICAL AND BIOLOGICAL PRESENTATION AT DIAGNOSIS IN A RETROSPECTIVE SERIES OF 103 PATIENTS**
L Garcon[19] ([19]CHU Amiens, Amiens CEDEX1, France)

12:15 – 12:30
S454 **CRIZANLIZUMAB, A P-SELECTIN INHIBITOR, INCREASES THE LIKELIHOOD OF NOT EXPERIENCING A SICKLE CELL-RELATED PAIN CRISIS WHILE ON TREATMENT: RESULTS FROM THE PHASE II SUSTAIN STUDY**
A Kutlar[1] ([1]Medical College of Georgia, Augusta University, Augusta, United States)

12:30 – 12:45
S455 **FREE IRON IN SERA OF PATIENTS WITH SICKLE CELL DISEASE CONTRIBUTES TO THE RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS**
K Van Avondt[1] ([1]Sanquin Research, and Landsteiner Laboratory, AMC, University of Amsterdam, Amsterdam, the Netherlands)

→ PATIENT ADVOCACY SESSION II 2 3 4 8 10 **C**
11:30 - 12:45, Room N115

PREGNANCY DURING AND AFTER TREATMENT: MYTHS AND REALITY

Chairs: D Turner (King's College Hospital, Ipswich, United Kingdom)
J Geissler (Leukemia Patient Advocates Foundation, Munich, Germany)

- **Hematologist perspective: The trade-off between treatment and real life**
  J Apperley (Imperial College, London, United Kingdom)
- **Patient perspective on myths, reality and appropriate patient information**
  A Plate (Myeloma Patients Europe, Munich, Germany)
- **Overcoming infertility after cancer treatment: IVF and egg/sperm donation**
  A Guillén (IVI Madrid, Spain)

LEARNING GOALS

J Apperley
An up-to-date program is available via the mobile app.

A Plate
An up-to-date program is available via the mobile app.

A Guillén
After attending this lecture, the participant will be able to
– Describe the state of the art in ovarian stimulation and the new improvements in IVF techniques.
– Describe selection and matching in sperm and oocyte donation.
– Discuss treatment options in different countries and legislations.

→ MEET-THE EXPERT 2 C
11:30 - 12:30, Room N107
Availability on first come first serve basis

HOW I TREAT ELDERLY AML

Speakers: H Dombret (University Hospital Saint-Louis, Paris, France)

→ MEET-THE EXPERT 1 2 5 9 C
11:30 - 12:30, Room N108
Availability on first come first serve basis

APLASTIC ANEMIA OR MDS IN A CHILD - HOW TO DISTINGUISH?

Speaker: MM van den Heuvel-Eibrink (Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands)

→ MEET-THE EXPERT 1 2 8 C
11:30 - 12:30, Room N117
Availability on first come first serve basis

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS

Speaker: JR Gotlib (USA)

→ SPECIAL SESSION 2 3 9 B T
13:15 - 14:30, Hall A

JEAN BERNARD LIFETIME ACHIEVEMENT AWARD

- **Introduction**
  AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

PLENARY SESSION I

Chairs: S Izraeli (Sheba Medical Center, Ramat Gan, Israel)
J Sierra (Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona, Spain)

- **Heterogeneity in the making of blood**
  D Scadden (Harvard University / Mass General Hospital, Boston, USA)
- **From stem cells and stem cell niche to acute lymphoblastic leukemia**
  T Enver (UCL Cancer Institute, London, United Kingdom)

LEARNING GOALS

D Scadden

After attending this lecture, the participant will be able to

– Understand experimental approaches to overcoming differentiation blockade in acute myeloid leukemia.
– Define specific metabolic processes that represent vulnerabilities of AML cells.

T Enver

An up-to-date program is available via the mobile app.

→ CLINICAL DEBATE 3 C
14:45 - 15:45, Hall A

TREATMENT SHOULD BE STARTED IN EVERY PATIENT WITH HIGH RISK SMOLDERING MULTIPLE MYELOMA

Chair: H Ludwig (Wilhelminen Cancer Research Institute, Vienna, Austria)

- **Yes**
  MV Mateos (University Hospital of Salamanca, Spain)
- **No**
  S Kristinsson (University of Iceland, Reykjavik, Iceland)

→ HEMATOLOGY-IN-FOCUS 3 T C
14:45 - 15:45, Hall B

RICHTER TRANSFORMATION IN CLL

Chair: C Moreno (Hospital Santa Creu I Sant Pau, Barcelona, Spain)

- **Molecular pathogenesis of Richter syndrome**
  G Gaidano (University of Eastern Piedmont, Novara, Italy)
- **New developments in Richter syndrome**
  N Jain (MD Anderson Cancer Center, Houston, USA)

LEARNING GOALS

G Gaidano

After attending this lecture, the participant will be able to

– Describe the risk factors for Richter's syndrome development.
– Understand the molecular genetics of Richter's syndrome.
– Discuss the clinical implications of the genetic profile of Richter's syndrome.

N Jain

After attending this lecture, the participant will be able to

– Describe current and emerging therapies for patients with Richter transformation of CLL.
– Select appropriate therapies based upon patient and disease characteristics.

→ HEMATOLOGY-IN-FOCUS 3 C
14:45 - 15:45, Hall C

RARE LYMPHOMA SUBTYPES

Chair: A Engert (University Hospital of Cologne, Germany)

- **"Double hit" lymphomas**
  ME Chamuleau (VU University Medical Center, Amsterdam, the Netherlands)
- **NLPHL - A forgotten entity?**
  A Engert (University Hospital of Cologne, Germany)

LEARNING GOALS

ME Chamuleau

After attending this lecture, the participant will be able to

– Describe biological and clinical features of patients with double-hit and double-expressor lymphoma.
– Discuss the current knowledge on heterogeneity of these

lymphomas (double-hit vs double-expressor, double-hit vs single-hit, MYC-IG translocation partner vs MYC-non-Ig translocation partner).
– Discuss different treatment schedules, outcome and new therapeutic strategies.

A Engert
After attending this lecture, the participant will be able to
– Discuss the diagnostics for NLPHL and differences between NLPHL and cHL.
– Describe current and emerging therapies and outcomes for patients with newly diagnosed NLPHL.
– Discuss treatment options for relapsing patients.

→ HEMATOLOGY-IN-FOCUS 2 4 **B T C**
14:45 - 15:45, Hall D

NEW STRATEGIES IN CELLULAR THERAPY TO PREVENT RELAPSE OF ACUTE LEUKEMIA

Chair: T Fry (Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, USA)
- **CAR-T cells in AML**
  A Bondanza (San Raffaele University Hospital and Scientific Institute, Milan, Italy)
- **T cell subsets for preventing relapse**
  J Kuball (University Medical Center Utrecht, the Netherlands)

LEARNING GOALS

A Bondanza
After attending this lecture, the participant will be able to
– Discuss target-antigen choice for CAR-T cells against AML.
– Describe the options for maximising CAR-T cell efficacy in AML, while minimising toxicity.
– Position CAR-T cell therapy of AML in the context of hematopoietic stem cell transplantation.

J Kuball
An up-to-date program is available via the mobile app.

→ CLINICAL DEBATE 1 4 9 **C**
14:45 - 15:45, Hall E

ALL CHILDREN WITH SICKLE CELL ANEMIA AND AN HLA IDENTICAL SIBLING SHOULD BE OFFERED HEMATOPOIETIC STEM CELL TRANSPLANTATION

Chair: R Colombatti (Azienda Ospedaliera-Università di Padova, Italy)
- **Yes**
  L Krishnamurti (Children's Healthcare of Atlanta, Emory University, USA)
- **No**
  M de Montalembert (Hôpital Necker, Paris, France)

→ HEMATOLOGY-IN-FOCUS 6 9 **C**
14:45 - 15:45, Room N101

NOVEL APPROACHES FOR TREATMENT OF HEMOPHILIA

Chair: J Windyga (Institute of Hematology and Transfusion Medicine, Warsaw, Poland)
- **Factor VIII based**
  F Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)
- **Non substitutive therapies for hemophilia**
  M Makris (University of Sheffield, United Kingdom)

LEARNING GOALS

F Peyvandi
After attending this lecture, the participant will be able to
– Describe current treatment landscape and its limits for hemophilia A patients
– Illustrate the evolution of emerging therapies obtained by bioengineering technologies as PEGylation and fusion proteins
– Report data on efficacy in prophylactic treatment and safety of these innovative drugs
– Discuss new treatment options and requirement of a systematic approach for their marketing surveillance

M Makris
After attending this lecture, the participant will be able to
– Appreciate the limitations of the current haemophilia treatments that are based on substitution of the missing clotting factor as a concentrate.
– Describe the new disruptive technologies undergoing clinical trials and targeting antithrombin, TFPI and factors IX/X.
– Describe the current status of gene therapy for haemophilia A and B.

→ HEMATOLOGY-IN-FOCUS 9 **C**
14:45 - 15:45, Room N105

PEDIATRIC HEMATOLOGY: NEW DRUGS FOR CHILDREN

Chair: A Baruchel (France)
- **How to introduce new drugs for children with hematological malignancies? The US perpective**
  P Adamson (The Children's Hospital of Philadelphia, USA)
- **Early phase clinical trials in children: The European perspective**
  CM Zwaan (Erasmus MC Sophia Children's Hospital & Princess Máxima Center, Rotterdam, the Netherlands)

LEARNING GOALS

P Adamson
An up-to-date program is available via the mobile app.

CM Zwaan
After attending this lecture, the participant will be able to
– Describe the medical need in pediatric leukemia and have an

overview of the drugs currently in development in Europe.
– Understand the role of the European Pediatric Regulation including discussion points raised in the 10-year report after its implementation.
– Discuss the design and minimal dataset required for pediatric leukemia studies.

→ EHA - CHINESE SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM 2 3 4 C
14:45 - 15:45, Room N103

STEM CELL TRANSPLANTATION FOR RELAPSED LEUKEMIA

Chairs: J Wang (Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, China)
S Izraeli (Sheba Medical Center, Ramat Gan, Israel)

- **SCT for relapsed leukemia - The Chinese perspective**
  X Huang (Peking University Institute of Hematology, China)
- **SCT for relapsed leukemia - The European perspective**
  A Nagler (Chaim Sheba Medical Center, Tel Hashomer, Israel)

LEARNING GOALS

X Huang

After attending this lecture, the participant will be able to
– Review the poor prognosis of relapse acute leukemia, and review the outcomes of HSCT for relapsed leukemia.
– Present the current strategies to improve the outcome of HSCT for relapse leukemia adopted by Chinese physicians, including optimizing the conditioning regimen, modified donor lymphocyte infusion, selection of optimal donor and MRD-guided strategies.
– Evaluate potential benefits of using haploidentical donor, including stronger GVL effect and shorter waiting time led to increased chance to receive transplant.

A Nagler

After attending this lecture, the participant will be able to
– Discuss prognostic factors for AML relapse.
– Delineate therapeutic options for relapsed AML.
– Evaluate the role of allogeneic transplantation for relapsed AML.
– Present potential strategies to prevent relapse post allogeneic transplantation for AML.

→ EHA - EUROPEAN SCHOOL OF HEMATOLOGY JOINT SYMPOSIUM 1 2 3 4 8 9 C
14:45 - 15:45, Room N109

DOCTOR-PATIENT COMMUNICATION REGARDING BAD NEWS AND FUTURE PROSPECTS

Chairs: S Johnson (ESH, South Petherton, United Kingdom)
E Hellström Lindberg (EHA, Karolinska Institutet, Stockholm, Sweden)

- **Introduction, session overview, intro consultation and communication issues**
  S Johnson (ESH, South Petherton, United Kingdom)
  E Hellström Lindberg (EHA, Karolinska Institutet, Stockholm, Sweden)
- **Consultation role play**
  B Kennedy (Leicester Royal Infirmary, United Kingdom)
  Actors:
  D Manship (RoleCall, United Kingdom)
  C Webber (RoleCall, United Kingdom)

CLINICAL SCENARIO

Patient is a 62 year old man who has a relapsed Hodgkin Lymphoma. Initial chemotherapy about a year earlier had failed despite early intensification and six months ago an autologous stem cell transplant was performed. The patient tolerated this well but seems to have had a rather slow general recovery. More recently there was evidence of active lymphoma once more. He is now undergoing a programme of salvage therapy with a view to allogeneic transplant. Both patient and wife have come to the consultation. The patient, his wife and the hematologist are expecting to discuss the recent FDG-PET Scan and to confirm plans regarding the transplant. The patient is very anxious for the future and feels the transplant is in his best interest. However, during the consultation it will become apparent to the clinician that a transplant is no longer viable. He will need to break this news and manage the couple's expectations of the future.

- **Summary and conclusions**
  S Johnson (ESH, South Petherton, United Kingdom)
  E Hellström Lindberg (Karolinska Institutet, Stockholm, Sweden)

→ EARLY CAREER SESSION 8 B T C
14:45 - 15:45, Room N111

BIOLOGIC, TRANSLATIONAL AND CLINICAL HEMATOLOGY: WHAT IS BEYOND?

Chair: M Gruber (Center for Molecular Medicine, Vienna, Austria)

- **Introduction: Early Career Committee, Overview on Early Career Session 2 and the two Bite-size classes**
  V Gaidzik (University Hospital of Ulm, Germany)
- **How to present and how to get published: Personal perspective from the Blood Editor-in-chief**
  B Lowenberg (Erasmus University Medical Center, Rotterdam, the Netherlands)

LEARNING GOALS

V Gaidzik

After attending this lecture, the participant will be able to
– Know about the Early Career Committee of EHA.
– Describe current EHA career development opportunities and how to apply for them.

B Lowenberg

After attending this lecture, the participant will be able to
– Understand the biomedical publication processes.
– Identify and avoid common pitfalls in manuscript preparation and submission.

→ EU FUNDED PROJECTS
14:45 - 15:45, Room N115

HARMONY: ENABLING BETTER AND FASTER TREATMENT FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Chairs: R Hehlmann (Medizinische Fakultät Mannheim Universität Heidelberg, Mannheim, Germany)
P Bacon (Celgene, Switzerland)

- **HARMONY: Bench to Bed Projects**
  JM Hernández (IECSCYL-IBSAL, Spain)
  P van Dijck (Novartis, Switzerland)
- **HARMONY research projects: AML, MDS, CLL.**
  L Bullinger (University Hospital of Ulm, Germany)
  P Fenaux (Hôpital St Louis, Paris, France)
  LA Ann Sutton (Upssala Universitet, Sweden)
  A Vasconcelos (Celgene, Switzerland)
  C Löfgren (Janssen-Cilag, Sweden)
- **Multi stakeholder involvement**
  J Geissler (Leukemia Patient Advocates Foundation, Munich, Germany)
  H Chevrou-Séverac (Celgene, Switzerland)
- **Q&A**
- **Conclusion: join the HARMONY journey: invitation to "informal meeting", booth, website**
  G Sanz (HULAFE, Spain)

→ MEET-THE-EXPERT 2 **C**
14:45 - 15:45, Room N107
Availability on first come first serve basis

STOP OF TKI IN CML

Speaker: JL Steegmann (Hospital de la Princesa & IIS-IP, Madrid, Spain)

→ MEET-THE EXPERT 1 2 **C**
14:45 - 15:45, Room N108
Availability on first come first serve basis

EOSINOPHILIA

Speaker: A Reiter (University Medical Centre Mannheim, Germany)

→ MEET-THE-EXPERT 7 8 **C**
14:45 - 15:45, Room N117
Availability on first come first serve basis

HOW I PLAN AND RUN A HOSPITAL PATIENT BLOOD MANAGEMENT PROGRAM?

Speaker: K Pendry (NHS Blood and Transplant and Central Manchester University Hospitals NHS Foundation Trust, United Kingdom)

→ SIMULTANEOUS SESSIONS 3 10 **T C**
16:00 – 17:15, Hall A

NEW DRUGS FOR RESCUE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Chairs: S Giralt (Memorial Sloan Kettering Cancer Center, New York, USA)
A Alegre (Hospital Universitario de La Princesa, Madrid, Spain)

16:00 – 16:15
S456 **PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**
MA Dimopoulos[1] ([1]National and Kapodistrian University of Athens School of Medicine, Athens, Greece)

16:15 – 16:30
S457 **A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)**
J Mikhael[1] ([1]Mayo Clinic, Pheonix, United States)

16:30 – 16:45
S458 **OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL**
M Dimopoulos[1] ([1]National and Kapodistrian University of Athens, Athens, Greece)

16:45 – 17:00
S459 **EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR**
K Weisel[1] ([1]Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen, Germany)

17:00 – 17:15
S460 **A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**
P Moreau[1] ([1]CHU de Nantes, Hotel Dieu–HME, Nantes, France)

→ SIMULTANEOUS SESSIONS 3 5 10 T C
16:00 – 17:15, Hall B

IMPROVING PROGNOSTICATION AND FRONT-LINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chairs: A Tedeschi (Niguarda Cancer Center, Niguarda Hospital, Milan, Italy)
S Mulligan (Royal North Shore Hospital, Sydney, Australia)

16:00 – 16:15
S461 **CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC**
P Baliakas[1] ([1]Uppsala University, Uppsala, Sweden)

16:15 – 16:30
S462 **IS FCR THE TREATMENT OF CHOICE FOR IGHV MUTATED CLL WITHOUT POOR FISH CYTOGENETICS?**
C Cuéllar-García[1] ([1]Hospital Santa Creu i Sant Pau, Barcelona, Spain)

16:30 – 16:45
S463 **IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)**
N Jain[1] ([1]MD Anderson Cancer Center, Houston, United States)

16:45 – 17:00
S464 **BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)**
P Cramer[1] ([1]University Hospital Cologne, Cologne, Germany)

17:00 – 17:15
S465 **SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDELALISIB PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH DEL(17P)**
P Hillmen[1] ([1]The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom)

→ SIMULTANEOUS SESSIONS 3 C
16:00 – 17:15, Hall C

AGGRESSIVE NON-HODGKIN LYMPHOMA - RELAPSED/REFRACTORY

Chairs: D Caballero (University Hospital, Salamance, Spain)
M Hutchings (Rigshospitalet, Copenhagen University Hospital, Denmark)

16:00 – 16:15
S466 **CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)**
Y Lin[10] ([10]Mayo Clinic, Rochester, United States)

16:15 – 16:30
S467 **CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): PHASE IB STUDY IN RELAPSED OR REFRACTORY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR MARGINAL ZONE LYMPHOMA**
R Bouabdallah[1] ([1]Institut Paoli-Calmettes, Marseille, France)

16:30 – 16:45
S468 **POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY**
M Matasar[1] ([1]Memorial Sloan Kettering Cancer Center, New York, United States)

16:45 – 17:00
S469 **SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY**
M Maerevoet[1] ([1]Institute Jules Bordet, Brussels, Belgium)

17:00 – 17:15
S470 **L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY**
K Maddocks[1] ([1]The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States)

→ SIMULTANEOUS SESSIONS 2 5 9 10 T C
16:00 – 17:15, Hall D

TARGETED TREATMENT OF AML

Chairs: A Ganser (Medizinische Hochschule Hannover, Germany)
F Ravandi (University of Texas, M. D. Anderson Cancer Center, Houston, USA)

16:00 – 16:15
S471 **ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY**
EM Stein[1], [2] ([1]Memorial Sloan Kettering Cancer Center, New York, United States, [2]Weill Cornell Medical College, New York, United States)

16:15 – 16:30
S472 **SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (↗65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)**
K Pratz[1] ([1]Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States)

16:30 – 16:45
S473 **UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAÏVE ACUTE MYELOID LEUKEMIA PATIENTS AGED ↗65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY**
AH Wei[1] ([1]The Alfred Hospital and Monash University, Melbourne, Australia)

16:45 – 17:00
S474 **PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)**
N Daver[1] ([1]University of Texas MD Anderson Cancer Center, Houston, United States)

17:00 – 17:15
S475 **QUIZARTINIB AND BRIDGE TO TRANSPLANT IN FLT3-ITD AML PATIENTS AFTER FAILURE OF SALVAGE CHEMOTHERAPY: A HISTORICAL COMPARISON WITH UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) DATA**
R Hills[1] ([1]Cardiff University, Cardiff, United Kingdom)

→ SIMULTANEOUS SESSIONS 3 4 5 9 10 T C
16:00 – 17:15, Hall E

IMMUNOTHERAPY IN ALL

Chairs: A Fielding (UCL, London, United Kingdom)
K Porkka (Helsinki University Hospital Comprehensive Cancer Center, Finland)

16:00 – 16:15
S476 **GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS**
J Buechner[1] ([1]Oslo University Hospital Rikshospitalet, Oslo, Norway)

16:15 – 16:30
S477 **CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**
K Thudium Mueller[1] ([1]Novartis Pharmaceuticals Corporation, East Hanover, United States)

16:30 – 16:45
S478 **BLINATUMOMAB VS SOC CHEMOTHERAPY IN FIRST SALVAGE COMPARED WITH SECOND OR GREATER SALVAGE IN A PHASE 3 STUDY**
H Dombret[1] ([1]Hôpital Saint-Louis, Paris, France)

16:45 – 17:00
S479 **DURABLE LONG-TERM SURVIVAL OF ADULT PATIENTS WITH B-ALL AFTER CD19 CAR (19-28Z) T CELL THERAPY**
J Park[1] ([1]MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, United States)

17:00 – 17:15
S480 **STANDARD-RISK RANDOMIZATION OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN TRIAL AIEOP-BFM ALL 2000 INDICATES EQUAL OUTCOME WITH REDUCED-INTENSITY DELAYED INTENSIFICATION IN ETV6-RUNX1-POSITIVE PATIENTS**
K Bleckmann[1] ([1]University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany)

→ SIMULTANEOUS SESSIONS 2 5 10 T C
16:00 – 17:15, Room N101

BIOLOGY AND DISEASE MONITORING IN CML

Chairs: D Krause (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany)
J Janssen (VU University Medical Center , Amsterdam, the Netherlands)

16:00 – 16:15
S481 **A SECOND GENERATION LYSOSOMOTROPIC AGENT DRIVES LEUKAEMIC STEM CELL DIFFERENTIATION AND SENSITIZES THEM TO TYROSINE KINASE INHIBITOR TREATMENT IN VITRO AND IN VIVO**
P Baquero[1] ([1]University of Glasgow, Glasgow, United Kingdom)

16:15 – 16:30
S482 **FC GAMMA RECEPTOR 2B IS CRITICAL FOR BCR-ABL MEDIATED LEUKEMOGENESIS**
O Herrmann[1] ([1]Faculty of Medicine, University Hospital RWTH Aachen, Aachen, Germany)

16:30 – 16:45
S483 **MYC-DEPENDENT REPRESSION MECHANISM OF THE MIR-150 TRANSCRIPTIONAL REGULATION IN CHRONIC MYELOID LEUKEMIA.**
N Čuřík[1, 2] ([1]Institute of Hematology and Blood Transfusion, Prague, Czech Republic, [2]Institute of Pathological Physiology, 1st Medical faculty, Charles University in Prague, Prague, Czech Republic)

16:45 – 17:00
S484 **COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY**
DM Ross[4] ([4]Royal Adelaide Hospital and SA Pathology, Adelaide, Australia)

17:00 – 17:15
S485 **ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY**
S Soverini[1] ([1]Hematology/Oncology "L. e A. Seràgnoli", Bologna, Italy)

→ SIMULTANEOUS SESSIONS 3 5 10 T C
16:00 – 17:15, Room N105

PROGNOSTIC MARKERS AND NEW TREATMENT IN MDS

Chairs: L Adès (Hôpital Saint Louis, Paris, France)
V Santini (AOU Careggi, University of Florence, Italy)

16:00 – 16:15
S486 **PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS.**
JW Hansen[1] ([1]Rigshospitalet, University of Copenhagen, Copenhagen, Denmark)

16:15 – 16:30
S487 **AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS)**
G Garcia-Manero[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

16:30 – 16:45
S488 **ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND RELAPSED/REFRACTORY PATIENTS**
S Navada[1] ([1]Icahn School of Medicine at Mount Sinai, New York, United States)

16:45 – 17:00
S489 **IMPACT OF THE MUTATIONAL PROFILE AT THE TIME OF DIAGNOSIS IN RESPONSE OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS**
G Montalban-Bravo[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

17:00 – 17:15
S490 **STUDY OF THE EFFECT OF MIRNAS TARGETING RPS14 ON CELLULAR BIOLOGICAL BEHAVIOR OF MYELODYSPLASTIC SYNDROMES**
Y Nie[1] ([1]Zhongnan Hospital of Wuhan University, Wuhan, China)

→ SIMULTANEOUS SESSIONS 4 9 C
16:00 – 17:15, Room N103

STEM CELL TRANSPLANTATION - CLINICAL 1

Chairs: H Einsele (University Hospital Wuerzburg, Germany)
E Olavarria (Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom)

16:00 – 16:15
S491 **SERIAL SEQUENCING REVEALS CLONAL ORIGINS AND STRATEGIES FOR EARLY DETECTION OF POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)**
T Kim[1, 2] ([1]University of Toronto, Toronto, Canada, [2]University of Toronto, Toronto, Canada)

16:15 – 16:30
S492 **IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY**
I Pusic[1] ([1]Washington University School of Medicine, St. Louis, United States)

16:30 – 16:45
S493 **OUTCOMES OF NON T CELL-DEPLETED HAPLOIDENTICAL HSCT VERSUS HSCT FROM MATCHED SIBLING DONORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION, AN ALWP-EBMT STUDY**
D Salvatore[1] ([1]Federico II, Naples, Italy)

16:45 – 17:00
S494 **INDIVIDUAL OUTCOME PREDICTION FOR MDS AND SECONDARY AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BASED ON GENETIC, PATIENT- AND TRANSPLANTATION-ASSOCIATED RISK FACTORS**
M Heuser[1] ([1]Hannover Medical School, Hannover, Germany)

17:00 – 17:15
S495 **IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΔLPHA-BETA T-CELL DEPLETED HAPLO-HSCT**
P Merli[1] ([1]Ospedale Pediatrico Bambino Gesu, Rome, Italy)

→ SIMULTANEOUS SESSIONS 1 9 B T C
16:00 – 17:15, Room N104

BONE MARROW FAILURE AND PNH

Chairs: H Hasle (Aarhus University Hospital, Denmark)
MM van den Heuvel-Eibrink (Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands)

16:00 – 16:15
S496 **HEREDITARY HEMATOLOGIC MALIGNANCIES: GENETIC COUNSELING IMPLEMENTATION IN A LARGE LEUKEMIA CENTER**
C Dinardo[1] ([1]The University of Texas MD Andesron Cancer Center, Houston, United States)

16:15 – 16:30
S497 **SECONDARY LEUKEMIAS IN GENETIC SUBTYPES OF CONGENITAL NEUTROPENIA (ELANE, HAX1, WASP, G6PC3, ETC.): A LONG-TERM ANALYSIS OF THE SCNIR EUROPE**
C Zeidler[1] ([1]Medical School Hannover, Hannover, Germany)

16:30 – 16:45
S498 **EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY**
B Höchsmann[1] ([1]Institute for Clinical Transfusion Medicine and Immunogenetics, University Hospital Ulm, Ulm, Germany)

16:45 – 17:00
S499 **CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA: FUNCTIONAL RESCUE OF A NOVEL MPL MUTANT IN PRIMARY HEMATOPOIETIC CELLS USING CRISPR-CAS9**
C Cleyrat[1] ([1]University of New Mexico Cancer Center, Albuquerque, United States)

17:00 – 17:15
S500 **DISCOVERY OF ORALLY BIOAVAILABLE SMALL MOLECULES FOR INHIBITION OF COMPLEMENT C5**
A Ricardo[1] ([1]Ra Pharmaceuticals, Inc., CAMBRIDGE, United States)

→ SIMULTANEOUS SESSIONS 1 8 C
16:00 – 17:15, Room N109

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS

Chairs: M Delforge (UZ Leuven, Belgium)
JL Harrousseau (Groupe Confluent, Nantes, France)

16:00 – 16:15
S501 **QUALITY OF LIFE WITH MELPHALAN/PREDNISONE PLUS EITHER THALIDOMIDE (MPT-T) OR LENALIDOMIDE (MPR-R) IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE HOVON87/NMSG18 STUDY**
C Stege[1] ([1]VU University Medical Center, Amsterdam, the Netherlands)

16:15 – 16:30
S502 **HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED INDOLENT NON-HODGKIN LYMPHOMA**
A Davies[1] ([1]Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom)

16:30 – 16:45
S503 **EFFECTIVE KEY WORKERS REDUCE THE NEED FOR CANCER SUPPORT GROUPS: RESULTS OF A POPULATION BASED SURVEY FROM GREATER MANCHESTER CANCER PATHWAY BOARD (GMCPB)**
J Tomlins[1] ([1]The Christie NHS Foundation Trust, Manchester, United Kingdom)

16:45 – 17:00
S504 **FRONT-LINE VASCULAR ACCESS DEVICES IN ACUTE LEUKEMIAS – PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) VERSUS TRADITIONAL CENTRAL VENOUS CATHETER (CVC): A PHASE IV RANDOMIZED TRIAL (NCT02405728)**
C Cerchione[1] ([1]Ematologia e trapianto/au federico ii, Napoli, Italy)

17:00 – 17:15
S505 **THE SIMM STUDY: SURVEY OF INTEGRATIVE MEDICINE IN MYELOPROLIFERATIVE NEOPLASMS**
K Gowin[1] ([1]Mayo Clinic Arizona, Phoenix, United States)

→ EARLY CAREER SESSION 8 C
16:00 - 17:15, Room N111

BITE-SIZE CRTH

Chair: H Becker (University of Freiburg - Medical Center, Germany)
- **Pitfalls in the design of clinical trials**
  R Hills (Cardiff University, United Kingdom)
- **Execution of clinical trials: How to do it right?**
  M Hutchings (Rigshospitalet, Copenhagen University Hospital, Denmark)

LEARNING GOALS

R Hills

After attending this lecture, the participant will be able to
- Describe and evaluate traditional trial designs in hematology.
- Understand the shortcomings of many traditional designs.
- Describe the advantages of more modern trial designs.

M Hutchings

An up-to-date program is available via the mobile app.

→ EARLY CAREER SESSION 8 T
16:00 - 17:15, Room N113

BITE-SIZE TRTH

Chair: C Scharenberg (Karolinska Institute, Stockholm, Sweden)

- **Pitfalls in biostatistics**
  D Neuberg (Dana-Farber Cancer Institute, Boston, USA)
- **Personal journey through a career in translational hematology**
  J Gribben (Queen Mary University of London, United Kingdom)

LEARNING GOALS

D Neuberg

After attending this lecture, the participant will be able to

– Appreciate the importance of statistical advice in planning, executing, and reporting a study.
– Have a clear understanding of the role of variability in study design and analysis.
– Realize improved ability to manage both inherent and induced variability in research.

J Gribben

An up-to-date program is available via the mobile app.

→ EHA ADVOCACY SESSION 1 2 3 4 8 9 10 C
16:00 - 17:15, Room N115

NEW DRUGS IN HEMATOLOGY: FAIR PRICING & ACCESS

Chair: A Hagenbeek (University of Amsterdam, the Netherlands)

- **A new economic model for medicine pricing in hemato-oncology**
  R Sullivan (Kings College London, United Kingdom)
- **Fixing the fundamental flaws in medicine pricing: what can regulators and public health authorities do?**
  S Garner (World Health Organization (WHO), Geneva, Switzerland)
- **The patient perspective**
  P Kapitein (Inspire2Live, Amsterdam, the Netherlands)
- **Panel discussion**

LEARNING GOALS

R Sullivan

An up-to-date program is available via the mobile app.

S Garner

An up-to-date program is available via the mobile app.

P Kapitein

After attending this lecture, the participant will be able to

– Realize that a lower price is blocked by industry, politics and government.
– Experience that this blocking is not caused by bad intention but by The Medical Industrial Complex that we created and therefore can change.
– Be shocked that we in healthcare are distracted from our essence: the patient.
– Contribute to the solution by working with patients and put them in the centre of healthcare again. Where they belong.

→ UPDATES-IN-HEMATOLOGY
17:30 - 19:00, Room N105

BROADENING OUR HORIZONS IN RELAPSED/ REFRACTORY ALL

Chair: D Marks, University of Bristol, Bristol, United Kingdom

Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease associated with low response rates and high toxicity in the salvage setting following standard chemotherapy. Therefore, there remains an unmet need for improved treatment options for patients with relapsed/refractory ALL. In this meeting, we will explore the latest understanding around prognostic tools which help predict outcomes and stratify treatment selection for patients with ALL. We will also discuss the latest clinical data surrounding innovative antibody-targeted approaches at the forefront of the evolving treatment paradigm in the relapsed/refractory setting. Finally, interactive case studies will be used to demonstrate how novel antibody-targeted therapies are transforming the lives of patients with relapsed/refractory ALL.

– To explore how prognostic tools can help predict patient outcomes and facilitate treatment decisions in ALL
– To discuss innovative antibody-targeted approaches in the treatment of relapsed/refractory ALL, and their potential to change the treatment paradigm
– To discuss the use of emerging antibody-targeted therapies in clinical practice through interactive case-based presentations

PROGRAM

- **Prognostic tools to optimise outcomes in ALL: What do we know?**
  M Brüggemann, University Schleswig Holstein in the City Hospital, Kiel, Germany
- **A new era in the treatment of relapsed/refractory ALL**
  E Jabbour, University of Texas M. D. Anderson Cancer Center Houston, Houston, Texas, United States
- **Advancing the treatment of relapsed/refractory ALL: A case-based discussion**
  D Marks, University of Bristol, Bristol, United Kingdom

POSTER SESSION II

The main goal of the Poster Session is to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators (senior experts in the field) and interested congress participants. The Poster Session consists of two parts: the Poster Walk and Poster Browsing Time. This setup guarantees sufficient time for all posters that have been selected for a presentation. The first hour of the Poster Walk is moderated and then followed by the Poster Browsing Time, where the rest of the posters can be browsed on the e-poster screens available in the poster area.

Poster walks will be organized during the poster sessions on Friday, June 23 at 17:15 – 18:45 and Saturday, June 24 at 17:30 - 19:00. Poster authors and moderators are requested to be present at the first poster in their poster session, at the beginning of the presentation time (Friday at 17:15 and Saturday at 17:30).
Poster Browsing Time will be organized after the Poster Walk, on Friday, June 23 18:15 – 18:45 and Saturday, June 24 at 18:30 – 19:00.

→ POSTER SESSION
17:30 – 19:00, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY 2

Moderator: C Baldus (Charité, Berlin, Germany)

P506 **T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT**
L Liu[1] ([1]Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China)

P507 **RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL**
Y Kong[1] ([1]Peking University Institute of Hematology, Beijing, China)

P508 **PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING**
F Seyfried[1] ([1]Ulm University Medical Center, Ulm, Germany)

P509 **CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA**
L Fernandez[1] ([1]CNIO, Madrid, Spain)

P510 **A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR**
A Gonzalez-Murillo[1] ([1]HOSPITAL UNIVERSITARIO NIÑO JESUS, MADRID, Spain)

P511 **CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSPR2) TRANSCRIPT LEVELS CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NORMAL CYTOGENETICS**
SJ Wang[1] ([1]Peking University Peoples Hospital and Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China)

P512 **THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA**
A Alhammer[1], [2] ([1]Northern Institute for Cancer research, Newcastle upon Tyne, United Kingdom, [2]Biotechnology research Center, Baghdad, Iraq)

P513 **BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME**
L Fernández-Sevilla[1] ([1]Universidad Complutense, Madrid, Spain)

P514 **TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
A Buffière[1] ([1]UMR1231 Inserm, Université Bourgogne Franche-Comté, AgroSup, Dijon, France)

17:30 – 19:00, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL 2

Moderator: To be announced

P515 **SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL**
M Kuhlen[1] ([1]Medical Faculty, Heinrich Heine University, Duesseldorf, Germany)

P516 **FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS**
D Lang[1] ([1]Klinikum der Goethe Universität, Frankfurt, Germany)

P517 **ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)**
S Maude[1], [2] ([1]Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, [2]Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, United States)

P518 **UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA**
N Short[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

P519 **PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN**
E Jabbour[1] ([1]MD Anderson Cancer Center, Houston, United States)

P520 **A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS**
R Bassan[1] ([1]Ospedale dell'Angelo, Mestre Venezia, Italy)

P521 **BLINATUMOMAB USE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY**
F Locatelli[1], [2] ([1]Bambino Gesù Children's Hospital, Rome, Italy, [2]University of Pavia, Pavia, Italy)

P522 **PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**
F Locke[1] ([1]H. Lee Moffitt Cancer Center, Tampa, United States)

P523 **KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3**
B Shah[1] ([1]H. Lee Moffitt Cancer Center, Tampa, United States)

P524 **EXPOSURE-ADJUSTED ADVERSE EVENTS COMPARING BLINATUMOMAB WITH STANDARD OF CARE CHEMOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A RANDOMIZED PHASE 3 STUDY**
M Topp[1] ([1]Universitätsklinikum Würzburg, Würzburg, Germany)

P525 **FACTORS ASSOCIATED WITH STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN VERSUS CONVENTIONAL CHEMOTHERAPY**
M Stelljes[1] ([1]University of Münster, Münster , Germany)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - BIOLOGY 3

Moderator: O Abdel-Wahab (Memorial Sloan Kettering Cancer Center, New York, USA)

P526 **DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS**
S Adams[1] ([1]ImmunoGen, Waltham, United States)

P527 **THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION**
R Slany[1] ([1]Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany)

P528 **PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.**
D Di Marcantonio[1] ([1]Fox Chase Cancer Center, Philadelphia, United States)

P530 **ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2**
R Pandey[1] ([1]Indiana University School of Medicine, Indianapolis, United States)

P531 **CLUSTER REGULATION OF RUNX FAMILY BY "GENE SWITCH" TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS.**
K Morita[1] ([1]Graduate School of Medicine, Kyoto University, Kyoto, Japan)

P532 **PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS**
P Casado-Izquierdo[1] ([1]Barts Cancer Institute, London, United Kingdom)

P533 **CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)**
F Theis[1] ([1]University Hospital of Ulm, Ulm, Germany)

P534 **GFI1B – A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS**
A Thivakaran[1] ([1]University Hospital of Essen, Essen, Germany)

P535 **VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB**
M Agrawal[1] ([1]Universitätsklinikum Ulm, Ulm, Germany)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - BIOLOGY 4

Moderator: T Mercher (INSERM U1170, Gustave Roussy institute, Villejuif, France)

P536 **P38Đ MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA**
E Arriazu[1] ([1]Center for applyed medical research University of Navarre, Pamplona, Spain)

P537 **GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA**
J Takeda[1] ([1]Kyoto Univrsity, Kyoto, Japan)

P538 **THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES**
A Al Hinai[1], [2] ([1]Erasmus University Medical Center, Rotterdam, the Netherlands, [2]National Genetic Centre, Muscat, Oman)

P539 **EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML**
J Smith[1] ([1]Queens University Belfast, Belfast, United Kingdom)

P540 **NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA**
IJ Lau[1] ([1]Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom)

P541 **CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA**
S Chitre[1] ([1]KINGS COLLEGE LONDON, London, United Kingdom)

P542 **TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML**
I Uras[1] ([1]University of Veterinary Medicine, Vienna, Vienna, Austria)

P543 **CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.**
M Medrano[1] ([1]Instituto de Biomedicina de Sevilla, Seville, Spain)

P544 **PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.**
E Sala[1], [2] ([1]San Raffaele Scientific Institute, Milano, Italy, [2]San Raffaele Scientific Institute, Milano, Italy)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 4

Moderator: B Gjertsen (University of Bergen, Norway)

P546 **AML PATIENTS AGED ↗75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?**
V Prassek[1] ([1]University of Munich, Munich, Germany)

P547 **GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE**
D DeAngelo[1] ([1]Dana-Farber Cancer Institute, Boston, United States)

P548 **BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY**
T Zuckerman[1], [2] ([1]Technion, Haifa, Israel, [2]Rambam Health Care Campus, Haifa, Israel)

P549 **FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES**
C Haferlach[1] ([1]MLL Munich Leukemia Laboratory, Munich, Germany)

P550 **COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)**
K Morita[1], [2] ([1]The University of Texas MD Anderson Cancer Center, Texas, United States, 2The University of Tokyo, Tokyo, Japan)

P551 **THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY**
DH Kwak[1] ([1]Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)

P552 **VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML**
E Wang[1] ([1]Roswell Park Cancer Institute, Buffalo, United States)

P553 **PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH "7+3" DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD**
D Gupta[1] ([1]Mount Sinai Hospital, New York, United States)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 5

Moderator: J Esteve (University of Barcelona, Spain)

P554 **VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL.**
J Ballesteros[2] ([2]Vivia Biotech, Tres Cantos, Spain)

P555 **RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS → 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP**
N Jaekel[1] ([1]University Hospital of Leipzig, Leipzig, Germany)

P556 **OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY**
J Lancet[1] ([1]H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States)

P557 **HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA**
S Bertoli[1], [2], [3] ([1]Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France, [2]Université Toulouse III Paul Sabatier, Toulouse, France, [3]Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France)

P558 **NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE – IMPACT OF AGE ON MUTATIONAL LOAD**
L Pleyer[1], [2], [3] ([1]Paracelsus Medical University, Salzburg, Austria, [2]Center for Clinical Cancer and Immunology Trials, Salzburg, Austria, [3]Cancer Cluster, Salzburg, Austria)

P559 **PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY**
S Machherndl-Spandl[1] ([1]Ordensklinikum Elisabethinen Linz, Linz, Austria)

P560 **EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT WITH GILTERITINIB**
M Levis[1] ([1]John Hopkins University, Baltimore, United States)

P561 **CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION**
DH Kwak[1] ([1]Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)

P562 **INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML**
J Cortes[1] ([1]MD Anderson Cancer Center, Houston, United States)

17:30 – 19:00, Poster area

AGGRESSIVE NON-HODGKIN LYMPHOMA - RELAPSED/REFRACTORY

Moderator: To be announced

P563 **COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA**
M Lunning[1] ([1]University of Nebraska Medical Center, Omaha, NE, United States)

P564 **VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)**
M Davids[1] ([1]Dana-Farber Cancer Institute, Boston, United States)

P565 **WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA**
K De Paepe[1] ([1]University Hospitals Leuven, Leuven, Belgium)

P566 **CLINICAL OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA, FOLLICULAR LYMPHOMA AND RICHTER'S TRANSFORMATION PATIENTS TREATED WITH IBRUTINIB: A REAL-WORLD EXPERIENCE OF OFF LABEL, IBRUTINIB USE.**
K Isaac[1] ([1]Lankenau Medical Center, Wynnewood, United States)

P567 **PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.**
J Vermaat[1] ([1]Leiden University Medical Center, Leiden, the Netherlands)

P568 **HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY**
M Hentrich[2] ([2]Rotkreuzklinikum München GmbH , München, Germany)

P569 **RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA**
DH Yang[1] ([1]Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic Of)

P570 **LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES.**
F Farina[1], [2], [3] ([1]Milano Bicocca University, Monza, Italy, [2]San Gerardo Hospital, Monza, Italy, [3]San Raffaele Scientific Institute, Milano, Italy)

P571 **PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.**
T Witzig[1] ([1]Mayo Clinic, Rochester, United States)

P572 **BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC).**
J Cornillon[1] ([1]Institut de Cancérologie de la Loire, Saint-Etienne, France)

17:30 – 19:00, Poster area

BONE MARROW FAILURE SYNDROMES INCL. PNH - CLINICAL

Moderator: H Tamary (Schneider Children's Medical Center of Israel, Petah Tikva, Israel)

P573 **ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA**
I Martínez[1], [2] ([1]Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain, [2]Instituto de Salud Carlos III (ISCIII), Madrid, Spain)

P575 **SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA**
F Fioredda[1] ([1]IRCCS Istituto Giannina Gaslini, Genova, Italy)

P576 **TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS**
S Halkes[1] ([1]LUMC, Leiden, the Netherlands)

P577 **IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION**
X Pei[1] ([1]Peking University People's Hospital, Beijing, China)

P578 **DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY**
A Röth[1] ([1]University Hospital Essen, Essen, Germany)

P579 **DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS.**
B Van Dooijeweert[1] ([1]Wilhemina Children's Hospital, Utrecht, the Netherlands)

P580 **NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES**
E Galvez[1] ([1]Hospital Infantil Niño Jesus, Madrid, Spain)

P581 **APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY**
E Nevill[1] ([1]Vancouver General Hospital, Vancouver, Canada)

P582 **RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS**
M Oelmüller[1] ([1]University Hospital Essen, Essen, Germany)

17:30 – 19:00, Poster area

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY 2

Moderator: JA Garcia-Marco (Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain)

P583 **NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS**
F Pozzo[1] ([1]Centro di Riferimento Oncologico, Aviano, Italy)

P584 **CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.**
I Criado[1] ([1]Center for Cancer Research, Salamanca, Spain)

P585 **NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES**
A Braunx[1] ([1]Queen Mary University of London, London, United Kingdom)

P586 **MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
F Morabito[1], [21] ([1]Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), Italy, [21]Annunziata Hospital of Cosenza, Cosenza, Italy)

P587 **IL-4 INCREASES EXPRESSION OF POSITIVE REGULATORS OF BCR SIGNALLING IN CLL WHICH CAN BE OVERCOME BY CERDULATINIB**
M Blunt[1] ([1]University of Southampton, Southampton, United Kingdom)

P588 **INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE**
E Tissino[1] ([1]Centro di Riferimento Oncologico, Aviano, Italy)

P589 **IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY**
T Munir[1] ([1]St. James's Institute of Oncology, Leeds, United Kingdom)

P590 **EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53**
S Post[1] ([1]MD Anderson, Houston, United States)

17:30 – 19:00, Poster area

CHRONIC MYELOID LEUKEMIA - BIOLOGY

Moderator: To be announced

P591 **THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA**
M Copland[1] ([1]Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom)

P592 **SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS**
J Toda[1] ([1]Osaka University Graduate School of Medicine, Osaka, Japan)

P593 **TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT**
AS Bouillon[1] ([1]Medical Faculty, Uniklinik RWTH Aachen, Aachen, Germany)

P594 **GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS PREEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION TO BLASTIC PHASE INDEPENDENTLY OF BCR-ABL1 MUTATIONS**
M Machnicki[1], [2] ([1]Medical University of Warsaw, Warsaw, Poland, [2]Medical University of Warsaw, Warsaw, Poland)

P595 **INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE**
S Sopper[1] ([1]Medizinische Universität Innsbruck, Innsbruck, Austria)

P596 **BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB**
K Byrgazov[1] ([1]Children's Cancer Research Institute, Vienna, Austria)

P597 **IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO.**
R Gale[1] ([1]Imperial College London, London, United Kingdom)

P598 **MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY**
F Albano[1] ([1]Hematology - University of Bari, Bari, Italy)

P599 **THE AUTOMATED MOLECULAR TECHNIQUE "ULTRA" ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.**
S Galimberti[1] ([1]Clinical and Experimental Medicine, University of Pisa, Hematology, Italy, Pisa, Italy)

P600 **ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS**
M Mancini[1] ([1]Istituto di Ematologia Seràgnoli-DIMES, Bologna, Italy)

17:30 – 19:00, Poster area

CHRONIC MYELOID LEUKEMIA - CLINICAL 2

Moderator: FE Nicolini (Centre Hospitalier Lyon Sud, France)

P601 **DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE**
D Ross[1] ([1]SA Pathology, Adelaide, Australia)

P602 **RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT**
L Kjaer[1] ([1]Zealand University Hospital, Roskilde, Roskilde, Denmark)

P603 **5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)**
J Cortes[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, TX, United States)

P604 **LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE**
I Capodanno[39] ([39]Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy)

P605 **IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY**
G Gugliotta[1] ([1]University of Bologna, Bologna, Italy)

P606 **ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS**
Q Jiang[1] ([1]Peking University Institute of Hematology, Beijing, China)

P607 **COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS**
S Bernardi[1], [2] ([1]University of Brescia, Brescia, Italy, [2]AO Spedali Civili of Brescia, Brescia, Italy)

P608 **OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA**
C Talati[1] ([1]University of South Florida/Moffitt Cancer Center, Tampa, United States)

P609 **EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS**
J Steegmann[1] ([1]Hospital Universitario de la Princesa/ IIS-IP Madrid, Madrid, Spain)

P610 **GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB**
G Caocci[1] ([1]University of Cagliari, Cagliari, Italy)

P611 **THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT**
M Gniot[1] ([1]Poznan University of Medical Sciences, Poznań, Poland)

17:30 – 19:00, Poster area

ENZYMES AND SICKLE CELL DISEASE

Moderator: M de Montalembert (Hopital Necker, Paris, France)

P612 **ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA**
K Saito[1] ([1]Tohoku University Graduate School of Medicine, Sendai, Japan)

P613 **BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL.**
S Berentsen[1] ([1]HAUGESUND HOSPITAL, Haugesund, Norway)

P614 **EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.**
R van Wijk[1] ([1]University Medical Center Utrecht, Utrecht, the Netherlands)

P615 **IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING**
M Mañu Pereira[1] ([1]JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE, BARCELONA, Spain)

P616 **CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME**
B Fattizzo[1] ([1]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy)

P617 **HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING SICKLE CELL DISEASE**
O Blanc-Brude[1] ([1]INSERM, Paris, France)

P618 **USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY**
H Misra[1] ([1]Prolong Pharmaceuticals, South Plainfield, United States)

P619 **NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE**
K Gardner[1, 2] ([1]King's College Hospital, London, United Kingdom, [2]King's College London, London, United Kingdom)

P620 **THE PHARMACOKINETICS (PK) OF GBT440 ARE SIMILAR IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE (SCD)**
C Washington[1] ([1]Global Blood Therapeutics, South San Francisco, United States)

17:30 – 19:00, Poster area

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION

Moderator: Z Berneman (Antwerp University Hospital, Edegem, Belgium)

P621 **DEVELOPMENT OF TAX-REDIRECTED T-CELL IMMUNOTHERAPY FOR ADULT T CELL LEUKEMIA**
K Kawamura[1] ([1]Saitama Medical Center, Jichi Medical University, Saitama, Japan)

P623 **NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS**
F Roman-Rodriguez[1, 2] ([1]CIEMAT/CIBERER, Madrid, Spain, [2]IIS-Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain)

P624 **NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES**
A Rotolo[1] ([1]Imperial College London, London, UK, United Kingdom)

P625 **A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS**
Y Kasahara[1] ([1]Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan)

P626 **NKP30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT MODELS**
U Hartwig[1] ([1]University Medical Center Mainz, Mainz, Germany)

P627 **PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA**
H Echchannaoui[0], [2] ([1]University Medical Center Mainz, Mainz, Germany, [2]German Cancer Consortium (DKTK), partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany)

P628 **ENGINEERED T CELLS TOWARDS BAFF RECEPTOR: A NOVEL STRATEGY TO EFFICIENTLY TARGET B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
N Turazzi[1] ([1]M. Tettamanti Reserach Center, Department of pediatrics, University of Milano Bicocca S.Gerardo Hospital/ Fondazione MBBM, Monza, Italy)

P629 **EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR ADOPTIVE CELLULAR THERAPY**
U Hartwig[1] ([1]University Medical Center Mainz, Mainz, Germany)

P630 **SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR).**
M Rotiroti[1] ([1]Tettamanti Research Center, Monza, Italy)

P631 **UPDATE ON THE FIRST PATIENTS WITH SEVERE HEMOGLOBINOPATHIES TREATED WITH LENTIGLOBIN GENE THERAPY**
M Cavazzana[1] ([1]Necker Hospital, Paris, France)

17:30 – 19:00, Poster area

INDOLENT NON-HODGKIN LYMPHOMA - CLINICAL

Moderator: A Davies (Southampton General Hospital, United Kingdom)

P632 **A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA**
M Van den Bergh[1] ([1]H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States)

P633 **ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)**
A Forero-Torres[1] ([1]University of Alabama Birmingham, Birmingham, AL, United States)

P634 **PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/ REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS**
J Burke[1], [2] ([1]Rocky Mountain Cancer Centers, Aurora, CO, United States, [2]The US Oncology Network, The Woodlands, TX, United States)

P635 **A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA**
M Ogura[1] ([1]Department of Hematology, Tokai Central Hospital, Gifu, Japan)

P636 **DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA**
S Rupoli[1],[1] ([1]Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, ancona, Italy, [1]Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, ancona, Italy)

P637 **PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN'S CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA (CTCL):NUMBER NEEDED TO TREAT ANALYSIS**
M Dalal[1] ([1]Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)

P638 **PRIMARY OCULAR ADNEXAL LYMPHOMA OF ALL HISTOLOGIC SUBTYPES: SURVIVAL OUTCOMES AND RISK FACTORS IN LARGE COHORT OF PATIENTS AND LONG-TERM FOLLOW-UP**
YW Jeon[1] ([1]ST.MARY HOSPITAL,SEOUL, CATHOLIC MEDICAL CENTER, SEOUL, Korea, Republic Of)

P639 **CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES**
C Kalpadakis[1] ([1]University Hospital, University of Crete, Heraklion, Greece)

P640 **SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY**
C Panizo[1] ([1]Clínica Universidad de Navarra, Pamplona, Spain)

P641 **REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN WALDENSTROM MACROGLOBULINEMIA : A RETROSPECTIVE STUDY FROM 163 PATIENTS**
C Protin[1] ([1]IUC Toulouse-Oncopole, Toulouse, France)

17:30 – 19:00, Poster area

INFECTIOUS DISEASES, SUPPORTIVE CARE

Moderator: A Bondanza (San Raffaele University Hospital and Scientific Institute, Milan, Italy)

P642 **MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL**
T Oyake[1] ([1]Iwate Medical University School of Medicine, Morioka, Japan)

P643 **ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE ASPERGILLOSIS**
D Teschner[1] ([1]University Medical Center of the Johannes Gutenberg University, Mainz, Germany)

P644 **CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA**
C Cattaneo[1] ([1]Hematology, Spedali Civili, Brescia, Italy)

P645 **ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP)**
V Ong[1] ([1]Cidara Therapeutics, Inc., San Diego, United States)

P646 **SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS – EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA**
C Nagarajan[1] ([1]Singapore General Hospital, Singapore, Singapore)

P647 **INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER**
M Von Lilienfeld-Toal[1] ([1]Universitätsklinikum Jena, Jena, Germany)

P648 **HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
U Schnetzke[1] ([1]Universitätsklinikum Jena, Jena, Germany)

P649 **PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE).**
P Rodon[1] ([1]Ch De Perigueux, Perigueux, France)

P650 **TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL**
P Richardson[2] ([2]Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

P651 **ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS**
A Hasibeder[1] ([1]Johannes Gutenberg-Universitiy Medical Center, Mainz, Germany)

17:30 – 19:00, Poster area

MYELODYSPLASTIC SYNDROMES - BIOLOGY

Moderator: A Pellagatti (University of Oxford, United Kingdom)

P652 **IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES**
I Gañán-Gómez[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

P653 **FUNCTIONAL STUDY ON THE COOPERATION OF ASXL1 AND RUNX1 MUTATIONS FOR LEUKEMIC TRANSFORMATION**
R Bera[1] ([1]Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China)

P654 **A NOVEL MASS SPECTROMETRY METHOD REVEALS THE INTRACELLULAR PHARMACOKINETICS OF AZACYTIDINE THERAPY IN VIVO**
A Unnikrishnan[1] ([1]UNSW Sydney, Sydney, Australia)

P655 **CLONAL EVOLUTION OF STAG2 AND NRAS DURING PROGRESSION FROM MDS TO SAML ASSESSED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING**
M Martín-Izquierdo[1] ([1]IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Salamanca, Spain)

P656 **PROGRESSION OF MDS TO AML FEATURES GAIN OF SINGLE DRIVER MUTATIONS WITH CONSEQUENT CHANGES IN CLONAL COMPOSITION AND OCCURRENCE OF MULTIPLE CLONES WITH MUTATIONS IN IDENTICAL GENES**
J Stosch[1] ([1]Medical Center - University of Freiburg, Freiburg, Germany)

P657 **PRECLINICAL MODELING OF MYELODYSPLASTIC SYNDROMES**
K Rouault-Pierre[1] ([1]The Francis Crick Institute, London, United Kingdom)

P658 **MYELODYSPLASTIC SYNDROMES WITH IRON OVERLOAD ARE CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON CHELATION. A FISM STUDY**
D Cilloni[1] ([1]University of Turin, Orbassano, Italy)

P659 **V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTITUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES**
Y Kuribayashi-Hamada[1] ([1]Nippon Medical School, Japan, Sendagi, Bunkyo-ku, Tokyo, Japan)

P660 **TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS**
A Hurtado López[1] ([1]IMIB, Murcia, Spain)

P661 **DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE**
M Cedena[1] ([1]H. 12 Octubre, Madrid, Spain)

17:30 – 19:00, Poster area

MYELODYSPLASTIC SYNDROMES - CLINICAL 2

Moderator: T Braun (Hôpital Avicenne-APHP-Université Paris XIII, France)

P662 **A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES**
A Gerds[1] ([1]Cleveland Clinic, Cleveland, United States)

P663 **EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS (LTRS)**
M Daskalakis[1] ([1]German Cancer Research Center, Heidelberg, Germany)

P664 **LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R**
T Silzle[1] ([1]Cantonal Hospital St. Gallen, St. Gallen, Switzerland)

P665 **IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS**
A Alfonso Pierola[1] ([1]MD Anderson Cancer Center, Houston, United States)

P666 **LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY**
A Giagounidis[1] ([1]Marien Hospital Düsseldorf, Düsseldorf, Germany)

P667 **RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)**
M Clavio[1], [2] ([1]IRCCS AOU San Martino-IST, Genova, Italy, [2](FISM), Alessandria, Italy)

P668 **COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS**
E Louka[1] ([1]Weatherall Institute of Molecular Medicine University of Oxford, Oxford, United Kingdom)

17:30 – 19:00, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 3

Moderator: S Kristinsson (University of Iceland, Reykjavik, Iceland)

P669 **OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)**
K Yong[1] ([1]University College London, London, United Kingdom)

P670 **PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS AFTER RVD AND ASCT**
S Luoma[1], [2] ([1]Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, [2]University of Helsinki, Helsinki, Finland)

P671 **VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF PATIENTS AFFECTED BY MULTIPLE MYELOMA.**
S Galimberti[1] ([1]hematology, Pisa, Italy)

P672 **INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA**
R Hájek[1], [2] ([1]University Hospital in Ostrava, Ostrava, Czech Republic, [2]University of Ostrava, Ostrava, Czech Republic)

P673 **PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**
S Sidana[1] ([1]Mayo Clinic, Rochester, United States)

P674 **RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY**
P Ho[1] ([1]Royal Prince Alfred Hospital, Sydney, Australia)

P675 **VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA**
S Kumar[1] ([1]Mayo Clinic, Rochester, United States)

P676 **AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)**
S Usmani[1] ([1]Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, United States)

P677 **GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY**
R Kuiper[1] ([1]SkylineDx, Rotterdam, the Netherlands)

P678 **MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY**
I Sverrisdottir[1], [2] ([1]Landspitali, Reykjavik, Iceland, [2]University of Iceland, Reykjavik, Iceland)

17:30 – 19:00, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 4

Moderator: B Aguado Bueno (Hospital Universitario de La Princesa, Madrid, Spain)

P679 **DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS**
B Sanchez-Vega[1] ([1]Hospital 12 de Octubre, Madrid, Spain)

P680 **FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY**
A Jakubowiak[1] ([1]University of Chicago, Chicago, IL, United States)

P681 **PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTS THE ANTI-MYELOMA EFFICACY OF DARATUMUMAB**
E Garcia-Guerrero[1] ([1]Universitätsklinikum Würzburg, Würzburg, Germany)

P682 **BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**
J Ross[1] ([1]AbbVie, Inc., North Chicago, United States)

P683 **THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY**
B Oortgiesen[1] ([1]Medical Centre Leeuwarden, Leeuwarden, the Netherlands)

P684 **TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS**
P Milani[1] ([1]Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy)

P685 **MYOCARDIAL UPTAKE OF 99MTC-DPD IN PATIENTS WITH AL AMYLOIDOSIS**
C De Miguel[1] ([1]Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain)

P686 **WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS**
M Brink[1] ([1]Comprehensive Cancer Center the Netherlands, Utrecht, the Netherlands)

P687 **AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS**
S Kumar[1] ([1]Division of Hematology, Mayo Clinic, Rochester, MN, United States)

P688 **PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS**
P Rodriguez Otero[1] ([1]Clinica Universidad de Navarra, Pamplona, Spain)

17:30 – 19:00, Poster area

MYELOPROLIFERATIVE NEOPLASMS - BIOLOGY

Moderator: N Pallisgaard (Sjællands Universitetshospital, Roskilde, Denmark)

P689 **MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS**
T Maekawa[1] ([1]National Defense Medical College, Tokorozawa, Saitama, Japan)

P690 **ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID-g MICE**
T Manshouri[1] ([1]The University of Texas/ MD. Anderson Cancer Center, Houston, United States)

P691 **ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS**
H Takei[1] ([1]Juntendo University Graduate School of Medicine, Tokyo, Japan)

P692 **QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS**
N Socoro Yuste[1] ([1]TIMC-IMAG Laboratory - TheREx team, GRENOBLE, France)

P693 **THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS**
M Schneeweiss[1], [2] ([1]Medical University of Vienna, Vienna, Austria, [2]Medical University of Vienna, Vienna, Austria)

P694 **DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA**
A Senín[1], [2] ([1]Hospital del Mar-IMIM. Universitat Autónoma de Barcelona, Barcelona, Spain, [2]IMIM, Barcelona, Spain)

P695 **RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS**
J Martínez-López[1] ([1]Hospital 12 de Octubre, Madrid, Spain)

P696 **INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING**
C Fernández-Rodríguez[1] ([1]Hospital del Mar, Barcelona, Spain)

P697 **METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE**
S McPherson[1] ([1]Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, United Kingdom)

P698 **ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION**
N Tata[1] ([1]University Hospital Basel, Basel, Switzerland)

17:30 – 19:00, Poster area

MYELOPROLIFERATIVE NEOPLASMS - CLINICAL 2

Moderator: T Devos (UZ Leuven, Belgium)

P699 **PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL**
M Talpaz[1] ([1]University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, United States)

P700 **COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)**
F Stegelmann[1] ([1]University Hospital of Ulm, Ulm, Germany)

P701 **PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL**
C Harrison[1] ([1]Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom)

P702 **SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (↗ 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY**
P Raanani[1] ([1]Rabin Medical Center, Petah Tikva, Israel)

P703 **PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS**
J Hernández-Boluda[1] ([1]Hospital Clínico Universitario, Valencia, Spain)

P704 **LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY**
G Birgegård[1] ([1]Uppsala University, Uppsala, Sweden)

P705 **EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS**
N Polverelli[1] ([1]ASST Spedali Civili di Brescia, Brescia, Italy)

P706 **TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY**
S Koschmieder[1] ([1]RWTH Aachen University, Aachen, Germany)

P707 **SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B – AN UPDATE FROM THE PEGINVERA STUDY**
H Gisslinger[8] ([8]Medical University Vienna, Vienna, Austria)

P708 **NO IMPROVEMENT IN SURVIVAL OVER TIME FOR PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS WHO TRANSFORM TO ACCELERATED OR BLAST PHASE**
C Mcnamara[1] ([1]Princess Margaret Cancer Centre, Toronto, Canada)

17:30 – 19:00, Poster area

OTHER NON-MALIGNANT HEMATOPOIETIC DISORDERS

Moderator: W Barcellini (Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy)

P709 **MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY**
O Hermine[1], [2], [3] ([1]University of Paris Descartes, Institut Imagine INSERM U1163, Paris, France, [2]CNRS ERL8654, Centre de Reference des Mastocytoses, Paris, France, [3]AB Science, Paris, France)

P710 **THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE**
M Machaczka[1], [2] ([1]KAROLINSKA UNIVERSITY HOSPITAL HUDDINGE, Stockholm, Sweden, [2]University of Rzeszow, Rzeszow, Poland)

P711 **WHOLE-EXOME SEQUENCING IN CHILDREN WITH IMMUNE CYTOPENIA: THE APPLICABILITY AND CLINICAL IMPACT**
M Svatoň[1] ([1]Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic)

P712 **SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING**
F Girodon[1], [2] ([1]PLATEAU TECHNIQUE DE BIOLOGIE, DIJON CEDEX, France, [2]Faculté médecine, Dijon, France)

P713 **CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.**
A Mayado[1] ([1]University of Salamanca, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain)

P714 **MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY**
L Vinas[1], [2] ([1]Vall d'Hebron University Hospital, Barcelona, Spain, [2]A. Meyer Children's University Hospital, Florence, Italy)

P715 **PRIMARY AND CONGENITAL ERYTHROCYTOSIS IN PEDIATRICS: THE EXPERIENCE OF ITALIAN CENTERS**
G Geranio[1] ([1]Haematology-Oncology, University of Padua, Padua, Italy)

P716 **NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS**
T Pincez[1] ([1]APHP - Hôpital Trousseau, Paris, France)

P717 **AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY**
P Farruggia[1] ([1]Pediatric Hematology and Oncology Unit, Oncology Department, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy)

P718 **PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT DURING PREGNANCY**
M Vinogradova[1] ([1]Federal Scientific Center for Obstetrics, Gynecology and Perinatology, Moscow, Russian Federation)

17:30 – 19:00, Poster area

PLATELET DISORDERS: CLINICAL

Moderator: To be announced

P719 **LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT**
E Lukina[1] ([1]National Research Center for Hematology, Moscow, Russian Federation)

P720 **REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY**
E Gutiérrez[1] ([1]Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain)

P721 **BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES**
N Revilla[1] ([1]Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)

P722 **SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS**
S Cantoni[2] ([2]Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, MIlan, Italy)

P723 **THROMBOEMBOLIC EVENT MANAGEMENT AND OUTCOMES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ELTROMBOPAG (EPAG): RESULTS FROM THE EXTEND STUDY**
M Saleh[1] ([1]Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, United States)

P724 **SEVERE BLEEDING IN THE ELDERLY WITH PRIMARY IMMUNE THROMBOCYTOPENIA: CHARACTERISTICS, RESPONSE TO THERAPY AND LONG-TERM OUTCOME**
M Lyu[1], [2] ([1]Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College, Tianjin, China, [2]Affiliated Suzhou Hospital of Nanjing Medical University (Suzhou Municipal Hospital), Suzhou , China)

P725 **ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION**
XN Cao[1] ([1]Peking University Institute of Hematology, Beijing, China)

P726 **PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL**
X Li[1] ([1]Qilu Hospital, Shandong University, Jinan, China, Jinan, China)

P727 **SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)**
J Bussel[1] ([1]Weill Cornell Medicine, New York, United States)

17:30 – 19:00, Poster area

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS 2

Moderator: MT Petrucci (Italy)

P728 **IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT**
W Wierda[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

P729 **THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE**
S Riva[1] ([1]University of Milan, Milan, Italy)

P730 **BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES**
F Rencz[1], [2] ([1]Corvinus University of Budapest, Budapest, Hungary, 2HTA Consulting Budapest, Budapest, Hungary)

P731 **AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION – IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.**
D De-Silva[1] ([1]University College London, London, United Kingdom)

P732 **COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
M Seftel[3], [4] ([3]CancerCare Manitoba, Winnipeg, Canada, [4]University of Manitoba, Winnipeg, Canada)

P733 **THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESMENT IN ONCOHEMATOLOGIC PATIENTS**
C Terán [1] ([1]Fundacion Jimenez Diaz, Madrid, Spain)

P734 **RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY**
A Nikkilä[1] ([1]University of Tamepre, Tampere, Finland)

P735 **HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)**
P Hari[1] ([1]Medical College of Wisconsin, Milwaukee, United States)

P736 **MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES**
O Annibali[1] ([1]university Campus Biomedico, rome, Italy)

P737 **EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA**
V Martínez-Robles[1] ([1]Complejo Asistencial Universitario de León, LEON, Spain)

17:30 – 19:00, Poster area

STEM CELL TRANSPLANTATION - CLINICAL 2

Moderator: To be announced

P738 **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN**
M Gabelli[1] ([1]Università di Padova, Padova, Italy)

P739 **PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
P Kebriaei[1] ([1]University of Texas M.D. Anderson Cancer Center, Houston, United States)

P740 **DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM**
P Richardson[1] ([1]Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

P741 **ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA – 12 YEARS OF EXPERIENCE**
M Markiewicz[1] ([1]MEDICAL UNIVERSITY OF SILESIA, Katowice, Poland)

P742 **A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA**
S Shin[1] ([1]Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)

P743 **HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS**
S Hongeng[1] ([1]Ramathibodi hospital, Mahidol University, Bangkok, Thailand)

P744 **AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA**
V Sheth[1] ([1]HADASSAH, Jerusalem, Israel)

P745 **PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES**
C Cho[1] ([1]Memorial Sloan Kettering Cancer Center, New York, NY, United States)

P746 **THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?**
R Parody[1], [2] ([1]H.Universitario Virgen del Rocío, Seville, Spain, [2]ICO-Duran i Reynals, Barcelona, Spain)

P747 **FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR.**
E Pérez López[1] ([1]Hospital Universitario de Salamanca, Salamanca, Spain)

P748 **EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS**
P Richardson[1] ([1]Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

17:30 – 19:00, Poster area

STEM CELL TRANSPLANTATION - EXPERIMENTAL

Moderator: L Vago (San Raffaele Scientific Institute, Milan, Italy)

P749 **GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE**
E Doma[1] ([1]Veterinärmedizinische Universität Wien, Wien, Austria)

P750 **INHIBITING BCL2 AND NK CELLS IMPROVES STEM CELL TRANSPLANT OUTCOMES.**
J Davis[1], [2] ([1]The Royal Melbourne Hospital, Melbourne, Australia, [2]The University of Melbourne, Melbourne, Australia)

P751 **MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING THEIR HEMATOPOIETIC-SUPPORTING ABILITY**
S Preciado Pérez[1] ([1]IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain)

P752 **DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE**
Y Song[1], [2] ([1]Peking University People's hospital, Beijing, China, [2]Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China)

P753 **INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS**
T Toubai[1], [2] ([1]Yamagata University Faculty of Medicine, Yamagata, Japan, [2]University of Michigan, Ann Arbor, United States)

P754 **GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS**
G Strauss[1] ([1]University Medical Center Ulm, Ulm, Germany)

P755 **IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS**
M Fernandez-Garcia[1], [2] ([1]Centro de Investigaciones Energéticas Medioambientales y Tecnológicas/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER), Madrid, Spain, [2]Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain)

P756 **EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFCATIONS.**
I Alvarez Laderas[1] ([1]Insituto de Biomedicina de Sevilla, Seville, Spain)

P757 **MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL**
JY Lim[1] ([1]Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of)

P758 **C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION**
A Morales Hernandez[1] ([1]St Jude Children's Research Hospital, Memphis, United States)

17:30 – 19:00, Poster area

THROMBOTIC DISORDERS

Moderator: JB Hansen (UiT, The Arctic University of Norway, Tromsø, Norway)

P759 **GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS**
R Angel F.[3] ([3]Hospital de Sant Pau, Barcelona, Spain)

P760 **ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION**
A Vignoli[1] ([1]Hospital Papa Giovanni XXIII, Bergamo, Italy)

P761 **DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK**
B Badugama[1] ([1]Royal Stoke University Hospital, Stoke on Trent, United Kingdom)

P763 **INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?**
P Smith[1] ([1]MacNeal Hospital, Berwyn, United States)

P764 **THE ROLE OF INFLAMMATION IN THROMBOEMBOLISM IN RESECTABLE RENAL CELL CARCINOMA PATIENTS**
H Park[1] ([1]Seoul National University Hospital, Seoul, Korea, Republic Of)

P765 **GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.**
R Angel F.[1] ([1]Hospital de Sant Pau, Barcelona, Spain)

P766 **CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)**
C Tartari[1] ([1]Hospital Papa Giovanni XXIII, Bergamo, Italy)

P767 **ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT?**
J Sharif[1] ([1]Central Manchester University Hospitals, Manchester, United Kingdom)

P768 **RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE**
M García Ruiz[1] ([1]Complejo Hospitalario Universitario de Granada, Granada, Spain)

EUROPEAN HEMATOLOGY ASSOCIATION

EHA-SWG SCIENTIFIC MEETING

Shaping the future of mesenchymal stromal cells therapy

Dates: November 23-25, 2017
Location: Amsterdam, The Netherlands

Organized by:
EHA Scientific Working Group on Mesenchymal Stromal Cells

Chair:
WE Fibbe

Co-chairs:
F Dazzi, K Le Blanc

Topics:

- Basic developmental biology of MSC and their role in immune regulation
- Mechanisms of MSC immune regulation
- Potency assay design
- Technological development
- Clinical trial results with MSC
- Clinical issues
- Regulatory and ethical aspects of clinical trials using MSC

EBAH CME ACCREDITED

EHASWG SCIENTIFIC WORKING GROUPS

SUNDAY, JUNE 25

SPECIAL SESSIONS OF THE DAY

Next to the high quality scientific and education sessions of the day we would like to draw your attention to the following interesting sessions::

→ SIMULTANEOUS SESSIONS 3 10 **B T**
08:00 – 09:15, Hall A

TARGETED THERAPIES IN RELAPSED IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chairs: To be announced
A Kater (Lymphoma and Myeloma Center, Academic Medical Center Amsterdam, University of Amsterdam, the Netherlands)

08:00 – 08:15
S769 **IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP**
C Moreno[1] ([1]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

08:15 – 08:30
S770 **THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY**
P Hillmen[1] ([1]University of Leeds, Leeds, United Kingdom)

08:30 – 08:45
S771 **VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL**
S Stilgenbauer[1] ([1]University of Ulm, Ulm, Germany)

08:45 – 09:00
S772 **CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL**
L Nastoupil[1] ([1]MD Anderson Cancer Center, Houston, United States)

09:00 – 09:15
S773 **THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES**
P Hamlin[1] ([1]Memorial Sloan Kettering Cancer Center, New York, United States)

→ SIMULTANEOUS SESSIONS 3 **C**
08:00 – 09:15, Hall C

FOLLICULAR LYMPHOMA – CLINICAL

Chairs: D Caballero (University Hospital, Salamanca, Spain)
I Aurer (University Hospital Centre Zagreb, Croatia)

08:00 – 08:15
S774 **COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY**
J Trotman[1] ([1]Concord Repatriation General Hospital, University of Sydney, Sydney, Australia)

08:15 – 08:30
S775 **IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN**
W Hiddemann[1] ([1]Ludwig-Maximilians-University Munich, Munich, Germany)

08:30 – 08:45
S776 **EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY**
PL Zinzani[1] ([1]Institute of Hematology "L. e A. Seràgnoli"- University of Bologna, Bologna, Italy)

08:45 – 09:00
S777 **DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA**
PL Zinzani[1] ([1]University of Bologna, Bologna, Italy)

09:00 – 09:15
S778 **13-YR FOLLOW UP OF MULTICENTER RANDOMIZED CHOP-R VS R-HDS TRIAL IN HIGH RISK FOLLICULAR LYMPHOMA PATIENTS: PROLONGED SURVIVAL AND HIGH RATE OF LONG-TERM DISEASE FREE SURVIVORS**
C Tarella[26],[29] ([26]University of Milan, Milano, Italy, [29]European oncology Institute, Milano, Italy)

→ SIMULTANEOUS SESSIONS 3 **C**
08:00 – 09:15, Hall D

CHANGING THE STRATEGY OF THERAPY IN MULTIPLE MYELOMA

Chairs: JF San-Miguel (Universidad de Navarra, Pamplona, Spain)
H Ludwig (Wilhelminen Cancer Research Institute, Vienna, Austria)

08:00 – 08:15
S779 **PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA**
I Ghobrial[1] ([1]Dana-Farber Cancer Institute, Boston, United States)

08:15 – 08:30
S780 **TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION (SCT)**
P Richardson[1] ([1]Dana-Farber Cancer Institute, Boston, United States)

08:30 – 08:45
S781 **LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY**
C Pawlyn[1] ([1]The Institute of Cancer Research, London, United Kingdom)

08:45 – 09:00
S782 **COMPARISON OF DENOSUMAB (DMB) WITH ZOLEDRONIC ACID (ZA) FOR THE TREATMENT OF BONE DISEASE IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; AN INTERNATIONAL, RANDOMIZED, DOUBLE BLIND TRIAL**
E Terpos[1] ([1]National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)

09:00 – 09:15
S783 **PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY**
P Rodriguez Otero[1] ([1]Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain)

→ SIMULTANEOUS SESSIONS 2 10 **T** **C**
08:00 – 09:15, Hall E

OLD AND NEW DRUGS IN MPN

Chairs: E Gottlieb (Technion, Israel Institute Of Technology, Haifa, Israel)
M Griesshammer (Johannes Wesling Medical Center Minden, UKRUB, University of Bochum, Minden, Germany)

08:00 – 08:15
S784 **RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL**
M Greisshammer[1] ([1]Johannes Wesling Clinic, Minden, Germany)

08:15 – 08:30
S785 **PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY**
JR Gotlib[1] ([1]Stanford University Medical Center, Stanford, United States)

08:30 – 08:45
S786 **PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY**
C Harrison[1] ([1]Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom)

08:45 – 09:00
S787 **MOLECULAR RESPONSE TO HYDROXYUREA AND ROPEGINTERFERON ALFA-2B IN THE PROUD-PV RANDOMIZED PHASE 3 TRIAL**
JJ Kiladjian[1], [2], [3] ([1]Hopital Saint-Louis, Paris, France, [2]INSERM UMRS-1131, Paris, France, [3]Paris Diderot University, Paris, France)

09:00 – 09:15
S788 **POOLED SURVIVAL ANALYSIS OF MIDOSTAURIN CLINICAL STUDY DATA (D2201 + A2213) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) COMPARED WITH HISTORICAL CONTROLS**
A Reiter[1] ([1]University Medical Centre Mannheim, Mannheim, Germany)

→ SIMULTANEOUS SESSIONS 2 4 9 10 **T** **C**
08:00 – 09:15, Room N101

CHILDHOOD AND MORE INTENSIVE TREATMENT OF AML

Chairs: C Craddock (Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom)
J Sierra (Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona, Spain)

08:00 – 08:15
S789 **LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY**
M Flasinski[1] ([1]Hannover Medical School, Hannover, Germany)

08:15 – 08:30
S790 **FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70**
A Garrido[1] ([1]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

08:30 – 08:45
S791 **MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY**
C Craddock[1] ([1]University of Birmingham, Birmingham, United Kingdom)

08:45 – 09:00
S792 **SORAFENIB MAINTENANCE IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANT**
B Oran[1] ([1]UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER, Houston, United States)

09:00 – 09:15
S793 **A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)**
MY Levy[1] ([1]Baylor University Medical Center, Dallas, TX, United States)

→ SIMULTANEOUS SESSIONS 4 9 **C**
08:00 – 09:15, Room N105

STEM CELL TRANSPLANTATION - CLINICAL 2

Chairs: T Ruutu (Clinical Research Institute, Helsinki University Hospital, Finland)
To be announced

08:00 – 08:15
S794 **21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)**
K Staser[1] ([1]Washington University in Saint Louis, Saint Louis, United States)

08:15 – 08:30
S795 **GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE**
Z Peric[1], [2] ([1]University Hospital Centre Zagreb, Zagreb, Croatia, 2School of Medicine, University of Zagreb, Zagreb, Croatia)

08:30 – 08:45
S796 **IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE**
L Giannoni[1] ([1]IRCCS AOU San Martino IST, Genoa, Italy)

08:45 – 09:00
S797 **CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR ADULTS WITH PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**
S Giebel[1] ([1]Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland)

09:00 – 09:15
S798 **ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH DELETION 5Q OR MONOSOMY 5: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (ALWP) OF THE EBMT**
X Poiré[1] ([1]Cliniques Universitaires St-Luc, Brussels, Belgium)

→ SIMULTANEOUS SESSIONS 3 5 9 10 **B T**
08:00 – 09:15, Room N103

BIOMARKERS IN ALL

Chairs: J Trka (CLIP - Childhood Leukaemia Investigation Prague, Second Faculty of Medicine, Charles University, Prague, Czech Republic)
JP Bourquin (University Children's Hospital, Zurich, Switzerland)

08:00 – 08:15
S799 **IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
M Seki[1] ([1]The University of Tokyo Hospital, Tokyo, Japan)

08:15 – 08:30
S800 **PROGNOSTIC IMPACT OF ADDITIONAL MOLECULAR LESIONS IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**
S Chiaretti[1] ([1]Sapienza University, Rome, Italy)

08:30 – 08:45
S801 **MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA – A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM**
M Brüggemann[1] ([1]University Hospital Schleswig-Holstein, Kiel, Germany)

08:45 – 09:00
S802 **POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14,ISRCTN 66541317)**
D Okasha[1], [2] ([1]Cancer Institute, UCL, London, United Kingdom, [2]Faculty of Medicine, Alexandria University, Alexandria, Egypt)

09:00 – 09:15
S803 **T-CELL RECEPTOR Ð (TRB) REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) ON BLINATUMOMAB TREATMENT.**
M Kotrova[1], [2] ([1]contributed equally, Kiel, Germany, [2]Laboratory for Hematological Diagnostics, University Hospital Schleswig-Holstein, Kiel, Germany)

→ SIMULTANEOUS SESSIONS 1 2 3 4 8 C
08:00 – 09:15, Room N104

INFECTIOUS DISEASES, SUPPORTIVE CARE

Chairs: M von Lilienfeld-Toal (Universitätsklinikum Jena, Germany)
J Canaani (Chaim Sheba Medical Center, Tel Hashomer, Israel)

08:00 – 08:15
S804 **DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)**
I Espigado[1] ([1]Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain)

08:15 – 08:30
S805 **CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA A RANDOMIZED STUDY BY THE SWEDISH CLL GROUP**
T Svensson[1] ([1]Institution of Medical Sciences, Uppsala, Sweden)

08:30 – 08:45
S806 **INFECTION-RELATED MORTALITY (IRM) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM**
A Forcina[1] ([1]IRCCS San Raffaele Scientific Institute, Milan, Italy)

08:45 – 09:00
S807 **LETERMOVIR (LET) FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)**
R Duarte[1] ([1]Hospital Universitario Puerta de Hierro, Barcelona, Spain)

09:00 – 09:15
S808 **EFFICACY AND SAFETY OF DEFIBROTIDE TO TREAT HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) POST-CHEMOTHERAPY: A POST HOC ANALYSIS OF FINAL DATA OF AN EXPANDED-ACCESS PROTOCOL**
P Richardson[2] ([2]Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

→ SIMULTANEOUS SESSIONS 1 7 8 B T C
08:00 – 09:15, Room N109

IRON: DEFICIENCY AND OVERLOAD

Chairs: A Iolascon (University of Naples Federico II, Italy)
C Camaschella (Vita-Salute San Raffaele University, Milan, Italy)

08:00 – 08:15
S809 **LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION.**
S Altamura[1], [2] ([1]MMPU - Molecular Medicine Partnership Unit, Heidelberg, Germany, [2]University of Heidelberg, Heidelberg, Germany)

08:15 – 08:30
S810 **IDENTIFICATION OF GUANOSINE 5Đ-DIPHOSPHATE AS POTENTIAL IRON MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY**
S Angmo[1] ([1]National Agri Food Biotechnology , Mohali, India)

08:30 – 08:45
S811 **UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT**
G De Rosa[1] ([1]CEINGE - Biotecnologie Avanzate, Naples, Italy)

08:45 – 09:00
S812 **INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**
A Weigl[1] ([1]University Hospital Cologne, Cologne, Germany)

09:00 – 09:15
S813 **DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES**
F Vinchi[1] ([1]University of Heidelberg & EMBL, Heidelberg, Germany)

→ SIMULTANEOUS SESSIONS 2 3 4 5 9 10 C
08:00 – 09:15, Room N111

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION 2

Chairs: H Dolstra (Radboudumc, Nijmegen, the Netherlands)
JM Almeida (University of Salamanca, Spain)

08:00 – 08:15
S814 **A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Ð-THALASSEMIA IN PATIENTS WITH NON-Ð0/Ð0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL**
M Walters[1] ([1]UCSF Benioff Children's Hospital and Research Center, Oakland, United States)

08:15 – 08:30
S815 **CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY**
N Huntington[1] ([1]Walter and Eliza Hall, Parkville, Australia)

08:30 – 08:45
S816 **GENERATION OF MEMORY STEM T CELLS (TSCM) MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES**
L Escribà-Garcia[1] ([1]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

08:45 – 09:00
S817 **MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES**
A Galleu[1] ([1]King's College London, London, United Kingdom)

09:00 – 09:15
S818 **CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND TUMOR GROWTH IN MICE**
T Haas[1] ([1]Klinikum rechts der Isar, TU München, München, Germany)

→ EDUCATION SESSION 3 10 **B T C**
09:30 - 11:00, Hall A
Repeated from:
Saturday, June 24, 09:45 - 11:15, Hall B

CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: B Eichhorst (University Clinic of Cologne, Germany)
- **Relevance of microenvironment in CLL**
  F Caligaris-Cappio (Italian Association for Cancer Research, Milan, Italy)
- **Prognostic factors in CLL: When, which and how?**
  S Pospisilova (Masaryk University and University Hospital Brno, Czech Republic)
- **Prioritisation therapies in CLL**
  C Wendtner (Klinikum Schwabing, Munich, Germany)

LEARNING GOALS

F Caligaris-Cappio

After attending this lecture, the participant will be able to
- Describe how malignant CLL cells entail a bi-directional dialogue with a host of non-malignant elements within the microenvironment.
- Describe the key cellular elements in the microenvironment.
- Describe how cell-cell interactions favour malignant cell growth, survival and prevent anti-tumour response.

S Pospisilova

After attending this lecture, the participant will be able to
- Describe the biological and clinical factors applicable in CLL prognostication.
- Define the predictive markers currently used for therapy response assessment in CLL patients.
- Indicate the timepoints when the prognostic and predictive factors should be analyzed during the disease course.

C Wendtner

After attending this lecture, the participant will be able to
- For CLL patients we have to prioritize treatment options based on clinical and novel molecular markers.
- Chemoimmunotherapy remains the standard-of-care for the majority of CLL patients in the frontline setting.
- Novels drugs like ibrutinib, idelalisib and venetoclax are nowadays treatment standards for CLL patients with relapsed/refractory disease.

→ EDUCATION SESSION 3 **B T C**
09:30 - 11:00, Hall C
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Hall C

AGGRESSIVE LYMPHOMA

Chair: S Rule (Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom)
- **The biological basis of aggressive lymphoma**
  E Campo (Hospital Clínic, Barcelona, Spain)
- **Relapsed aggressive lymphoma: Can we optimize the therapy**
  G Salles (Hospices Civils de Lyon - Université Claude Bernard, Pierre Benite, France)
- **Treatment of aggressive lymphomas focused on elderly patients**
  M Pfreundschuh (Saarland University Medical School, Homburg (Saar), Germany)

LEARNING GOALS

E Campo

After attending this lecture, the participant will be able to
- Understand the biological heterogeneity of aggressive mature B-cell lymphomas and recognize its clinical impact.
- Describe the main molecular features that may be of clinical interest in aggressive mature B-cell lymphomas.

G Salles

After attending this lecture, the participant will be able to
- Describe the population heterogeneity and prognostic factors of patient with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- Discuss the current management strategies of patients with R/R DLBCL, their indications, their results and their limitations.
- Describe the different developments of innovative approaches in

R/R DLBCL, including targeted therapies, new antibodies, and CAR-T cells.

M Pfreundschuh

After attending this lecture, the participant will be able to
- Describe the biological and clinical peculiarities of elderly patients with aggressive lymphomas.
- Discuss treatment options for elderly patients who may or may not be candidates for standard treatment.
- Select the appropriate treatment based upon patient's individual characteristics, comorbidities and the specific biology of his/her aggressive lymphoma.
- Provide specific supportive measures that increase the patient's tolerability for the treatment.

→ SCIENTIFIC WORKING GROUPS 2 4 **B T C**
09:30 - 10:30, Hall D

CHRONIC MYELOID LEUKEMIA: ELN-EHA-SWG ON CML

Chair: R Hehlmann (Medizinische Fakultät Mannheim Universität Heidelberg, Mannheim, Germany)
- **Prognostic indicators of successful TKI-discontinuation**
  FX Mahon (France)
- **HSCT for CML: The fine tuned balance between transplantation and disease risks**
  A Gratwohl (University of Basel, Switzerland)
- **The role of the bone marrow microenvironment in CML**
  D Krause (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany)
- **The CML 'omics of initiation, progression, and response**
  J Radich (Fred Hutchinson Cancer Research Center, Seattle, USA)

LEARNING GOALS

FX Mahon

An up-to-date program is available via the mobile app.

A Gratwohl

After attending this lecture, the participant will be able to
- Describe the specific disease, patient, donor and environment related risks of HSCT.
- As patient: know the conditions, when HSCT is an optimal treatment option, when not.
- As physician: recognize the trigger points to initiate/continue the HSCT process.
- As health care organization: improve the deficiencies in the longitudinal treatment path for CML patients who qualify for HSCT.

D Krause

After attending this lecture, the participant will be able to
- Describe the physiology of the bone marrow microenvironment in health and disease.
- Describe the pathophysiology of the bone marrow microenvironment in chronic myeloid leukemia.
- Describe strategies to target the bone marrow microenvironment in chronic myeloid leukemia.

J Radich

After attending this lecture, the participant will be able to
- Understand the genetic differences between chronic and blast phase chronic myeloid leukemia.
- Appreciate the similarities and differences between treatment resistance and disease progression.

→ EDUCATION SESSION 2 4 **B T C**
09:30 - 11:00, Hall E
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Hall E

MYELODYSPLASTIC SYNDROMES

Chair: P Fenaux (Hôpital St Louis, Paris, France)
- **Clonal evolution in MDS**
  J Jansen (Radboud UMC, Nijmegen, the Netherlands)
- **The role of immune response in MDS pathophysiology**
  G Mufti (Kings College, London, United Kingdom)
- **Indications for transplantation in MDS**
  MG Della Porta (Cancer Center - Humanitas Research Hospital & Humanitas University, Milan, Italy)

LEARNING GOALS

J Jansen

After attending this lecture, the participant will be able to
- Describe the concept of linear and branched evolution of subclones in MDS.
- Understand the effect of disease modifying therapy on clonal evolution and resistance to therapy in MDS.
- Discuss the significance of clonal hematopoiesis of indeterminate potential (CHIP).

G Mufti

After attending this lecture, the participant will be able to
- The role of immune system in MDS pathophysiology and genomic instability.
- The importance of immune-signature "switch" in disease progression.

MG Della Porta

After attending this lecture, the participant will be able to
- Provide a basis to select candidate patients based on both disease and patient-related factors.
- Provide a basis to define optimal timing of transplantation in individual patient.
- Discuss the use of hypomethylating agents as part of a comprehensive strategy to prevent relapse after transplantation in high risk patients.
- Discuss the clinical utility of somatic mutations in MDS transplantation decision-making.

→ EDUCATION SESSION 2 5 9 10 T C
09:30 - 11:00, Room N101
Repeated from:
Saturday, June 24, 09:45 - 11:15, Hall C

ACUTE MYELOID LEUKEMIA

Chair: G Ossenkoppele (VU University Medical Center, Amsterdam, the Netherlands)

- **Molecular diagnostics in AML**
  L Bullinger (University Hospital of Ulm, Germany)
- **Targeting mutated FLT3 in AML**
  M Levis (Johns Hopkins University, Phoenix, USA)
- **3+7 and beyond**
  N Vey (Institut Paoli Calmettes, Marseille, France)

LEARNING GOALS

L Bullinger

After attending this lecture, the participant will be able to

- There is a growing need to implement novel next-generation-sequencing (NGS) based gene panel diagnostic tools to rapidly capture inter- and intra-individual disease heterogeneity.
- Future technological developments will enable genome-wide comprehensive genomic, epigenomic and transcriptomic characterization of the disease (at single cell level), but for now these approaches are reserved for research questions.
- Molecular genomics have started to inform patient care with regard to improved disease classification and risk prediction (knowledge databases), MRD monitoring and guiding targeted therapeutic approaches.

M Levis

After attending this lecture, the participant will be able to

- Identify the subsets of AML patients that might benefit from FLT3 inhibition
- Describe the different points in AML therapy where FLT3 inhibitors are likely to be incorporated.
- Discuss the different potential roles for selective versus non-selective FLT3 inhibitors.

N Vey

After attending this lecture, the participant will be able to

- Describe current and emerging therapies for patients with AML.
- Describe the main mechanisms of action of current new drugs and the rationale for their combination.
- Discuss how emerging therapies might be combined to or replace 3+7.

→ EHA - INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS JOINT SYMPOSIUM 1 6 T C
09:30 - 10:30, Room N105

ANTICOAGULATION IN DIFFICULT PATIENTS

Chairs: W Ageno (University of Insubria, Varese, Italy)
S Eichinger (Medical University of Vienna, Austria)

- **Introduction**
  F Rodeghiero (Hematology Project Foundation / Fondazione Progetto Ematologia, Vicenza, Italy)
- **Anticoagulation in the frail patient**
  PW Kamphuisen (Tergooi Hospital, Hilversum, the Netherlands)
- **Epidemiology and management of venous thrombosis in unusual sites**
  W Ageno (University of Insubria, Varese, Italy)

LEARNING GOALS

PW Kamphuisen

After attending this lecture, the participant will be able to

- Describe current and newer anticoagulant therapies for older patients.
- Discuss risk factors for bleeding in frail patients.
- Select appropriate dose and type of therapy based upon patient characteristics and comorbidity.

W Ageno

After attending this lecture, the participant will be able to

- Identify the most prevalent and clinically relevant risk factors for thrombosis in unusual sites.
- Select appropriate treatment strategies for the management of patients with acute thrombosis in unusual sites.
- Decide appropriate treatment durations and long-term management strategies.

→ BASIC-SCIENCE-IN-FOCUS 1 2 B T
09:30 - 10:30, Room N103

HEMATOPOIETIC STEM CELLS AND THE MICROENVIRONMENT

Chair: N Taylor (Institut de Genetique Moleculaire de Montpellier, France)

- **Manipulating dormancy of HSC**
  M Essers (HI-STEM gGmbH / DKFZ, Heidelberg, Germany)
- **Leukemic stem cell interactions with their microenvironment in AML**
  D Bonnet (The Francis Crick Institute, London, United Kingdom)

LEARNING GOALS

M Essers

After attending this lecture, the participant will be able to

- Inflammation induces emergency megakaryopoiesis through the activation of haematopoietic stem cell-like megakaryocyte progenitors (SL-MkPs).
- Lineage commitment of haematopoietic stem cells is a continuous process.
- The bone marrow niche plays an important role in stress-induced activation of HSCs in vivo.

D Bonnet

After attending this lecture, the participant will be able to

- Define HSC niche and discuss the complexity of the niche.
- Describe the potential roles niche might play in leukemia development.

– Discuss potential avenues to target leukemia via interfering with niche components.

→ BASIC-SCIENCE-IN-FOCUS 3 **B T C**
09:30 - 10:30, Room N104

VACCINES & ANTIBODIES

Chair: M Subklewe (LMU-University Hospital Munich, Germany)

- **The use of antibodies to redirect T-cells in the treatment of leukemia and lymphoma**
  D Maloney (Fred Hutchinson Cancer Research Center, Seattle, USA)
- **Immunotherapy of hematological malignancies using dendritic cell vaccines**
  H Dolstra (Radboud UMC, Nijmegen, the Netherlands)

LEARNING GOALS

D Maloney

After attending this lecture, the participant will be able to

– Describe the structures critical for the development of chimeric antigen receptors.
– Understand the relationship between T-cell proliferation on efficacy and toxicity.

H Dolstra

After attending this lecture, the participant will be able to

– Describe current dendritic cell vaccine therapies for patients with myeloid malignancies.
– Discuss novel and innovative developments to improve dendritic cell vaccines.
– Discuss results of dendritic cell based therapies to boost immunity against hematological malignancies.

→ EDUCATION SESSION 5 7 10 **B T C**
09:30 - 11:00, Room N109
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Room N109

CHALLENGES IN BLOOD TRANSFUSION

Chair: A Brand (Leiden University Medical Centre & Sanquin blood supply, the Netherlands)

- **Cell-derived microvesicles and microparticles in blood components: Consequences for transfusion recipients**
  T Burnouf (Taipei Medical University, Taiwan)
- **Challenges in typing and matching strategies in patients with hematological malignancies in the era of immunotherapy**
  KMK de Vooght (University Medical Center Utrecht, the Netherlands)
- **Red blood celll transfusion: When to transfuse in patients with hematological malignancies?**
  M Lozano (University Clinic Hospital, Barcelona, Spain)

LEARNING GOALS

T Burnouf

Participants should be able to realize that

– Extracellular vesicles (EVs) are present in abundance in collected blood since they are released in the circulation by platelets, red and white cells as well as from the endothelium upon activation or as a result of apoptosis.
– The amount of EVs is also largely dependent on the component preparation and storage methods and that the impact of pathogen inactivation methods should be studied with respect to EV content and types.
– EVs play a controversial role in transfusion and often exhibit potent pro-thrombotic and inflammatory potentials.
– Pre-clinical and clinical studies should objectively delineate EV role and possible pathological implications.

KMK de Vooght

After attending this lecture, the participant will be able to

– Describe the impact of CD38 monoclonal antibodies on blood bank serologic testing.
– Discuss strategies to mitigate the impact of these antibodies on serologic testing.
– Evaluate options to provide optimal transfusion support for patients on anti-CD38 therapy.

M Lozano

After attending this lecture, the participant will be able to

– Describe the current evidence to indicate red blood cell transfusion in different patient populations.
– Discuss the particular challenges that the patients with hematological malignancies pose when indicating a red blood cell transfusion.
– Select the hemoglobin threshold for red blood cell transfusion for patients with hematological malignancies based on the available evidence.

→ EDUCATION SESSION 1 4 7 **B T C**
09:30 - 11:00, Room N111
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Room N111

ACQUIRED PROBLEMS IN RED CELLS

Chair: S Menzel (King's College London, United Kingdom)

- **Transferrin and TfR1 in co-regulation of erythropoiesis and iron metabolism**
  Y Ginzburg (Icahn School of Medicine at Mount Sinai, New York, USA)
- **Iron overload before, during and after bone marrow transplantation**
  E Angelucci (Ospedale Oncologico di Riferimento Regionale "A. Businco", Cagliari, Italy)
- **Heat Shock Protein 70 (HSP70), one of the major key factors in Diamond-Blackfan anemia**
  L Da Costa (France)

LEARNING GOALS

Y Ginzburg

After attending this lecture, the participant will be able to

– Identify disease characteristics commonly found in β-thalassemia.

- Describe the mechanisms regulating iron availability for and utilization during erythropoiesis in physiologic and pathologic conditions.
- Understand the compensatory role of exogenous transferrin and effects on TfR1 in ineffective erythropoiesis.

E Angelucci
After attending this lecture, the participant will be able to
- Recognize principal iron toxicity mechanisms.
- Make a correct diagnosis of iron overload and identify patients at risk of iron toxicity before and during hemopoietic cell transplantation.
- Minimize iron toxicity in the setting of hemopoietic cell transplantation.
- Diagnosis and treat iron overload after hemopoietic cell transplantation.

L Da Costa
An up-to-date program is available via the mobile app.

→ SCIENTIFIC WORKING GROUPS 3 5 9 **C**
09:30 - 10:30, Room N113

ESLHO-EUROMRD AND ESLHO-EUROFLOW: EUROFLOW: HIGH THROUGHPUT FLOWCYTOMETRY IN HEMATO-ONCOLOGY

Chair: JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)

- **Introduction: EuroFlow strategies for high throughput flowcytometry**
  JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)
- **Reference data bases for automated gating strategies in flowcytometric diagnosis and monitoring of hematological malignancies**
  A Orfao (University of Salamanca, Spain)
- **Rapid flowcytometric diagnosis of acute leukemias: application of the EuroFlow ALOT data base**
  L Lhermitte (France)
- **Fast, sensitive and standardized flowcytometric monitoring of multiple myeloma**
  JA Flores-Montero (University of Salamanca, Cancer Research Center, Spain)

LEARNING GOALS

A Orfao
After attending this lecture, the participant will be able to
- Understand the way flow cytometric data bases for automated gating are constructed and used in routine laboratory diagnostics in onco-hematology.
- Recognize the need for full standardization of the flow cytometric procedures and how to reach it.
- Select specific data bases for the diagnosis and monitoring of distinct hematologic malignancies.

L Lhermitte
An up-to-date program is available via the mobile app.

JA Flores-Montero
After attending this lecture, the participant will be able to
- Understand the strengths of the EuroFlow flowcytometric approach for monitoring of multiple myeloma and identify the comparative advantages of this methodology over conventional flow cytometry and current molecular methods
- Discuss how the approach satisfies current requirements for the efficient follow-up of myeloma patient after treatment.

→ BASIC-SCIENCE-IN-FOCUS 1 2 3 **B** **T**
09:30 - 10:30, Room N115

METABOLOMICS AND LEUKEMIA

Chair: V Sexl (Pharmacology and Toxicology, Vienna, Austria)

- **Metabolic dependencies of leukemic stem cells**
  E Gottlieb (Technion, Israel Institute Of Technology, Haifa, Israel)
- **Metabolomics and macrophages**
  M Müschen (Beckman Research Institute, Pasadena, USA)

LEARNING GOALS

E Gottlieb
After attending this lecture, the participant will be able to
- Have a general understanding of the role of metabolic alterations in supporting tumorigenesis.
- Appreciate metabolic traits that are associated with leukemic stem cells.
- Realize potential therapeutic approaches that capitalize on metabolic vulnerabilities of cancer.

M Müschen
After attending this lecture, the participant will be able to
- Understand the role of transcription factors in B cell vs myeloid lineage commitment and differentiation.
- Describe how B-lymphoid and myeloid transcription factors regulate glucose uptake and energy metabolism in opposite directions.
- Understand the mechanistic basis of why glucorticoids only work in B-lymphoid but not myeloid malignancies.
- Appreciate the role of B-lymphoid transcription factors as metabolic gatekeepers by restricting the amount of energy available.

→ LATE BREAKING ORAL SESSION
11:15 – 12:45, Hall A

The best abstracts selected from the late breaking abstract submission are presented during this oral session.

A complete session overview is available via the mobile app or the online program at ehaweb.org

→ EDUCATION SESSION 3 B T C
11:15 - 12:45, Hall C
Repeated from:
Sunday, June 25, 09:30 - 11:00, Hall C

AGGRESSIVE LYMPHOMA

Chair: S Rule (Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom)

- **The biological basis of aggressive lymphoma**
  E Campo (Hospital Clínic, Barcelona, Spain)
- **Relapsed aggressive lymphoma: Can we optimize the therapy**
  G Salles (Hospices Civils de Lyon - Université Claude Bernard, Pierre Benite, France)
- **Treatment of aggressive lymphomas focused on elderly patients**
  M Pfreundschuh (Saarland University Medical School, Homburg (Saar), Germany)

LEARNING GOALS

E Campo

After attending this lecture, the participant will be able to
– Understand the biological heterogeneity of aggressive mature B-cell lymphomas and recognize its clinical impact.
– Describe the main molecular features that may be of clinical interest in aggressive mature B-cell lymphomas.

G Salles

After attending this lecture, the participant will be able to
– Describe the population heterogeneity and prognostic factors of patient with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
– Discuss the current management strategies of patients with R/R DLBCL, their indications, their results and their limitations.
– Describe the different developments of innovative approaches in R/R DLBCL, including targeted therapies, new antibodies, and CAR-T cells.

M Pfreundschuh

After attending this lecture, the participant will be able to
– Describe the biological and clinical peculiarities of elderly patients with aggressive lymphomas.
– Discuss treatment options for elderly patients who may or may not be candidates for standard treatment.
– Select the appropriate treatment based upon patient's individual characteristics, comorbidities and the specific biology of his/her aggressive lymphoma.
– Provide specific supportive measures that increase the patient's tolerability for the treatment.

→ EDUCATION SESSION 3 5 10 T C
11:15 - 12:45, Hall D
Repeated from:
Saturday, June 24, 08:00 - 09:30, Hall B

MULTIPLE MYELOMA

Chair: A Alegre (Hospital Universitario de La Princesa, Madrid, Spain)

- **Immunopathology of MM**
  N Munshi (Dana-Farber Cancer Institute, Boston, USA)
- **Genetic classification of myeloma for prognostication and treatment selection**
  H Avet-Loiseau (IUC-Oncopole, Toulouse, France)
- **New treatment approaches in myeloma in 2017**
  JF San-Miguel (Universidad de Navarra, Pamplona, Spain)

LEARNING GOALS

N Munshi

After attending this lecture, the participant will be able to
– Describe the immune status in multiple myeloma.
– Discuss the impact of immune dysfunction on myeloma cell growth and survival.
– Elucidate various methods and mechanisms to augment immune function for potential therapeutic application.

H Avet-Loiseau

After attending this lecture, the participant will be able to
– Understand the genetic heterogeneity in myeloma.
– Know what main prognostic parameters are.
– Understand how these factors may influence treatment choices.

JF San-Miguel

After attending this lecture, the participant will be able to
– Better tools for diagnosis and monitoring treatment efficacy are being implemented.
– Early treatment and the use of more efficient drugs upfront prolong survival.
– The treatment goal is to find the best possible balance between efficacy, toxicity and cost, particularly at the time of relapse.

→ EDUCATION SESSION 2 4 B T C
11:15 - 12:45, Hall E
Repeated from:
Sunday, June 25, 09:30 - 11:00, Hall E

MYELODYSPLASTIC SYNDROMES

Chair: P Fenaux (Hôpital Saint Louis, Paris, France)

- **Clonal evolution in MDS**
  J Jansen (Radboud UMC, Nijmegen, the Netherlands)
- **The role of immune response in MDS pathophysiology**
  G Mufti (Kings College, London, United Kingdom)
- **Indications for transplantation in MDS**
  MG Della Porta (Cancer Center - Humanitas Research Hospital & Humanitas University, Milan, Italy)

LEARNING GOALS

J Jansen

After attending this lecture, the participant will be able to
- Describe the concept of linear and branched evolution of subclones in MDS.
- Understand the effect of disease modifying therapy on clonal evolution and resistance to therapy in MDS.
- Discuss the significance of clonal hematopoiesis of indeterminate potential (CHIP).

G Mufti

After attending this lecture, the participant will be able to
- The role of immune system in MDS pathophysiology and genomic instability.
- The importance of immune-signature "switch" in disease progression.

MG Della Porta

After attending this lecture, the participant will be able to
- Provide a basis to select candidate patients based on both disease and patient-related factors.
- Provide a basis to define optimal timing of transplantation in individual patient.
- Discuss the use of hypomethylating agents as part of a comprehensive strategy to prevent relapse after transplantation in high risk patients.
- Discuss the clinical utility of somatic mutations in MDS transplantation decision-making.

→ EDUCATION SESSION 2 3 4 8 9 **T** **C**
11:15 - 12:45, Room N101
Repeated from:
Saturday, June 24, 09:45 - 11:15, Room N101

FERTILITY PRESERVATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Chair: D Meirow (Sheba Medical Center, Tel Hashomer, Israel)
- **The effects of chemotherapy and radiotherapy on reproduction**
  WH Wallace (University of Edinburgh, United Kingdom)
- **What patients expect from hematologists**
  A Plate (Myeloma Patients Europe, Munich, Germany)
- **Fertility preservation in female patients**
  CA Amorim (Université catholique de Louvain, Belgium)
- **Fertility preservation in pre-pubertal and adult males**
  R Mitchell (University ot Edinburgh, United Kingdom)

LEARNING GOALS

WH Wallace

After attending this lecture, the participant will be able to
- More high quality research is required to provide the evidence for impaired testicular and ovarian function after chemotherapy and radiation.
- Conditioning treatments for BMT that include chemotherapy and or radiotherapy are likely to impair gonadal function irrespective of the age of the patient at treatment.
- Radiotherapy to a field that includes the pelvis in females may impair uterine function with increased risk of miscarriage and preterm delivery.

A Plate

An up-to-date program is available via the mobile app.

CA Amorim

After attending this lecture, the participant will be able to
- Cite and outline currently available fertility preservation options.
- Select the most appropriate course of action according to disease type and treatment, as well as patient age.
- Describe recent advances and successes in oocyte and ovarian tissue cryopreservation.

R Mitchell

After attending this lecture, the participant will be able to
- Understand the key differences between the prepubertal and adult testis.
- Describe how cancer treatments can damage the prepubertal testis.
- Discuss the options available for fertility preservation in prepubertal and adolescent males.
- Describe the experimental approaches that are currently under investigation for young males at risk of infertility.

→ SCIENTIFIC WORKING GROUPS 3 **C**
11:45 - 12:45, Room N105

EUROPEAN RESEARCH INITIATIVE ON CHRONIC LYMPHOCYTIC LEUKEMIA (ERIC): A ROADMAP FOR CLL TREATMENT: WHAT TO CHOOSE AND WHY

Chair: M Doubek (University Hospital, Brno, Czech Republic)
- **First-line therapy for CLL in 2017**
  A Tedeschi (Niguarda Cancer Center, Niguarda Hospital, Milan, Italy)
- **New drugs for old? What is the role of B-cell receptor pathway inhibition in the front line therapy of CLL in 2017?**
  S Devereux (King's College Hospital, London, United Kingdom)
- **Managing CLL patients after BCR inhibitor failure**
  JA Jones (The Ohio State University, Columbus, USA)

LEARNING GOALS

A Tedeschi

After attending this lecture, the participant will be able to
- Describe current clinical data and emerging therapies relating to management of treatment naive CLL.
- Select appropriate upfront therapy based upon biological features.
- Identify patients clinical characteristics that may influence treatment choice.

S Devereux

After attending this lecture, the participant will be able to
- Describe the currently available therapies for the front line therapy of CLL.
- Discuss the patient and disease related factors that influence the

selection of front line therapy for patients with CLL.

JA Jones
After attending this lecture, the participant will be able to
– Discuss the mechanisms and patterns of relapse among CLL patients progressing after BCR inhibitor treatment.
– Select appropriate relapse therapy based upon emerging clinical data.
– Describe investigational strategies for managing CLL patients after BCR inhibitor failure.

→ SCIENTIFIC WORKING GROUPS 2 4 **B T C**
11:45 - 12:45, Room N103

ACUTE MYELOID LEUKEMIA

Chair: G Ossenkoppele (VU University Medical Center, Amsterdam, the Netherlands)
- **Role of enhancers in the pathogenesis of AML**
  R Delwel (Erasmus MC, Rotterdam, the Netherlands)
- **Harnessing T cells for immunotherapy of AML**
  M Subklewe (LMU-University Hospital Munich, Germany)

LEARNING GOALS

R Delwel
After attending this lecture, the participant will be able to
– Acute myeloid leukemia is a heterogeneous disease with distinct genetic defects associated with various responses to therapy.
– AML with 3q26 aberrations overexpress the EVI1 oncogene and are among the cases with the worst outcome.
– In 3q26 AMLs myeloid specific enhancers are reallocated near EVI1 causing its overexpression.

M Subklewe
After attending this lecture, the participant will be able to
– Gain an overview of current concepts with bispecific antibodies for AML and the challenges in the clinical translation of these therapeutic strategies.

→ SCIENTIFIC WORKING GROUPS 5 6 **C**
11:45 - 12:45, Room N104

BLEEDING AND THROMBOSIS: ACQUIRED BLEEDING DISORDER EMERGENCIES

Chair: A Falanga (Hospital Papa Giovanni XXIII - Bergamo, Italy)
- **Hyperfibrinolysis in trauma induced coagulopathy**
  C Longstaff (National Institute for Biological Standards and Control, South Mimms, United Kingdom)
- **Perioperative and emergency management of patients on direct oral anticoagulants (DOACs)**
  H ten Cate (Maastricht University Medical Center, the Netherlands)
- **The coagulopathy of APL: Still a challenge?**
  A Falanga (Hospital Papa Giovanni XXIII - Bergamo, Italy)

LEARNING GOALS

C Longstaff
After attending this lecture, the participant will be able to
– Understand what is meant by the terms fibrinolysis and hyperfibrinolysis.
– Appreciate the current thinking on how hyperfibrinolysis develops after trauma and how it is assessed.
– Better understand treatment options and their current limitations.

H ten Cate
After attending this lecture, the participant will be able to
– Understand the principles of peri-operative continuation or cessation of DOACs.
– Now when and how to apply laboratory testing for DOACs.
– Consider the need for antidotes.

A Falanga
After attending this lecture, the participant will be able to
– Learn about the pathogenesis and management of hyperfibrinolysis in trauma-induced coagulopathy.
– Learn about the perioperative and emergency management of patients on anticoagulant treatments with DOACs.
– Acquire the most recent insights in APL-associated coagulopathy epidemiology and treatment.

→ EDUCATION SESSION 5 7 10 **B T C**
11:15 - 12:45, Room N109
Repeated from:
Sunday, June 25, 09:30 - 11:00, Room N109

CHALLENGES IN BLOOD TRANSFUSION

Chair: A Brand (Leiden University Medical Centre & Sanquin blood supply, the Netherlands)
- **Cell-derived microvesicles and microparticles in blood components: Consequences for transfusion recipients**
  T Burnouf (Taipei Medical University, Taiwan)
- **Challenges in typing and matching strategies in patients with hematological malignancies in the era of immunotherapy**
  KMK de Vooght (University Medical Center Utrecht, the Netherlands)
- **Red blood cell transfusion: When to transfuse in patients with hematological malignancies?**
  M Lozano (University Clinic Hospital, Barcelona, Spain)

LEARNING GOALS

T Burnouf
Participants should be able to realize that
– Extracellular vesicles (EVs) are present in abundance in collected blood since they are released in the circulation by platelets, red and white cells as well as from the endothelium upon activation or as a result of apoptosis.
– The amount of EVs is also largely dependent on the component preparation and storage methods and that the impact of pathogen inactivation methods should be studied with respect to EV content and types.

– EVs play a controversial role in transfusion and often exhibit potent pro-thrombotic and inflammatory potentials.
– Pre-clinical and clinical studies should objectively delineate EV role and possible pathological implications.

KMK de Vooght
After attending this lecture, the participant will be able to
– Describe the impact of CD38 monoclonal antibodies on blood bank serologic testing.
– Discuss strategies to mitigate the impact of these antibodies on serologic testing.
– Evaluate options to provide optimal transfusion support for patients on anti-CD38 therapy.

M Lozano
After attending this lecture, the participant will be able to
– Describe the current evidence to indicate red blood cell transfusion in different patient populations.
– Discuss the particular challenges that the patients with hematological malignancies pose when indicating a red blood cell transfusion.
– Select the hemoglobin threshold for red blood cell transfusion for patients with hematological malignancies based on the available evidence.

→ EDUCATION SESSION 1 4 7 **B T C**
11:15 - 12:45, Room N111
Repeated from:
Sunday, June 25, 09:30 - 11:00, Room N111

ACQUIRED PROBLEMS IN RED CELLS

Chair: S Menzel (King's College London, United Kingdom)

- **Transferrin and TfR1 in co-regulation of erythropoiesis and iron metabolism**
  Y Ginzburg (Icahn School of Medicine at Mount Sinai, New York, USA)
- **Iron overload before, during and after bone marrow transplantation**
  E Angelucci (Ospedale Oncologico di Riferimento Regionale "A. Businco", Cagliari, Italy)
- **Heat Shock Protein 70 (HSP70), one of the major key factors in Diamond-Blackfan anemia**
  L Da Costa (France)

LEARNING GOALS

Y Ginzburg
After attending this lecture, the participant will be able to
– Identify disease characteristics commonly found in β-thalassemia.
– Describe the mechanisms regulating iron availability for and utilization during erythropoiesis in physiologic and pathologic conditions.
– Understand the compensatory role of exogenous transferrin and effects on TfR1 in ineffective erythropoiesis.

E Angelucci
After attending this lecture, the participant will be able to
– Recognize principal iron toxicity mechanisms.
– Make a correct diagnosis of iron overload and identify patients at risk of iron toxicity before and during hemopoietic cell transplantation.
– Minimize iron toxicity in the setting of hemopoietic cell transplantation.
– Diagnosis and treat iron overload after hemopoietic cell transplantation.

L Da Costa
An up-to-date program is available via the mobile app.

→ BASIC-SCIENCE-IN-FOCUS 2 **B T**
11:45 - 12:45, Room N113

METHYLATION AND EPIGENETICS

Chair: K Gronbaek (Rigshospitalet, Copenhagen Ø, Denmark)

- **DNA methyltransferase 3A in normal and malignant hematopoiesis**
  P Goodell (Baylor College of Medicine, Houston, USA)
- **Activating the immune system by DNA hypomethylating agents**
  D De Carvalho (Princess Margaret Cancer Centre, Toronto, Canada)

LEARNING GOALS

P Goodell
After attending this lecture, the participant will be able to
– Understand how mutations in DNMT3A impact DNA methylation patterns in the genome.
– Understand some of the molecular mechanisms behind DNMT3A function that account for its mutation prevalence in hematologic malignancies.

D De Carvalho
An up-to-date program is available via the mobile app.

→ BASIC-SCIENCE-IN-FOCUS 2 3 9 **B T**
11:45 - 12:45, Room N115

MOUSE MODELS OF ACUTE LEUKEMIA

Chair: J Barata (Instituto de Medicina Molecular, Universidade de Lisboa, Portugal)

- **Infections as predisposing for childhood ALL - Lessons from mouse models**
  A Borkhardt (Pediatric Oncology,-Haematology and Clinical Immunology, Düsseldorf, Germany)
- **Modeling the cellular origin of AML**
  J Schwaller (University Children's Hospital Basel, Switzerland)

LEARNING GOALS

A Borkhardt

After attending this lecture, the participant will be able to

- Infectious theory of childhood acute lymphoblastic leukemia (ALL).
- Susceptibility to childhood ALL due to germline variations.
- Mouse models to study the complex interplay between inherited germline risk and postnatal infection.
- Infection-dependent versus infection-independent mouse models of ALL.

J Schwaller

After attending this lecture, the participant will be able to

- Functional cooperation of genetic alteration leading to AML.
- Possibilities and limitations of different AML mouse models.
- The role of the cellular origin for the biology of AML.

→ SPECIAL SESSION 1 2 3 9 **B T C**
13:00 - 14:30, Hall A

PLENARY SESSION II

Chair: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
P Sonneveld, President Elect of EHA (Erasmus Medical Center, Rotterdam, the Netherlands)

- **What's new in myeloproliferative neoplasms?**
  R Skoda (University Hospital Basel, Switzerland)
- **Hemophilia treatment: Navigating speed bumps on the innovation highway**
  D Di Michele (National Institutes of Health, USA)
- **From biology to targeted therapies in chronic lymphocytic leukemia**
  S Stilgenbauer (Ulm University, Germany)

LEARNING GOALS

R Skoda

After attending this lecture, the participant will be able to

- Understand the role of early molecular events in the initiation of myeloproliferative neoplasms.

D Di Michele

After attending this lecture, the participant will be able to

- Describe recent advances in knowledge and therapeutics that inform state of art approaches to the prevention of hemorrhagic complications associated with hemophilia A and B of all severities, and incorporate these strategies into their clinical practices.
- Understand the science behind our current understanding of how and why neutralizing antibodies to factor VIII (FVIII inhibitors) develop, as well as the new NIH research initiatives intended to generate a more complete and actionable understanding of FVIII immunogenicity.
- Discuss the disruptive technologies that currently drive the novel therapeutic pipeline for the treatment of individuals with FVIII inhibitors.
- Describe the resurgence of gene therapy and the progress toward a cure for hemophilia B.

S Stilgenbauer

After attending this lecture, the participant will be able to

- Understand biology underlying pathogenesis and progression of CLL.
- Describe current and emerging prognostic and predictive factors.
- Select appropriate therapy based on patient and disease characteristics.
- Discuss mechanisms conferring resistance to various treatment options.

→ SPECIAL SESSION
14:30 – 15:00, Hall A

BUSINESS MEETING

Chair: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

All EHA members are invited to the yearly EHA Business Meeting, where the EHA Board presents the highlights of the past year and looks ahead to EHA's future. Furthermore, the results of the nomination and ballot are presented and new Board members are installed in their positions.

E-POSTERS

E-POSTERS

On the next pages you can find the overview of E-posters. They have been categorized by abstract topic to allow for easy navigation. The E-posters can be viewed in the Poster Area on the E-poster screens as of Friday, June 23, 09:30 until Saturday, June 24, 19:00. All posters will be available on the EHA Learning Center. Delegates will have complimentary access after the Congress.

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY

E819 **PRECLINICAL COMBINATION OF A NOVEL IRE1 RNASE INHIBITOR MKC-8866 AND TYROSINE KINASE INHIBITION ACTS SYNERGISTIC IN ACUTE LYMPHOBLASTIC LEUKEMIA.**
M Vieri[1] ([1]Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany)

E820 **HIGH-THROUGHPUT COPY NUMBER PROFILING IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA USING MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION IN COMBINATION WITH NEXT-GENERATION SEQUENCING**
D Alpar[1] ([1]MTA-SE Lendulet Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary)

E821 **CRITICAL ROLE FOR NOTCH SIGNALLING IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) DRUG RESPONSE.**
P Takam Kamga[1] ([1]Medicine, University of Verona, Verona, Italy)

E822 **REGULATION OF NOTCH AND WNT SIGNALING PATHWAYS BY NRARP IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
R Fragoso[1] ([1]JBarata Lab, Instituto de Medicina Molecular, Lisboa, Portugal)

E823 **ETV6/RUNX1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA: A NOVEL B-CELL PRECURSOR LEUKEMIA SUBTYPE IDENTIFIED BY THE CD27/CD44 IMMUNOPHENOTYPE**
M Vaskova[1] ([3],[1]Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic, [3] CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic)

E825 **GENETIC ALTERATIONS IN CHILDREN WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN TAIWAN**
DC Liang[1] ([1]Mackay Children's Hospital and Mackay Medical College, Taipei, Taiwan, Republic of China)

E826 **COMPUTATIONAL METHODS TO FIND NEW THERAPEUTIC TARGETS IN ALL, SYSTEMATICAL IDENTIFICATION OF ESSENTIAL GENES**
L Ekdahl[1] ([1]Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden)

E827 **TARGETING ANTIOXIDANT ENZYMES FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
K Fidyt[1] ([1]Department of Immunology, Medical University of Warsaw, Warsaw, Poland)

E828 **RNA-BINDING PROTEIN IGF2BP1 PROMOTES SURVIVAL OF ETV6/RUNX1 LEUKEMIA CELLS**
M Stoškus[1] ([1] Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania)

E829 **6-MERCAPTOPURINE PROMOTES ENERGETIC FAILURE IN LEUKEMIC T-CELL LINE JURKAT**
AA Fernandez Ramos [1], [2] ([1]Université Paris Descartes, Paris, France, 2 INSERM UMRS-1147, Paris, France)

E830 **GENETIC ABERRATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA AND THEIR IMPACT ON CLINICAL OUTCOME**
K Takahashi[1] ([1]Leukemia, UT MD ANDERSON CANCER CENTER, Houston, United States)

E831 **PROFILING OF RECURRENT COPY NUMBER ALTERATIONS IN RELAPSED ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA**
J Ribera [1], [2] ([1]Josep Carreras Leukemia Research Institute, Badalona, Spain, [2]Universitat Autònoma de Barcelona, Badalona, Spain)

E832 **IGF1R/IRS PHARMACOLOGICAL INHIBITION REDUCES CELL PROLIFERATION AND MIGRATION IN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS**
APN Rodrigues Alves[1] ([1]Internal Medicine, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil)

E833 **LEUKEMIA-PROPAGATING CELLS DEMONSTRATED DISTINCTIVE GENE EXPRESSION PROFILES COMPARED WITH THE OTHER CELL FRACTIONS IN PATIENTS WITH DE NOVO PHILADELPHIA CHROMOSOME-POSITIVE ALL**
HY Zhao[1] ([1]Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China)

E834 **T-CELL LEUKEMIA SENSITIVITY TO FARNESYL TRANSFERASE INHIBITION USING TIPIFARNIB**
R Mondejar[1] ([1]Cancer Genomics Lab, IDIVAL, Santander, Spain)

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL

E835 **HOSPITALIZATION FOR PATIENTS IN THE U.S. AND EU TREATED WITH INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN A GLOBAL PHASE 3 TRIAL**
Y Su[1] ([1]Pfizer Inc, New York, United States)

E836 **NON-INTENSIVE BUT NON-INTERRUPTIVE TREATMENT WITH FEWER ALLO-HSCT IS EFFECTIVE STRATEGY FOR ADULT PH-NEGATIVE B-CELL PRECURSOR (BCP-) ALL: OUTCOME OF THE RUSSIAN PROSPECTIVE MULTICENTER ALL-2009 STUDY**
E Parovichnikova[1] ([1]BMT department, National Research Center for Hematology, Moscow, Russian Federation)

E837 **POST-INDUCTION MINIMAL RESIDUAL DISEASE RESPONSE DETERMINED BY MULTICOLOR FLOW CYTOMETRY IS A POWERFUL INDICATOR OF EVENT-FREE-SURVIVAL IN THE CHILDHOOD T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
P Tembhare[1] ([1]Hematopathology Laboratory, Tata Memorial Centre, Mumbai, Navi Mumbai, India)

E838 **SMAC MIMETICS - A NOVEL THERAPEUTIC APPROACH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA**
M Meyer[1] ([1]Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany)

E839 **SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM PHASE II STUDY**
R Klisovic[1] ([1]Department of Internal Medicine, Division of Hematology & Oncology, The Ohio State University, Columbus, OH, United States)

E840 **UPDATED RESULTS FROM ZUMA-4: A PHASE 1/2 STUDY OF KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**
DW Lee[1] ([1]Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, United States)

E841 **COMPARISON OF 8-COLOR FLOW CYTOMETRY AND PCR-BASED METHODS IN MEASUREMENT OF MINIMAL RESIDUAL DISEASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA.**
S Hrabovsky[1,2] ([1]Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic, [2] Faculty of Medicine, Masaryk University, Brno, Czech Republic)

E842 **QUALITY-ADJUSTED LIFE YEARS (QALY) FOR INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)**
I van Oostrum[1] ([1]Ingress-health the Netherlands, Rotterdam, the Netherlands)

E843 **A COST-EFFECTIVE, HIGH SENSITIVITY 10-COLOR SINGLE TUBE FLOW-CYTOMETRY BASED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA MINIMAL RESIDUAL DISEASE (MRD) ASSAY WITH STUDY OF ARTIFACTS AND MIMICS**
G Chatterjee[1] ([1]Hematopathology, Tata Memorial Hospital, Mumbai, Mumbai, India)

E844 **SPECKLE TRACKING ECHOCARDIOGRAPHY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY STUDY**
M Belloni[1] ([1]Clinic of Pediatric Hemato-Oncology - Department of Woman and Child Health, University of Padua, Padova, Italy)

E845 **NUDT15 VARIANT CAUSING HEMATOPOIETIC TOXICITY WITH LOW 6-TGN LEVEL IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
HH Koo[1] ([1]Pediatrics, Sungkyunkwan Univ School of Medicine, Samsung Medical Center, Seoul, Korea, Republic Of)

E846 **USING NEXT GENERATION SEQUENCING TO DETECT CLONAL TRG AND TRB GENE REARRANGEMENTS**
P Shah[1] ([1]Invivoscribe Technologies, Inc., San Diego, United States)

E847 **DETECTION OF CLONALITY IN CLINICAL SPECIMENS FROM SUSPECTED B-CELL MALIGNANCIES USING COMPREHENSIVE IGH LYMPHOTRACK® MISEQ® AND PGM® ASSAYS**
Y Huang[1] ([1]Invivoscribe Technologies, San Diego, United States)

E848 **CORRELATION BETWEEN A 10-COLOR FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS AND MOLECULAR MRD IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA**
J Singh[1] ([1]Laboratory Haematology, Alfred Pathology, Melbourne, Australia)

E849 **HYPOGLYCEMIC EVENTS DURING TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: OBSERVATIONS FROM TRIAL AIEOP-BFM ALL 2009**
K Bleckmann[1] ([1]Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany)

E850 **NUDT15 VARIANT IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
JM Lee[1] ([1]Pediatrics, Yeungnam University, College of Medicine, Daegu, Korea, Republic Of)

E851 **SURVIVAL OUTCOMES OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH MODIFIED BFM90 AND ALTERNATE ALL PROTOCOLS IN RESOURCE LIMITED SETTINGS: A 10 YEAR PROSPECTIVE STUDY**
A Jandial[1] ([1]INTERNAL MEDICINE, PGIMER Chandigarh, CHANDIGARH, India)

E852 **TREATMENT OUTCOME OF ACUTE LYMPHOBLASTIC LEUKEMIA IN KOREAN ADOLESCENTS AND YOUNG ADULTS**
HJ Park[1] ([1]Center for Pediatric Oncology, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic Of)

E853 **AUTOLOGOUS TRANSPLANTATION AS TIME-DEPENDENT FACTOR FOR SURVIVAL OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: STUDY DATA AND SIMULATION MODEL**
S Kulikov[1] ([1]Biostatistics, National Research Center for Hematology, Moscow, Russian Federation)

E854 **INDUCTION WITH TYROSINE KINASE INHIBITORS, CONSOLIDATION WITH FLUDARABINE, ARA-C AND DAUNOXOME FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANT IS AN EFFECTIVE AND FEASIBLE STRATEGY FOR PH+ ALL PATIENTS.**
N Di Felice[1] ([1]Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)

E855 **BONE MARROW MRD EVALUATION ON DAY 7 OF STEROID TREATMENT OF MODIFIED ST JUDE TOTAL XV THERAPY IN STANDART/LOW RISK PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
S Aytac[1] ([1]Pediatric Hematology, Hacettepe University, Ankara, Turkey)

E856 **PONATINIB (PON) IN PHILADELPHIA CHROMOSOME (PH)-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRELIMINARY REPORT OF THE OPAL OBSERVATORY.**
S Tavitian[1] ([1]Hematology, IUCT-O, TOULOUSE, France)

E857 **JL1 ANTIGEN EXPRESSION OF LEUKEMIC CELLS IN CHILDHOOD ACUTE LEUKEMIA**
E You[1] ([1]Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of)

E858 **SERUM LEVELS OF CYTOKINES AND ADHESION MOLECULES AND THEIR ASSOCIATION WITH PROGNOSTIC FACTORS IN NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**
JM Horacek[1], [2] ([1] 4th Department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic, [2] Department of Military Internal Medicine and Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), Hradec Kralove, Czech Republic)

E859 **IMATINIB VS. DASATINIB FOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.**
A Shigematsu[1] ([1]Department of Hematology, Sappro Hokuyu Hospital, Sapporo, Japan)

E860 **IS OLDER AGE AN EXCLUSION CRITERION FOR ALLOGENEIC HEMOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA?**
O Gavrilina[1] ([1]Chemotherapy and BMT, National Research Center for Hematology, Moscow, Russian Federation)

E861 **TARGETABLE BLINATUMOMAB + TYROSINE KINASE INHIBITORS TREATMENT IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: CLINICAL EFFECTIVENESS AND PERIPHERAL LYMPHOCYTES SUBPOPULATIONS KINETICS.**
A Sokolov[1] ([1]National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E862 **VERY VERY LATE RELAPSES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA, A CASE SERIES**
M NIKITA[1] ([1]Pediatric Oncology Department, P.&A. Kyriakou, ATHENS, Greece)

E863 **NOVEL CRLF2 MUTATIONS AND CLINICAL SIGNIFICANCE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA**
C Song [2], [4] ([2]International Cooperative Leukemia Group and International Cooperative Laboratory of Hematology, Zhongda Hospital, Southeast University Medical School, Nanjing, China, [4]Pediatrics Department, Penn State University College of Medicine, Hershey, United States)

ACUTE MYELOID LEUKEMIA - BIOLOGY

E864 **THE MUTATIONAL SPECTRUM OF T(8;21)(Q22;Q22) POSITIVE ACUTE MYELOID LEUKEMIA DETERMINED BY HIGH-THROUGHPUT TARGETED SEQUENCING**
N Jahn[1] ([1]Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany)

E865 **NFKB PATHWAY PROMOTES TUMOR PROGRESSION THROUGH BRUTON'S TYROSINE KINASE IN MLL+ ACUTE MYELOID LEUKEMIA**
SC Nimmagadda[1] ([1]Department for Hematology and Oncology, University Clinic of Magdeburg, Magdeburg, Germany)

E866 **A PRECISION MEDICINE PLATFORM FOR ACUTE MYELOID LEUKEMIA TO HELP UNRAVELING THE MOLECULAR ADDICTIONS OF FLT3-ITD-DRIVEN AML**
P Ayuda-Durán[1] ([1]Department of Molecular Cell biology - Institute for Cancer Research, Oslo University Hospital - Radiumhospitalet, Oslo, Norway)

E867 **SECRETION OF SOLUBLE FACTORS BY AML CELLS INFLUENCE CD33/CD3 BITE® ANTIBODY MEDIATED CYTOTOXICITY AND T-CELL PROLIFERATION**
M Costanzi[1], [2] ([1] Department of Internal Medicine III, Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany, [2]Laboratory for Translational Cancer Immunology - Gene Center, Munich, Germany)

E868 **CLONAL EVOLUTION OF FLT3-ITD POSITIVE AML AT DIAGNOSIS AND RELAPSE IN PATIENTS TREATED WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS**
LK Schmalbrock[1] ([1]Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany)

E869 **MICROENVIRONMENT SECRETED PROTEINS MEDIATE RESISTANCE TO TARGETED THERAPY IN PRIMARY AML CELLS**
A Dokal[1] ([1]Haemato-Oncology, Barts Cancer Institute, London, United Kingdom)

E870 **CHARACTERIZATION OF FLT3 MUTATIONS AT DIAGNOSIS, REFRACTORY DISEASE OR RELAPSE IN AML PATIENTS TREATED WITH MIDOSTAURIN WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS**
LK Schmalbrock[1] ([1]Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany)

E871 **A NOVEL PML-RARG FUSION IN ACUTE PROMYELOCYTIC LEUKEMIA**
JS Ha[1] ([1]Keimyung University School of Medicine, Daegu, Korea, Republic Of)

E872 **COOPERATION OF MLL-PTD WITH DNMT3A OR RUNX1 MUTATIONS IN AML LEUKEMOGENESIS**
HW Kao[1] ([1]Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, Republic of China)

E873 **AML BLASTS INDUCE A SENESCENT PHENOTYPE IN THE BM-MSC THROUGH THE UPREGULATION OF P21**
E Forde[1] ([1]Norwich Medical School, University of East Anglia, Norwich, United Kingdom)

E874 **HYPOXIA DRIVES AML PROLIFERATION IN THE TUMOR MICROENVIRONMENT THROUGH HIF1Ð/MIF SIGNALLING**
A Abdul-Aziz[1] ([1]Norwich Medical School, University of East Anglia, Norwich, United Kingdom)

E875 **BONE MARROW ECOLOGICAL COLLAPSE IN ACUTE MYELOID LEUKEMIA IS MEDIATED BY REMODELING OF ENDOSTEAL VESSELS**
D Duarte [1], [2] ([1]Department of Life Sciences, Imperial College London, London, United Kingdom, [2]The Francis Crick Institute, London, United Kingdom)

E876 **CLONAL HETEROGENEITY IN PATIENT-DERIVED XENOGRAFT OF ADULT ACUTE MYELOID LEUKAEMIA**
F Gonzales[1], [2] ([1]UMR-S 1172, Inserm, Lille, France, [2]Service d'hématologie pédiatrique, CHU Lille, Lille, France)

E877 **COSTIMULATION INCREASES INTRACELLULAR SIGNALLING IN BITE® ANTIBODY CONSTRUCT MEDIATED T-CELL ACTIVATION**
L Pachzelt[1], [2] ([1]Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany, [2]Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany)

E878 **ESTABLISHING SINGLE CELL WHOLE EXOME SEQUENCING ANALYSIS AS A DISCOVERY TOOL IN NPM1/FLT3 POSITIVE PEDIATRIC ACUTE MYELOID LEUKEMIA**
C Walter[1] ([1]Department of Pediatrics III, University Children's Hospital Essen, Essen, Germany)

E879 **RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA**
V Caraffini[1] ([1]Division of Hematology, Medical University of Graz, Graz, Austria)

E880 **INHIBITING MIR-10A OVERCOMES CYTARABINE-RESISTANCE IN ACUTE MYELOID LEUKAEMIA**
TT Vu[1] ([1] Haematology, St Vincent's Hospital, Sydney, Australia)

E881 **BY AN MCL-1-DEPENDENT MECHANISM, ALVOCIDIB POTENTIATES THE ACTIVITY OF CYTARABINE AND MITOXANTRONE WHEN ADMINISTERED IN A TIME SEQUENTIAL REGIMEN IN AML**
S Warner[1] ([1]Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States)

E882 **DYSREGULATION IN KEY REGULATOR GENES OF AUTOPHAGY AS A MECHANISM OF THERAPY RESISTANCE AND POOR PROGNOSIS IN ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM MICROARRAY ANALYSIS ON 148 PATIENTS**
MC Fontana[1] ([1]Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy)

E883 **NO EVIDENCE FOR MICROSATELLITE INSTABILITY (MSI) IN 1,394 PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)**
C Walker[1] ([1]The Ohio State University, Columbus, United States)

E884 **SY-1425, A POTENT AND SELECTIVE RARĐ AGONIST, REPROGRAMS AML CELLS FOR DIFFERENTIATION ALONG DISTINCT LINEAGES, UNCOVERING PD MARKERS FOR CLINICAL STUDIES**
M Mckeown[1] ([1]Translational Medicine, Syros Pharmaceuticals, Cambridge, United States)

E885 **GENETIC CHARACTERIZATION OF A LARGE GROUP OF CEBPA MUTATED AML PATIENTS AND THE EFFECT OF TET2 AND GATA2 MUTATIONS ON OUTCOME**
NP Konstandin[1] ([1]Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany)

E886 **MECHANISMS OF SYK-MEDIATED SUPPRESSION OF DIFFERENTIATION AND APOPTOSIS IN ACUTE MYELOID LEUKEMIA (AML)**
A Polak[1] ([1]Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland)

E887 **MUTATIONAL PROFILE OF RELAPSE-RISK GROUPS IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS**
M Prieto-Conde[1] ([1]Hematology Department, University Hospital of Salamanca-IBSAL, SALAMANCA, Spain)

E888 **ANALYSIS OF THE PD-1/PD-L1 AXIS POINTS TO ASSOCIATION OF UNFAVORABLE RECURRENT MUTATIONS WITH PD-L1 EXPRESSION IN AML**
K Giannopoulos [1], [2] ([1]Department of Hematology, St. John's Cancer Center, Lublin, Poland, [2]Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland)

E889 **DISSECTING THE DYNAMICS OF SINGLE-TUMOR-CELL-LINEAGES THAT UNDERPIN RELAPSE OF AML**
H Norell[1], [2] ([1]Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal)

E891 **MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR ACUTE MYELOID LEUKEMIA FOLLOW-UP**
E Onecha De La Fuente[1], [2] ([1]Hematologia traslacional, Hospital 12 de Octubre, Madrid, Spain, [2]Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain)

E892 **THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS-LIKE BLASTS WHICH SUPPRESS T CELL PROLIFERATION IN LEUKEMIC CELL GROWTH**
SY Hyun[1] ([1]Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic Of)

E893 **GENERATION OF NEW CELLULAR MODELS FOR THE STUDY OF PEDIATRIC NON DOWN SYNDROME ACUTE MEGAKARYOBLASTIC LEUKEMIA BASED ON HUMAN PLURIPOTENT STEM CELLS**
J Domingo-Reinés[1] ([1]Genyo, Granada, Spain)

E894 **CHARACTERIZATION OF HEMATOLOGIC MALIGNANCIES WITH ANCHORED MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING**
D Fugere1 (1 ArcherDX, Boulder, CO, United States)

E895 **ASXL1 MUTATIONS IN AML ARE ASSOCIATED WITH SPECIFIC CLINICAL AND CYTOGENETIC CHARACTERISTICS**
K Manola[1] ([1]Laboratory of Health Physics, Radiobiology & Cytogenetics, NCSR "Demokritos", ATHENS, Greece)

E896 **ENTOSPLETINIB, A POTENT AND SELECTIVE SYK INHIBITOR, BLOCKS CONSTITUTIVE AND FCGR ACTIVATED SIGNALING IN FLT3-ITD CELL LINES**
K Keegan[1] ([1]Oncology, Gilead Sciences Inc, Foster City, United States)

E897 **A COMPREHENSIVE DNA TEST FOR THE DETECTION OF TRANSLOCATIONS IN ACUTE LEUKEMIA**
E Van Den Berg-De Ruiter[1] ([1]Genetics, UMCG, Groningen, the Netherlands)

E898 **ALTERATIONS IN NECROPTOSIS PATHWAY AFFECT PROGNOSIS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA**
S Lo Monaco[1] ([1]University of Bologna, Bologna, Italy)

E899 **NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT RELAPSE AND REFRACTORINESS STATUS IN AML PATIENTS**
E Onecha De La Fuente[1], [2] ([1]Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain, 2 Hematologia traslacional, Hospital 12 de Octubre, Madrid, Spain)

E900 **PRECLINICAL EVIDENCE THAT TRAMETINIB ENHANCES THE RESPONSE TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA**
ML Morales[1] ([1]Servicio de Hematologia, Hospital Universitario 12 de Octubre, Madrid, Spain)

E901 **IDENTIFICATION OF NOVEL THERAPEUTIC DRUGS IN DISTINCT PEDIATRIC AML SUBTYPES BY TARGETING EPIGENETIC REGULATORS**
C Wiggers[1, 2] ([1]Pediatrics, University Medical Center Utrecht, Utrecht, the Netherlands, 2 Hubrecht Institute, Utrecht, the Netherlands)

E902 **ALVOCIDIB SYNERGIZES WITH CYTARABINE AND DAUNORUBICIN (7+3) IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA**
C Whatcott[1] ([1]Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States)

E903 **COMBINATION OF INTERFERON-ALPHA AND VALPROIC ACID IN ACUTE MYELOID LEUKEMIA CELLS IN VITRO AND IN VIVO**
BT Gjertsen[1, 3] ([1] Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway, 3 Department of Internal Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway)

E904 **KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ACUTE MYELOID LEUKEMIA**
R Napolitano[1] ([1]Bioscience Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy)

E905 **CLEARANCE OF 'DRIVER-COSMIC' MUTATIONS POST CR1 WITH PERSISTING RUNX1_L56S IS UNLIKELY TO CONTRIBUTE TOWARDS DISEASE PROGRESSION IN AML**
L Rai[1] ([1]Onco-Cytogenomics, HSL Analytics LLP, LONDON, United Kingdom)

ACUTE MYELOID LEUKEMIA - CLINICAL

E906 **PROGNOSTIC SIGNIFICANCE OF FLT3 STATUS, CYTOGENETIC, ECOG AND 50% BLAST DECREASE IN PRIMARY REFRACTORY OR EARLY RELAPSED AML PATIENTS BEFORE SALVAGE THERAPY.**
E Paubelle[1] ([1]Hematology, Chu Lyon Sud, Pierre Benite, France)

E907 **PRELIMINARY RESULTS FROM A PHASE 1 STUDY EXAMINING THE NOVEL BCL-2 INHIBITOR S55746/BCL201 AS SINGLE AGENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME**
A Wei[1] ([1]Department of Clinical Haematology, The Alfred Hospital and Monash University, Melbourne, Australia)

E908 **DISSECTING THE CLINICAL HETEROGENEITY OF NUCLEOPHOSMIN-1 (NPM1) MUTATED ADULT ACUTE MYELOID LEUKEMIA : THE CONTRIBUTION OF FLOW-CYTOMETRIC DETERMINATION OF MINIMAL RESIDUAL DISEASE**
F Buccisano[1] ([1]Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy)

E909 **EXPRESSION OF IMMUNE CHECKPOINT MOLECULES (PD-1, PD-L1, AND PD-L2) ON BONE MARROW T CELLS IN ACUTE MYELOID LEUKEMIA**
E You[1] ([1]Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of)

E910 **ACUTE LEUKEMIA IN HIV PATIENTS : EPIDEMIOLOGY, THERAPEUTIC STRATEGY AND PROGNOSIS**
F Rabian[1] ([1] St Louis Hospital, Paris, France)

E911 **TEN-DAY DECITABINE AS INDUCTION THERAPY FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA FIT FOR INTENSIVE CHEMOTHERAPY**
J Wang[1] ([1]Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China)

E912 **INDOXIMOD IN COMBINATION WITH IDARUBICIN AND CYTARABINE FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): PHASE 1 REPORT**
A Emadi[1, 2, 3] ([1]University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, United States, [2]Medicine, University of Maryland, Baltimore, United States, [3]Pharmacology, University of Maryland, Baltimore, United States)

E913 **PHASE I/II STUDY OF MEK INHIBITOR (MEK-162; BINIMETINIB) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYELOID MALIGNANCIES**
K Naqvi[1] ([1]Department of Leukemia, UTMD Anderson Cancer Center, Houston, United States)

E914 **HAPLOIDENTICAL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR OLDER PATIENTS WITH AML/MDS**
S Ciurea[1] ([1]Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, United States)

E915 **OPTIMIZATION OF MINIMAL RESIDUAL DISEASE EVALUATION IN ACUTE MYELOID LEUKEMIA TO DRIVE POST REMISSION THERAPY**
P Minetto[1] ([1]Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCSS AOU San Martino-IST, Genoa, Italy)

E916 **THE NUMBER OF CD34+CD38+CD117+H-LA-DR+CD13+CD33+ CELLS INDICATES POST-CHEMOTHERAPY NEUTROPHIL RECOVERY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
J Wang[2] ([2]State Key laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China)

E917 **MICRORNAS (MIRS) IN HIGH RISK PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) AS PREDICTION TOOLS FOR RELAPSE INCIDENCE**
PP Leoncini[1] ([1]Oncohaematology, Bambino Gesù Children Hospital, Roma, Italy)

E918 **CYTOKINE RECEPTORS AND SOLUBLE ADHESION MOLECULE LEVELS ARE ASSOCIATED WITH PROGNOSIS OF NEWLY DIAGNOSED AML**
JM Horacek[1], [2] ([1] Department of Military Internal Medicine and Hygiene, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic, [2] 4th department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Hradec Kralove, Czech Republic)

E919 **MRD-DRIVEN CHOICE OF CONSOLIDATION AND MODULATION OF INDUCTION AND CONSOLIDATION INTENSITY RESULTED IN A SIGNIFICANTLY IMPROVED OUTCOME OF YOUNGER AML PATIENTS IN THE LAST THREE YEARS**
M Clavio[1] ([1]Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)

E920 **EFFECTIVENESS OF TREATMENT ACUTE MYELOID LEUKEMIA IN THE ELDERLY USING CLADRIBINE WITH LOW-DOSE ARAC**
M Wątek[1] ([1]Department of Hematology, Holy Cross Oncology Center of Kielce, Kielce, Poland)

E921 **SMALL CUSTOMIZABLE NGS BASED TARGET CAPTURE PANELS DETECT VARIANTS IN CLINICAL SPECIMENS AT FREQUENCIES AS LOW AS 0.5%**
L Chamberlain[1] ([1]Invivoscribe, Inc., San Diego, United States)

E922 **EFFICACY BY OUTPATIENT VS INPATIENT ADMINISTRATION OF CONSOLIDATION: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA**
JE Kolitz[1] ([1]Monter Cancer Center, Northwell Health System, Lake Success, NY, United States)

E923 **MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ENROLLED IN THE CONNECT® MDS/AML DISEASE REGISTRY**
D Pollyea[1] ([1]University of Colorado Cancer Center, Aurora, United States)

E924 **PHASE 1, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFECT OF CYTOCHROME P450 (CYP) 3A4 INHIBITION ON THE PHARMACOKINETICS (PK) AND SAFETY OF QUIZARTINIB (Q) AND ITS ACTIVE METABOLITE, AC886**
J Li[1] ([1]Daiichi Sankyo, San Diego, CA, United States)

E925 **SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY**
A Forsythe[1] ([1]Purple Squirrel Economics, New York, United States)

E926 **CLINICAL OUTCOMES OF CHILDHOOD ACUTE MEGAKARYOBLASTIC LEUKEMIA: THE CHILDREN CANCER HOSPITAL EGYPT 57357 EXPERIENCE**
N Maarouf[1] ([1]Pediatric Oncology, 57357 CCHE, Cairo, Egypt)

E927 **IDENTIFICATION OF RESISTANCE ASSOCIATED CPG METHYLATION CHANGES IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING INDUCTION CHEMOTHERAPY**
C Niederwieser[1] ([1]Department of Internal Medicine IV, Hematology and Oncology, University Hospital Halle, Halle, Germany)

E928 **OVER-EXPRESSION OF ZEB2-AS1 LNCRNA PREDICTS POOR OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
X Shi[1], [2] ([1] The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology, Suzhou, China, [2]Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

E929 **INTENSIFICATION OF ANTHRACYCLINE DURING INDUCTION AND CONSOLIDATION IS SAFE AND WELL TOLERATED IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA**
S Fleming[1] ([1]Department of Haematology, Alfred Hospital, Melbourne, Australia)

E930 **PROGNOSTIC IMPACT OF IDH1 AND IDH2 MUTATIONS IN LOW AND INTERMEDIATE RISK AML: A MULTICENTER RETROSPECTIVE STUDY**
M Riva[1] ([1]Department of Medicine, University of Padua, Hematology and Clinical Immunology Unit, Padova, Italy)

E931 **DECITABINE COMBINED WITH HAAG REGIMEN IS AN EFFECTIVE SALVAGE TREATMENT FOR ADVANCED ACUTE MYELOID LEUKEMIA**
X Tang[1], [2] ([1] Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, [2]The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology, Suzhou, China)

E932 **LESS-INTENSIVE TREATMENT LEADS TO DECREASED SURVIVAL IN UNMARRIED ACUTE MYELOID LEUKEMIA PATIENTS AND PATIENTS LIVING ALONE. A DANISH NATIONAL POPULATION-BASED COHORT STUDY**
LSG Østgård [1], [2] ([1] Department of Hematology, Aarhus University Hospital, Aarhus, Denmark, [2]Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark)

E933 **TREATMENT OF MOLECULAR RELAPSE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 REDUCES TOXICITY OF SALVAGE TREATMENT AND IMPROVES DISEASE CLEARANCE**
F Guolo[1] ([1]Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)

E934 **MINIMAL RESIDUAL DISEASE AND LAIP CHANGES BY FLOW CYTOMETRY IN DE NOVO ACUTE MYELOID LEUKEMIA DURING CHEMOTHERAPY AND CLINICAL OUTCOMES**
T Lobanova[1] ([1]Hematological Oncology and BMT, National Research Center for Hematology, Moscow, Russian Federation)

E935 **LENALIDOMIDE MAINTENANCE IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA**
T Kadia[1] ([1]Leukemia, MD Anderson Cancer Center, Houston, United States)

E936 **POSTREMISSION THERAPY FOR AML WITH INTERMEDIATE RISK CYTOGENETICS IN FIRST COMPLETE REMISSION**
J Vydra[1] ([1]Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

E937 **LONG TERM FOLLOW UP OF PATIENTS OVER 60 YEARS TREATED WITH INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**
S Blum[1] ([1]Haematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland)

E938 **FLAG-IDA FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE 5-YEAR STUDY**
C Agbuduwe[1] ([1]Haematology, CAMBRIDGE UNIVERSITY HOSPITALS NHS TRUST, Cambridge, United Kingdom)

E939 **A MULTICENTER, RETROSPECTIVE ANALYSIS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO WERE TREATED WITH DECITABINE**
JH Yi[1] ([1]Hematology-Oncology, Chung-Ang university Hospital, Seoul, Korea, Republic Of)

E940 **DRUG-DRUG INTERACTION POTENTIAL OF GILTERITINIB IN HEALTHY SUBJECTS AND PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA**
M Levis[1] ([1]John Hopkins University, Baltimore, United States)

E941 **A FLUDARABINE-BASED ACUTE MYELOID LEUKEMIA INDUCTION IS WELL TOLERATED UP TO 75Y OF AGE ALLOWS EARLY CONSOLIDATION AND LONG TERM SURVIVAL. A SINGLE CENTRE EXPERIENCE OF 136 CONSECUTIVE PATIENTS**
M Bocchia[1] ([1]Hematology Unit, University of Siena, Siena, Italy)

E942 **OVEREXPRESSION OF SOX4 CORRELATEDS WITH POOR PROGNOSIS OF ACUTE MYELOID LEUKEMIA**
CY Hu[1] ([1]Clinical Laboratory Sciences And Medical Biotechnology, National Taiwan University, Taipei, Taiwan, Republic of China)

E943 **AN OPEN-LABEL, MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY OF RECOMBINANT HUMAN THROMBOPOIETIN AS AN ADJUNCT AFTER INTENSIVE CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA**
XH Sui[1] ([1]Hematology department of Shandong provincial hospital affiliated to Shandong University, Jinan, China)

E944 **TREATMENT-ASSOCIATED SURVIVAL RATES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A SYSTEMATIC LITERATURE REVIEW**
J Bell[1] ([1]Global Outcomes Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)

E945 **SYSTEMATIC REVIEW OF HEALTH STATE UTILITY VALUES FOR ECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA**
A Forsythe[1] ([1]Purple Squirrel Economics, New York, United States)

E946 **ITALIAN REAL LIFE EXPERIENCE OF DECITABINE IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF MULTICENTRIC OBSERVATIONAL DEA65 STUDY.**
L Aprile[1] ([1]Hematology Unit, University of Siena, Siena, Italy)

E947 **ASPARAGINASE ERWINIA CHRYSANTHEMI EFFECTIVELY DEPLETES PLASMA GLUTAMINE, HAS CLINICAL ACTIVITY, AND IS WELL TOLERATED IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA**
A Emadi[1], [2], [3] ([1] University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, United States, [2]Medicine, University of Maryland, Baltimore, United States, [3]Pharmacology, University of Maryland, Baltimore, United States)

E948 **PROGNOSTIC SIGNIFICANCE OF SOX2, SOX3, SOX11, SOX14 AND SOX18 GENE EXPRESSION IN DE NOVO ACUTE MYELOID LEUKEMIA (AML) PATIENTS**
N Tosic[1] ([1]Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia, Belgrade, Serbia)

E949 **ACUTE ANTHRACYCLINE INDUCED CARDIOTOXICITY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
O Pasvolsky[1] ([1]beilinson hospital, Petach Tikva, Israel)

E950 **AN INTEGER WEIGHTED GENOMIC MUTATION SCORING (IWGMS) USING THE TRUSIGHT MYELOID SEQUENCING PANEL SHOWS HIGHER MORTALITY IN PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA- A RETROSPECTIVE STUDY**
Q Qin[1] ([1]Internal Medicine, Houston Methodist Hospital, Weill Cornell Medical College, Houston, United States)

AGGRESSIVE NON-HODGKIN LYMPHOMA - CLINICAL

E951 **SUCCESSFUL IDENTIFICATION OF SPECIFIC AMINO ACID-DEPENDENCE IN ADULT T-CELL LEUKEMIA / LYMPHOMA (ATL) AND PRECLINICAL APPLICATION FOR NEW THERAPY**
T Ishigaki[1], [2] ([1] Division of Stem Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, [2]Department of Laboratory Medicine, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

E952 **VEGF AND VEGFR2 POLYMORPHISMS ARE INVOLVED IN AGGRESSIVENESS AND PROGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA**
A Borsarelli Carvalho Brito[1] ([1]Department of Internal Medicine, University of Campinas, Campinas, Brazil)

E953 **BONE MARROW BIOPSY SUPERIORITY OVER PET/CT IN PREDICTING PROGRESSION FREE SURVIVAL IN A HOMOGENOUSLY-TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA**
TH Chen Liang[1] ([1]Department of Hematology and Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain)

E954 **THE PROGNOSTIC SIGNIFICANCE OF CD11B+CX-3CR1+ MONOCYTES IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA**
JY Kwak[1] ([1]Internal Medicine, CHONBUK NATIONAL UNIVERSITY HOSTPITAL, Jeonju, Korea, Republic Of)

E955 **RARE NON-HODGKIN LYMPHOMAS (R-NHLS) IN CHILDREN: THE AIEOP EXPERIENCE**
G Biddeci[1] ([1]Clinic of Pediatric Hematology-Oncology, Department of Women's and Children's Health, Padova, Italy)

E956 **PRIMARY ANALYSIS OF THE EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF 110 CASES OF T CELL LYMPHOMA**
C Li[1], [2] ([1] Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, [2]The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology, Suzhou, China)

E957 **SHORT COURSE OF R-HYPERCVAD/MTX/ARA-C FOLLOWED BY ASCT AS FIRST-LINE THERAPY IN MANTLE CELL LYMPHOMA PATIENTS PROLONGS PROGRESSION FREE SURVIVAL TO MORE THAN 9 YEARS. SINGLE CENTER EXPERIENCE.**
M Andrade-Campos[1], [2] ([1] CIBER de Enfermedades Raras, CIBERER, IISCIII, Zaragoza, Spain, [2]Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Barcelona, Spain)

E958 **THE FREQUENCY OF INCIDENTAL MALIGNANCIES DETECTED BY PET/CT SCANS IN PATIENTS WITH LYMPHOMA AND THE ASSOCIATED CLINICAL IMPLICATIONS**
J Falconer[1] ([1]Haematology, Concord Repatriation General Hospital, Sydney, Australia)

E959 **CLINICAL IMPACT OF KARYOTYPIC EVOLUTION ON THE PROGNOSIS OF DIFFUSE LARGE B CELL LYMPHOMA**
Y Mizuno[1] ([1]Hematology, Kyoto Prefectural University of Medicine, Kyoto, Japan)

E960 **REGIMEN INTENSIFICATION MAY IMPROVE OUTCOMES IN PATIENTS WITH HIGHER RISK HUMAN IMMUNODEFICIENCY VIRUS (HIV) RELATED AGGRESSIVE B-CELL LYMPHOMAS**
E Wang[1] ([1]Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, United States)

E961 **EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1-MEDIATED OVEREXPRESSION OF MYC AND BCL2 CAN PREDICT POOR PROGNOSIS IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE**
L Wang[1] ([1]Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)

E962 **SOLUBLE INTERLEUKIN-2 RECEPTOR AS A PREDICTIVE MARKER FOR SPONTANEOUS REGRESSION OF OTHER IATROGENIC IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS; A RETROSPECTIVE STUDY**
Y Nakajima[1] ([1]Department of hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan)

E963 **PROGRAMMED DEATH-1 PROTEIN EXPRESSION AND ITS RELATION WITH HISTOLOGIC AND CLINICAL VARIABLES IN MYCOSIS FUNGOIDES.**
S Novelli[2] ([2] Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

E964 **CIRCULATING MICRORNAS AS BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY**
C Bouvy[1] ([1]Department of Pharmacy, University of Namur, Namur, Belgium)

E965 **COMBINED CHEMOTHERAPY PLUS RADIATION THERAPY IS MORE EFFECTIVE IN LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA OF THE TONSIL**
SN Lim[1] ([1]Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of)

E967 **SEQUENTIAL TREATMENT WITH BENDAMUSTINE, RITUXIMAB AND DEXAMETHASONE FOLLOWED BY RITUXIMAB CONSOLIDATION AND LENALIDOMIDE MAINTENANCE FOR FRAIL ELDERLY PATIENTS WITH AGGRESSIVE B-NON HODGKIN LYMPHOMA.**
C Selleri[1] ([1]Hematology, AUO San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy)

E968 **CLINICAL RELEVANCE OF SARCOPENIA IN DIFFUSE LARGE B-CELL LYMPHOMA - TWO ARE BETTER THAN ONE**
GW Lee[1] ([1]Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea, Republic Of)

E969 **INTENSIFIED TREATMENT REGIMENS IMPROVE EVENT-FREE AND OVERALL SURVIVAL IN YOUNGER NEWLY DIAGNOSED HIGH-RISK PATIENTS WITH B-LARGE CELL LYMPHOMA; A RETROSPECTIVE OBSERVATIONAL STUDY OF KROHEM**
S Basic-Kinda[1] ([1]Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia)

E970 **HIGH COMORBIDITY INDEX ALONG WITH HIGH NCCN-IPI STRONGLY INFLUENCE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS: SERBIAN LYMPHOMA GROUP EXPERIENCE**
J Jelicic[1] ([1]Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia)

E971 **SUBSTITUTING DOXORUBICIN WITH ETOPOSIDE IN R-CHOP RESULTS IN A REGIMEN WITH SIMILAR EFFICACY FOR TREATMENT OF NEWLY DIAGNOSED ELDERLY PATIENTS WITH B-LARGE CELL LYMPHOMA (B-LCL)**
I Hude[1] ([1]Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia)

E972 **POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: A SINGLE-CENTER CASE SERIES**
C De Miguel[1] ([1]Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain)

E973 **SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A UNITED STATES (US) ELECTRONIC MEDICAL RECORD (EMR)-BASED COHORT**
A Galaznik[1] ([1]Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)

BLEEDING DISORDERS (CONGENITAL AND ACQUIRED)

E974 **AN EXPERIENCE WITH LONG ACTING FACTOR VIII PROPHYLAXIS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH HAEMOPHILIA A**
A Tripathi[1] ([1]K G. Medical University Lucknow, Lucknow, India)

E975 **NOVEL MUTATIONS IN THAI CHILDREN WITH CONGENITAL FACTOR VII DEFICIENCY**
D Sosothikul[1] ([1]Department of Pediatrics, Chulalongkorn University, Bangkok, Thailand)

E976 **RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF A-HYPO-FIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS.**
C Santoro[1] ([1]Cellular Biotechnology and Hematology, HEMATOLOGY SAPIENZA UNIVERSITY, Rome, Italy)

E977 **RETROSPECTIVE REVIEW OF FOUR DAYS OF VON WILLEBRAND'S FACTOR AS SURGICAL PROPHYLAXIS IN VON WILLEBRAND'S DISEASE**
S Bal[1] ([1]Hematology and Oncology , University of Cincinnati Medical Center, Cincinnati , United States)

E978 **AUDIT ON MANAGEMENT OF HIGH INTERNATIONAL NORMALIZED RATIO (INR) IN WARFARINISED INPATIENTS**
V Gorur1 (1 Haematology, Broomfield Hospital, Chelmsford, United Kingdom)

E979 **NOVEL AND RECURRENT F7 MUTATIONS IN KOREAN PATIENTS WITH COAGULATION FACTOR VII DEFICIENCY**
H Kim[1] ([1]Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of)

BONE MARROW FAILURE SYNDROMES INCL. PNH - CLINICAL

E981 **UTILITY OF CD157 IN A FLAER BASED SINGLE TUBE FIVE COLOR COMBINATION FOR SCREENING OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE.**
K Rahman[1] ([1]Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India)

E982 **IMMUNOPHENOTYPIC DYSPLASTIC FEATURES IN PATIENTS WITH APLASTIC ANEMIA**
Y Davydova[1] ([1]Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E983 **SURGICAL MANAGEMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) – DATA FROM THE SPANISH PNH REGISTRY**
S De La Iglesia[1] ([1]Hematology, H. Universitario de Gran Canaria Doctor Negrín., Las Palmas de Gran Canaria, Spain)

E984 **EFFICACY OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT APLASTIC ANEMIA; PROSPECTIVE STUDY OF KOREAN PNH COHORT**
CW Choi[1] ([1]Internal Medicine, Korea University Guro Hospital, Seoul, Korea, Republic Of)

E985 **DIAGNOSIS AND FOLLOW-UP OF THE CLONES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA BY FLOW CYTOMETRY.**
S Oukid[1] ([1]Hematoloy, EHS ELCC CAC, Blida, Algeria)

E986 **ASSOCIATION OF T-, B-, NK AND NKT CELLS WITH THE DURATION, COMPLETENESS AND OTHER CHARACTERISTICS OF REMISSION IN PATIENTS WITH APLASTIC ANEMIA**
O Rozanova[1] ([1]laboratory of immunohematology, Russian research institute of hematology and transfusiology, Saint-Petesburg, Russian Federation)

E987 **A NOVEL DUAL-REAGENT SINGLE TUBE FLOW CYTOMETRIC ASSAY TO SCREEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.**
K Bommannan[1] ([1]Hematology, Post Graduate Institute of Medical Education and Research, CHANDIGARH, India)

E988 **TREATMENT OF REFRACTORY APLASTIC ANEMIA WITH ELTROMBOPAG: EXPERIENCE OF A CENTER**
M Gomes[1] ([1] Clinical Hematology , São João Hospital Centre, Porto, Portugal)

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY

E989 **DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH IBRUTINIB**
A Guarini[1], [2] ([1] Department of Molecular Medicine, Hematology, Sapienza University, Rome, Italy, [2]Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy)

E991 **CLL CELLS UNDERGO METABOLIC REPROGRAMMING AND UTILIZE FREE FATTY ACIDS AS THEIR PRIMARY ENERGY SOURCE.**
U Rozovski[1] ([1]Hematology, Davidof Cancer Center, Beilinson Campus, Petah Tikva, Israel)

E992 **INHIBITION OF ARGININE UPTAKE VIA HUMAN CATIONIC AMINO ACID TRANSPORTER-1 (CAT-1): A NOVEL APPROACH FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) THERAPY**
M Munder[2], [3], [4] ([2] Third Department of Medicine (Hematology, Oncology, and Pneumology), University Medicine Mainz, Mainz, Germany, [3]German Cancer Consortium (DKTK), partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany, [4]Research Center for Immunotherapy, University Medicine Mainz, Mainz, Germany)

E993 **FCMR IS A NEGATIVE REGULATOR OF B-CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS**
S Gobessi[1] ([1]Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Trieste, Italy)

E994 **TRANSCRIPTION FACTORS AND CHECKPOINT INHIBITORS EXPRESSION WITH AGE: MARKERS OF IMMUNOSENESCENCE?**
D Bron[1] ([1]Clinical and Experimental Hematology, INSTITUT JULES BORDET, ULB, Brussels, Belgium)

E995 **T-CELL EXHAUSTED PHENOTYPE IS ENHANCED DURING DISEASE PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
I Jiménez[1] ([1]Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain)

E996 **EARLY SPECIFIC INCREASED EXPRESSION OF SURFACE IGM BUT NOT OF OTHER ASSOCIATED MOLECULES APPEARS TO REFLECT ANTIGEN DISENGAGEMENT IN CLL PATIENTS ON IBRUTINIB THERAPY**
S Drennan[1] ([1]Haematology Oncology Group, Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom)

E997 **TRB REPERTOIRE PROFILING OF TCL-1 TRANSGENIC MICE USING NOVEL NGS TECHNOLOGIES REVEALS OLIGOCLONAL EXPANSIONS: SIMILARITIES WITH CHRONIC LYMPHOCYTIC LEUKEMIA**
L Scarfò[1] ([1]Strategic Research Program on CLL and B-cell neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy)

E998 **ROLE OF THE COMBINATION MEK1/2 INHIBITOR BINIMETINIB AND AKT INHIBITOR MK2206 IN CLL**
S Sandhu[1], [2] ([1] Northern Blood Research Centre, Kolling Institute of Medical Research, St Leonards, Australia, [2]Acute Medical Unit, Royal Melbourne Hospital, Parkville, Australia)

E999 **TARGETING HIF-1Ð AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA**
C Vitale[1], [2] ([1] Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, [2]Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy)

E1000 **THE ROLE OF GENETIC-BASED PROGNOSTIC FACTORS IN PREDICTING MINIMAL RESIDUAL DISEASE NEGATIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND OFATUMUMAB**
S Raponi[1] ([1]Cellular Biotechnologies and Hematology, Sapienza University, Rome, Rome, Italy)

E1001 **ISOCHROMOSOME 17Q, UNBALANCED TRANSLOCATIONS AND 8Q GAIN REPRESENT ADVERSE PROGNOSTIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION. A GFCH STUDY**
E Chapiro[1], [2] ([1] UNIVERSITE PIERRE ET MARIE CURIE, Paris, France, [2]Service d'Hematologie Biologique, Hopital Pitie-Salpetriere, AP-HP, Paris, France)

E1002 **THE MICROENVIRONMENT REGULATES THE EXPRESSION OF MIR-21 AND TUMOR SUPPRESSOR GENES PTEN, PIAS3 AND PDCD4 THROUGH ZAP-70 IN CHRONIC LYMPHOCYTIC LEUKEMIA**
J Carabia[1] ([1]Experimental Hematology, Vall d'Hebron Institute of Oncology, BARCELONA, Spain)

E1003 **IMPACT OF RECURRENT MUTATIONS ON PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED REGIMENS**
M Hlozkova[1] ([1]University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic)

E1004 **BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO**
G Pavlasova[1], [2] ([1] Molecular Medicine, CEITEC MU, Brno, Czech Republic, [2]Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic)

E1005 **REGULATION OF BCR SIGNALLING IN CHRONIC LYMPHOCITYC LEUKEMIA: ROLE OF E3 UBIQUITIN LIGASE C-CBL**
L Trentin[1] ([1]Department of Medicine, University of Padua, Padua, Italy)

E1006 **ACTIVATION OF SHP-1/PP2A PATHWAYS TRIGGERS APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS**
L Trentin[1], [2] ([1]Department of Medicine, University of Padua, Padova, Italy, [2]Venetian Institute of Molecular Medicine (VIMM), Padova, Italy)

E1007 **TARGETING NANOPARTICLES TO CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPLOITING THE PROPERTIES OF CXCR4**
C Mccallion[1] ([1]School of Chemistry, University of Manchester, Manchester, United Kingdom)

E1008 **THE ROLE OF THROMBOPOIETIN AS A TOOL OF IMMUNE MODULATION IN CHRONIC LYMPHOCYTIC LEUKEMIA**
S Ringelstein-Harlev[1] ([1]Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel)

E1009 **TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS**
J Kotaskova[1], [2] ([1] CMBGT, Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, [2]Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic)

E1010 **NORMAL SERUM PROTEIN ELECTROPHORESIS IDENTIFIES AN EXCELLENT PROGNOSIS GROUP AMONG IGHV MUTATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, WITH A MEDIAN TFS OVER 18 YEARS**
J Chauzeix[1], [2] ([1] Service d'hématologie biologique, CHU Limoges, Limoges, France, [2]UMR7276, Université de Limoges, Limoges, France)

E1011 **HSP70 EXPRESSION IS MODULATED BY ITS MASTER REGULATOR HSF1 VIA MAPKS AND PI3K/AKT/MTOR PATHWAYS IN CHRONIC LYMPHOCYTIC LEUKEMIA**
L Trentin[1], [2] ([1]Department of Medicine, University of Padua, Padova, Italy, [2]Venetian Institute of Molecular Medicine (VIMM), Padova, Italy)

E1012 **THE INTERPLAY BETWEEN TH17 AND TREGS: A NEW IMMUNOSUPPRESSIVE INSIGHT IN CHRONIC LYMPHOCYTIC LEUKEMIA**
S De Matteis[1] ([1]Bioscience Laboratory, IRCCS Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST), Meldola, Italy)

E1013 **LOW EXPRESSION OF CD25 IN CHRONIC LYMPHOCYTIC LEUKEMIA NOTCH1-MUTATED CASES INDEPENDENT OF CDK4/6 MISREGULATION**
TH Chen Liang[1] ([1]Hematology and Oncology Department, Hospital Morales Meseguer,Centro Regional de Hemodonación. Universidad de Murcia, IMIB, Murcia, Spain)

E1014 **GENE MUTATIONS ANALYZED BY NEXT-GENERATION SEQUENCING ALLOW US TO DEFINE THE PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH EARLY-STAGE DISEASE AND 13Q DELETION**
M Hernández-Sánchez[1] ([1]Cancer Research Center/Hospital Universitario de Salamanca, SALAMANCA, Spain)

E1015 **ALTERED COMPLEX C5 IS ASSOCIATED WITH COMPROMISED COMPLEMENT ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA**
A Braester[1], [2] ([1]Faculty of Medicine, Bar-Ilan University, Safed, Israel, [2]Haematology, Galilee Medical Center, Nahariya, Israel)

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL

E1016 **ASSOCIATIONOF CPG-STIMULATED KARYOTYPE WITHTIME-TO-FIRST TREATMENT FOR CLL**
FP Tambaro[1] ([1]Bone Marrow Transplantation, OSPEDALE PAUSILIPON, NAPOLI, Italy)

E1017 **COMPARISON OF THE CHRONIC LYMPHOCYTIC LEUKEMIA INTERNATIONAL PROGNOSTIC INDEX (CLL-IPI) WITH THE BARCELONA-BRNO PROGNOSTIC MODEL: ANALYSIS OF 1299 NEWLY DIAGNOSED CASES**
M Gentile[1] ([1]HEMATOLOGY, HOSPITAL ANNUNZIATA, COSENZA, Italy)

E1018 **PRELIMINARY RESULTS OF S55746/BCL201 (A NEW BCL2 INHIBITOR) IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AND EFFECT OF CALIBRATED MODERATE MEAL ON THE PHARMACOKINETICS**
V Ribrag[1] ([1]Institut Gustave Roussy, Villejuif, France)

E1019 **INCREASED VIRUS-SPECIFIC IMMUNE RESPONSES PARALLELED BY A PNEUMOCOCCUS-SPECIFIC-IMMUNODEFICIENCY STATE AND HYPOGAMMAGLOBULINEMIA: ALREADY EMERGE IN HIGH-COUNT MONOCLONAL B LYMPHOCYTOSIS PRIOR TO CLL.**
I Criado[1] ([1]Department of Medicine, Cancer Research Center (IBMCC, CSIC-USAL), Salamanca, Spain)

E1020 **AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS**
GM Rigolin[1] ([1]Scienze Mediche, Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy)

E1021 **SHOULD CLL-IPI BE USED TO ASSESS OVERALL SURVIVAL OF EVERY CLL PATIENT? A SYSTEMATIC REVIEW AND META-ANALYSIS.**
S Molica[1] ([1]Hematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy)

E1022 **IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA: IMPACT OF THE CANADIAN YOU&I™ PATIENT SUPPORT PROGRAM ON TREATMENT ADHERENCE**
A Peters[1] ([1]University of Alberta, Endmonton, Canada)

E1023 **TREATMENT AND 17P DELETION TESTING PATTERNS IN COMMUNITY PRACTICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES**
T Kapustyan[1] ([1]AbbVie Inc., North Chicago, United States)

E1024 **SINGLE-AGENT IBRUTINIB VS REAL WORLD TREATMENT FOR PATIENTS WITH TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE-2™ WITH THE CLLEAR AND LYON-SUD DATABASES**
M Doubek[1] ([1]Department of Internal Medicine – Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic)

E1025 **CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ↗ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP**
O Al-Sawaf[1] ([1]Department I of Internal Medicine, German CLL Study Group, University Hospital of Cologne, Köln, Germany)

E1026 **THE ROLE OF CD200 IN THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA**
A Mora[1], [2] ([1]Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain, [2]Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

E1027 **COMPARISON OF CHROMOSOME BANDING ANALYSIS AND GENOMIC MICROARRAY TECHNIQUES FOR THE DETECTION OF COMPLEX KARYOTYPES IN CHRONIC LYMPHOCYTIC LEUKEMIA**
A Puiggros[1], [2] ([1]Laboratori de Citogenètica Molecular, Hospital del Mar, Barcelona, Spain, [2]Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain)

E1028 **ABNORMAL SERUM FREE LIGHT CHAINS RATIO ASSESSMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SIMPLE YET POWERFUL TEST CORRELATING WITH CLINICAL OUTCOME AND MINIMAL RESIDUAL DISEASE**
F Durrieu[1] ([1]Laboratory of hematology, Institut Bergonie, BORDEAUX, France)

E1029 **PLATELET FUNCTION ASSAYS FOR STRATIFICATION OF BLEEDING RISKS IN CLL PATIENTS ON IBRUTINIB TREATMENT**
E Nikitin[1] ([1]Outpatient department for hematology oncology and chemotherapy, S.P.Botkin hospital, Moscow, Russian Federation)

E1030 **HYPOGAMMAGLOBULINEMIA IS A STRONG PREDICTOR OF TIME TO FIRST TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA**
R Cassin[1] ([1]Oncohematology Department, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Italy, Milan, Italy)

E1031 **CLL: IS LYMPHOCYTE DOUBLING TIME (LDT) A RELEVANT PROGNOSTIC PARAMETER IN THE ERA OF PROGNOSTIC BIOMARKERS?**
T Baumann[1] ([1]Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain)

E1032 **INDICATIONS FOR TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICO-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT**
P Mozas[1] ([1]Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain)

E1033 **UNCOVERING PRIMARY TP53-DELETED CLONES WITH FISH THROUGH FACS-SUPPORTED PURIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA LYMPHOCYTES**
M Pereira[2], [3] ([2]Faculty of Medicine, University of Coimbra, Coimbra, Portugal, [3]Clinical Hematology Department, Coimbra University Hospital Centre, Coimbra, Portugal)

E1034 **PRIMARY PEGFILGRASTIM PROPHYLAXIS VERSUS FILGRASTIM GIVEN "ON DEMAND" FOR CLADRIBINE - INDUCED NEUTROPENIA IN HAIRY CELL LEUKEMIA**
T Tadmor[14] ([14]Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel)

E1035 **REDUCED HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ACHIEVING COMPLETE REMISSION TO FIRST-LINE THERAPY**
S Heitner Enschede[1] ([1]AbbVie, Inc., North Chicago, United States)

E1036 **RITUXIMAB (R) USED AS A SINGLE AGENT FOR AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS INDUCES ALSO SIGNIFICANT DISEASE RESPONSE WITHOUT TOXICITY**
S Sachanas[1] ([1]Hematologic, Athens Medical Center, Psychiko Branch, Athens, Greece)

E1037 **ATTAINMENT OF COMPLETE REMISSION IS SIGNIFICANTLY ASSOCIATED WITH LONGER SURVIVAL OUTCOMES IN RELAPSED/REFRACTORY (R/R) CLL: A META-ANALYSIS**
VU Ektare[1] ([1]Pharmerit International, Bethesda, United States)

E1038 **APLICATION OF THE CLL-IPI AND THE MDACC PRGNOSTIC INDEXES IN A LOCAL COHORT OF CLL PATIENTS**
I González-Gascón Y Marín1 (1 Hospital Universitario Infanta Leonor, MADRID, Spain)

E1039 **CHRONIC LYMPHOCYTIC LEUKEMIA: PROGNOSTIC VALUE OF CLINICAL STAGES AND CLASSICAL PROGNOSTIC PARAMETERS DEPENDING ON TREATMENT MODALITY**
T Baumann[1] ([1]Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain)

E1040 **AN OBSERVATIONAL STUDY EVALUATING THE USE OF BENDAMUSTINE AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN RUSSIA**
E Stadnik[1] ([1]Almazov Federal North-West Medical Research Centre, Saint Petersburg, Russian Federation)

CHRONIC MYELOID LEUKEMIA - BIOLOGY

E1041 **MUTAGENESIS OF BCR-ABL1 IS REQUIRED FOR RESISTANCE DEVELOPMENT IN DE NOVO CHRONIC MYELOID LEUKEMIA KCL-22 CELLS BUT NOT IN RELAPSED KCL-22 CELLS EXPRESSING BCR-ABL1 INDEPENDENT RESISTANCE.**
K Machova Polakova[1], [5] ([1] Institute of Hematology and Blood Transfusion, Prague, Czech Republic, [5]Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University and Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

E1042 **FLOW-CYTOMETRY DETECTION OF CD26+ LEUKEMIA STEM CELLS IN PERIPHERAL BLOOD: A SIMPLE AND RAPID NEW DIAGNOSTIC TOOL FOR CHRONIC MYELOID LEUKEMIA**
L Aprile1 (1 Hematology Unit, University of Siena, Siena, Italy)

E1043 **LIPID PEROXIDATION AND INFLAMMATORY STATUS DURING TKI TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF A PROSPECTIVE MULTICENTER STUDY**
A Sicuranza[1] ([1]Hematology Unit, University of Siena, Siena, Italy)

E1044 **TRANSCRIBED ULTRACONSERVED NONCODING RNAS (T-UCRS) IN CHRONIC MYELOID LEUKEMIA: EXPRESSION PROFILES ASSOCIATED WITH MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS**
P Rodrigues Santos[1], [2], [3] ([1] Centro de Investigação em Meio Ambiente, Genética e Oncobiologia (CIMAGO), Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal, [2]Laboratório de Imunologia e Oncologia, Centro de Neurociências e Biologia Celular, Coimbra, Portugal, [3]Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal)

E1045 **MAINTENANCE OF LEUKAEMOGENIC POTENTIAL OF BCR/ABL+ CELLS REQUIRES PAK2 BUT NOT PAK1**
A Hoelbl-Kovacic[1] ([1]Institute of Pharmacology and Toxicology, Veterinary University of Vienna, Vienna, Austria)

E1046 **MIRNA PROFILING OF CIRCULATING EXTRACELLULAR VESICLES IN CML PATIENTS WITH MUSCULOSKELETAL PAIN ASSOCIATED WITH DISCONTINUATION OF TYROSINE KINASE INHIBITORS**
K Ohyashiki[1] ([1]Department of Hematology, Tokyo Medical University, Tokyo, Japan)

E1047 **SOLUBLE AND MEMBRANE-BOUND RECEPTOR–LIGAND IMMUNE CHECKPOINTS AND CHRONIC MYELOID LEUKEMIA: CORRELATIONS WITH MOLECULAR RESPONSE AND TYROSINE KINASE INHIBITOR THERAPY**
P Rodrigues-Santos[1], [2], [3] ([1] Centro de Investigação em Meio Ambiente, Genética e Oncobiologia (CIMAGO), Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal, [2]Laboratório de Imunologia e Oncologia, Centro de Neurociências e Biologia Celular, Coimbra, Portugal, [3]Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal)

E1048 **TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA.**
S Grassi[1] ([1]Medical Biotechnologies, University of Siena, Siena, Italy)

E1049 **IDENTIFICATION OF PROGNOSTIC AND SUSCEPTIBILITY MARKERS IN CHRONIC MYELOID LEUKEMIA USING NEXT GENERATION SEQUENCING**
Y Shokeen[1] ([1]Department of Medical Oncology, Sir Ganga Ram Hospital, Delhi, India)

E1050 **FEATURES OF THE A2455G POLYMORPHISM OF GENE CYP 1A1 IN PATIENTS WITH CML**
K Karimov[1], [1] ([1] institute of hemotology and blood transfuzion, tashkent, Uzbekistan, [1]institute of hemotology and blood transfuzion, tashkent, Uzbekistan)

CHRONIC MYELOID LEUKEMIA - CLINICAL

E1051 **HEMATOLOGIC TOXCITIY GRADE III-IV IS ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS**
LF Casado Montero, MD[1] ([1]Hematology, Hospital Virgen de la Salud, Toledo, Spain)

E1052 **5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION**
A Hochhaus[1] ([1]Universitätsklinikum Jena, Jena, Germany)

E1053 **EFFECT OF PLASMA TROUGH CONCENTRATION OF NILOTINIB AND POLYMORPHISMS OF DRUG TRANSPORTER GENES ON THE FREQUENCY OF ADVERSE EVENTS IN CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA: STAT1 AND STAT2 TRIALS**
N Takahashi[1] ([1]Hematology, AKITA UNIV., Akita, Japan)

E1054 **VERY EARLY MOLECULAR RESPONSE (VEMR) WITH FRONTLINE DASATINIB TREATMENT IS A STRONG PREDICTOR OF LONG-TERM BCR-ABL1 TRANSCRIPT LEVELS IN CHRONIC MYELOID LEUKEMIA PATIENTS: PCR-DEPTH STUDY**
WS Lee[1] ([1]Int. Medicine, Hemato-Oncology, INJE UNIVERSITY BUSAN PAIK HOSPITAL, Busan, Korea, Republic Of)

E1055 **SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD- OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB**
L McGarry[2] ([2]ARIAD Pharmaceuticals, Inc., Cambridge, MA, United States)

E1056 **DETECTION AND MONITORING OF BCR-ABL1 KINASE DOMAIN MUTATIONS IN CML AND ALL PATIENTS BY NEXT GENERATION SEQUENCING AND DROPLET DIGITAL PCR, A BELGIAN PROSPECTIVE STUDY.**
C De Rop[1] ([1]Molecular Biology, IPG, Gosselies, Belgium)

E1057 **CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION WITH PEGYLATED INTERFERON-Ð2B IN PATIENTS WITH SUBOPTIMAL MOLECULAR RESPONSE ON IMATINIB (NORDDUTCH-CML009)**
I Geelen[1] ([1]Albert Schweitzer Hospital, Dordrecht, the Netherlands)

E1058 **ANALYSIS OF VASCULAR ADVERSE EVENTS IN TKI TREATED JAPANESE CML PATIENTS: RETROSPECTIVE LARGE COHORT STUDY OF CML COOPERATIVE STUDY GROUP**
I Fujioka[1] ([1]Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan)

E1059 **UPDATE OF CMREGISTRY: AN OBSERVATIONAL, MULTI CENTER, PROSPECTIVE FOLLOW-UP REGISTRY OF PATIENTS WITH CHRONIC PHASE CML WITH A HIGH PROBABILITY OF OBTAINING A DEEP MOLECULAR RESPONSE →CMR4 (IS).**
JM Alonso-Dominguez[1] ([1]Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain)

E1060 **ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION**
G Saglio[1] ([1]University of Turin, Turin, Italy)

E1061 **ADHERENCE TO SECOND LINE THERAPY WITH NILOTINIB AND QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY**
T Sacha[1] ([1]Department of Hematology, Jagiellonian University, Kraków, Poland)

E1062 **RADOTINIB TREATMENT IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TKIS: 36 MONTHS UPDATE OF RADOTINIB PHASE 2 STUDY**
SH Kim[1] ([1]Internal Medicine, Dong-A University College of Medicine, Busan, Korea, Republic Of)

E1063 **100 YEARS OF CHRONIC MYELOID LEUKEMIA PREVALENCE IN FRANCE**
M Delord[1] ([1]Biostatistics, Université Paris 7 - INSERM - UMR-S 717, PARIS, France)

E1064 **THE ROLE OF MICRORNAS IN CHRONIC MYELOID LEUKEMIA THERAPEUTIC SELECTION**
AB Sarmento-Ribeiro[1, 2, 5] ([1]CIMAGO, Faculty of Medicine University of Coimbra, Coimbra, Portugal, [2]Applied Molecular Biology and University Clinic of Hematology, Faculty of Medicine University of Coimbra, Coimbra, Portugal, [5]Clinical Hematology Department, Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, Portugal)

E1065 **IMPACT OF ABCB1 AND ABCG2 POLYMORPHISMS ON RESPONSE TO IMATINIB AND 2G-TKIS THERAPY IN PATIENTS WITH CHRONIC PHASE CML**
M Tiribelli[1] ([1]Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy)

E1066 **THE INTRODUCTION OF SECOND-GENERATION TYROSINE KINASE INHIBITORS MAY REDUCE THE PROGNOSTIC IMPACT OF HIGH-RISK PATIENTS ACCORDING TO EUROPEAN TREATMENT AND OUTCOME STUDY (EUTOS) SCORE**
E Sato[1] ([1]Department of Hematology, Juntendo University School of Medicine Nerima Hospital, Tokyo, Japan)

E1067 **CHRONIC MYELOID LEUKEMIA DIAGNOSED DURING PREGNANCYI: THERAPY TACTICS AND OUTCOMES**
E Chelysheva[1] ([1]National Research Center for Hematology, Moscow, Russian Federation)

E1068 **IMPACT OF KIR3DL1*00501 IN TYROSINE KINASE INHIBITOR-TREATED CML**
H Ureshino[1] ([1]Div. Hematology, respiratory medicine and oncology, Japan, Saga University, Saga city, Japan)

E1069 **COMPARISON OF MOLECULAR KINETICS AFTER THE FIRST AND SECOND IMATINIB DISCONTINUATION: RESULTS FROM THE KID STUDY**
SE Lee[1] ([1]Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of)

E1070 **CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB**
YR Do[1] ([1]Keimyung University, Dongsan Medical Center, Daegu, Korea, Republic Of)

E1071 **HYDROXYUREA SUPPRESSES BCR-ABL1 T315I+ CML CLONES IN VIVO AND IN VITRO AND SYNERGIZES WITH PONATINIB IN ELIMINATING TKI-RESISTANT CML CELLS**
M Schneeweiss[1], [2] ([1] Department of Internal Medicine I/Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria, [2]Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria)

E1072 **ASSOCIATION OF BCL2L11 (BIM) DELETION POLYMORPHISM WITH MOLECULAR RELAPSE AFTER TYROSINE KINASE INHIBITOR CESSATION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE**
S Katagiri[1] ([1]Department of Hematology, Tokyo Medical University, Tokyo, Japan)

E1073 **XPERT® BCR-ABL ULTRA, A HIGH SENSITIVITY ASSAY WITH A LIMIT OF DETECTION REACHING MR4.5 AND BELOW ON AN INTERNATIONAL REPORTING SCALE**
GJ Day[2] ([2] Oncology, R&D, Cepheid, Sunnyvale, United States)

ENZYMOPATHIES, MEMBRANOPATHIES AND OTHER ANEMIAS

E1074 **IDENTIFICATION OF INCIDENTS CASES OF GAUCHER DISEASE IN SPLENOMEGALY AND/OR THROMBOCYTOPENIA PATIENTS IN SPECIALIZED MEDICAL SERVICES IN COLOMBIA THROUGH THE USE OF A SELECTION ALGORITHM**
JG Duque[3] ([3] Antioquia, Clínica Sagrado Corazón, Medellín, Colombia)

E1075 **IMPACT OF PEROXIREDOXIN 2, GLUTATHIONE PEROXIDASE AND CATALASE INHIBITION ON OXIDATIVE STRESS MODIFICATIONS OF RED BLOOD CELL MEMBRANE AND CYTOSOL**
S Rocha[2] ([2] UCIBIO, REQUIMTE, Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, Porto, Portugal)

E1076 **MOLECULAR BASIS OF PKLR MUTATIONS IN PATIENTS WITH PYRUVATE KINASE (PK) DEFICIENCY: THE FIRST REPORT FROM SOUTHEAST ASIAN POPULATION**
S Riolueang[1] ([1]Siriraj-Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand)

E1077 **PRELIMINARY RESULTS OF GAU-PED STUDY: PREVALENCE OF GAUCHER DISEASE IN PAEDIATRIC PATIENTS SELECTED BY AN APPROPRIATE DIAGNOSTIC ALGORITHM**
W Morello[1] ([1]Pediatric Hematology and Oncology Unit, Sant'Orsola-Malpighi University Hospital, Bologna, Italy)

E1078 **CIRCULATING MICROPARTICLES IN CONGENITAL AND ACQUIRED HAEMOLYTIC ANAEMIA**
W Barcellini[1] ([1]UOC Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy)

E1079 **THE PREVALENCE, ETIOLOGY AND PROGNOSTIC IMPACT OF ANEMIA IN OLDER POPULATION**
L Gil[2] ([2] Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland)

E1080 **PIEZO1 MECHANOTRANSDUCTIVE PROTEIN MUTATIONS IN RBCS: WHEN THE PHENOTYPE IS BEYOND HAEMOLYTIC ANAEMIA**
D Mota[1] ([1]Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)

E1081 **MODELLING PYRUVATE KINASE DEFICIENCY IN HUMAN PROGENITORS USING CRISPR/CAS9**
S López-Manzaneda[1], [2] ([1] Cell Differentiation and Cytometry Unit. Hematopoietic Innovative Therapies Division, CIEMAT/CIBERER, Madrid, Spain, [2]Unidad Mixta de Terapias Avanzadas, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain)

E1082 **PHYSIOPATHOLOGY OF HEREDITARY XEROCYTOSIS : PIEZO1 GAIN OF FUNCTION MUTATIONS IMPACT HEMOGLOBIN OXYGEN AFFINITY**
V Picard[5] ([5]Service d'hématologie biologique, APHP, Hôpital Bicêtre, Le Kremlin Bicêtre, France)

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION

E1083 **SAFETY AND EFFICACY OF MULTI-PATHOGEN-SPECIFIC T CELLS IN A HUMANIZED MODEL OF INVASIVE ASPERGILLOSIS : A PROOF OF CONCEPT STUDY**
A Papadopoulou[1] ([1]Gene and Cell Therapy Center- Hematology Dpt- BMT Unit, George Papanicolaou Hospital, Thessaloniki, Greece)

E1084 **DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES LEADS TO DIVERSITY OF LEUKEMIA-ASSOCIATED-ANTIGENS-SPECIFIC T CELL RESPONSES AND TO REDUCTION IN REGULATORY T CELL FREQUENCY**
J Greiner[2], [4] ([2]Clinic for Internal Medicine III, University of Ulm, Ulm, Germany, [4]Department of Internal Medicine, Diakonie Klinikum, Stuttgart, Germany)

E1085 **GENE-MODIFIED NK-92MI CELLS EXPRESSING A CHIMERIC CD16/CD64-BB-Ð RECEPTOR EXHIBIT ENHANCED CANCER-KILLING ABILITY IN COMBINATION WITH THERAPEUTIC ANTIBODY**
Y Chen[1] ([1]The Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu, China)

E1086 **A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES.**
J Ballesteros[1] ([1]ViviaBiotech, Madrid, Spain)

E1087 **HUMANIZED CD7 NANOBODY-BASED IMMUNOTOXINS EXHIBIT PROMISING ANTI-T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA POTENTIAL**
Y Yu[1] ([1]The Cyrus Tang Hematology Center, Soochow University, Suzhou, China)

E1088 **STATINS MAY IMPROVE CAR-NK IMMUNOTHERAPY IN MM BY PREVENTING LOSS OF BCMA EXPRESSION ON MM CELLS**
G Suñe[1] ([1]Hematology, Hospital Clinic/IDIBAPS/Josep Carreras Leukemia Research Institute, Barcelona, Spain)

E1089 **DENDRITIC CELL VACCINATION COMBINED WITH LENALIDOMIDE AND PROGRAMMED DEATH-1 (PD-1) BLOCKADE HAS SYNERGISTICALLY INDUCED A MARKED TUMOR REGRESSION IN A MURINE MYELOMA MODEL**
SH Jung[1] ([1]Department of Hematology-Oncology, CHONNAM NATIONAL UNIVERSITY HWASUN HOSPITAL, Hwasun-Eup, Korea, Republic Of)

E1090 **B- AND T-CELL IMMUNE REPERTOIRE PROFILING WITH ANCHORED MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING**
D Fugere[1] ([1]ArcherDX, Boulder, CO, United States)

E1091 **SYNERGISTIC ANTITUMOR IMMUNITY BY DENDRITIC CELLS IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN A MURINE MYELOMA MODEL**
SH Jung[1] ([1]Department of Hematology-Oncology, CHONNAM NATIONAL UNIVERSITY HWASUN HOSPITAL, Hwasun-Eup, Korea, Republic Of)

E1092 **ALTERATIONS IN T-CELL SUBPOPULATIONS AFTER CO-CULTURING WITH MSCS DERIVED FROM DIFFERENT DONORS**
N Kapranov[1] ([1]Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E1093 **GRANULOCYTE COLONY STIMULATING FACTOR AND ERYTHROPOIETIN ENTERALLY GIVEN FOR NEONATES RECOVERING FROM GIT SURGERIES: RANDOMIZED CONTROLLED TRIAL**
R El-Farrash[1] ([1]Pediatrics Department, Faculty of Medicine-Ain Shams University, Cairo, Egypt)

E1094 **GENE EDITING OF HUMAN HEMATOPOIETIC PROGENITORS TO CORRECT PYRUVATE KINASE DEFICIENCY**
S Fañanas-Baquero[1], [2] ([1]Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER), Madrid, Spain, [2]Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain)

E1095 **BLAST KINETICS AFTER NON-ENGRAFTING HAPLOIDENTICAL MICROTRANSPLANTATION IN PATIENTS WITH REFRACTORY ACUTE MYELOID LEUKEMIA**
Z Emarah[1], [2] ([1]Medical Oncology Unit, Oncology Center, Mansoura University, Mansoura, Egypt, [2]Medical Oncology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt)

E1096 **ALTERATIONS IN T-CELLS SUBPOPULATIONS AFTER CO-CULTIVATION WITH MULTIPOTENT MESENCHYMAL STROMAL CELLS**
Y Davydova[1] ([1]Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E1097 **OPTIMIZATION OF TRANSDUCTION CONDITIONS WITH GMP LIKE LENTIVIRAL VECTORS FOR THE GENE THERAPY OF PYRUVATE KINASE DEFICIENCY**
S Navarro[1], [2] ([1]Unidad Mixta de Terapias Avanzadas, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain, [2]Hematopoietic Innovative Therapies, CIEMAT/CIBERER, Madrid, Spain)

E1098 **INTERACTION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS WITH LYMPHOCYTES REDUCES THEIR IMMUNO PRIVILEGED PROPERTY**
N Petinati[1] ([1]Physiology of hematopoiesis lab., NATIONAL RESEARCH CENTER FOR HEMATOLOGY, Moscow, Russian Federation)

HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT

E1099 **SPECIFICATION OF MURINE HEMOGENIC ENDOTHELIAL HEMATOPOIETIC PRECURSORS CEASES ABRUPTLY BY E10.25 AND CONSTITUTES A FUNCTIONALLY HETEROGENEOUS POPULATION.**
M Ganuza Fernandez[1] ([1]Experimental Hematology, St. Jude Children's Research Hospital, Memphis, United States)

E1100 **C-TYPE LECTIN-LIKE RECEPTOR 2 SPECIFIES A FUNCTIONALLY DISTINCT SUBPOPULATION OF MEGAKARYOCYTE-BIASED LONG-TERM HEMATOPOIETIC STEM CELLS.**
T Kumode[1] ([1]Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan)

E1101 **PRE-TRANSPLANT DEFECTS OF BONE MARROW ENDOTHELIAL CELLS MAY CAUSE THE OCCURRENCE OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
MM Shi[1], [2] ([1]Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China, 2 Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China)

E1102 **EFFICIENT LYMPHOID DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS REQUIRES CXCR4 DESENSITIZATION**
K Balabanian[1] ([1]INSERM U996, Clamart, France)

E1103 **A SUBSET OF ADULT HSC DERIVES FROM GATA4-EXPRESSING PROGENITORS LOCATED IN THE PLACENTA AND LATERAL MESODERM OF MICE**
A Cañete Sánchez[1] ([1]ANIMAL BIOLOGY, SCIENCE FACULTY, UNIVERSITY OF MÁLAGA, MÁLAGA, Spain)

E1104 **EXPLORING THE MECHANISM OF FOG1-DEPENDENT TRANSCRIPTIONAL REGULATION IN ERYTHROID CELLS**
T Fujiwara[1] ([1]Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan)

E1105 **THE STEM CELL ZINC FINGER 1 (SZF1) / ZNF589 PROTEIN INHIBITS TUMOR DEVELOPMENT IN A K562 XENOGRAFT MOUSE MODEL, BLOCKING CELL CYCLING AND INDUCING PREMATURE CELLULAR SENESCENCE**
L Venturini[1] ([1]Hematology, Hemostasis, Oncology, Stem Cell Transplantantion, Hannover Medical School, Hannover, Germany)

E1106 **THE FUNCTIONAL RELEVANCE OF DNMT3A SPLICE VARIANTS IN HEMATOPOIETIC DIFFERENTIATION**
W Wagner[1] ([1]Stem Cell Biology and Cellular Engineering, Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany)

E1107 **ERYTHROPOIETIN STIMULATES TRANSDIFFERENTIATION OF BONE MARROW PRO-B CELLS INTO BONE-RESORBING OSTEOCLASTS**
D Neumann[1] ([1]Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel)

E1109 **THE SPINDLE ASSEMBLY CHECKPOINT CONTRIBUTES TO PROPER HEMATOPOIETIC FUNCTION OF HSPCS**
A Brown[1] ([1]Ulm University, Institute for Molecular Medicine, Ulm, Germany)

E1110 **BONE MARROW MYELOPOIESIS INDEPENDENTLY OF CANONICAL NOTCH SIGNALING**
S Duarte[1], [2] ([1]Clinical Hematology Department, Coimbra Hospital and Universitary Centre, Coimbra, Portugal, [2]Haematopoietic Stem Cell Biology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom)

E1111 **IDENTIFICATION OF NOVEL HUMAN HEMATOPOIETIC STEM CELL SUBPOPULATIONS VIA COMPREHENSIVE SURFACE MARKER ANALYSIS**
T Jiromaru[1] ([1]Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan)

E1112 **DEVELOPMENT OF A 3-DIMENSIONAL CULTURE TO MIMICK THE BONE MARROW MICROENVIRONMENT AND RECAPITULATE DRUG RESISTANCE FOR IN VITRO STUDY**
M Karimpoor[1] ([1]Biomechanical engineering/Pharmacy, University College London, London, United Kingdom)

E1113 **WHOLE EXOME SEQUENCING REVEALED SEQUENTIAL GAIN OF MUTATIONS IN TWO CASES OF DONOR CELL HAEMATOLOGICAL MALIGNANCY AFTER HEMATOPOIETIC TRANSPLANTATION**
J Suárez González[1], [2] ([1]Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, [2]Genomic Unit, Instituto de Investigación Sanitaria Gregorio Marañón y Hospital General Universitario Gregorio Marañón, Madrid, Spain)

E1114 **LEUKEMIC STEM CELL-RELATED MRNA EXPRESSION ANALYSIS USING A NOVEL FLOW CYTOMETRY-BASED ASSAY**
B Depreter[1], [2] ([1]Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium, [2]Department of Paediatric Haematology-Oncology and Stem Cell Transplantation, Ghent University, Ghent, Belgium)

E1115 **POTENTIAL PREDISPOSING GERMLINE MUTATIONS IN PATIENTS WITH CONCOMITANT MYELOID AND LYMPHOID MALIGNANCIES**
F Asmar[1] ([1]Department of Hematology, Rigshospitalet, Copenhagen, Denmark)

E1116 **THE MUTATIONAL LANDSCAPE OF DNMT3A MUTATIONS IN CLONAL HAEMATOPOIESIS OF INDETERMINATE POTENTIAL . CHIPPING AWAY AT THE PROBLEM.**
S Chaudry[1] ([1]Brighton and Sussex Medical School, Brighton, United Kingdom)

E1117 **NEXT-GENERATION REFERENCE INTERVALS FOR PEDIATRIC HEMATOLOGY**
J Zierk[1] ([1]Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany)

E1118 **GROWTH FACTOR INDEPENDENCE 1 (GFI1) REGULATES THE AML SUPPORTING FUNCTION OF MESENCHYMAL STROMAL CELLS**
Y Al-Matary[1] ([1]University Hospital of Essen/ West centre of tumor, Essen, Germany)

HODGKIN LYMPHOMA - CLINICAL

E1119 **BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION**
I Hude[1], [2] ([1]German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany, [2]Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Zagreb, Croatia)

E1120 **THE PROGNOSTIC SIGNIFICANCE OF BETA-2 MICROGLOBULIN (B2M) LEVELS IN PATIENTS WITH HODGKIN LYMPHOMA (HL) TREATED WITH ABVD OR EQUIVALENT (ABVDEQ) CHEMOTHERAPY OR COMBINED MODALITY THERAPY (CT/CMT).**
T Vassilakopoulos[1] ([1]Department of Hematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece)

E1121 **THE PREDICTIVE VALUE OF INTERIM PET-CT IN ELDERLY PATIENTS WITH HODGKIN LYMPHOMA**
OS Bentur[1] ([1]Hematology, Tel Aviv Sourasky medical center, Tel Aviv, Israel)

E1122 **HIGH-DOSE BENDAMUSTINE PLUS BRENTUXIMAB COMBINATION IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA**
C Cerchione[1] ([1]Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy)

E1123 **NEED OF HORMONAL THERAPY TO PRESERVE FEMALE FERTILITY IN HODGKIN E NON-HODGKIN LYMPHOMA PATIENTS FOLLOWING CHEMOTHERAPY: A TWO-CENTER SURVEY.**
O Annibali[1] ([1]UOC Hematology, Stem cell Transplantation, University Campus Biomedico, Rome, Italy)

E1124 **25(OH)VITAMIN D SERUM LEVELS IN HODGKIN LYMPHOMA**
A Cuccaro[1] ([1]Hematology, Catholic University of Sacred Heart, Rome, Italy)

E1125 **NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: A NEW RISK ADAPTED TREATMENT STRATEGY BASED ON RITUXIMAB**
R Della Pepa[1] ([1]Hematology, Federico II University, Naples, Italy)

E1126 **CASE-BASED LEARNING IN CONTINUING EDUCATION: IMPROVING HEMATOLOGIST/ONCOLOGIST EVIDENCE-BASED DECISIONS FOR PREVENTING HOGDKIN LYMPHOMA POST-TRANSPLANT RELAPSE**
P Repetto[1] ([1]Oncology, Medscape, Groveville, United States)

E1127 **QUANTITATIVE PET PARAMETERS PREDICTS OUTCOME IN PATIENTS WITH HODGKIN'S LYMPHOMA**
I Kriachok[1] ([1]Oncohematology, National Cancer Institute, Kiev, Ukraine)

INDOLENT NON-HODGKIN LYMPHOMA – CLINICAL

E1129 **BIOMARKER ANALYSIS OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IBRUTINIB IN THE PHASE 2 DAWN STUDY**
G Salles[1] ([1]Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite cedex, Lyon, France)

E1130 **DYNAMO: THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA IN A PHASE 2 STUDY**
PL Zinzani[1] ([1]Institute of Hematology Serágnoli, University of Bologna, Bologna, Italy)

E1132 **WALDENSTROM MACROGLOBULINEMIA: UK REAL WORLD EXPERIENCE**
D El-Sharkawi[1] ([1]Cancer Division, University College London Hospital (UCLH), London, United Kingdom)

E1133 **CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF INDOLENT NON-HODGKIN'S LYMPHOMA ASSOCIATED WITH HEPATITIS C (IL + C)**
S Lepkov[1] ([1]Russian National Research Medical University named after N.I. Pirogov, Moscow, Russian Federation)

E1134 **90Y-IBRITUMOMAB-TIUXETAN AS FIRST-LINE CONSOLIDATION IN COMPLETE RESPONSE FOLLICULAR LYMPHOMA PATIENTS. SINGLE CENTER ANALYSIS AFTER SIX YEARS MEDIAN FOLLOW-UP.**
M Andrade-Campos[1] ([1]Translational Research Unit - Hematology, IIS-Aragon. CIBERER., Zaragoza, Spain)

E1135 **ASSESSING RISK OVER TIME IN PATIENTS WITH SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA (WM). A STUDY ON 114 PATIENTS (PTS).**
P Morel[4] ([4]Service d'Hematologie, CHU d'Amiens, Amiens, France)

E1136 **TIME TO NEXT TREATMENT ANALYSIS FOR EARLY AND ADVANCED STAGES OF MYCOSIS FUNGOIDES / SEZARY SYNDROME TREATED WITH BEXAROTENE AND PUVA IN COMBINATION**
S Rupoli[1] ([1]Clinica di Ematologia, Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, ancona, Italy)

E1137 **PERIPHERAL BLOOD INVOLVEMENT IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA: CLINICAL-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT**
A Rivas-Delgado[1] ([1]Hematology department, Hospital Clinic, Barcelona, Spain)

E1138 **TREATMENT PATTERNS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN A LARGE US-INSURED DATABASE FROM 2010 TO 2014**
M Mehra[1] ([1]Janssen Research & Development, LLC, Raritan, NJ, United States, United States)

E1139 **A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS (PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)**
K Yamamoto[1] ([1]Department of Clinical Research and Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan, Japan)

E1140 **A SIMPLIFIED APPROACH IN THE ASSESSMENT OF T-CELL CLONALITY BY FLOW CYTOMETRY**
M Sartor[1] ([1]Haematology, Weatmead Hospital, Sydney, Australia)

E1141 **A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS**
A Kolstad MD, PhD[1] ([1]Radiumhospitalet, Oslo, Norway)

E1142 **PHARMACOKINETICS AND TOLERABILITY OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA**
A Forero-Torres[1] ([1]Division of Hematology / Clinical Oncology, University of Alabama at Birmingham, Alabama , United States)

INFECTIOUS DISEASES, SUPPORTIVE CARE

E1143 **ASSESSMENT OF INTERNATIONAL CONSENSUS GROUP FOR HEMATOLOGY (ICGH) SMEAR REVIEW RULES FOR AUTOMATED PLATFORMS IN THE DETECTION OF MALARIA**
J Vaughan[1, 2] ([1] Haematology, National Health Laboratory Services, Johannesburg, South Africa, [2]Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa)

E1144 **A PROSPECTIVE MULTICENTER STUDY OF CANDIDEMIA IN NEUTROPENIC PATIENTS WITH HEMATOLOGICAL DISEASES: INCIDENCE, RISK FACTOR AND OUTCOMES**
CH Yan[1] ([1]Peking University People's Hospital, Beijing, China)

E1145 **BRONCHOALVEOLAR LAVAGE AS SYSTEMATIC APPROACH FOR EARLY DIAGNOSIS OF LUNG INFILTRATES AND INVASIVE PULMONARY ASPERGILLOSIS IN HEMATOLOGIC PATIENTS: A PROSPECTIVE SINGLE INSTITUTION STUDY**
F Marchesi[1] ([1]Hematology and Stem Cell Transplant, Regina Elena National Cancer Institute, Rome, Italy)

E1146 **ESCAPE DRUG-RESISTANT INFECTIONS IN HEMATOLOGICAL MALIGNANCIES. DARE TO REVIEW!**
C Gentille Sanchez[1] ([1]Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, United States)

E1147 **PROPOSED PEGIFLGRASTIM BIOSIMILAR CHS-1701 DEMONSTRATES PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY TO MARKETED PEGFILGRASTIM IN A RAT NEUTROPENIA MODEL AND IN HEALTHY SUBJECTS**
P O'Connor[1] ([1]Coherus BioSciences, Inc., Redwood City, United States)

E1148 **A RETROSPECTIVE REVIEW IDENTIFYING RESISTANT MICROBIAL STRAINS, ANTIMICROBIAL SENSITIVITIES AND RISK STRATIFICATION OF FIRST LINE ANTIBIOTIC USE IN ADULT CANCER PATIENTS WITH NEUTROPENIC SEPSIS**
A Danga[1] ([1]Haematology, North West London NHS Trust, London, United Kingdom)

E1149 **PRELIMINARY RESULTS FROM A LONG-TERM REPEAT DOSE TOXICITY AND TOXICOKINETIC STUDY OF ANF-RHO, A NOVEL ANTI-NEUTROPENIC FACTOR**
H Misra[1] ([1]Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, United States)

E1150 **USE OF MICAFUNGIN IN PROPHYLAXIS IN ONCO-HEMATOLOGY : RESULTS OF AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE FRENCH STUDY (OLYMPE)**
J El-cheikh[1] ([1] American Hospital, Beirut, Lebanon)

E1151 **OUTBREAK OF MULTI-DRUG RESISTANT PSEUDOMONAS AERUGINOSA (MPA) IN A HAEMATOLOGY WARD (HW): MANAGEMENT AND INFECTION CONTROL MEASURES**
D Armiento[1] ([1]Haematology and Stem Cell Transplantation Division, Campus Bio-Medico University Hospital, Rome, Italy)

E1152 **MONITORING VORICONAZOLE PHARMACOGENOMICS AND PLASMA CONCENTRATIONS IN THE TREATMENT AND PREVENTION OF INVASIVE FUNGAL DISEASE FOR HEMATOLOGICAL PATIENTS - A SINGLE CENTER EXPERIENCE**
X Tang[1], [2] ([1]The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology, Suzhou, China, [2]Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

E1153 **BACTEREMIA AND SEPSIS FOLLOWING INTENSIVE CHEMOTHERAPY OF ADULT ONCOHEMATOLOGICAL PATIENTS**
S Bessmeltsev[1] ([1]Haematilogy, Russian Institute of Haematology andTtransfusiology, St. Petersburg, Russian Federation)

IRON METABOLISM, DEFICIENCY AND OVERLOAD

E1154 **GLYCOSYLATED FERRITIN MEASURING SIGNIFICANCE FOR SECONDARY HEMOPHAGOCYTIC SYNDROME DIAGNOSTICS**
V Potapenko[1] ([1]Municipal clinical hospital №31, Saint-Petersburg, Russian Federation)

E1155 **SERUM HEPCIDIN QUANTIFICATION IN INFLAMMATORY BOWEL DISEASES**
V Manolov[1] ([1]Dept. of Clinical laboratory and clinical immunology, Medical University, Sofia, Sofia, Bulgaria)

E1156 **MUTATIONS IN YARS2 CAUSE CONGENITAL SIDEROBLASTIC ANEMIA WITHOUT SHOWING EVIDENCES OF MYOPATHY AND LACTIC ACIDOSIS**
B Cadenas[1] ([1]Iron Metabolism: Regulation and Diseases, Josep Carreras Leukaemia Research Institute (IJC), BADALONA, Spain)

E1157 **IRON CHELATION DATA OF CONGENITAL DYSERYTHROPOIETIC ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE**
M Cetin[1] ([1]Hacettepe University, Divison Of Pediatric Hematology, Ankara, Turkey)

E1158 **ORAL IRON CHELATION FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS IN CHILDREN**
M Moraki[1] ([1]Thalassemia Unit,First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece)

E1159 **NEUTROPHIL HYPERSEGMENTATION IN ADULTS WITH IRON DEFICIENCY: A CASE-CONTROL STUDY**
I Erdogan Ozunal[1] ([1]Department of Internal Medicine, Division of Hematology, Istanbul Universitiy Cerrahpasa Faculty of Medicine, Istanbul, Turkey)

E1160 **M-TOR INHIBITORS-ASSOCIATED MICROCYTIC ANEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.**
R Angel F,[1] ([1]Hematology, Hospital de Sant Pau, Barcelona, Spain)

E1161 **IRON METABOLISM IN PATIENTS WITH PAROXISMAL NOCTURNAL HEMOGLOBINURIA**
E Lukina[1] ([1]Department of Orphan Diseases, National Research Center for Hematology, Moscow, Russian Federation)

E1162 **ORAL IRON ELEVATES SERUM IRON AND CONSEQUENTLY CHANGES IRON DISTRIBUTION IN LIVER AND ERYTHROCYTES**
Y Matsuo-Tezuka[1] ([1]Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan)

E1163 **DEFERASIROX FOR SEVERE ANAEMIAS IN YOUNG CHILDREN**
A Gunawan[1], [2] ([1] Haematology, Guy's and St Thomas' NHS Trust, London, United Kingdom, [2]Pediatric, Evelina Hospital, Guy's and St Thomas' NHS Trust, London, United Kingdom)

E1164 **MONITORING ORAL IRON THERAPY IN CHILDREN WITH IRON DEFICIENCY ANEMIA. AN OBSERVATIONAL, PROSPECTIVE, MULTICENTRIC STUDY**
G Russo[1], [2] ([1] Clinical and Experimental Medicine, University of Catania, Catania, Italy, [2]Pediatric Hemato-Oncology Unit, Azienda Policlinico Vittorio Emanuele, Catania, Italy)

E1165 **AN INVESTIGATION ABOUT WEIGHT GAIN WITH TREATMENT OF IRON DEFICIENCY ANEMIA: CHANGES OF GHRELIN AND HEPCIDIN LEVELS WITH TREATMENT**
B Onec[2] ([2]Hematology, Duzce University Faculty of Medicine, Duzce, Turkey)

MYELODYSPLASTIC SYNDROMES - BIOLOGY

E1166 **SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING**
T Stopka[1], [2] ([1] Hematology Clinic, General Hospital, Prague, Czech Republic, [2]Biocev, Charles University, Vestec, Czech Republic)

E1167 **WHOLE GENOME MBD-SEQ REVEALS DIFFERENT CPG METHYLATION PATTERNS IN AZACYTIDINE-TREATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) PATIENTS**
PP Leoncini[1] ([1]Oncohaematology, Bambino Gesù Children Hospital, Roma, Italy)

E1168 **RESPONSE MONITORING IN MDS WITH DEL(5Q) USING DIFFERENT FLOW CYTOMETRIC (FCM)-SCORES IN COMPARISON TO CYTOGENETICS – AN ELNET IMDS-FLOW EXPERIENCE**
U Oelschlaegel[1] ([1]Medical Clinic and Policlinic I, MK1-L06, UNIVERSITY HOSPITAL of TU DRESDEN, Dresden, Germany)

E1169 **EVALUATION OF MUTATIONS AT RELAPSE IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION**
M Cabrero[1] ([1]Hematology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain)

E1170 **RIGOSERTIB COMBINED WITH AZACITIDINE EPIGENETICALLY MODULATES CHROMATIN AND HEMATOPOIETIC STEM CELL POPULATIONS IN THE MYELODYSPLASTIC SYNDROME (MDS)**
LR Silverman[1] ([1]ICAHN SCHOOL OF MEDICINE, MOUNT SINAI, NEW YORK, United States)

E1171 **UNEXPLAINED CYTOPENIAS IN HOSPITAL : INDICATIONS AND BENEFITS OF NEXT-GENERATION SEQUENCING**
D Beauvais[1] ([1]Department of Adult Hematology, CHRU University Hospital of Lille, Lille, France)

E1173 **RESISTANCE TO AZACITIDINE IS DETERMINED AT CELLULAR LEVEL BY LOWER EXPRESSION OF NUCLEOSIDE ACTIVATING ENZYMES UCK1 AND UCK2**
E Masala[1] ([1]Experimental and Clinical Medicine, University of Florence, Florence, Italy)

E1174 **FAMILIAL TIN2 N-TERMINAL LOSS OF FUNCTION MUTATION IN TELOMERE SYNDROME**
D Di Giacomo[1] ([1]Haematology and Bone Marrow Transplantation Unit, University of Perugia, Perugia, Italy)

E1175 **FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES**
T Asayama[1] ([1]Division of hematology, Department of medicine, Nippon Medical School, Tokyo, Japan)

E1176 **PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE LOCI OF GENE VARIANCES**
T Boneva[1] ([1]OncoGenomics, HSL Analytics LLP, LONDON, United Kingdom)

E1177 **SUPPRESSION OF DNA METHYLTRANSFERASE ENZYMES BY A NOVEL HYPOMETHYLATING AGENT, SGI-1027, IN AZACITIDINE- AND DECITABINE-RESISTANT CELL LINES**
EH Hur[1] ([1]Hematology, Asan Medical Center, University of Ulsan College of Medicine, SEOUL, Korea, Republic Of)

E1178 **MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES**
M Mathieu[1], [2] ([1] Clinique Universitaire d'hématologie, CHU Grenoble Alpes, Grenoble, France, [2]Equipe TheREx-laboratoire TIMC, Université Grenoble Alpes, Grenoble, France)

MYELODYSPLASTIC SYNDROMES – CLINICAL

E1179 **EVALUATING ERYTHROBLAST PAS POSITIVITY IN THE DIAGNOSTIC APPROACH OF MYELODYSPLASTIC SYNDROME**
R Invernizzi[1] ([1]IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy)

E1180 **A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)**
U Platzbecker[1] ([1]University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany)

E1181 **PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY.**
F López Cadenas[1] ([1]Department of Hematology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA (SANIDAD CASTILLA Y LEÓN), Salamanca, Spain)

E1182 **MYELODYSPLASIA-RELATED MORTALITY REMAINS THE MAIN CAUSE OF DEATH ALONG DIFFERENT GROUPS OF RISKS: AN ANALYSIS FROM MDS ARGENTINEAN STUDY GROUP**
A Enrico[2] ([2] Hospital Italiano de La Plata, La Plata, Argentina)

E1183 **PROSPECTIVE STUDY OF FLOW CYTOMETRY OF BONE MARROW IN 105 CONSECUTIVE PATIENTS WITH CYTOPENIA AND SUSPICION OF MYELODYSPLASTIC SYNDROME: STRONG CORRELATION WITH RISK OF AML-EVOLUTION AND SURVIVAL**
F Marco De Lucas[1] ([1]HEMATOLOGÍA, HOSPITAL UNIVERSITARIO BASURTO, BILBAO, Spain)

E1184 **ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY**
J Bell[1] ([1]Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)

E1185 **INTRAVENOUS IMMUNOGLOBULIN IS AN EFFECTIVE TREATMENT FOR CYTOPENIAS ASSOCIATED TO CIRCULATING T-CELL CLONES IN MYELODYSPLASTIC SYNDROMES**
F Schieppati[1] ([1]Hematology, ASST Spedali Civili di Brescia, Brescia, Italy)

E1186 **DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES**
F Efficace[1] ([1]Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy)

E1187 **PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF SIGNIFICANT MARROW FIBROSIS IN COMBINATION WITH P53 OVER-EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: A SINGLE CENTRE STUDY**
E Groarke[1] ([1]Department of Haematology, Tallaght Hospital, Dublin 24, Ireland)

E1188 **FACS PURIFICATION OF BLAST CELLS IN MDS IMPROVES THE FISH DETECTION RATE FOR DEL(5Q) AND DEL(20Q), BUT NOT FOR DEL(7Q) OR T8**
M Pereira[1], [2] ([1]Clinical Hematology Department, Coimbra University Hospital Centre, Coimbra, Portugal, [2] Faculty of Medicine, University of Coimbra, Coimbra, Portugal)

E1189 **COUNTING BONE MARROW BLASTS AS A PERCENTAGE OF NON-ERYTHROID CELLS PROVIDES SUPERIOR RISK STRATIFICATION FOR MDS PATIENTS WITH ERYTHROID PREDOMINANCE**
A Sun[1], [2] ([1]The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, [2]Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

E1190 **SUCCESSFUL TREATMENT WITH DANAZOL FOR MYELODYSPLASTIC SYNDROMES AND APLASTIC ANEMIA REFRACTORY OR INELIGIBLE TO STANDARD THERAPY**
F Schieppati[1] ([1]Hematology, ASST Spedali Civili di Brescia, Brescia, Italy)

E1191 **SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY**
J Bell[1] ([1]Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)

E1192 **DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)**
G Garcia-Manero[1] ([1]UT MD Anderson Cancer Center, Houston, United States)

E1193 **FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER- RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE.**
K Mądry[1] ([1]Hematology, Oncology and Internal Diseases, Medical University , Warsaw, Poland)

E1194 **OVERALL SURVIVAL, INITIAL TREATMENT AND TREATMENT DURATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME, A DETAILED POPULATION BASED STUDY**
H Rozema[1], [2] ([1]Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen, the Netherlands, [2]Medical Centre Leeuwarden, Leeuwarden, the Netherlands)

E1195 **DANAZOL TREATMENT FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A REAL LIFE EXPERIENCE**
E Ravano[1] ([1]Hematology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy)

E1196 **TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY**
J Bell[1] ([1]Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, United States)

E1197 **APPRECI8: A PIPELINE FOR PRECISE VARIANT CALLING INTEGRATING 8 TOOLS**
S Sandmann[1] ([1]Institute of Medical Informatics, University of Münster, Münster, Germany)

E1198 **COMPARISON OF ADMINISTRATION OF HYPOMETHYLATING AGENTS WITH EFFICIENCY OF ALLOGENEIC SCT IN ELDERLY PATIENTS WITH ADVANCED MDS**
J Cermak[1] ([1]Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha, Czech Republic)

E1199 **A MULTICENTER, OPEN-LABEL, PHASE I CLINICAL STUDY: SAFETY, EFFICACY, AND PHARMACOKINETICS OF ORAL RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES**
K Ishizawa[1], [2] ([1]Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, [2]Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan)

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY

E1200 **NON-OVERLAPPING PROMOTER AND SUPERENHANCER DRIVEN PROCESSES SUPPORT MYELOMA CELL GROWTH AND SURVIVAL VIA DISTINCT REGULATORY AXES**
M Fulciniti[1] ([1]Dana Farber Cancer Institute, Boston, United States)

E1201 **ANALYSIS OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA HIGHLIGHTS NOVEL CANDIDATE PROGNOSTIC MARKERS AND DISEASE SUBGROUPS**
N Bolli[1] ([1]Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy)

E1202 **A NOVEL METHOD FOR GENOME-WIDE COPY NUMBER ASSESSMENT FROM TARGETED SEQUENCING DATA AND CLINICAL APPLICATION IN PATIENTS WITH MULTIPLE MYELOMA**
G Ryland[1] ([1]Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia)

E1203 **THE MULTIPLE MYELOMA GENOME PROJECT: DEVELOPMENT OF A MOLECULAR SEGMENTATION STRATEGY FOR RISK STRATIFICATION OF MULTIPLE MYELOMA**
G Morgan[2] ([2]Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, United States)

E1204 **ALVOCIDIB SYNERGIZES WITH VENETOCLAX IN PRECLINICAL MODELS OF MULTIPLE MYELOMA**
C Whatcott[1] ([1]Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States)

E1205 **NOVEL COMPOUND, OSSL_325096, INDUCES APOPTOSIS IN MULTIPLE MYELOMA CELLS THROUGH VCP INHIBITION**
N Nishimura[1] ([1]Department of Hematology, Kumamoto University, Kumamoto, Japan)

E1206 **A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA**
M Samur[1], [2] ([1]Harvard Medical School, Boston, United States, [2]Dana Farber Cancer Institute, Boston, United States)

E1207 **DYNAMIC IMMUNOHISTOCHEMICAL EVALUATION OF MARROW MICROENVIRONMENT MODIFICATIONS IN PATIENTS WITH SMOLDERING MYELOMA**
A Mussetti[1] ([1]Hematology and Adult Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy)

E1208 **IMMUNE CELL PROFILING IN BONE MARROW OF MYELOMA PATIENTS POST AUTOLOGUS STEM CELL TRANSPLANT SHOWS PRESENCE OF CYTOTOXIC CD4 AND CD8 CELLS, WITH PROMINENT LAG-3 EXPRESSION AND OTHER CHECKPOINT MARKERS**
N Alrasheed[1] ([1]UCL Cancer institute, university college london, London, United Kingdom)

E1209 **INHIBITION OF EXTRACELLULAR VESICLE SECRETION INDUCES APOPTOSIS OF BONE MARROW STROMAL CELLS: TOWARDS SOIL-TARGETED THERAPY IN MULTIPLE MYELOMA**
T Umezu[1] ([1]Department of Hematology, Tokyo Medical University, Tokyo, Japan)

E1210 **SINGLE-NUCLEOTIDE POLYMORPHISM IN THE PBK GENE IS CLOSELY ASSOCIATED WITH MYELOMA CELL PROLIFERATION.**
I Hanamura[1] ([1]Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan)

E1211 **THE HISTONE METHYLTRANSFERASES G9A/GLP REPRESENT NEW PROMISING TARGETS FOR THE TREATMENT OF MULTIPLE MYELOMA**
E De Smedt[1] ([1]Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium)

E1212 **CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPUTIC OPPORTUNITIES**
F Seymour[1] ([1]Haemato-Oncology, Barts Cancer Institute, London, United Kingdom)

E1213 **P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE MYELOMA**
Y Arihara[1] ([1]Department of Medical Oncology, Sapporo Medical University, Sapporo, Japan)

E1214 **TUMOR MICROENVIRONMET TRANSFORMATION FROM MGUS TO MYELOMA IS ASSOCIATED WITH PRO-TUMORAL ACTIVATION OF MESENCHYMAL STROMAL CELLS (MSC)**
C Giallongo[1] ([1]Clinical and Molecular Biomedicine, section of Hematology, University of Catania, catania, Italy)

E1215 **LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NEXT GENERATION FLOW SHOW PREDOMINANTLY CURED VS MGUS-LIKE MINIMAL RESIDUAL DISEASE PATTERNS: A STUDY OF THE GTMM-TUSCAN GROUP FOR MULTIPLE MYELOMA**
A Gozzetti[1] ([1]Hematology Unit, University of Siena, Siena, Italy)

E1216 **THE NOTCH PATHWAY IN THE INTERPLAY BETWEEN MYELOMA CELLS AND ENDOTHELIUM IN THE BONE MARROW NICHE**
MT Palano[1] ([1]Scienze della Salute, Università degli Studi di Milano, Milano, Italy)

E1217 **MIR-101-3P REGULATES BONE MARROW STROMA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA CELLS BY TARGETING SURVIVIN AND MODULATING CELL-CELL ADHESION**
J Abdi[1] ([1]University Health Network, Toronto, Canada)

E1218 **ARQ-197, A SMALL-MOLECULE INHIBITOR OF C-MET, REDUCES TUMOUR BURDEN AND PREVENTS TUMOUR-ASSOCIATED BONE DISEASE IN A MURINE MODEL OF MYELOMA**
A Chantry[1] ([1]Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom)

E1220 **THE GENETIC LANDSCAPE OF THE MURINE 5T MODELS FOR MULTIPLE MYELOMA**
K Maes[1] ([1]Hematology and Immunology, Vrije Universiteit Brussel, Brussel, Belgium)

E1221 **CHARACTERIZING THE CONTRIBUTION OF BONE MARROW STROMA-DERIVED IL-6 TO MYELOMA GROWTH AND RESISTANCE**
T Csikos[1] ([1]Hematology, VU University Medical Center, Amsterdam, the Netherlands)

E1222 **THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VITRO AND IN VIVO MODELS OF MULTIPLE MYELOMA**
T Paíno[1, 2] ([1]Centro de Investigación del Cáncer (CIC-IBMCC), Salamanca, Spain, [2]Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain)

E1223 **EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA.**
F Costa[1] ([1]Medicine and Surgery, University of Parma, PARMA, Italy)

E1224 **TRIM33 IS A POTENTIAL TUMOR SUPPRESSOR IN MULTIPLE MYELOMA**
CK Johnston[1] ([1]Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom)

E1225 **LONG NON-CODING RNAS EXPRESSION HETEROGENEITY AND FUNCTIONAL INVOLVEMENT IN MULTIPLE MYELOMA**
A Carrasco[1] ([1]Onco-hematology, Center for Applied Medical Research (CIMA), Pamplona, Spain)

E1226 **ROLE OF EPHA3 IN MULTIPLE MYELOMA: A PERSPECTIVE FOR A NOVEL TARGET THERAPY?**
F La Rocca[1] ([1]Laboratory of Clinical Research and Advanced Diagnostics, IRCCS, Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy)

E1227 **PROGNOSTIC SIGNIFICANCE OF AMP1Q21 IN MULTIPLE MYELOMA**
T Abramova[1] ([1]Hematology Research Center, Moscow, Russian Federation)

E1228 **ADAPTIVE IMMUNE RESPONSE IN PLASMA CELL DYSCRASIAS: IMMUNE PROFILING AND DETERMINATION OF CIRCULATING B CELL LEVELS AS A SURROGATE ASSAY FOR BONE MARROW TESTING**
S Drain[1] ([1]Stratified Medicine, C-tric, Ulster University, Derry, United Kingdom)

E1229 **NOVEL MONOCLONAL ANTIBODY THERAPY TARGETING CD26 IN MULTIPLE MYELOMA**
H Nishida[1] ([1] Pathology, Keio University, School of Medicine, Tokyo, Japan)

E1230 **KYNURENINE INHIBITS T-CELLS THROUGH THE ARYL HYDROCARBON RECEPTOR AT IDO-POSITIVE TUMOR MICROENVIRONMENT**
S Ninomiya[1] ([1]Hematology, Gifu University Graduate School Of Medicine, Gifu, Japan)

E1231 **THE ANTI-MYELOMA ACTIVITY OF PERK KINASE INHIBITOR IN TARGETING MORE THAN 50 UPR-RELATED GENES INVOLVED IN THE PROLIFERATION OF MM CELLS**
T Bagratuni[1] ([1]National And Kapodistrian University Of Athens, Athens, Greece)

E1232 **ENVIRONMENTAL CONTROL OF PLASMA CELL FITNESS IN MULTIPLE MYELOMA: MALIGNANT CO-OPTATION OF ARGININE AS NOVEL IMMUNO-METABOLIC CHECKPOINT**
A Romano[1], [2] ([1]Division of Hematology, Azienda Ospedaliera Policlinico e Vittorio Emanuele di Catania, Catania, Italy, [2]Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy)

E1233 **ESTIMATED GLOMERULAR FILTRATION (EGFR) CALCULATED BY CKD-EPI EQUATION COMBINED WITH THE INTERNATIONAL STAGING SYSTEM PROVIDES A POWERFUL PROGNOSTIC MODEL FOR EARLY MORTALITY IN MYELOMA PATIENTS**
E Katodritou[1] ([1]Hematology Department , Theagenion Cancer Hospital, THESSALONIKI, Greece)

E1234 **ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND CLONOGENIC TUMOR CELLS**
A Leivas[1], [2] ([1]Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain, [2]Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain)

E1235 **UNMASKING THE RETROTRANSPOSON-ORCHESTRATED PRODUCTION OF SOLUBLE RANKL IN MULTIPLE MYELOMA CELLS**
S Papamichos[1] ([1]Laboratory of General Biology, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece)

E1236 **THE RATIO OF PATHOLOGICAL PLASMOCYTES, ASSESSED BY 8-COLOR FLOW CYTOMETRY, PREDICTS OF RISK OF EVOLUTION IN MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AND SMOULDERING MULTIPLE MYELOMA.**
C Brouzes[1] ([1]Laboratory Onco Hematology, Necker Enfants Malades Hospital and Descartes University, Paris, France)

E1237 **ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION.**
A Horenstein[1], [2] ([1]CERMS, A.O.U. Citta della Salute e della Scienza , Turin, Italy, [2]Medical Sciences, University of Turin, Turin, Italy)

E1238 **TREATMENT OPTIMIZATION FOR MULTIPLE MYELOMA: SCHEDULE-DEPENDENT SYNERGISTIC CYTOTOXICITY OF POMALIDOMIDE AND CARFILZOMIB ON AN IN VITRO AND EX-VIVO MODEL**
E Borsi1 (1Fondazione Umberto Veronesi (FUV), Milano, Italy)

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL

E1239 **ASSESSMENT OF THE IMPACT OF POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE COMMUNITY-BASED CONNECT MM REGISTRY**
S Jagannath[1] ([1]Mount Sinai Hospital, New York, United States)

E1240 **DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRETREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA**
P Kapoor[1] ([1]Division of Hematology, Mayo Clinic, Rochester, United States)

E1241 **IMPACT OF METFORMIN USE IN THE OUTCOMES OF MULTIPLE MYELOMA PATIENTS POST STEM CELL TRANSPLANT.**
N Duma[1] ([1]Hematology, Mayo Clinic, Rochester, United States)

E1242 **COMPARING WHOLE BODY MRI WITH PET-CT IMAGING AT DIAGNOSIS OF MYELOMA**
J Vidler[1] ([1]Department of Haematological Medicine, King's College Hospital, London, United Kingdom)

E1243 **PERSISTENCE OF MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY CAN HINDER RECOVERY OF ORGAN DAMAGE IN PATIENTS WITH AL AMYLOIDOSIS**
P Milani[1] ([1]Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia , Pavia, Italy)

E1244 **RATES OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CARFILZOMIB VS COMPARATORS IN PIVOTAL PHASE 3 TRIALS**
R Niesvizky[1] ([1]Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, United States)

E1245 **EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA IS A POOR PROGNOSTIC MARKER FOR OVERALL SURVIVAL AND IS DIFFICULT TO PREDICT AT DIAGNOSIS OR DURING INDUCTION TREATMENT.**
I Walker[1] ([1]Department of Haematology, King's College Hospital Foundation Trust, London, United Kingdom)

E1246 **PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTRÖM MACROGLOBULINEMIA (WM)**
J Trotman[1] ([1]Haematology, Concord Repatriation General Hospital, Concord, Australia)

E1247 **INCIDENCE AND RISK FACTORS OF CARDIOVASCULAR ADVERSE EVENTS IN A LARGE POPULATION OF NEWLY-DIAGNOSED, TRANSPLANT INELIGIBLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB.**
S Bringhen[1] ([1]Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

E1248 **POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS**
DS Siegel[1] ([1]John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, United States)

E1249 **"REAL WORLD" DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE GREEK MYELOMA STUDY GROUP**
E Terpos[1] ([1]Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)

E1250 **EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY IN A LARGE COHORT OF PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB**
B Gamberi[1] ([1]Arcispedale S. Maria Nuova, Reggio Emilia, Italy)

E1251 **NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE OF MULTIPLE MYELOMA PATIENTS**
JP Glossmann[1] ([1]CIO Köln Bonn, University Hospital of Cologne, Cologne, Germany)

E1252 **WT1 HETEROCLITIC EPITOPE IMMUNIZATION FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM)**
G Koehne[1] ([1]MEMORIAL SLOAN KETTERING CANCER CENTER, New York, United States)

E1253 **ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH PROGRESSIVE DISEASE AT TIME OF FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION: PREDICTORS OF PROGRESSIVE DISEASE AND FACTORS AFFECTING SURVIVAL**
J Blocka[1] ([1]University Hospital Heidelberg, Heidelberg, Germany)

E1254 **SEVERE INFECTIONS IMPACTS OVERALL SURVIVAL IN ACTIVE MULTIPLE MYELOMA PATIENTS**
G Barila'[1] ([1]Dept of Medicine, Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy)

E1255 **EVALUATION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES OF MULTIPLE MYELOMA IN THE REAL-WORLD SETTING IN THE UNITED STATES**
C Chen[3] ([3]Bristol-Myers Squibb, Lawrenceville, United States)

E1256 **LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW**
K Kupas[1] ([1]Bristol-Myers Squibb, Munich, Germany)

E1257 **HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP**
I Hus[1] ([1]Clinical Transplantology, Medical University of Lublin, Lublin, Poland)

E1258 **HIGH CUT OFF HEMODIALYSIS FOR RENAL RECOVERY IN PATIENTS WITH MULTIPLE MYELOMA: FIVE YEARS OF EXPERIENCE**
A Berni Wennekers[1] ([1]Nephrology, Hospital Clinico Universitario "Lozano Blesa" Zaragoza, Zaragoza, Spain)

E1259 **IMPACT OF IMMUNOPARESIS IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS**
LG Rodríguez-Lobato[1] ([1]Department of Haematology, Hospital Clínic, Barcelona, Spain)

E1260 **TREATMENT PATTERNS AND DURATION OF TREATMENT IN JAPANESE MULTIPLE MYELOMA PATIENTS RECEIVING SECOND LINE THERAPY WITH NOVEL AGENTS**
G Jun[1], [2] ([1] Department of Public Health, Juntendo University School of Medicine, Tokyo, Japan, [2]Japan Medical Affairs, Takeda Pharmaceutical Company Limited, Tokyo, Japan)

E1261 **ROLE OF HEAVY/LIGHT CHAIN RATIO IN MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST LINE THERAPY**
F D'auria[1] ([1]IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy)

E1262 **REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE POLISH MYELOMA GROUP.**
K Jamroziak[1] ([1]Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland)

E1263 **REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE**
A Fernandez[1] ([1]EUCAN Medical Affairs, Takeda, CH-8152 Glattpark-Opfikon (Zurich), Switzerland)

E1264 **FRAILTY AND MORTALITY IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA**
N Schutz[1] ([1]Medicina Interna - Hematología, Hospital Italiano de Buenos Aires, CABA, Argentina)

E1265 **PROGNOSIS OF AL AMYLOIDOSIS WITH KIDNEY INJURY**
A Talbot[1] ([1]Immulogy, hopital Saint Louis, paris, France)

E1266 **REAL-WORLD DATA ON THE TREATMENT OF RELAPSED/REFRACTORY MYELOMA WITH LENALIDOMIDE AND DEXAMETHASONE IN 2ND LINE (LEGEND STUDY): THE PROGNOSTIC SIGNIFICANCE OF BIOCHEMICAL VS. CLINICAL RELAPSE**
E Katodritou[1] ([1] Department of Hematology, Theaganion Cancer Hospital, THESSALONIKI, Greece)

E1267 **FDG-PET IN MULTIPLE MYELOMA: DUAL TIME POINT FDG UPTAKE IN FOCAL LESIONS CORRELATE TO RESPONSE TO CHEMOTHERAPY.**
B Oestergaard[1] ([1]Hematology, Odense University Hospital, Odense, Denmark)

E1268 **UNDERSTANDING THE CONTRIBUTE OF THE NOTCH PATHWAY IN MULTIPLE MYELOMA BONE MARROW NICHE: A FOCUS ON EXTRACELLULAR VESICLES-MEDIATED COMMUNICATION**
M Colombo[1] ([1]Dept. of Health Sciences, Università degli Studi di Milano, Milano, Italy)

E1269 **THE USE OF CARFILZOMIB AND BORTEZOMIB IN ROUTINE CLINICAL PRACTICE: RESULTS FROM PREAMBLE, AN ONGOING, OBSERVATIONAL COHORT STUDY IN MULTIPLE MYELOMA**
B Durie[1] ([1]Cedars-Sinai Medical Center, Los Angeles, United States)

E1270 **ROLE OF SERUM FREE LIGHT CHAIN VS BENCE JONES MEASUREMENT IN LIGHT CHAIN MULTIPLE MYELOMA (LCMM) AT DIAGNOSIS, DURING TREATMENT AND FOLLOW-UP FOR RESPONSE EVALUATION AND RELAPSE DETECTION**
M Staderini[1] ([1]Hematology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy)

E1271 **SUPPRESSION OF THE NON-MONOCLONAL PAIR AS NEW BIOMARKER OF POOR PROGNOSIS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS AND AFTER AUTOLOGOUS STEM CELL TRANSPLANT**
JL García De Veas Silva[1] ([1]Department of Laboratory Medicine, Complejo Hospitalario Universitario de Granada, Granada, Spain)

E1272 **SURVIVAL STRATIFICATION OF PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER FIRST RELAPSE: SENSITIVITY ANALYSES OF A NOVEL RISK STRATIFICATION ALGORITHM (RSA)**
R Hajek[1] ([1]Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic)

E1273 **REAL-WORLD DATA ON MULTIPLE MYELOMA: A PROSPECTIVE NATIONAL REGISTRY IN URUGUAY ON 224 NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM 2012-2015**
E Riva[1] ([1]Hematology Department, Hospital de Clínicas, Facultad de Medicina, Montevideo, Uruguay)

E1274 **REPRESENTATION OF MINORITIES, THE ELDERLY AND WOMEN IN MULTIPLE MYELOMA CLINICAL TRIALS**
N Duma[1] ([1]Hematology, Mayo Clinic , Rochester, United States)

E1275 **EVALUATION OF TREATMENT INDUCED NEUROPATHY IN MULTIPLE MYELOMA AND ITS INFLUENCE ON PHYSICAL AND ROLE FUNCTIONING**
B Sidi Mohamed El Amine[1] ([1]Hematology department, Universitary hospital of Sidi Bel Abbés, Sidi Bel Abbes, Algeria)

E1276 **PROGNOSTIC SIGNIFICANCE OF T(11;14) EXPRESSION BY FISH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES**
M Gonzalez Velez[1] ([1]Internal Medicine, Rutgers NJMS, Newark, United States)

E1277 **ANALYSIS OF THE CONNECT MM REGISTRY: TREATMENT OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED LENALIDOMIDE MAINTENANCE OR NO MAINTENANCE**
RM Rifkin[1] ([1]US Oncology Research, Rocky Mountain Cancer Centers, Denver, United States)

E1278 **SERUM-FREE LIGHT-CHAINS (SFLC) INSTEAD OF URINE PROTEIN ELECTROPHORESIS (UPEP) FOR MONITORING LIGHT-CHAIN MULTIPLE MYELOMA (LCMM)**
L Lopez Anglada Fernandez[1] ([1]Haematology, Hospital 12 de Octubre, Madrid, Spain)

E1279 **TOPSPIN: A NOVEL ALGORITHM TO PREDICT TREATMENT SPECIFIC SURVIVAL IN CANCER**
J Ubels[1], [2], [3] ([1]SkylineDx, Rotterdam, the Netherlands, [2]Department of Hematology, Erasmus MC Cancer Institute , Rotterdam, the Netherlands, [3]Center for Molecular Medicine, UMC Utrecht, Utrecht, the Netherlands)

E1280 **AMYLOIDOSIS RESEARCH CONSORTIUM CARDIAC AMYLOIDOSIS SURVEY: RESULTS FROM PATIENTS WITH AL AMYLOIDOSIS AND THEIR CAREGIVERS**
I Lousada[1] ([1]Amyloidosis Research Consortium, Boston, United States)

E1281 **EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS**
MA Dimopoulos[1] ([1]National and Kapodistrian University of Athens, Athens, Greece)

E1282 **TRENDS IN TREATMENT PATTERNS AND SEQUENCING IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED 2011-2016 IN THE UNITED STATES USING AN ENHANCED ELECTRONIC HEALTH RECORDS DATABASE**
S Abouzaid[1] ([1]Celgene Corporation, Summit, NJ, United States)

E1283 **HLC PAIR SUPPRESSION AS A RISK FACTOR FOR BLOODSTREAM INFECTIONS AND EARLY DEATH IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS**
JL García De Veas Silva[1] ([1]Department of Laboratory Medicine, Complejo Hospitalario Universitario de Granada, Granada, Spain)

E1284 **DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA**
D Katalinic[1] ([1]Depatment of Internal Medicine, Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia)

E1285 **COMPARISON BETWEEN IMMUNOFIXATION NEGATIVITY AND NORMAL FREE LIGHT CHAIN RATIO WITH MULTICOLOUR FLOW CYTOMETRY FOR RESPONSE ASSESSMENT IN PATIENTS WITH MULTIPLE MYELOMA WITH VGPR OR BETTER**
K Narita[1] ([1]Department of Medicine, Hematology/Oncology Kameda Medical Center, Kamogawa, Japan)

E1286 **DARATUMUMAB IS AN EFFECTIVE AND SAFE SALVAGE THERAPY IN RELAPSED/REFRACTORY PATIENTS WITH MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.**
E Klyuchnikov[1] ([1]Department for Stem Cell Transplantation, UNIVERSITY CANCER CENTER HAMBURG-EPPENDORF, Hamburg, Germany)

E1287 **PROGNOSTIC RELEVANCE OF VEGF AND VEGFR EXPRESSION IN CD138+/CD19- AND CD138+/CD19+ PLASMA CELLS FROM PATIENTS WITH MONOCLONAL GAMMOPATHIES**
C Geraldes[1], [2] ([1]Applied Molecular Biology and University Clinic of Hematology, Faculty of Medicine University of Coimbra, Coimbra, Portugal, [2]Clinical Hematology Department, Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, Portugal)

E1288 **RACIAL DIFFERENCES OF FISH ABNORMALITIES IN MINORITIES WITH MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE**
M Gonzalez Velez[1] ([1]Internal Medicine, Rutgers NJMS, Newark, United States)

E1289 **POMALIDOMIDE ALONE OR IN COMBINATION WITH LOW DOSE DEXAMETHASONE AS MAINTENANCE FOLLOWING INDUCTION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MYELOMA (ALLG MM14)**
A Kalff[1], [2] ([1]Alfred Hospital, Melbourne, Australia, [2]Monash University, Melbourne, Australia)

E1290 **POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP**
L Pour[1] ([1]departement hematology and oncology , University hospital Brno, Brno, Czech Republic)

E1291 **UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN EUROPE**
T Bacon[1] ([1]Janssen Health Economics & Market Access EMEA, Dublin, Ireland)

E1292 **RAD REGIMEN AS INDUCTION BEFORE ASCT: OUTCOMES, SAFETY AND EFFECTS ON BONE METABOLISM AND ANGIOGENESIS; FINAL RESULTS OF A PHASE 2 STUDY OF THE GREEK MYELOMA STUDY GROUP**
E Terpos[1] ([1] Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)

E1293 **MULTIPLE MYELOMA IN THE REAL WORLD: HOW THERAPEUTIC LANDSCAPE HAS CHANGED IN THE LAST 15 YEARS**
F Cocito[1] ([1]Hematology, Policlinico S. Matteo, Pavia, Italy)

E1294 **CUL4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS**
A Malenda[1] ([1]Department of Hematology, Insititute of Hematology and Transfusion Medicine, Warsaw, Poland)

E1295 **MAINTENANCE THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER ASCT AND MINIMAL RESIDUAL DISEASE (MRD)**
M Solovev[1] ([1]Dept. of High-Dose Chemotherapy of Paraproteinemic Hemoblastosis, Research Center for Hematology, Moscow, Russian Federation)

E1296 **LONG-TERM OUTCOME OF MULTIPLE MYELOMA (MM) PATIENTS TREATED UP-FRONT WITH SINGLE OR TANDEM AUTOLOGUS STEM CELL TRANSPLANTATION (ASCT) - SINGLE CENTRE EXPERIENCE WITH 334 PATIENTS**
J Batinic[1], [2] ([1]Medical School, University of Zagreb, Zagreb, Croatia, [2]Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia)

E1297 **EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: CLINICAL IMPACT IN DIAGNOSIS, TREATMENT AND OUTCOME**
A Roque[1], [2] ([1]Faculty of Medicine, University of Coimbra, Coimbra, Portugal, [2]Clinical Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)

E1298 **DIFFERENCES IN PATIENT AND DISEASE CHARACTERISTICS OBSERVED AT INITIATION OF FIRST-LINE AND INITIATION OF SECOND-LINE TREATMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA IN THE CZECH REPUBLIC**
V Maisnar[1], [2] ([1]4th Department of Medicine – Haematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic, [2]Faculty of Medicine, Charles University Hospital , Hradec Kralove, Czech Republic)

E1299 **AN EARLY GOOD RESPONSE AFTER BORTEZOMIB-BASED INDUCTION REGIMENS REPRESENTS A SIGNIFICANT PREDICTOR FOR IMPROVED PFS IN NDMM PATIENTS**
G Rivoli[1] ([1]Clinica Ematologica, IRCCS San Martino IST, Genova, Italy)

E1300 **RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA**
D Makenbaeva[2] ([2]Bristol-Myers Squibb, Inc., Plainsboro, NJ, United States)

E1301 **POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY**
R Wester[1] ([1]Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands)

E1302 **INVOLVED/UNINVOLVED HEAVY/LIGHT CHAIN INDEX CAN PREDICT PROGRESSION IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM TRANSPLANT. PRELIMINARY EXPERIENCE**
M Espiño Martinez[1] ([1]Immunology, UNIVERSITY HOSPITAL RAMON Y CAJAL, Madrid, Spain)

E1303 **MULTIPLE MYELOMA IMMUNOPHENOTYPIC REMISSION IS A SIGNIFICANT PREDICTOR OF PROGRESSION FREE SURVIVAL AFTER FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION - PILOT STUDY**
K Beranova[1] ([1]IV. interni hematologicka klinika, Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic)

E1304 **REGULATION OF NORMAL AND MONOCLONAL IMMUNOGLOBULIN SECRETION BY CYTOKINES (S- SYNDECAN-1, BLYS & TGF-BETA-1) IN PATIENTS WITH IG-SECRETING B-CELL DISORDERS AT PRESENTATION. PROGNOSTIC IMPLICATIONS.**
P Papaioannou[1] ([1]Hematology Section - 1st Department Of Propaedeutic Internal Medicine, Laikon General Hospital, Athens, Greece)

E1305 **PATIENTS WITH MULTIPLE MYELOMA (MM) IN LONG TERM COMPLETE REMISSION (LTCR) AFTER AUTOLOGOUS TRANSPLANT (APBSCT) EXPRESS A DISTINCTIVE INMUNE PROFILE WITH POTENTIAL PROGNOSIS VALUE**
A Arteche-Lopez[1] ([1]Clinical Analisis, UNIVERSITY HOSPITAL LA PRINCESA, Madrid, Spain)

E1306 **IMPACT OF THE AFFORDABILITY OF NOVEL AGENTS IN PATIENTS WITH MULTIPLE MYELOMA: REAL WORLD DATA ON CURRENT CLINICAL PRACTICE IN MEXICO**
L Tarin-Arzaga[1] ([1]Hematology, Hospital Universitario Dr Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Mexico)

MYELOPROLIFERATIVE NEOPLASMS - BIOLOGY

E1307 **BASAL CALCIUM, AN IMPORTANT ELEMENT IN THE DEVELOPMENT OF CALR MUTANT MPNS**
M Morlan Mairal[1] ([1]Salford University, Manchester, United Kingdom)

E1308 **THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS**
B Beleslin Čokić[2] ([2]Clinic for endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia)

E1309 **CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB?**
L Catani[1] ([1]Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seragnoli", University of Bologna, Bologna, Italy)

E1310 **A COMPARATIVE FUNCTIONAL AND PHENOTYPIC PLATELET ANALYSIS AMONG GENETIC GROUPS OF ESSENTIAL THROMBOCYTHEMIA PATIENTS.**
P Papadopoulos[1], [2] ([1]Hematology, IdISCC (HCSC), Madrid, Spain, [2]Human Genetics, KU Leuven, Leuven, Belgium)

E1311 **ASSOCIATION ANALYSIS OF CYTOGENETIC AND GENETIC ALTERATIONS IN PRIMARY MYELOFIBROSIS**
R Norvilas[1], [2] ([1]Department of Innovative Medical Technologies and Health Resort Science, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, 2 Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania)

E1312 **FREQUENCY OF CONCURRENT BCR-ABL1, JAK2, CALR AND MPL MUTATIONS IN A COHORT OF 5,545 CASES WITH SUSPECTED MPN BY A DEEP SEQUENCING APPROACH**
S Jeromin[1] ([1]MLL Munich Leukemia Laboratory, Munich, Germany)

E1313 **A COMPREHENSIVE ASSESSMENT OF MOLECULAR AND CYTOGENETIC MARKERS OF PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS**
L Polushkina[1] ([1]Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation)

E1314 **JAK2 HAPLOTYPE 46/1 (GGCC) HAS NO EFFECT ON THE PRIMARY RISK OF JAK2 V617F MUTATION, BUT IT STRONGLY POTENTIATES THE PROGRESSION OF GROWN ALLELE BURDEN IN MYELOPROLIFERATIVE NEOPLASMS**
M Stolyar[1], [2] ([1]Siberian Federal University, Krasnoyarsk, Russian Federation, [2]Krasnoyarsk Branch of the Federal State-Funded Institution «National Research Center for Hematology» of the Ministry of Healthcare of the Russian Federation, Krasnoyarsk, Russian Federation)

E1315 **MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL PCR FOR JAK2V617F DETECTION IN PATIENTS WITH MYELOFIBROSIS (MF) OR ACUTE MYELOID LEUKEMIA SECONDARY TO MF AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**
S Salmoiraghi[1] ([1]Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Bergamo, Italy)

E1316 **S100A8/9 ACTIVATION OF MAPK PATHWAY IS SUPPORTED BY ITS RECEPTORS RAGE AND TLR4 IN POLYCYTHEMIA VERA**
M Kovačić[1] ([1]Laboratory of neuroendocrinology, Institute for Medical Research, Belgrade, Serbia)

E1317 **MUTATIONAL PROFILE STUDY OF DOUBLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS)**
G Carreno-Tarragona[1] ([1]Haematology, Hospital Universitario 12 de Octubre, Madrid, Spain)

E1318 **TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES**
S Galimberti[1] ([1]Clinical and Experimental Medicine, University of Pisa, Hematology, Pisa, Italy)

E1319 **PROINFLAMMATORY CYTOKINE IL-6 STIMULATION OF ANGIOGENIC FACTORS AND DNA REPLICATION IS BLOCKED BY JAK-STAT PATHWAY INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS**
T Subotički[1] ([1]Laboratory of neuroendocrinology, Institute for Medical Research, University of Belgrade, Belgrade, Serbia)

MYELOPROLIFERATIVE NEOPLASMS - CLINICAL

E1320 **PERCEPTION OF SYMPTOM BURDEN AND TREATMENT GOALS BETWEEN PHYSICIANS AND PATIENTS WITH MPNS: AN ANALYSIS FROM THE INTERNATIONAL MPN LANDMARK SURVEY**
L Foltz[1] ([1]St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada)

E1321 **BASELINE QUALITY OF LIFE INDEPENDENTLY PREDICTS OVERALL SURVIVAL IN THE MYELOFIBROSIS: KEY INSIGHTS FROM THE COMFORT-I STUDY**
R Scherber[1], [2] ([1]Hematology and Oncology, Mayo Clinic, Scottsdale, United States, [2]Hematology and Oncology, Oregon Health and Science University, Portland, United States)

E1322 **CHARACTERIZATION OF DISEASE AND OUTCOMES OF PATIENTS WITH MYELOFIBROSIS: A POPULATION BASED STUDY**
J He[1] ([1]Janssen Global Services LLC, Raritan, United States)

E1323 **SERUM ALBUMIN IS A STRONG PREDICTOR OF SURVIVAL IN MYELOFIBROSIS, INDEPENDENT OF IPSS, DIPSS, AND DIPSS+ SCORES**
AT Kuykendall[1] ([1]University of South Florida/Moffitt Cancer Center, Tampa, United States)

E1324 **CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING IN THE MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS**
W Alduaij[1] ([1]MPN program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada)

E1325 **IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB**
F Palandri[1] ([1]Department of Hematology, University of Bologna, Bologna, Italy)

E1326 **ANALYSES OF 845 PATIENTS WITH PMF, PET-MF AND PPV-MF TREATED IN 35 GERMAN HEMATOLOGY CENTERS – A RETROSPECTIVE FIELD STUDY**
B Kragl[1] ([1] Department of internal medicin 3, Hematology, Oncology, Palliative Care, University of Rostock, Rostock, Germany)

E1327 **CALR MUTATION TYPE INFLUENCES THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTEMIA ACCORDING TO A COOPERATIVE STUDY BETWEEN TWO SPANISH CENTERS**
A Abuín Blanco[1] ([1]Hematology, Complexo Hospitalario Universitario of Santiago of Compostela, Santiago, Spain)

E1328 **MONITORING OF LEUKOCYTE-PLATELET AGGREGATES AND SELECTIN LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS**
D Šefer[1] ([1]Outpatient Clinics and Diagnostic Department, Clinic for Hematology,Clinical Center of Serbia, Belgrade, Serbia)

E1329 **HEAT SHOCK PROTEIN 27 EXPRESSION IS INCREASED IN PATIENTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS AND MAY BE AFFECTING THEIR SURVIVAL**
R Kusec[2] ([2]Clinical Institute of Laboratory Diagnosis, Divison of Molecular Diagnosis and Genetics, Universitiy Hospital Dubrava, Zagreb, Croatia)

E1330 **NON-DRIVER MUTATIONS IDENTIFIED BY A 190-GENE NEXT GENERATION SEQUENCING PANEL IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST-POLYCYTHAEMIC/ESSENTIAL THROMOCYTHAEMIA MYELOFIBROSIS**
B Li[1] ([1]MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China)

E1331 **DETERMINING MEANINGFUL CHANGE IN THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V2.0 USING A COMBINATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES IN THE COMFORT-I TRIAL**
A Dueck[1] ([1]Mayo Clinic, Scottsdale, AZ, United States)

E1332 **ERYTHROPOIESIS STIMULATING AGENTS CAN IMPROVE ANEMIA IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB**
E Crisà[1] ([1]Hematology Division, A.O.U. Città della Salute e della Scienza di Torino,University of Turin, Torino, Italy)

E1333 **COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1–, INTERMEDIATE-2–, AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY**
F Passamonti[1] ([1]Universtiy of Insubria, Varese, Italy)

E1334 **SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) WHO STARTED TREATMENT AT 10 MG BID AND HAD THE DOSE UPTITRATED IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY**
L Foltz[1] ([1]St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada)

E1335 **HYDROXYUREA IS ASSOCIATED WITH SKIN TOXICITY IN MYELOPROLIFERATIVE NEOPLASMS: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL STUDY**
F Stegelmann[1] ([1]University Hospital of Ulm, Ulm, Germany)

E1336 **THE NEGATIVE PROGNOSTIC IMPACT OF BASOPHILIA, EOSINOPHILIA AND MONOCYTOSIS AT DIAGNOSIS IN PRIMARY MYELOFIBROSIS**
M Pereira[1], [2] ([1]Faculty of Medicine, University of Coimbra, Coimbra, Portugal, [2]Clinical Hematology Department, Coimbra University Hospital Centre, Coimbra, Portugal)

E1337 **BLAST PHASE IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF 85 PATIENTS**
E Roncoroni[1] ([1]Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy)

E1338 **TELOMERE LENGTH IS REDUCED IN ESSENTIAL THROMBOCYTHAEMIA PATIENTS COMPARED TO AGE AND GENDER MATCHED HEALTHY CONTROLS**
S Alimam[1] ([1]Haematology, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom)

E1339 **NUTRITION IN MYELOFIBROSIS: CORRELATES FROM THE COMFORT-1 STUDY**
R Scherber[1], [2] ([1]Hematology and Oncology, Mayo Clinic, Scottsdale, United States, [2]Hematology and Oncology, Oregon Health and Science University, Portland, United States)

E1340 **IS THE SURVIVAL OF PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BETTER IN THE LAST DECADE? RETROSPECTIVE ANALYSIS OF DATABASE OF LATIAL GROUP FOR THE STUDY OF NMP, PH NEGATIVE.**
A Andriani[2] ([2]UOSD of Hematology, ASL Roma1, Ospedale Santo Spirito & Nuovo Regina Margherita, Rome, Italy)

E1341 **CUTANEOUS INVOLVEMENT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS-SINGLE-CENTER EXPERIENCE.**
JM Sanchez-Raga[1], [2] ([1]Hematology and Hemotherapy, Fundación de Investigación Sanitaria de las Islas Baleares Ramon Llull, Palma de Mallorca, Spain, [2]Hematology and Hemotherapy, Hospital Universitari Son Espases, Palma de Mallorca, Spain)

E1342 **HEMOGLOBIN AND WHITE CELL COUNT IN PATIENTS CLINICALLY SUSPECTED TO HAVE ESSENTIAL THROMBOCYTHEMIA MAY HELP IN PREDICTING EARLY PRIMARY MYELOFIBROSIS OR UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASM**
S Sirhan[1] ([1]Jewish General Hospital Montreal, Montreal, Canada)

E1343 **PK/PD MODELING COMPARING DIVIDED DOSING (200 MG TWICE-DAILY [BID]) VS SINGLE DOSING (400 MG ONCE-DAILY [QD]) OF PACRITINIB (PAC) IN PATIENTS WITH MYELOFIBROSIS (MF) ON THE PERSIST-2 PHASE 3 TRIAL**
S Al-Fayoumi[1] ([1]CTI BioPharma Corp., Seattle, WA, United States)

E1344 **ZMYM2-FLT3 IS A RARE, RECURRENT, CYTOGENTICALLY CRYPTIC FUSION IN MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA THAT IS RESPONSIVE TO FLT3 INHIBITION**
M Jawhar[1] ([1]Department of Hematology and Oncology, Medical Faculty Mannheim of University of Heidelberg, Mannheim, Germany)

E1345 **COMPLETE HEMATOLOGIC AND CYTOGENETIC RESPONSE IN A PATIENT WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 ACTIVATED MYELOPROLIFERATIVE NEOPLASM RECEIVING INCB054828**
N Daver[1] ([1]MD Anderson Cancer Center, Houston, TX, United States)

E1346 **THE GRADE OF STROMAL CHANGES IMPACTS ON PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS**
U Gianelli[1] ([1]Division of Pathology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation and University of Milan, Milano, Italy)

E1347 **INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS**
M Bak[1] ([1]Department of Haematology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark)

E1348 **ESSENTIAL THROMBOCYTHEMIA WITH AQUAGENIC PRURITUS: AN ENTITY WITH MORE AGRESSIVE CLINICAL AND BIOLOGICAL PROFILE AT THE DIAGNOSIS AND A HIGH MORBIDITY DURING THE FOLLOW-UP.**
C Le Gall-Ianotto[1], [2] ([1]Service dermatologie, CHU Brest - Hôpital Augustin Morvan, Brest, France, [2]laboratory of interactions epitheliums-neurones, university of Brest, Brest, France)

E1349 **ANAGRELIDE RESPONSE ACCORDING TO THE MOLECULAR PROFILE: SOMETHING TO CONCLUDE ON THE MECHANISM OF ACTION OF THE DRUG IN MYELOPROLIFERATIVE NEOPLASMS (MPN)?**
M Montero[1] ([1]Haematology and haemotherapy Service, Hospital Universitario Virgen del Rocío, Sevilla, Spain)

E1350 **THE DELAYED DIAGNOSIS OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN) IS COMMON AND RESULTS IN A HIGH INCIDENCE OF POTENTIALLY PREVENTABLE THROMBOTIC COMPLICATIONS.**
C Forsyth[1] ([1]Medicine, Wyong Hospital, Kanwal, Australia)

E1351 **LONG-TERM AND LOW-DOSE BUSULFAN IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA**
R Renso[1] ([1]Hematology Division, San Gerardo Hospital, Monza, Italy)

E1352 **DIFFERENCES IN JAK2V617F POSITIVE PATIENTS WITH AND WITHOUT THROMBOSIS ACCORDING TO DIAGNOSIS, AGE, SEX AND V617F ALLELE BURDEN**
I Horvat[1] ([1]Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia)

NON-HODGKIN & HODGKIN LYMPHOMA - BIOLOGY

E1353 **PROTECTION AGAINST DEVELOPMENT OF B CELL LYMPHOMA BY TETRASPANIN CD37**
A Van Spriel[1] ([1]Radboud University Medical Center, Nijmegen, the Netherlands)

E1354 **CONCOMITANT DUAL ABLATION OF BLIMP1 AND P53 IN B-CELLS AS A NOVEL IN VIVO MODEL FOR HIGH-GRADE B-CELL LYMPHOMA**
A Roccaro[1] ([1]ASST Spedali Civili di Brescia, Brescia, Italy)

E1355 **IDENTIFICATION AND CHARACTERISATION OF THE LYMPHOMA INITIATING CELL (LIC) POPULATION IN AN ALCL MOUSE MODEL**
S Kreutmair[1] ([1]Hematology, Oncology and Stem Cell Transplantation, University medical center Freiburg, Freiburg, Germany)

E1356 **HSP110 SUSTAINS MYD88-DEPENDENT NFKB SIGNALING IN ACTIVATED B CELL DIFFUSE LARGE B CELL LYMPHOMA**
G Jego[1] ([1]University of Burgundy, Dijon, France)

E1357 **STAT3 ACTIVATION MEDIATES CD8+/CD16+/CD56- T-LGLL NEUTROPENIA THROUGH FAS LIGAND SECRETION**
G Barila'[1], [2] ([1]Dept of Medicine, Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy, [2]Venetian Institute of Molecular Medicine, Padua, Italy)

E1358 **CYCLIN D2 OVEREXPRESSION RECAPITULATES MANTLE CELL LYMPHOMA IN MICE**
T Pieters[1] ([1]Ghent University, Ghent, Belgium)

E1359 **HDAC6 INHIBITION INCREASES CD20 LEVEL BY STIMULATING TRANSLATION OF CD20 MRNA**
A Graczyk-Jarzynka[1] ([1]Department of Immunology, Medical University of Warsaw, Warsaw, Poland)

E1360 **CARD11 DUPLICATION AT DIAGNOSIS IDENTIFIES VERY LOW-RISK MANTLE CELL LYMPHOMA PATIENTS:RESULTS OF THE LYMA-GENOMIC PROJECT CONDUCTED ON BEHALF OF THE LYSA GROUP.**
Y Le Bris[1], [2] ([1]Hematology biology, Nantes University Hospital, Nantes, France, [2]CRCINA, INSERM UMR1232, Nantes, France)

E1361 **CLINICOBIOLOGICAL FEATURES OF B-CELL NEOPLASMS WITH CDK6 TRANSLOCATIONS: FREQUENT ASSOCIATION WITH MARGINAL-ZONE LYMPHOMA, CONTINGENT OF PROLYMPHOCYTIC CELLS AND TP53 ABNORMALITIES. A GFCH STUDY.**
E Chapiro[2], [4] ([2]Service d'Hematologie biologique, Hopital Pitie-Salpetriere, AP-HP, PARIS, France, [4]UNIVERSITE PIERRE ET MARIE CURIE, Paris, France)

E1362 **PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE, EXPRESS STEREOTYPED B-CELL RECEPTORS WITH UNIQUE NONSYNONYMOUSLY MUTATED CONSTANT REGIONS**
MT Koning[1] ([1]Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands)

E1363 **LOSS OF NR4A1 ACCELERATES MYC-DRIVEN LYMPHOMAGENESIS ACCOMPANIED BY OVEREXPRESSION OF GENES INVOLVED IN IMMUNOREGULATION**
K Fechter[1] ([1]Department of Hematology/ University Clinic for Internal Medicine, Medical University of Graz, Graz, Austria)

E1364 **DISSECTING THE PI3K PATHWAY IN A CYCLIN D1-DRIVEN MODEL OF MCL**
S Ehrenfeld[1], [2], [3], [4] ([1]Department of Medicine I: Hematology, Oncology, and Stem-Cell Transplantation, Medical Center, University Freiburg, Freiburg, Germany, [2]German Cancer Consortium (DKTK) Partnersite Freiburg, Freiburg, Germany, [3]German Cancer Research Center (DKFZ), Heidelberg, Germany, [4]Faculty of Biology, University Freiburg, Freiburg, Germany)

E1365 **MUTATIONAL PROFILING OF HODGKIN- AND REED-STERNBERG CELLS (HRSC) OF CLASSICAL HODGKIN LYMPHOMA (CHL) ENRICHED FROM ARCHIVAL FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE SAMPLES**
D Juskevicius[1] ([1]Institute of Pathology, University Hospital Basel, Basel, Switzerland)

E1366 **LACK OF STAT1 PREDISPOSES TO A DIFFUSE LARGE B-CELL LYMPHOMA-LIKE DISEASE**
S Tripolt[1] ([1]Institute of Pharmacology and Toxicology, Veterinary University of Vienna, Vienna, Austria)

E1367 **MOLECULAR HETEROGENEITY OF MANTLE CELL LYMPHOMA**
O Cédile[1] ([1]Haematology-Pathology Research Laboratory, Department of Haematology, Odense University Hospital, Odense C, Denmark)

E1368 **NOVEL TARGET GENES OF DEREGULATED MIRNAS IN DLBCL REVEALED BY ENDOGENOUS AGO2 PAR-CLIP**
M Fernandez-Mercado[1], [2] ([1]Oncology, Biodonostia HRI, San Sebastian, Spain, [2]Biomedical Engineering, School of Engineering, University of Navarra, San Sebastian, Spain)

E1369 **DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA**
A Matas-Céspedes[1] ([1]Hematology-Oncology, IDIBAPS, Barcelona, Spain)

E1370 **ECTONUCLEOTIDASES CD39/CD73 ARE HIGHLY EXPRESSED ON ATLL CELLS AND RESPONSIBLE FOR GENERATING AMP/ADENOSINE.**
Y Nagate[1] ([1]Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan)

E1372 **ACTIVATION OF SYK TYROSINE KINASE PLAYS A ROLE IN RESISTANCE AGAINST THE SELECTIVE BTK INHIBITOR ONO/GS-4059 IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).**
K Tsukamoto[1] ([1]Cancer studies, University of Leicester, Leicester, United Kingdom)

E1373 **STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA (NHL)**
A Molina[1] ([1]Sutro Biopharma, South San Francisco, United States)

E1374 **DETECTING MALIGNANT B-CELLS IN CEREBROSPINAL FLUID: DOES THE IDEAL METHOD EXIST?**
M Le Garff-Tavernier[1] ([1]Biological Haematology Department, Pitie-Salpetriere Hospital, Paris, France)

E1375 **THE SYK INHIBITOR R406 DRAMATICALLY INCREASES THE SENSITIVITY OF GCB AND ABC DLBCL CELL LINES TO THE BCL-2 INHIBITOR VENETOCLAX**
B Sasi[1] ([1]Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Trieste, Italy)

E1376 **VĐ EXPRESSION ASSESSMENT AND CLONALITY DETECTION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) BY FLOW CYTOMETRY (FCM) AND NEXT GENERATION SEQUENCING (NGS): A COMPARISON OF BOTH METHODS**
M Kotrová[1, 2] ([1]Medical Department II, Unit for Hematological Diagnostics, University Hospital Schleswig-Holstein, Kiel, Germany, [2]contributed equally, Kiel, Germany)

E1377 **IRF4 EXPRESSION IS ASSOCIATED WITH RESPONSE OF MANTLE CELL LYMPHOMA TO BRUTON'S TYROSINE KINASE INHIBITORS**
HP Thompson[1] ([1]Institute of Translational and Stratified Medicine, Plymouth University, Peninsula Schools of Medicine and Dentistry , Plymouth , United Kingdom)

E1378 **LOSS OF TPL2 KINASE ACCELERATES MYC-INDUCED LYMPHOMAGENESIS**
E Stagakis[1, 2] ([1]Laboratory of Molecular and Cellular Biology, Medical School, University of Crete, Heraklion, Greece, [2]Department of Hematology, University Hospital of Heraklion, Heraklion, Greece)

E1379 **LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA**
F Marchesi[1] ([1]Hematology and Stem Cell Transplant, Regina Elena National Cancer Institute, Rome, Italy)

E1380 **INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL**
E Vilventhraraja1 (1Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom)

E1381 **CYCLIN D1 ONCOGENIC OVEREXPRESSION LEADS TO A GLOBAL TRANSCRIPTIONAL DOWNREGULATION IN MALIGNANT LYMPHOID CELLS**
R Albero[1] ([1]IDIBAPS, Barcelona, Spain)

E1382 **MICROENVIRONMENTAL EXPRESSION OF IMMUNOREGULATORY MOLECULES AND CYTOKINES IN CLASSICAL HODGKIN LYMPHOMA PROGNOSIS**
O Novosad[1] ([1]Oncohematology, National Cancer Institute, Kiev, Ukraine)

E1383 **AN IN VIVO TRACEABLE AND MULTIPLEXING CRISPR/CAS9 GENOME EDITING SYSTEM**
L Cheng[1] ([1]Department of Hematology and Research Laboratory of Hematology, West China Hospital Sichuan University, Chengdu, China)

E1385 **HDAC6 INHIBITION SENSITIZES TUMOR CELLS TO ANTI-CD20 IMMUNOTHERAPY IN VIVO**
M Bobrowicz[1] ([1]Department of Immunology, MEDICAL UNIVERSITY OF WARSAW, Warsaw, Poland)

E1386 **NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY.**
M Cheminant[1, 2] ([1]Hematology Unit, Necker Hospital - Paris Descartes – Sorbonne Paris Cité University, Paris, France, [2]U1163, IMAGINE Institute, Paris, France)

E1387 **HIGH EXPRESSION LEVELS OF MIR23A CLUSTER IN DLBCL ANTAGONIZE INDUCTION OF APOPTOSIS**
S Eberth[1] ([1]Junior Research Group Molecular Cancer Research, Leibniz-Institute DSMZ - German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany)

E1388 **PLASMA CELLS ARISE FROM DIFFERENTIATION OF CLONAL LYMPHOCYTES AND SECRETE IGM IN WALDENSTRÖM MACROGLOBULINEMIA**
D Talaulikar[1, 2] ([1]Haematology, Canberra Hospital, Canberra, Australia, [2]Australian National University, Australian National University, Canberra, Australia)

E1389 **LMP-1 MEDIATED UPREGULATION OF IL-2RĐ PROMOTES LYMPHOMAGENESIS AND CHEMOTHERAPY RESISTANCE IN NATURAL KILLER/T-CELL LYMPHOMA AND COULD BE A POTENTIAL THERAPY TARGET**
L Wang[2] ([2]Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)

E1390 **LENALIDOMIDE (LEN) DRIVES PROGRAMMED DEATH-1 (PD1) PATHWAY UPREGULATION IN A TUMOR MICROENVIRONMENT (TME) MODEL OF ACTIVATED LOW-GRADE LYMPHOMA CELLS**
F Morabito[1, 20] ([1]Unita di Ricerca Biotecnologica, Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), Italy, [20]Hematology Department, Annunziata Hospital of Cosenza, Cosenza, Italy)

E1391 **IDENTIFICATION AND DIAGNOSTIC APPLICATION OF GENOMIC NPM-ALK FUSION SEQUENCES IN ANAPLASTIC LARGE CELL LYMPHOMAS**
M Krumbholz[1] ([1]Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany)

E1392 **ARSENIC TRIOXIDE TARGETS BCL6 FOR DEGRADATION AND INHIBITS THE PROLIFERATION OF BCL6-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA**
E Tse[1] ([1]Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong)

E1393 **PROTEOMIC PHOSPHOSITE ANALYSIS IDENTIFIED CRUCIAL NIPA SERINE RESIDUES FOR NPM-ALK-MEDIATED TRANSFORMATION**
A Gengenbacher[1] ([1]Dept. of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany)

E1394 **APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B CELL LYMPHOMAS**
MJ Baptista[1] ([1]Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain)

E1395 **CXCR4 AND CXCL12 ARE IMPLICATED IN BONE MARROW INFILTRATION PROCESS OF AGGRESSIVE B CELL LYMPHOMAS AND THEIR INHIBITION SUPPRESSES LYMPHOMA CELL GROWTH IN VITRO**
A Deutsch[1] ([1]Hematology, Internal Medicine, Graz, Austria)

E1396 **EPSTEIN-BARR VIRUS LOAD IN PLASMA IS AN EARLY BIOMARKER OF HIV-RELATED LYMPHOMA**
J Muncunill[1] ([1]Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain)

E1397 **CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA**
A Teramo[1, 2] ([1]Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padova, Italy, [2]Venetian Institute of Molecular Medicine (VIMM), Padova, Italy)

E1398 **INCREASED EXPRESSION OF IRF8 IN TUMOR CELLS INHIBITS THE GENERATION OF TH17 CELLS AND PREDICTS UNFAVORABLE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS**
Q Li[1] ([1]Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China, Guangzhou, China)

E1399 **GENOMIC PROFILING OF BCL2 AND MYC DOUBLE EXPRESSOR DIFFUSE LARGE B CELL LYMPHOMA**
V Dirse[1, 2] ([1]Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, [2]Department of Internal, Family Medcine and Oncology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania)

E1400 **ARQ 531, A REVERSIBLE BTK INHIBITOR, DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN ABC-DLBCL AND GCB-DLBCL**
S Eathiraj[1] ([1]Clinical Development, ArQule Inc.,, Burlington, United States)

E1401 **ROLE OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY**
L Rigacci[1] ([1]Haematology, AOU Careggi and University of Florence, Florence, Italy)

E1402 **CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB**
L Fischer[1] ([1]Dept. of Medicine III, Univ. Hospital Grosshadern/LMU; Experimental Leukemia and Lymphoma Research (ELLF), Munich, Germany)

E1403 **CD8+ T-CELL CLONES PERSISTENT IN BONE MARROW AND PERIPHERIAL BLOOD DURING COURSE OF CD4+ ANGIOIMMUNOBLASTIC LYMPHOMA**
S Smirnova[1] ([1]Department of Molecular Hematology, National Research Center for Hematology, Moscow, Russian Federation)

E1404 **CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA SHOWED FREQUENT MYC EXPRESSION AND AGGRESSIVE CLINICAL BEHAVIOR**
JE Kim[8] ([8]Pathology, Seoul National University Boramae Hospital, Seoul, Korea, Republic Of)

E1405 **REACTIVE FLORID B-LINEAGE LYMPHOID PROLIFERATIONS IN HIV INFECTION MAY MIMIC LYMPHOMA**
T Wiggill[1] ([1]Molecular Medicine and Haematology, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa)

E1406 **MICROVESSEL DENSITY IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMAS.**
F Gaudio[1] ([1]Hematology, Bari, Italy)

E1407 **ANTIGEN SELECTION PROMOTES CLONAL CYTOTOXIC T-CELL RESPONSES: HIGH-THROUGHPUT IMMUNOGENETIC EVIDENCE**
E Stalika[1] ([1]Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece)

E1408 **MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES**
I Della Starza[1] ([1]Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy)

E1409 **RHOA GLY17VAL MUTATION AND T-CELL CLONALITY ANALYSIS IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA**
Y Sidorova[1] ([1]Department of Molecular Hematology, National Research Center for Hematology, Moscow, Russian Federation)

OTHER NON-MALIGNANT HEMATOPOIETIC DISORDERS

E1410 **USEFULNESS OF CHITOTRIOSIDASE ACTIVITY, CCL18/PARC, 7-KETOCHOLESTEROL AND GLUCOSYLSPHINGOSINE CONCENTRATIONS FOR SCREENING OF LYSOSOMAL STORAGE DISORDERS.**
P Irún[1], [2] ([1]Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Zaragoza, Spain, [2]Unidad Investigación Traslacional. Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain)

E1411 **THE VALUE OF SOLUBLE IL-2R APLHA SUBUNIT MEASUREMENT IN CSF OF CHILDREN WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH): PRELIMINARY OBSERVATIONS**
Y El Chazli[1] ([1]Department of Pediatrics, Hematology/Oncology unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt)

E1412 **GAUCHER DISEASE PATIENTS EXHIBIT A HIGH EXPRESSION OF LIPOCALINE (LCN2) AS POSSIBLE BIOMARKER OF RESIDUAL DISEASE ACTIVITY. EXPLORATORY STUDY AND CORRELATION WITH OTHER CYTOKINES.**
M Andrade-Campos[1] ([1]Translational Research Unit, IIS-Aragon. CIBERER. IISCIII, Zaragoza, Spain)

E1413 **COMPARISON OF TREATMENT AND OUTCOMES BETWEEN ACQUIRED PRIMARY AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA**
SH Wai[1], [2] ([1]Monash University, Melbourne, Australia, 2 Singapore General Hospital, Singapore, Singapore)

E1414 **EVANS SYNDROME IN CHILDHOOD: LONG TERM SINGLE CENTER EXPERIENCE**
M Economou[1] ([1]Aristotle Universtity of Thessaloniki, Thessaloniki, Greece)

E1415 **LOW DOSE RITUXIMAB IS A USEFUL ADDITION TO CORTICOSTEROIDS FOR NEWLY DIAGNOSED PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA**
A Gomez-De Leon[1] ([1]Hematology, Hospital Universitario Dr Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Mexico)

E1416 **INFECTIOUS COMPLICATIONS IN PRIMARY AUTOIMMUNE NEUTROPENIA OF CHILDHOOD**
A Makis[1] ([1]Department Of Pediatrics, University Hospital Of Ioannina, Ioannina, Greece)

E1417 **NEW EPO-RECEPTOR MUTATION IN A -17 YEAR OLD WOMAN WITH ERYTHROCYTOSIS**
B Robredo[1] ([1]Hematology, Hospital Universitario Son Espases, Palma De Mallorca, Spain)

E1418 **FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN**
Z Salcioglu[1] ([1]Pediatric Hematology and Oncology Clinic, İstanbul Kanuni Sultan Süleyman Education and Research Hospital, İstanbul, Turkey)

E1419 **ABNORMAL MONOCYTE POPULATIONS IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONID IDIOPATHIC NEUTROPENIA**
M Velegraki[1] ([1]Department of Haematology, University of Crete School of Medicine, Heraklion, Greece)

E1420 **DIAGNOSTIC VALUE OF CELL BOUND AND CIRCULATING ANTI-NEUTROPHIL ANTIBODY DETECTION IN PEDIATRIC NEUTROPENIA**
L Porretti[1] ([1]Flow Cytometry Service, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

E1421 **INAPPROPRIATE TREATMENT COULD MASK COBALAMIN DEFICIENCY: ROLE OF METHYLMALONIC ACID EVALUATION.**
R Angel F.[1] ([1]Hematology, Hospital de Sant Pau, Barcelona, Spain)

E1422 **ACTIVATED PI3K-D SYNDROME IN A PEDIATRIC PATIENT WITH RECURRENT EBV ASSOCIATED LYMPHOPROLIFERATION**
FB Belen[1] ([1]Department of Pediatric Hematology and Oncology, Izmir Katip Celebi University Medical Faculty, Izmir, Turkey)

E1423 **RITUXIMAB IN AUTOIMMUNE HEMOLYTIC ANEMIA OF INFANCY**
M Economou[1] ([1]Aristotle Universtity of Thessaloniki, Thessaloniki, Greece)

E1424 **EARLY LESSONS FROM WHOLE-GENOME SEQUENCING IN THE CLINICAL DIAGNOSIS OF RARE INHERITED ANAEMIAS**
N Roy[1, 2] ([1]Molecular Haematology Unit, OXFORD UNIVERSITY HOSPITALS NHS TRUST, Oxford, United Kingdom, [2]BRC Molecular Diagnostic Centre, OXFORD UNIVERSITY HOSPITALS NHS TRUST, Oxford, United Kingdom)

E1425 **CONGENITAL ERYTHROCYTOSIS: DISCOVER OF A NEW MUTATION**
J Barradas[1] ([1]Serviço de Hematologia Clínica, Centro Hospitalar Tondela-Viseu, Viseu, Portugal)

E1426 **A RETROSPECTIVE STUDY OF THE THROMBOTIC MICROANGIOPATHIES DIAGNOSED IN THE LAST 17 YEARS IN ONE SINGLE CENTRE**
A Esteban Figuerola[1] ([1]Hospital Joan XXIII Tarragona, Tarragona, Spain)

E1427 **CHILDREN WITH CHRONIC-REFRACTORY AUTOIMMUNE CYTOPENIAS: A SINGLE CENTER EXPERIENCE**
TH Karapınar[1] ([1]Pediatric Hematology and Oncology, Dr. Behcet Uz Children Training and Research Hospital, Izmir, Turkey)

E1428 **INHERITED PROTHROMBOTIC RISK FACTORS IN TURKISH CHILDREN WITH HEREDITARY ANGIOEDEMA. SINGLE CENTER**
T Patiroglu[1] ([1]Pediatric Hematology, Erciyes University Medical Faculty, Kayseri, Turkey)

E1429 **FLOW CYTOMETRIC ANALYSIS OF TISSUE SAMPLES IN 42 ADULT PATIENTS WITH MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS**
M Klimkowska[1] ([1]Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden)

PLATELETS DISORDERS

E1430 **BLEEDING IN PRIMARY IMMUNE THROMBOCYTOPENIA: WHO ARE MOST AT RISK?**
U Doobaree[1] ([1]Haematology, Barts and The London School of Medicine and Dentistry, London, United Kingdom)

E1431 **A MULTICENTRE, SINGLE ARM, OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ELTROMBOPAG IN PATIENTS WITH SEVERE PERSISTENT IMMUNE THROMBOCYTOPENIC PURPURA (ITP) WITHIN SIX MONTHS OF DIAGNOSIS**
H Tran[1, 2] ([1]Clinical Haematology, Monash University, Melbourne, Australia, [2]Clinical Haematology, The Alfred Hospital, Melbourne, Australia)

E1432 **A NOVEL RUNX1 MUTATION IN FAMILY WITH FAMILIAL PLATELET DISORDER WITH PREDISPOSITION TO ACUTE MYELOGENOUS LEUKEMIA**
L Krupkova[1] ([1]Department of Hemato-oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic)

E1434 **PROFILING CIRCULATING MICRORNAS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) TO EXPLORE THE ROLE OF MICRORNAS AND POSSIBLE BIOLOGICAL PATHWAYS INVOLVED IN THE PATHOGENESIS OF ITP**
L Garabet[1, 2, 3] ([1]Institute of Clinical Medicine, University of Oslo, Oslo, Norway, [2]Akershus University Hospital, Lørenskog, Norway, [3]Østfold Hospital Trust, Grålum, Norway)

E1435 **NORDIC COUNTRY PATIENT REGISTRY FOR IMMUNE THROMBOCYTOPENIA (NCPRITP): A COHORT OF PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA IN DENMARK, SWEDEN, AND NORWAY**
W Ghanima[3] ([3]Department of Medicine, Østfold Hospital Trust, Fredrikstad, Norway)

E1436 **EPIDEMIOLOGY OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ADULTS IN RUSSIAN FEDERATION (RESULTS OF REGISTRY OF NATIONAL HEMATOLOGIC ASSOCIATION)**
A Melikyan[1] ([1]Standartisation of methods of therapy, National Research Center for Hematology, Moscow, Russian Federation)

E1437 **ELTROMBOPAG (EPAG) FOR THE TREATMENT OF PATIENTS AGED ↗65 YEARS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP): SAFETY AND EFFICACY RESULTS FROM THE EXTEND STUDY**
A Salama[1] ([1]Charite-Universitätsmedizin, Berlin, Germany)

E1438 **SAFETY AND EFFICACY OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Y Yamada[1] ([1]Medicine, Mount Sinai Beth Israel, New York, United States)

E1439 **CHILDHOOD IMMUNE THROMBOCYTOPENIA: A NATIONWIDE COHORT STUDY ON CONDITION MANAGEMENT AND OUTCOMES**
C Nordon[2] ([2] LASER, PARIS, France)

E1440 **SIROLIMUS FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME. A SINGLE CENTRE EXPERIENCE**
M Miano[1] ([1]Haematology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy)

E1441 **ASSESSMENT OF ROMIPLOSTIM SELF-ADMINISTRATION BY PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA AND CAREGIVERS FOLLOWING RECEIPT OF HOME ADMINISTRATION TRAINING (HAT) MATERIALS: A CROSS-SECTIONAL STUDY**
M Schipperus[1] ([1]Department of Haematology, Haga Teaching Hospital, The Hague, the Netherlands)

E1442 **FCĐIIA 131 H/R (A→G) RECEPTOR GENE POLYMORPHISM IN PATIENTS OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)**
A Tripathi[1] ([1]Clinical Hematology, K.G. Medical University Lucknow India, Lucknow, India)

E1443 **SHORT- AND LONG-TERM RESULTS OF FIRST LINE THERAPY WITH PULSED HIGH-DOSE DEXAMETHASONE IN ADULT IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE SINGLE-CENTER REPORT.**
L Crucitti[1] ([1]Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, MILANO, Italy)

E1444 **EFFECT OF OSELTAMIVIR TREATMENT ON PLATELET COUNTS**
N Revilla[1] ([1]Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)

E1445 **CLINICAL UTILITY OF CARDIAC MRI IN IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA**
F Alwan[1] ([1] Haematology Department, University College London Hospital, London, United Kingdom)

E1446 **THE FREQUENCY AND CLINICAL SIGNIFICANCE OF MEFV GENE MUTATIONS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**
I Kaygusuz Atagunduz[1] ([1]Hematology, Marmara University Hospital, Istanbul, Turkey)

E1447 **PD-1 AND CTLA-4 POLYMORPHISMS AFFECT THE SUSCEPTIBILITY AND CLINICAL FEATURES OF CHRONIC IMMUNE THROMBOCYTOPENIA.**
R Ino[1] ([1] Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan)

E1448 **IS THE SPLENECTOMY OUTCOME PREDICTABLE IN PATIENTS WITH ITP?**
M Mitrovic[1], [2] ([1]Clinic of Hematology, CCS, Belgrade, Serbia, [2]Faculty of Medicine, University of Belgrade, Belgrade, Serbia)

E1449 **FINAL RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU) OF ADULT PATIENTS TREATED WITH ROMIPLOSTIM FOR PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE IN GERMANY**
M Reiser1 (1PIOH Koeln, Koeln, Germany)

E1450 **THE CLINICAL UTILITY OF NEUROPSYCHOLOGY TESTING IN IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA**
F Alwan1 (1Haematology Department, University College London Hospital, London, United Kingdom)

E1451 **FIVE NEW CASES OF HERMANSKY-PUDLAK SYNDROME: IDENTIFICATION OF NOVEL GENETIC VARIANTS IN HPS4 AND HPS3 ASSOCIATED TO RELEVANT CLINICAL COMPLICATIONS**
J Bastida[1] ([1]Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain)

E1452 **CHARACTERIZATION OF PLATELET ACTIVATION MARKERS IN EARLY ONSET PREECLAMPSIA**
D Angelov[1], [2] ([1] School of Medicine, University College Dublin, Dublin, Ireland, [2] UCD Conway SPHERE Research Group, University College Dublin, Dublin, Ireland)

E1453 **PRIMARY ITP IN ADULTS TREATED WITH ELTROMBOPAG: A RETROSPECTIVE STUDY USING DATA FROM THE UNITED KINGDOM ADULT IMMUNE THROMBOCYTOPENIA REGISTRY.**
D Provan[1] ([1]Haematology, Barts and The London School of Medicine and Dentistry, London, United Kingdom)

E1454 **EFFICACY OF TPO-MIMETICS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**
F Bacchiarri[1] ([1]Hematology, AOU Careggi, Firenze, Italy)

E1455 **PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP PATIENTS**
A Rovó[3] ([3]University Hospital of Bern, Bern, Switzerland)

E1456 **OSELTAMIVIR FOR THE TREATMENT OF ITP PATIENTS NOT RESPONDING TO CONVENTIONAL TREATMENT: BIOLOGICAL CHARACTERIZATION AND CLINICAL RESPONSES**
N Revilla[1] ([1]Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS

E1457 **BORTEZOMIB THERAPY IS ASSOCIATED WITH SIGNIFICANT RESOURCE IMPLICATIONS FOR BOTH PATIENTS AND PROVIDERS: RESULTS OF A TIME-IN-MOTION STUDY**
A Peniket[1] ([1]Haematology , Oxford University Hospitals NHS Trust , Oxford , United Kingdom)

E1458 **HOSPITAL CARE AT HOME ADMINISTRATION OF SUBCUTANEOUS AZACITIDINE IS FEASIBLE AND PREFERRED BY PATIENTS COMPARED TO HOSPITAL ADMINISTRATION: A FRENCH REGIONAL HEMATOLOGY NETWORK EXPERIENCE**
M Touati[1], [2] ([1]Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire, Limoges, France, [2]Réseau Hématolim, Centre Hospitalier Universitaire, Limoges, France)

E1459 **USE OF COMBINED ORAL FENTANYL CITRATE (ACTIQ®) AND MIDAZOLAM AS PREMEDICATION FOR BONE MARROW BIOPSY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED PATIENT BLINDED CLINICAL TRIAL**
C Cerchione[1] ([1]Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy)

E1460 **ASSESSMENT OF THE ECONOMIC IMPACT OF HORSE-ATG IN SWEDEN FOR APLASTIC ANAEMIA**
V Katkade[6] ([6] Pfizer, Philidelphia, United States)

E1461 **NEUROPSYCHOLOGICAL ANALYSIS OF LONG-TERM CONSEQUENCES OF ANTINEOPLASTIC TREATMENT**
S Khrushchev[2] ([2] National Research Institute for Hematology, Moscow, Russian Federation)

E1462 **A CLINICAL AUDIT OF NUTRITIONAL SCREENING AND SUPPORT OF HOSPITALIZED PATIENTS WITH HEMATOLOGIC DISEASES.**
P Diamantopoulos[1] ([1] 1st Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece)

E1463 **ASSESSING REAL-WORLD TREATMENT PATTERNS, OUTCOMES AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) POST AUTOLOGOUS STEM CELL TRANSPLANT ACROSS EUROPE**
D Judge[2] ([2]Adelphi Real World, Bollington, United Kingdom)

E1464 **NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US)**
MY Levy[1] ([1]Baylor University Medical Center, Dallas, TX, United States)

E1465 **THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS**
C Rowntree[3] ([3] University Hospital of Wales, Cardiff, United Kingdom)

E1466 **IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE 2, OPEN-LABEL STUDY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY**
W Wierda[1] ([1]The University of Texas MD Anderson Cancer Center, Houston, United States)

E1467 **WHICH HAEMATOLOGICAL CONDITIONS CAN THIRD YEAR MEDICAL STUDENTS RECOGNISE INTERPRETING FULL BLOOD COUNT RESULTS?**
S Lovato[1], [2] ([1]Postgraduate, London North West Healthcare NHS Trust, London, United Kingdom, 2 Undergraduate, Imperial College London, London, United Kingdom)

E1468 **LONGITUDINAL ASSOCIATIONS BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTHCARE UTILIZATION IN AL AMYLOIDOSIS**
KL McCausland[1] ([1]Optum, Lincoln, United States)

E1469 **SAFETY, FEASIBILITY AND EFFECTIVENESS OF ELECTRICAL MUSCLE STIMULATION IN HOSPITALIZED PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION AND INTENSIVE CHEMOTHERAPY**
A Klostermann[1] ([1]Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany)

E1470 **MYELOMA PATIENT VALUE MAPPING: A DISCRETE CHOICE EXPERIMENT**
J Galinsky[1] ([1]Research, Myeloma UK, Edinburgh, United Kingdom)

E1471 **COST-MINIMIZATION ANALYSIS OF RITUXIMAB SUBCUTANEOUS FORMULATION VERSUS INTRAVENOUS ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA IN THE REPUBLIC OF MACEDONIA**
O Nikolov[1] ([1]Roche Macedonia DOOEL Skopje, Skopje, Macedonia, The Former Yugoslav Republic Of)

E1472 **QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE INHIBITORS**
B Sidi Mohamed El Amine[1] ([1]Hematology department, Universitary hospital of Sidi Bel Abbes, Sidi Bel Abbes, Algeria)

E1473 **QUALITY OF LIFE AND EMPLOYMENT AFTER AN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A MEXICAN POPULATION.**
S Rivas-Vera[2] ([2]Hematology, National Cancer Institute, Mexico, Mexico City, Mexico)

E1474 **ANTHRACYCLINE INCREASES THE RISK OF DEVELOPING DIABETES IN B CELL LYMPHOMA**
HC Lin[1] ([1]Division of Hematology/Medical Oncology, VTaichung Veterans General Hospital , Taichung, Taiwan, Republic of China)

E1475 **THE COST-EFFECTIVENESS OF LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CHINA**
J Lu[1] ([1]Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China)

E1476 **DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE: HM-PRO**
P Goswami[1] ([1]School of Life and Medical Sciences, University Of Hertfordshire, Hatfield, United Kingdom)

E1477 **OVARIAN TISSUE CRYOPRESERVATION IN PEDIATRIC AND ADOLESCENT PATIENTS UNDERGOING CANCER CHEMOTHERAPY AND/OR HEMATOPOIETIC STEM CELL TRANSPLANTATION**
A Kinoshita[1] ([1]Pediatric hematology/oncology, St. Marianna University School of Medicine, Kawasaki, Japan)

E1478 **A MULTI-DISCIPLINARY APPROACH TO CHEMOTHERAPY PRESCRIBING AT NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST**
S Gabriel[1] ([1]Northern Centre for Cancer Care- Pharmacy, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom)

E1479 **FINANCIAL TOXICITY OF THE MANAGEMENT OF MULTIPLE MYELOMA**
B Sidi Mohamed El Amine[1] ([1]Hematology department, Universitary hospital of Sidi Bel Abbés, Sidi Bel Abbes, Algeria)

E1480 **THE IMPLICATIONS OF NON-PROPORTIONAL HAZARDS FOR THE MEASUREMENT OF SURVIVAL BENEFIT IN HEALTH TECHNOLOGY ASSESSMENT: CURRENT APPROACHES AND THE ROLE OF RESTRICTED MEAN SURVIVAL TIME**
G Monnickendam[1] ([1]PRMA Consulting, Fleet, United Kingdom)

SICKLE CELL DISEASE

E1481 **DISEASE SEVERITY AND SLOWER PSYCHOMOTOR SPEED IN ADULTS WITH SICKLE CELL DISEASE**
E Novelli[1] ([1]Medicine, Vascular Medicine Institute, University of Pittsburgh, BST E1240, 200 Lothrop St., Pittsburgh, United States)

E1482 **MONITORING OF CHRONIC HEPATIC DAMAGE IN SICKLE CELL DISEASE: LONGITUDINAL OBSERVATION OF A COHORT OF ADULT PATIENTS**
GL Forni[1] ([1]Haematology-Centro Microcitemia Anemie Congenite, Ospedale Galliera Genova, Genova, Italy)

E1483 **MICROSTRUCTURAL ANALYSIS OF RETINO-CHOROID LAYERS USING OPTICAL COHERENCE TOMOGRAPHY IN ADULT PATIENTS WITH SICKLE CELL DISEASE**
G Graziadei[1] ([1]Rare Diseases Center, Internal Medicine Unit, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

E1484 **NONĐABLATIVE TRANSPLANT CONDITIONING WITH TREOSULFAN IS CURATIVE IN A MURINE MODEL OF SICKLE CELL DISEASE**
D Devadasan[1] ([1]Pathobiology and Molecular Medicine theme, Department of Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, United States)

E1485 **SILENT CEREBRAL ISCHEMIA AND THROMBOEMBOLIC EVENTS IN SICKLE CELL DISEASE: ANALYSIS OF COAGULATION PARAMETERS AND THROMBOELASTOGRAPHY**
M Dimopoulou[1] ([1]Thalassemia and Sickle Cell Disease Center, Laikon General Hospital, Athens, Greece)

E1486 **ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS AND RISK OF VASCULOPATHY IN SICKLE CELL DISEASE**
H Ellithy[1] ([1]Internal medicine- Clinical hematology dep., Kasr Al-ainy school of medicine- Cairo university, Cairo, Egypt)

E1487 **INVASIVE BACTERIAL INFECTIONS IN GAMBIAN PATIENTS WITH SICKLE CELL ANEMIA IN AN ERA OF WIDESPREAD PNEUMOCOCCAL AND HAEMOPHILUS INFLUENZA TYPE B VACCINATION**
G Soothill[1] ([1]Royal Free Hospital, London, United Kingdom)

E1488 **THE ASSOCIATION OF IGF-1 AND IGFBP-3 SERUM LEVELS AND GENE EXPRESSION WITH THE PATHOGENESIS OF INFLAMMATION IN SICKLE CELL DISEASE**
S Ünal[1] ([1]mersin üniversity pediatic hematology department, mersin, Turkey)

E1489 **UNIVERSAL NEWBORN SCREENING FOR SICKLE CELL DISEASE: PRELIMINARY RESULTS OF THE FIRST YEAR OF A MULTICENTRIC ITALIAN PILOT PROJECT**
R Colombatti[1] ([1]Clinic of Pediatric Hematology Oncology, Department of Child and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, Italy, Padova, Italy)

E1490 **EXTENDING ACCESS TO CARE FOR CHILDREN WITH SICKLE CELL DISEASE THROUGH TELEHEALTH**
J Kanter[1] ([1]Pediatrics, Medical University of South Carolina, Charleston, United States)

E1491 **EMERGING NEED FOR SICKLE CELL DISEASE NEWBORN SCREENING PROGRAM IN ITALY, A EUROPEAN COUNTRY WITH INTENSE MIGRATION FLUXES**
D Venturelli[1] ([1]Servizio Immunotrasfusionale, Azienda Ospedaliero Universitaria Policlinico, Modena, Italy)

E1492 **GENETIC HEMOLYTIC MARKER IN SICKLE CELL ANAEMIA**
P Pereira Nascimento[1] ([1]Departamento de Biologia, Instituto de Biociências, Letras e Ciências Exatas - Ibilce/UNESP - São José do Rio Preto, São José do Rio Preto, Brazil)

E1493 **ASSESSMENT OF INTERNATIONAL DAY HOSPITALS/ INFUSION UNITS FOR THE EVALUATION AND TREATMENT OF SICKLE CELL DISEASE**
L De Castro[1] ([1]Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, United States)

E1494 **REDUCED SERUM HAEMOPEXIN LEVELS IN HAEMOGLOBIN SC DISEASE OCCUR INDEPENDENTLY FROM THE DEGREE OF HAEMOLYSIS**
F Vendrame[1] ([1]Hematology and Hemotherapy Center, Unicamp, Campinas, Brazil)

E1495 **ASSOCIATION OF TOLL-LIKE RECEPTOR 2 GENE POLYMORPHISM WITH THE INCIDENCE OF BACTERIAL INFECTIONS IN SICKLE CELL DISEASE.**
K Tozatto-Maio[1], [2], [3] ([1]Eurocord, Université Paris 7, Paris, France, [2] Monacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, Monaco, [3] Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil)

STEM CELL TRANSPLANTATION - CLINICAL

E1496 **HIGH PROGNOSTIC VALUE OF PRE-SCT MOLECULAR MINIMAL RESIDUAL DISEASE ASSESSMENT BY WT1 GENE EXPRESSION IN AML TRANSPLANTED IN CYTOLOGIC COMPLETE REMISSION.**
A Candoni[1] ([1]Division of Hematology and SCT, University Hospital, Udine, Udine, Italy)

E1497 **GOOD IMMUNOLOGICAL RECONSTITUTION IN ADULTS WITH ACUTE LEUKEMIA AFTER ĐLFA-BETA TCR/CD19+ DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).**
L Prezioso[1] ([1]Hematology and BMT Unit, Parma, Italy)

E1498 **UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION CONDITIONING WITH BUSULFAN, CYCLOPHOSPHAMIDE AND ANTI-THYMOGLOBULIN FOR ADULT SEVERE APLASTIC ANEMIA: GOOD OUTCOME AND PROGNOSIS ANALYSIS**
L Xu[1] ([1] Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China, Beijing, China)

E1499 **PLERIXAFOR EFFICIENTLY AND SAFELY MOBILIZES PERIPHERAL BLOOD STEM CELLS: HOVON-107 RESULTS IN HLA-IDENTICAL SIBLING DONORS AND TRANSPLANTED RECIPIENTS.**
G De Greef[1] ([1]Hematology, Erasmus Cancer Institute Rotterdam , Rotterdam, the Netherlands)

E1500 **A FEASIBILITY STUDY OF THE FULL OUTPATIENT CONDUCT OF HEMATOPOIETIC TRANSPLANTS IN PERSONS WITH MULTIPLE SCLEROSIS EMPLOYING AUTOLOGOUS NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS**
GJ Ruiz Argüelles[1] ([1]Hematologia, Centro de Hematologia y Medicina Interna, Puebla, Mexico)

E1501 **VEDOLIZUMAB IN STEROID REFRACTORY INTESTINAL GRAFT-VERSUS-HOST DISEASE**
AE Myhre[1] ([1]Hematology, Oslo University Hospital, Oslo, Norway)

E1502 **RISK FACTORS, OUTCOMES AND CHARACTERIZATION OF 'AUTOLOGOUS GRAFT VERSUS HOST DISEASE': THE MAYO CLINIC EXPERIENCE.**
T Anagnostou[1] ([1]Hematology/Medical Oncology, Mayo Clinic, Rochester, United States)

E1503 **CNS DEMYELINATION AFTER HAPLO-HSCT AND ITS ASSOCIATION WITH THE IGG INTRATHECAL SYNTHESIS INDEX AND ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY IN CEREBROSPINAL FLUID**
X Zhang[1] ([1]Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)

E1504 **BASELINE CREATININE CLEARANCE AND ALBUMIN ARE POWERFUL RISK FACTORS FOR ALLOGENEIC TRANSPLANTATION RELATED MORTALITY**
R Shouval[1] ([1]Hematology Division, Chaim Sheba Medical Center, Tel-HaShomer, Ramat- Gan, Israel)

E1505 **CYTOGENETIC AND MOLECULAR RISK FACTORS AT DIAGNOSIS ARE OVERCOME BY WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS**
F Guolo[1], [1] ([1]Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy, [1] Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)

E1506 **IMPACT OF ALLELE SPECIFIC PATIENT:DONOR HLA DISPARITY ON OUTCOME OF REDUCED INTENSITY TRANSPLANTS PERFORMED USING HLA MISMATCHED UNRELATED DONORS: ON BEHALF OF THE ALWP OF THE EBMT**
C Craddock[1] ([1]Department of Haematology, University of Birmingham, Birmingham, United Kingdom)

E1507 **PRE-EMPTIVE THERAPY WITH IFN-Ð-2B FOR ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT**
X Tang[1], [2] ([1]The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology, Suzhou, China, [2] Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

E1508 **PREDICTING SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. THE GATMO SCORE**
M Berro[1] ([1]Hematology, Transplant Unit, Hospital Universitario Austral, Derqui, Argentina)

E1509 **A RETROSPECTIVE ANALYSIS OF PATIENT CHARACTERISTICS AND RISK FACTORS FOR ADMISSION TO THE INTENSIVE CARE UNIT (ICU) FOLLOWING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT (HDC-ASCT)**
L Jeyaraj Nallathambi[1] ([1]Haematology, Kings college hospital, London, United Kingdom)

E1510 **AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BENDA-EAM (BENDAMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN) IN AGGRESSIVE NON HODGKIN AND HODGKIN´S LYMPHOMA**
R Simanek[1] ([1]Hematology and Oncology, Hanusch Krankenhaus, Vienna, Austria)

E1511 **THROMBOTIC MICROANGIOPATHY WITH CONCOMITANT AGVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RISK FACTORS, SEVERE OUTCOME AND TREATMENT EXPERIENCE**
X Zhang[1] ([1]Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)

E1512 **CANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY QUANTITATIVE RT-PCR IN CORE BINDING FACTOR AML ON TRANSPLANTATION OUTCOMES**
B Oran[1] ([1]Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, United States)

E1513 **LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT SEVERE APLASTIC ANEMIA WITH ABNORMAL CYTOGENETICS AT DIAGNOSIS**
SE Lee[1] ([1]Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)

E1514 **PROGNOSTIC VALUE OF PET/CT PRIOR TO AUTOLOGOUS HCT IN RELAPSED / REFRACTORY LYMPHOMA**
M Damlaj[1], [2] ([1] Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia, [2]King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia)

E1515 **COMPARISON OF OUTCOMES AFTER DONOR LYMPHOCYTE INFUSION WITH OR WITHOUT PRIOR CHEMOTHERAPY FOR MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.**
XD Mo[1] ([1]Peking University People's Hospital, Institute of Hematology, Beijing, China)

E1516 **DIFFERENTIAL PROGNOSTIC IMPACT OF HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX (HCT-CI) ON TRANSPLANT OUTCOMES BY STEM CELL SOURCES**
Y Adachi[1] ([1]Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan)

E1517 **LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD: RESULTS OF A PHASE II PROSPECTIVE TRIAL**
Y Wang[1] ([1]Peking university people's hospital, beijing, China)

E1518 **HEPATITIS B REACTIVATION IN HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS: 22 YEARS EXPERIENCE OF A SINGLE CENTRE**
T Soysal[2] ([2]Hematology, Cerrahpasa Medical Faculty, Istanbul, Turkey)

E1519 **ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WAS RELATED TO LESS INPATIENT COST COMPARED TO CORD BLOOD TRANSPLANTATION**
N Kurita[1] ([1]Department of Hematology, University of Tsukuba, Tsukuba, Japan)

E1520 **THE ROLE OF PPARĐ EXPRESSION IN PATIENTS WITH AGVHD FOLLOWING ALLO-HSCT**
X Wu[1], [2] ([1]The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, [2] Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

E1521 **HAPLOIDENTICAL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING REGIMEN COULD SERVE AS AN OPTIONAL SALVAGE THERAPY FOR YOUNGER PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA**
H Huang[1] ([1]Soochow University, Suzhou, China)

E1522 **OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA HARBORING INV(3)/(Q21;Q26.2)/T(3;3)(Q21;Q26.2)**
J Aoki[1] ([1]Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan)

E1523 **PHARMACOKINETICS (PK) OF PROPYLENE GLYCOL-FREE MELPHALAN HCL (PG-FREE MEL) IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION (AHCT)**
P Hari[1] ([1]Medical College of Wisconsin, Milwaukee, United States)

E1524 **IMPAIRED LYMPHOCYTE RECONSTITUTION AFTER AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH APOPTOSIS OF CD8+ T CELLS AND PREDICTS ADVERSE CLINICAL OUTCOME**
U Rozovski[1], [2] ([1]Hematology, Davidof Cancer Center, Beilinson Campus, Petah Tikva, Tel Aviv, Israel, [2]Tel Aviv University, Tel Aviv, Israel)

E1525 **COMPARISON OF TECAM AND BEAM HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMA: EFFICACY AND TOXICITY**
F Sahin[1] ([1]Hematology, Ege University Hospital Internal Medicine, Bornova, Turkey)

E1526 **GENETIC MARKERS OF THE NEUTROPENIA DURATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA**
E Nazarova[1] ([1]Laboratory of Immunology of Leukemia, Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation)

E1527 **SUCCESSFUL TREATMENT WITH GRANULOCYTE TRANSFUSION AND EARLY NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC TRANSPLANT PATIENTS WITH FEBRILE NEUTROPENIA;**
A Ünal[1] ([1]Erciyes University Medical Schoo, Kayseri, Turkey)

E1528 **DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION; A SINGLE CENTER EXPERIENCE**
B Antmen[1] ([1]Pediatric Bone Marrow Transplantation Unit, Department of Pediatric Hematology, ADANA ACIBADEM HOSPITAL, Adana, Turkey)

E1529 **ACUTE RENAL IMPAIRMENT IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS, A PREDICTOR OF MORTALITY**
AJ Mahdi[1] ([1]Department of Haematology, University hospital of Wales, Cardiff, United Kingdom)

E1530 **PREDICTIVE INDEXES FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A SINGLE-CENTER EXPERIENCE**
J Zanabili Al-Sibai[1] ([1]Hematology, HUCA, Oviedo, Spain)

E1531 **ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH-RISK PERIPHERAL T-CELL LYMPHOMAS**
H Huang[1], [1] ([1]Soochow University, Suzhou, China, [1]Soochow University, Suzhou, China)

E1532 **IMPACT OF BASELINE BILIRUBIN ON SURVIVAL IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME RECEIVING DEFIBROTIDE: POST-HOC ANALYSIS OF EXPANDED-ACCESS PROTOCOL FINAL DATA**
P Richardson[1] ([1]Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

E1533 **LONG-TERM FOLLOW-UP OF A PROSPECTIVE TRIAL OF INTENSIFIED CHEMO-IMMUNOTHERAPY WITH AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS AFFECTED BY PERIPHERAL T-CELL LYMPHOMA**
P Corradini[1] ([1]Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy)

E1534 **UNRELATED DONOR ATTRITION AT A LATE STAGE: THE BRITISH BONE MARROW REGISTRY EXPERIENCE**
K Balassa[1],[2] ([1]Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, [2] British Bone Marrow Registry, NHS Blood and Transplant, Filton, United Kingdom)

E1535 **POLIMORPHISM IN TGFB1 GENE PREDISPOSES TO RELAPSE AND DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE GRADES III-IV.**
N Meggyesi[1] ([1]Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, Budapest, Hungary)

E1536 **EARLY AND LATE LOST OF PROTECTIVE ANTIBODY LEVELS AGAINST MEASLES, MUMPS AND RUBELLA IN PATIENTS GIVEN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**
J Bögeholz[1] ([1]Hematology, University Hospital Zurich, Zurich, Switzerland)

E1537 **MICA AND NKG2D POLYMORPHISMS HAVE A SIGNIFICANT IMPACT ON GRAFT VERSUS HOST DISEASE AFTER HLA-MATCHED HEMATOPOÏETIC STEM CELL TRANSPLANTATION.**
MJ Apithy[1] ([1]Hematology and Histocompatibility, University Medical Center, AMIENS, France)

E1538 **STEM CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING USING TIMED SEQUENTIAL BUSULFAN IMPROVES OUTCOMES IN OLDER AML AND MDS PATIENTS**
B Oran[1] ([1]Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, United States)

E1539 **HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DEPLETION OF TCR ĐĐ (+) IN CHILDREN: ERCIYES PEDIATRIC BMT CENTER**
T Patiroglu[1] ([1]Department of Pediatrics, Division of Pediatric Hematology Oncology, Erciyes University, Faculty of Medicine, Kayseri, Turkey)

E1540 **SECONDARY MYELODYSPLASTIC SYNDROME AND/OR ACUTE LEUKEMIA INCIDENCE AFTER AUTOLOGOUS TRANSPLANTATION FOR LYMPHOMA PATIENTS IS CONNECTED WITH DECREASE OF HEMATOPOIETIC RESERVE.**
M Trněný[1] ([1]Charles University General Hospital, Prague, Czech Republic)

E1541 **USE OF DEFIBROTIDE TO TREAT TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY**
M Martinez-Muñoz[1] ([1]Hospital Universitario Puerta de Hierro Majadahonda (Madrid), Majadahonda, Spain)

E1542 **PRE-TRANSPLANT COMORBIDITY AS AN OUTCOME PREDICTOR IN HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**
SN Lim[1] ([1]Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of)

E1543 **EFFICACY AND SAFETY OF FILGRASTIM BIOSIMILAR COMPARED TO FILGRASTIM ORIGINATOR IN THE STEM CELL MOBILIZATION AND HEMATOPOIETIC ENGRAFTMENT IN PATIENTS UNDERGOING STEM CELL TRANSPLANTATION**
M López-Parra[1] ([1]Hematology, University Hospital of Salamanca, Salamanca, Spain)

E1544 **PERIPHERAL BLOOD STEM CELL DONATION IN OLDER SIBLING DONORS: IS IT SAFE?**
K Balassa[1] ([1]Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom)

E1545 **LONG-TERM RESULTS OF DONOR LYMPHOCYTE INFUSIONS IN RELAPSED AND MIXED CHIMERISM PATIENTS AFTER ALLOGENEIC STEM CELLS TRANSPLANTATION.**
O Koroleva[1] ([1]BMT, National Research Center for Hematology, Moscow, Russian Federation)

E1546 **MEMORY T CELLS DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION AS A SAFE PROCEDURE TO IMPROVE T-CELL RECONSTITUTION**
S Cortez[1] ([1]Hematology, Hospital Universitario La Paz, Madrid, Spain)

E1547 **FLAG REGIMEN WITH IDARUBICINE AS CYTOREDUCTION THERAPY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH REFRACTORY ACUTE MYELOID LEUKEMIA**
L Wang[1] ([1]Blood and marrow transplantation center, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China)

E1548 **STUTTER PCR PRODUCTS MAY NOT INTERFERE WITH STR BASED CHIMERISM MONITORING AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION**
N Kostritsa[1] ([1]School of Medicine, Lomonosov Moscow State University, Moscow, Russian Federation)

E1549 **INTRODUCING PLERIXAFOR TO IMPROVE MOBILIZATION IN MULTIPLE MYELOMA PATIENTS WHO BEHAVE AS POOR-MOBILIZERS IS COST-EFFECTIVE CONSIDERING THE WHOLE MOBILIZATION AND TRANSPLANT PROCEDURE**
C CHABANNON[1] ([1]Centre de Therapie Cellulaire. Departement de Biologie du Cancer, Institut Paoli-Calmettes, Marseille, France)

E1550 **PERIPHERAL BLOOD STEM CELL (PBSC) HAPLOIDENTICAL TRANSPLANTATION VERSUS MISMATCHED UNRELATED DONOR TRANSPLANTATION: A SINGLE UK CENTRE EXPERIENCE**
J O'Sullivan[1] ([1]Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom)

E1551 **IMPACT OF ABO BLOOD GROUP INCOMPATIBILITY ON THE OUTCOME OF RECIPIENTS UNDERGOING ALLOGENIC TRASPLANTATION: EXPERIENCE IN OUR CENTER BETWEEN 2013 AND 2016.**
GA Méndez Navarro[1] ([1]Servicio de Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal. Madrid, Madrid, Spain)

E1552 **LOW BLOOD CONCENTRATION OF TACROLIMUS CAN BE A RISK OF GRAFT FAILURE AFTER CORD BLOOD TRANSPLANTATION.**
A Fujimoto[1] ([1]Hematology, KOBE CITY MEDICAL CENTER GENERAL HOSPITAL, Kobe, Japan)

E1553 **THE EXPRESSION OF TOLL-LIKE RECEPTORS GENES IN PATIENTS WITH LYMPHOID MALIGNANCIES AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.**
J Rybka[1] ([1]Hematology, Wroclaw Medical University, Wroclaw, Poland)

E1554 **TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPANDED ACCESS PROGRAM FINAL DATA**
P Richardson[2] ([2]Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

E1555 **RED BLOOD CELL DISTRIBUTION WIDTH (RDW) AS AN ACUTE GRAFT VERSUS HOST DISEASE PREDICTOR MARKER IN ALLOGENIC STEM CELL TRANSPLANTATION.**
B Lopez Andrade[1] ([1]Hematology, Hospital Universitario Son Espases, Palma Mallorca, Spain)

E1556 **COMPARISON OF THE BEEAM CONDITIONING REGIMEN AND THE BEAM CONDITIONING REGIMEN IN THE AUTOLOGOUS TRANSPLANATAION FOR HL AND NHL.**
S Lozenov[1] ([1]NSHATHD, Sofia, Bulgaria)

E1557 **DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS: CORRELATION OF ALLELE-LEVEL HLA MATCHING WITH OUTCOME AND WHICH CORD BLOOD UNIT WILL BECOME DOMINANT**
M Westendorp[1] ([1]Leukemia/BMT Program of BC, Vancouver General Hospital, Vancouver, Canada)

E1558 **CLINICAL ANALYSIS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 46 ACTIVE RELAPSED AND REFRACTORY ACUTE PEDIATRIC LEUKEMIA**
J Wang[1] ([1]Department of Hematology, Aerospace Center Hospital, Beijing, China)

E1559 **POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE AFFECT T-CELL RECONSTITUTION IN BONE MARROW, BUT NOT IN PERIPHERAL BLOOD STEM CELLS RECIPIENTS**
E Mikhaltsova[1] ([1]BMT department, National Research Center for Hematology, Moscow, Russian Federation)

E1560 **OUTCOMES OF PATIENTS RELAPSING FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML IN FIRST CR: SINGLE CENTER EXPERIENCE**
D Pastore[1] ([1]Hematology with Transplantation-University Policlinico, Bari, Italy)

E1561 **ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH CHEMOREFRACTORY HODGKIN LYMPHOMAS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA PUGLIESE (REP).**
V Pavone[1] ([1]Haematology, Panico Hospital, Tricase, Italy)

E1562 **RESULTS OF THE IMPLEMENTATION OF CRYOTHERAPY IN PROTOCOLS OF ORAL MUCOSITIS PROPHYLAXIS IN PATIENTS SUBJECT TO A TRASPLANT OF HEMATOPOYETIC PROGENITORS. EXPERIENCE OF ONE CENTER.**
E Fernández Poveda[1] ([1]Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain)

E1563 **REDUCED INCIDENCE OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE.**
A Martínez-Velandia[1] ([1]Hematology and Hemotherapy, Hospital Universitario La Paz, Madrid, Spain)

E1564 **RESULTS OF HAPLOIDENTIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA: A SINGLE CENTER EXPERIENCE**
Z Gulbas[1], [1] ([1]Bone Marrow Transplantation Department, Anadolu Medical Center, Kocaeli, Turkey, [1]Bone Marrow Transplantation Department, Anadolu Medical Center, Kocaeli, Turkey)

E1565 **COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELLS (PBPC) FROM HEALTHY DONORS: 15 YEARS SINGLE CENTER EXPERIENCE.**
B Aguado[1] ([1]Hematology, H.U. LA PRINCESA, MADRID, Spain)

STEM CELL TRANSPLANTATION - EXPERIMENTAL

E1566 **ALLORESPONSES OF HUMAN T-CELLS FROM ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD ARE DIFFERENTIALLY IMPACTED BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT**
C Besley[1] ([1]Centre for Haemato-Oncology, BARTS CANCER INSTITUTE, London, United Kingdom)

E1567 **USING MARKER GENES ANALYSIS INSTEAD OF MLR ASSAY FOR IDENTIFICATION OF FUNCTIONAL CD4+-FOXP3+ REGULATORY T CELLS IN GVHD PROPHYLAXIS**
TJ Chiou[1] ([1]Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, Republic of China)

E1568 **OXIDANT-ANTIOXIDANT SYSTEM IN PATIENTS WITH MULTIPLE MYELOMA**
L Aleksanian[1] ([1]Biochemistry laboratory, Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation)

E1569 **SURFACE RECEPTOR EXPRESSION PROFILE DEFINES ALLOREACTIVE DONOR CD8+ T-CELLS AFTER MURINE ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION**
M Qureischi[1] ([1]Medical Department II, University Clinics Wuerzburg, Wuerzburg, Germany)

THALASSEMIAS

E1570 **SOLUBLE FORM OF TRANSFERRIN RECEPTOR IS ASSOCIATED WITH AGE AT DIAGNOSIS AND RISK OF THERAPEUTICAL INTERVENTION AND IRON OVERLOAD IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT THALASSAEMIA.**
P Ricchi[1] ([1] AORN A. Cardarelli, Naples, Italy)

E1571 **LOW SERUM FERRITIN LEVELS DO NOT PROTECT FROM CARDIAC AND HEPATIC IRON IN PATIENTS WITH THALASSEMIA MAJOR**
A Meloni[1] ([1]Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy)

E1572 **ISCHEMIA MODIFIED ALBUMIN AS A MARKER OF OXIDATIVE STRESS IN CHILDREN AND ADOLESCENTS WITH Ð-THALASSEMIA: RELATION TO LIPID PEROXIDATION, IRON OVERLOAD AND VASCULAR DYSFUNCTION**
AAM Adly[1] ([1]Pediatric Hematology&oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt)

E1573 **SERUM N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVEL AND ECHOCARDIOGRAPHIC TISSUE DOPPLER ABNORMALITIES IN PATIENTS WITH BETA THALASSEMIA MAJOR**
M El-Ghamrawy[1] ([1]Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt)

E1574 **PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES IN NORTHERN GREECE. 15 YEARS REPORT**
S Theodoridou[1] ([1]Thalassemia Unit, Hippokration General Hospital, Thessaloniki, Greece)

E1575 **THE IMPACT OF LIVER STEATOSIS ON THE ABILITY OF SERUM FERRITIN LEVELS TO PREDICT LIVER IRON CONCENTRATION AMONG NON-TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS: A CROSS-SECTIONAL EVALUATION.**
P Ricchi[1] ([1] AORN A. Cardarelli, Naples, Italy)

E1576 **CIRCULATING CELL-FREE DNA (CFDNA) AND INEFFECTIVE ERYTHROPOIESIS IN BETA-THALASSEMIA INTERMEDIA**
MD Cappellini[1] ([1]Dip. Scienze Cliniche e di Comunità, Università degli Studi di Milano, MILANO, Italy)

E1577 **LEFT VENTRICULAR HYPERTRABECULATION BY CARDIAC MAGNETIC RESONANCE IN THALASSEMIA INTERMEDIA PATIENTS: FREQUENCY AND PROGNOSTIC ROLE**
A Meloni[1] ([1]Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy)

E1578 **NITRIC OXIDE DYSREGULATION IN BETA-THALASSEMIA MAJOR: RELATION TO PULMONARY HYPERTENSION**
M Elshinawy[1], [2] ([1]Pediatric Hematology, SULTAN QABOOS UNIVERSITY HOSPITAL, Muscat, Oman, [2] Pediatric Hematology, Faculty of Medicine, Alexandria, Egypt)

E1580 **SPECKLE-TRACKING ECHOCARDIOGRAPHY FOR DIAGNOSIS OF EARLY MYOCARDIAL DISEASE IN EGYPTIAN BETA THALASSEMIA MAJOR PATIENTS**
AAG Tantawy[1] ([1]Pediatric Hematology&oncology, faculty of medicine, Ain Shams University, Cairo, Egypt)

E1581 **EFFICACY, SAFETY AND GENETIC BASIS OF VARIABILITY OF RESPONSE TO HYDROXYUREA THERAPY IN BETA THALASSEMIA: A SYSTEMATIC REVIEW**
S Khaliq[1],[2] ([1]Pathology, fauji foundation hospital/Foundation University Medical college Rawalpindi, rawalpindi, Pakistan, [2]Hematology, hemophilia Centre, Rawalpindi, Pakistan)

E1582 **EVALUATION OF CONTINUOUS BLOOD GLUCOSE MONITORING METHOD FOR DETECTION OF ALTERATIONS IN GLUCOSE HOMEOSTASIS IN BETA-THALASSEMIA PATIENTS**
A Tantawy[1] ([1]AinShams university, Cairo, Egypt)

E1583 **LEFT VENTRICULAR REGIONAL FUNCTION IN CHILDREN WITH BETA THALASSEMIA WITH NO CARDIAC MANIFESTATIONS (FOUR–DIMENSIONAL ECHOCARDIOGRAPHIC STUDY)**
M El-Shanshory[1] ([1]Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt)

E1584 **THE IMPORTANCE OF SERUM GDF-15 LEVELS TO ASSESS IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR**
U Caliskan[2] ([2]Pediatric Hematology and Oncology, NECMETTIN ERBAKAN UNIVERSITY MERAM MEDICAL FACULTY, Konya, Turkey)

E1585 **ASSOCIATION OF SP1 POLYMORPHISM IN THE COLLAGEN TYPE I ALPHA -1 (COLIA1) GENE WITH OSTEOPROSIS IN CHILDREN WITH BETA-THALASSEMIA**
M Hesham[1] ([1]Pediatric, Zagazig University Hospital, Zagazig, Egypt, Zagazig, Egypt)

E1586 **UNUSUAL MOLECULAR MECHANISMS IN THE ORIGIN OF ALPHA-THALASSEMIA**
P Faustino[1,11] ([1]Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisboa, Portugal, [11] ISAMB, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal)

E1588 **VALUE OF HBA2 IN THE DIAGNOSIS OF BETA-THALASSEMIA MINOR - "ATTENTION TO THE GRAY ZONE"**
L Relvas[1] ([1]Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)

E1589 **DIAGNOSIS OF HEMOGLOBINOPATHIES BY CAPILLARY ZONE ELECTROPHORESIS: EXPERIENCE WITH 925 CASES**
P Tripathi[1] ([1]dept of hematology, All India Institute of Medical Sciences, New Delhi, India)

THROMBOSIS AND VASCULAR BIOLOGY

E1590 **RELEVANT ROLE OF VON WILLEBRAND FACTOR-ADAMTS13 AXIS IN HEPATIC ISCHEMIA- REPERFUSION INJURY**
Y Urisono[1] ([1]Emergency and Critical Care Medicine, Nara Medical University, Kashihara, Japan)

E1591 **THE IMPORTANCE OF THE FULL BLOOD COUNT, JAK II AND ADAMTS 13 TESTING IN STROKE EVALUATION: A REVIEW OF 619 CONSECUTIVE YOUNG STROKE AND TIA PATIENTS**
A Taylor[1] ([1]Haematology, University College London Hospital, London, United Kingdom)

E1592 **PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) RELATED THROMBOSIS IN 230 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. A 6 YEARS SINGLE EXPERIENCE CENTER.**
JM Bastida[1] ([1]Hematology, Hospital Universitario de Salamanca, Salamanca, Spain)

E1593 **A STUDY OF VENOUS THROMBOEMBOLISM SUSCEPTIBILITY LOCI FACTOR XI, ABO AND FIBRINOGEN IN A PORTUGUESE POPULATION SAMPLE**
L Manco[1] ([1]Research Center for Anthropology and Health (CIAS), University of Coimbra, Coimbra, Portugal)

E1594 **PEDIATRIC VENOUS THROMBOEMBOLISM: INCIDENCE, RISK FACTORS AND MANAGEMENT OF HOSPITALIZED PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL**
P Raheja[1] ([1]Hematology Department, Vall d'Hebron University Hospital, Barcelona, Spain)

E1595 **CELL-BASED EVALUATION OF CHANGES IN COAGULATION ACTIVITY INDUCED BY ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA**
H Shinki[1] ([1]Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan)

E1596 **DESCRIPTION OF THROMBOTIC EVENTS AND/OR PREGNANCY LOSSES IN A COHORT OF HOMOZYGOUS CARRIERS FOR THE C46T POLYMORPHISM OF THE F12 GENE**
S Martín Herrero[1] ([1]Hematology, Fundación Jiménez Díaz, Madrid, Spain)

E1597 **ANALYSIS OF CHARECTERSISTICS OF HOSPITAL ASSOCIATED THROMBOSES**
N Smith[1] ([1]Haematology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom)

E1598 **THROMBOSIS DURING INFANCY AND NEWBORN PERIOD: AN UNRESOLVED ISSUE**
F Gumruk[1] ([1]Pediatric Hematology, Hacettepe University, Ankara, Turkey)

E1599 **THE QUALITY COMPOSITION OF SOLUBLE FIBRIN MONOMER COMPLEX FRACTION FOR ACUTE AND POST ACUTE ISCHEMIC STROKE PATIENTS**
T Katrii[1] ([1]Biochemistry, Educational and Scientific Centre "Institute Of biology and medicine", Kyiv, Ukraine)

E1600 **EVALUATION OF A RAPID NANOPARTICLE-BASED LATERAL FLOW IMMUNOASSAY (STIC EXPERT HIT) FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA IN A CARDIOTHORACIC HOSPITAL.**
G Soufla[1] ([1]Department of Haematology, Blood Transfusion Unit and Coagulation and Haemostasis, Onassis Cardiac Surgery Center, Athens, Greece)

E1601 **AUDIT OF 'DOOR TO NEEDLE' TIME IN ADMINISTRATION OF PROTHROMBIN COMPLEX CONCENTRATE TO PATIENTS REQUIRING URGENT REVERSAL OF ANTICOAGULATION**
S Elshafie[1] ([1]Haematology, HEART OF ENGLAND NHS FOUNDATION TRUST, Birmingham, United Kingdom)

E1602 **THE IMPORTANCE OF PLATELET MEMBRANE FLUIDITY AND OXIDATIVE STRESS IN THROMBOTIC COMPLICATIONS ACQUIRED BY CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS**
VM POPOV[1] ([1]HEMATOLOGY, COLENTINA CLINICAL HOSPITAL, Bucharest, Romania)

E1603 **USE OF ROTATIONAL THROMBOELASTOGRAPHY TO PREDICT CENTRAL VENOUS CATHETER RELATED VENOUS THROMBOSIS IN CHILDREN: PRELIMINARY RESULTS**
T Bayhan[1] ([1]Division of Pediatric Hematology, Hacettepe University, Ankara, Turkey)

E1604 **THE POTENCIAL ROLE OF ANTINEOPLASTIC DRUGS IN THE PREDICTION OF THROMBOTIC RISK IN ONCOLOGIC PATIENTS IN ADDITION TO THE KHORANA SCORE**
E Gómez[1] ([1]Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain)

TRANSFUSION MEDICINE

E1605 **CLINICAL OUTCOMES AND UTILIZATION OF BLOOD BANK RESOURCES OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP), HEMOLYTIC UREMIC SYNDROME (HUS), AND OTHER MICROANGIOPATHY- A 14 YEARS' EXPERIENCE**
CT Lee[1], [2] ([1]Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore, [2]Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore)

E1606 **HEPATITIS E VIRUS: INVESTIGATION IN NORTH ITALIAN BLOOD DONORS**
L Raffaele[1] ([1]Transfusion Medicine and Hematology, ASST-Lecco, Lecco, Italy)

E1607 **SHORT-TERM ADMINISTRATION OF RECOMBINANT HUMAN ERYTHROPOIETIN DECREASES B CELL IN HUMAN PERIPHERAL BLOOD**
T Nagashima[1] ([1]Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan)

E1608 **BLOODLESS TREATMENT OF HEMATOLOGIC MALIGNANCIES AND APLASTIC ANEMIA - JEHOVAH'S WITNESSES (JW)**
K Kim[1] ([1]Internal Medicine, Soonchunhyang University Hospital, Seoul, Seoul, Korea, Republic Of)

E1609 **PREOPERATIVE ANEMIA: A SINGLE INSTITUTION EXPERIENCE IN SPAIN**
G Pinto[1] ([1]Hematology, HOSPITAL RAMON Y CAJAL, Madrid, Spain)

E1610 **RED BLOOD CELLS (RBC) AND PLATELET (PLT) TRANSFUSIONS IN TRANSPLANTED AND NOT-TRANSPLANTED PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**
D Sotiropoulos[1] ([1]Haematology Department & BMT Unit, George Papanicolaou Hospital, Thessaloniki, Greece)

INDEX

Please find below the indexes of the congress and the special indications of the travel grant winners.

TRAVEL GRANT WINNERS → RED

GUISEPPE BIGI GRANT WINNER → GREEN

SPEAKER & DISCLOSURE INDEX (as of May 16)

EHA would like to thank the following persons for their contribution to the congress as speakers and chairs in the invited speaker program.

Abdel-Wahab O
Molecular Hemopoiesis Workshop, Poster Walk
Disclosures: *No Affiliations*

Adamson P
Hematology-in-Focus
Disclosures: *No Affiliations*

Adès L
Simultaneous Session
Disclosures: *Affiliations Unknown*

Ageno W
Education Session, Clinical Debate, EHA-ISTH Joint Symposium
Disclosures: *Bayer (Advisory Board, Research Support, Honoraria); Boehringer Ingelheim (Advisory Board, Honoraria); Daiichi Sankyo (Advisory Board, Honoraria); BMS/ Pfizer (Honoraria); Aspen (Honoraria)*

Aguado Bueno B
Poster Walk
Disclosures: *Affiliations Unknown*

Akashi K
EHA-JSH Joint Symposium
Disclosures: *No Affiliations*

Alegre A
Education Session, Simultaneous Session
Disclosures: *Celgene (Advisory Board, Research Support); Janssen (Advisory Board, Research Support); Amgen (Advisory Board); Takeda (Advisory Board)*

Almeida A
Poster Walk
Disclosures: *Affiliations Unknown*

Almeida JM
Simultaneous Session
Disclosures: *Affiliations Unknown*

Altamura S
Early Career Session
Disclosures: *No Affiliations*

Amorim CA
Education Session
Disclosures: *No Affiliations*

Anderson K
EHA-ASH Joint Symposium
Disclosures: Millennium Takeda (Advisory Board); Bristol Myers Squibb (Advisory Board); Gilead (Advisory Board); C4 Therapeutics (Scientific Founder); Oncopep (Scientific Founder)

Andolfo I
Scientific Working Groups
Disclosures: *No Affiliations*

Angelucci E
Education Session
Disclosures: *Novartis Oncology (Chair Steering Committee, Telesto Protocol, Advisory Board); Celgene (Chair DMC)*

Ann Sutton L
EU Projects in Hematology
Disclosures: *Affiliations Unknown*

Ansell S
Scientific Working Groups
Disclosures: *Bristol Myers Squibb (Research Funding); Merck (Research Funding); Affimed (Research Funding); Seattle Genetics (Research Funding); Celldex (Research Funding)*

Apperley J
Patient Advocacy Session 2
Disclosures: *Ariad (Advisory Board, Satellite Symposia Speaker, Research Support); Bristol Myers Squibb (Advisory Board, Satellite Symposia Speaker); Incyte (Advisory Board, Satellite Symposia Speaker); Novartis (Advisory Board, Satellite Symposia Speaker, Research Support); Pfizer (Advisory Board, Satellite Symposia Speaker, Research Support)*

Asmar F
Poster Walk
Disclosures: *Affiliations Unknown*

Aurer I
Simultaneous Session
Disclosures: *Affiliations Unknown*

Avet-Loiseau H
Education Session, Simultaneous Session
Disclosures: *Celgene (Advisory Board, Research Support); Janssen (Advisory Board, Research Support); Sanofi (Advisory Board, Research Support); Takeda (Advisory Board); Amgen (Advisory Board, Research Support)*

Bacon P
EU Projects in Hematology
Disclosures: *Affiliations Unknown*

Balduini CL
Scientific Working Groups
Disclosures: *No Affiliations*

Baldus C
Poster Walk
Disclosures: *Affiliations Unknown*

Barata J
Basic-Science-in-Focus
Disclosures: *No Affiliations*

Barcellini W
Poster Walk
Disclosures: *Affiliations Unknown*

Bartels M
Poster Walk
Disclosures: *Affiliations Unknown*

Baruchel A
Hematology-in-Focus
Disclosures: *Affiliations Unknown*

Basso G
Scientific Working Groups
Disclosures: *No Affiliations*

Becker H
Early Career Session
Disclosures: *BMS (Honoraria); Novartis (Honoraria)*

Bene MC
Laboratory Diagnosis Workshop, Scientific Working Groups
Disclosures: *Beckman Coulter (Research Support)*

Berneman Z
Simultaneous Session, Poster Walk
Disclosures: *Affiliations Unknown*

Bhatt A
Basic-Science-in-Focus
Disclosures: *No Affiliations*

Bocchia M
Simultaneous Session
Disclosures: *Affiliations Unknown*

Bodó I
Poster Walk
Disclosures: *Affiliations Unknown*

Bolli N
Poster Walk

Board, Speaker, Research Support); Qiagen (Advisory Board)

Da Costa L
Education Session
Disclosures: *Affiliations Unknown*

Davies A
Poster Walk
Disclosures: *Affiliations Unknown*

De Carvalho D
Basic-Science-in-Focus
Disclosures: *No Affiliations*

de la Rubia J
Poster Walk
Disclosures: *Affiliations Unknown*

de Montalembert M
Clinical Debate, Poster Walk
Disclosures: *Novartis (Advisory Board, Speaker's Bureau); Addmedica (Advisory Board)*

de Vooght KMK
Education Session
Disclosures: *No Affiliations*

Delforge M
Simultaneous Session
Disclosures: *Affiliations Unknown*

Della Porta MG
Education Session
Disclosures: *No Affiliations*

Delwel R
Scientific Working Groups
Disclosures: *No Affiliations*

Devereux S
Scientific Working Groups
Disclosures: *Gilead (Advisory Board, Speaker's Bureau, Travel Sponsorship); Roche (Advisory Board, Speaker's Bureau); Janssen (Advisory Board, Speaker's Bureau, Travel Sponsorship); Abbvie (Advisory Board); GSK (Advisory Board, Speaker's Bureau); BMS (Advisory Board)*

Devos T
Poster Walk
Disclosures: *Affiliations Unknown*

Di Michele D
Plenary Session 2, Clinical Debate
Disclosures: *No Affiliations*

Dolmans MM
Education Session
Disclosures: *No Affiliations*

Dolstra H
Basic-Science-in-Focus, Simultaneous Session
Disclosures: *No Affiliations*

Dombret H
Meet-the-Expert, Scientific Working Groups
Disclosures: *Roche/Genentech (Grants, Fees); Amgen (Grants, Fees); Pfizer (Fees); Ariad (Incyte) (Grants, Fees); Novartis (Fees); Celgene (Fees); Jazz Pharma. (Grants, Fees); Agios (Fees); Sunesis (Fees); Ambit (Daiichi Sankyo) (Fees); Karyopharm (Fees); Kite Pharma. (Grants, Fees); Menarini (Fees); Astellas (Fees); Janssen (Fees); Servier (Fees); Seattle Genetics (Fees); Cellectis (Fees)*

Donadieu J
Scientific Working Groups
Disclosures: *Roche (Research Support); Prolong (Research Support)*

Doubek M
Scientific Working Groups
Disclosures: *Gilead Sciences (Grant, Advisory Board); Janssen Cilag (Grant, Advisory Board); AbbVie (Research Support, Advisory Board); Roche (Advisory Board)*

Dreyling M
Scientific Working Groups, Simultaneous Session
Disclosures: *No Affiliations*

Dufour C
Scientific Working Groups
Disclosures: *No Affiliations*

Durie B
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*

Eichhorst B
Education Session
Disclosures: *Roche (Advisory Boards, Honoraria, Research); Abbvie (Advisory Boards, Honoraria, Research); Janssen (Advisory Boards, Honoraria, Research); Gilead (Advisory Boards, Honoraria, Research); Celgene (Advisory Boards, Honoraria); Novartis (Advisory Boards, Honoraria)*

Eichinger S
EHA-ISTH Joint Symposium, Simultaneous Session
Disclosures: *Bayer (Speaker Fees); Boehringer-Ingelheim (Speaker Fees); Daiichi-Sankyo (Speaker Fees); Pfizer (Speaker Fees); BMS (Speaker Fees)*

Einsele H
Simultaneous Session
Disclosures: *Affiliations Unknown*

Eisfeld AK
Early Career Session
Disclosures: *No Affiliations*

El-Galaly TC
Scientific Working Groups
Disclosures: *Takeda (Travel Funding); Roche (Advisory Board, Travel Funding)*

Engert A
Education Session, Hematology-in-Focus, Simultaneous Session
Disclosures: *Takeda (Advisory Board, Research Support); Bristol Myers Squibb (Honorarium, Research Support); Amgen (Honorarium, Research Support); Affimed (Advisory Board, Research Support)*

Enver T
Plenary Session 1
Disclosures: *Affiliations Unknown*

Essers M
Basic-Science-in-Focus
Disclosures: *No Affiliations*

Esteve J
Poster Walk
Disclosures: *Affiliations Unknown*

Estey EH
Patient Advocacy Session 1
Disclosures: *No Affiliations*

Fain O
Scientific Working Groups
Disclosures: *No affiliations*

Falkenburg JHF
Education Session
Disclosures: *No Affiliations*

Fenaux P
Education Session, Clinical Debate, EU Projects in Hematology
Disclosures: *No Affiliations*

Falanga A
Scientific Working Groups
Disclosures: *Pfizer (Speaker's Bureau); Janssen (Advisory Board); Aspen (Speaker's Bureau); Rovi (Speaker's Bureau)*

Fibbe W
Scientific Working Groups, Simultaneous Session
Disclosures: *No Affiliations*

Fielding A
Scientific Working Groups, Simultaneous Session
Disclosures: *Amgen (Advisory Board); Pfizer (Advisory Board)*

Fioredda F
Scientific Working Groups
Disclosures: *No Affiliations*

Flores-Montero JA
Scientific Working Groups
Disclosures: *No Affiliations*

Disclosures: *Affiliations Unknown*

Hasle H
Simultaneous Session
Disclosures: *Affiliations Unknown*

Hasselbalch H
Simultaneous Session
Disclosures: *Affiliations Unknown*

Hehlmann R
Scientific Working Groups, EU Projects in Hematology
Disclosures: *BMS (Consultation); Novartis (Research Support)*

Hellström Lindberg E
EHA-ESH Joint Symposium
Disclosures: *Celgene (Grant)*

Hermouet S
Simultaneous Session
Disclosures: *Affiliations Unknown*

Hernández JM
EU Projects in Hematology
Disclosures: *Affiliations Unknown*

Hills R
Early Career Session
Disclosures: *Celgene (Speaker); Janssen (Advisory Board); Pfizer (Advisory Board); Sunesis (Consultancy); CTI (Consultancy)*

Hochhaus A
Education Session
Disclosures: *Novartis (Research Support); BMS (Research Support); Pfizer (Research Support); Incyte (Research Support)*

Hrusak O
Hematology-in-Focus
Disclosures: *No Affiliations*

Huang X
EHA-CSH Joint Symposium
Disclosures: *No Affiliations*

Hübel K
Education Session
Disclosures: *Roche (Advisory Board, Speaker's Bureau); Sanofi (Advisory Board, Speaker's Bureau); Cell Therapeutics (Speaker's Bureau); Servier (Advisory Board, Speaker's Bureau), Gilead (Speaker's Bureau); Teva (Advisory Board); Hexal (Advisory Board), Amgen (Travel Grants, Speaker's Bureau)*

Huisman M
Education Session
Disclosures: *No Affiliations*

Hultcrantz M
Scientific Working Groups
Disclosures: *No Affiliations*

Hutchings M
Early Career Session, Simultaneous Session
Disclosures: *Affiliations Unknown*

Inaba H
Hematology-in-Focus
Disclosures: *No Affiliations*

Iolascon A
Hematology-in-Focus, Scientific Working Groups, Simultaneous Session
Disclosures: *No Affiliations*

Ionova T
Scientific Working Groups
Disclosures: *BMS (Research Grant); MSD (Lecturer)*

Itkin T
Poster Walk
Disclosures: *Affiliations Unknown*

Izraeli S
Opening Ceremony, Plenary Session 1, EHA-CSH Joint Symposium, Presidential Symposium
Disclosures: *prIMEOncology (Direct/Indirect); Jazz Pharmaceutical (Indirect)*

Jäger U
Hematology-in-Focus
Disclosures: *No Affiliations*

Jain N
Hematology-in-Focus
Disclosures: *BMS (Research Support); Pharmacyclics (Research Support, Advisory Board); Abbvie (Research Support); Genentech (Research Support); Pfizer (Research Support, Advisory Board); Incyte (Research Support); Infinity (Research Support); ADC Therapeutics (Research Support, Advisory Board); Seattle Genetics (Research Support); Celgene (Research Support); Servier (Research Support, Advisory Board); Novimmune (Advisory Board); Adaptive Biotechnologies (Advisory Board); Novartis (Advisory Board)*

Jansen J
Education Session
Disclosures: *No Affiliations*

Janssen J
Simultaneous Session
Disclosures: *Affiliations Unknown*

Jares P
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*

Johnson S
EHA-ESH Joint Symposium
Disclosures: *No Affiliations*

Jones JA
Scientific Working Groups
Disclosures: *Abbvie (Advisory Board, Research Support); Pharmacyclics (Advisory Board, Research Support); Janssen (Advisory Board, Research Support); Acerta (Research Support); Genentech (Research Support); Gilead (Advisory Board, Research Support)*

Jost P
Molecular Hemopoiesis Workshop
Disclosures: *Novartis (Advisory Board, Travel Support); Pfizer (Advisory Board, Travel Support); Ariad (Advisory Board, Travel Support); Abbvie (Research Support); Böhringer Ingelheim (Research Support)*

Jourdain P
Scientific Working Groups
Disclosures: *Affiliations Unknown*

Juffermans NP
Scientific Working Groups
Disclosures: *No Affiliations*

Kaiser M
Scientific Working Groups
Disclosures: *Amgen (Advisory Board, Honoraria); BMS (Advisory Board, Travel Support); Celgene (Advisory Board, Research Support); Chugai (Advisory Board); Janssen (Advisory Board); Takeda (Advisory Board, Travel Support)*

Kamphuisen PW
EHA-ISTH Joint Symposium
Disclosures: *Boehringer Ingelheim (Research Funding, Steering Board Committee); Daiichi Sankyo (Research Funding, Advisory Board); Pfizer (Research Funding)*

Kapitein P
EHA Advocacy Session
Disclosures: *No Affiliations*

Karlsson S
Simultaneous Session
Disclosures: *Affiliations Unknown*

Kastritis E
Hematology-in-Focus
Disclosures: *Janssen (Honoraria); Takeda (Honoraria); Amgen (Honoraria); Genesis Pharma (Honoraria)*

Kater A
Simultaneous Session
Disclosures: *Affiliations Unknown*

Kattamis A

Lozano M
Education Session
Disclosures: *Grifols (Advisory Board); Terumo BCT (Research Support)*
Ludwig H
Clinical Debate, Simultaneous Session
Disclosures: *Celgene (Advisory Board, Speaker's Bureau); Takeda (Advisory Board, Research Funding), Amgen (Advisory Board, Speaker's Bureau, Research Funding); Janssen (Advisory Board, Speaker's Bureau): AbbVie (Advisory Board), BMS (Advisory Board, Speaker's Bureau)*
Macintyre E
Simultaneous Session
Disclosures: *Affiliations Unknown*
Mahon FX
Scientific Working Groups
Disclosures: *Affiliations Unknown*
Makris M
Hematology-in-Focus
Disclosures: *NovoNordisk (Consultancy); CSL Behring (Consultancy); Grifols (Consultancy)*
Malcovati L
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*
Malmberg K
Basic-Science-in-Focus
Disclosures: *No Affiliations*
Maloney D
Basic-Science-in-Focus
Disclosures: *Juno Therapeutics (Institutional Research Support); Celgene (Advisory Board, Honoraria); F. Hoffmann La Roche (Advisory Board); Gilead (Advisory Board)*
Mannucci PM
Clinical Debate
Disclosures: *Alexion (Lecture Fee); Baxalta/Shire (Lecture Fee); Bayer (Lecture Fee, Advisory Board Membership); CSL Behring (Lecture Fee); Grifols (Lecture Fee); Kedrion (Lecture Fee, Advisory Board Membership); LFB (Lecture Fee); Novo Nordisk (Lecture Fee)*
Martinez-Lopez J
Hematology-in-Focus
Disclosures: *No Affiliations*
Martin-Subero JI
Basic-Science-in-Focus, Simultaneous Session
Disclosures: *No Affiliations*
Mateos MV
Hematology-in-Focus, Clinical Debate
Disclosures: *Janssen (Advisory Board, Lectures); Celgene (Advisory Board, Lectures); Takeda (Advisory Board, Lectures); Amgen (Advisory Board, Lectures); BMS (Advisory Board, Lectures)*
Mayer J
Poster Walk
Disclosures: *Affiliations Unknown*
McMahon C
Simultaneous Session
Disclosures: *Affiliations Unknown*
Meirow D
Education Session
Disclosures: *No Affiliations*
Menzel S
Education Session
Disclosures: *Shire Plc (Research Grant)*
Mercher T
Poster Walk
Disclosures: *Affiliations Unknown*
Merlini GP
Meet-the-Expert
Disclosures: *Millennium Takeda (Advisory Board); Janssen (Advisory Board)*
Mesa R
Scientific Working Groups
Disclosures: *Novartis (Advisor); Shire (Advisor); AOP (Advisor); Galena (Advisor); Ariad (Advisor); Incyte (Research Support); Celgene (Research Support); Gilead (Research Support); CTI (Research Support); Promedior (Research Support)*
Metzeler K
Early Career Session
Disclosures: *Celgene (Research Support)*
Milsom M
Basic-Science-in-Focus
Disclosures: *No Affiliations*
Mitchell R
Education Session
Disclosures: *No Affiliations*
Mohty M
EHA-EBMT Joint Symposium
Disclosures: *Amgen (Advisory Board, Speaker's Bureau, Research Support); Sanofi (Advisory Board, Speaker's Bureau, Research Support); Jazz (Advisory Board, Speaker's Bureau, Research Support); Janssen (Advisory Board, Speaker's Bureau, Research Support); Molmed (Advisory Board, Speaker's Bureau, Research Support); Celgene (Honoraria); Takeda (Honoraria); BMS (Honoraria, Research Support); Novartis (Honoraria); Pfizer (Honoraria); Keocyt (Honoraria); Keocyt (Research Support); EBMT (President)*
Moreau P
Simultaneous Session
Disclosures: *Affiliations Unknown*
Moreno C
Hematology-in-Focus, Meet-the-Expert
Disclosures: *Janssen (Advisory Board, Speaker´s Bureau); Gilead (Advisory Board, Grant)*
Muckenthaler M
Basic-Science-in-Focus
Disclosures: *No Affiliations*
Mufti G
Education Session
Disclosures: *Celgene (Advisory Board, Research Funding); Novartis (Research Funding)*
Mullally A
Education Session, Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
Muller-Tidow C
Poster Walk
Disclosures: *No Affiliations*
Mulligan S
Simultaneous Session
Disclosures: *Affiliations Unknown*
Munshi N
Education Session
Disclosures: *Celgene (Consulting Agreement); Merck (Consulting Agreement); Pfizer (Consulting Agreement); Takeda (Consulting Agreement); Oncopep (Consulting Agreement, Ownership Interest); Janssen (Consulting Agreement)*
Müschen M
Basic-Science-in-Focus
Disclosures: *Pfizer (Center of Therapeutic Innovation, Research Support); AbbVie (Research Support, Grant); ADC Therapeutics (Research Support, Grant)*
Mutch N
Education Session
Disclosures: *No Affiliations*
Nagler A
EHA-CSH Joint Symposium
Disclosures: *No Affiliations*

Scientific Working Groups
Disclosures: *No Affiliations*

Pleyer L
Poster Walk
Disclosures: *Affiliations Unknown*

Pluchino S
Scientific Working Groups
Disclosures: *No Affiliations*

Porkka K
Simultaneous Session
Disclosures: *Affiliations Unknown*

Pospisilova S
Education Session
Disclosures: *No Affiliations*

Prati D
Poster Walk
Disclosures: *Affiliations Unknown*

Puissant A
Poster Walk
Disclosures: *Affiliations Unknown*

Rachmilewitz E
Meet-the-Expert
Disclosures: *No Affiliations*

Raderer M
Education Session
Disclosures: *No Affiliations*

Radich J
Scientific Working Groups
Disclosures: Novartis (Advisory Board, Lab Contract); BMS (Advisory Board); Ariad (Advisory Board)

Ravandi F
Simultaneous Session
Disclosures: *Affiliations Unknown*

Reiter A
Meet-the-Expert
Disclosures: *Novartis Pharma (Advisory Board, Honoraria, Travel Expenses)*

Renné T
Education Session
Disclosures: *No Affiliations*

Rezvani K
Basic-Science-in-Focus
Disclosures: *No Affiliations*

Ribera JM
Education Session, Meet-the-Expert
Disclosures: *No Affiliations*

Rodeghiero F
Clinical Debate, EHA-ISTH Joint Symposium
Disclosures: *No Affiliations*

Roschewski M
Scientific Working Groups
Disclosures: *No Affiliations*

Rossi D
Basic-Science-in-Focus
Disclosures: *Gilead (Unrestricted Research Grant, Honoraria); AbbVie (Honoraria); Janssen (Honoraria)*

Rule S
Education Session, Scientific Working Groups
Disclosures: *Janssen (Advisory Board, Research Funding); Roche (Advisory Board); Astra Zeneca (Advisory Board); Celgene (Advisory Board)*

Ruutu T
Meet-the-Expert, Simultaneous Session
Disclosures: *No Affiliations*

Salek S
Scientific Working Groups
Disclosures: *No Affiliations*

Salles G
Education Session
Disclosures: *Amgen (Advisory Board); BMS (Honoraria); Celgene (Advisory Board, Honoraria); Gilead (Advisory Board, Honoraria); Janssen (Advisory Board); Novartis (Advisory Board); Roche (Advisory Board, Research Support); Servier (Honoraria); Merck (Advisory Board, Research Support)*

Samuelsson J
Education Session
Disclosures: *Novartis (Advisory Board)*

Sanders M
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*

Sankaran V
Hematology-in-Focus
Disclosures: *No Affiliations*

San-Miguel JF
Education Session, Simultaneous Session
Disclosures: *Millennium (Advisory Board); Celgene (Advisory Board); Novartis (Advisory Board); Onyx (Advisory Board); Janssen (Advisory Board); BMS (Advisory Board); MSD (Advisory Board); Amgen (Advisory Board)*

Sanz G
EU Projects in Hematology
Disclosures: *Affiliations Unknown*

Santini V
Simultaneous Session
Disclosures: *Affiliations Unknown*

Scadden D
Plenary Session 1
Disclosures: *Fate Therapeutics (Consultant, Stockholder); Magenta Therapeutics (Consultant, Stockholder, Director); Bone Therapeutics (Consultant); Bayer Therapeutics (Sponsored Research); Novartis (Sponsored Research)*

Scharenberg C
Early Career Session
Disclosures: *No Affiliations*

Schellong S
Education Session
Disclosures: *Bayer (Advisory Board, Speaker Fees); BMS (Speaker Fees); Boehringer (Advisory Board, Speaker Fees); Daiichi (Advisory Board, Speaker Fees); Pfizer (Speaker Fees)*

Schneider R
Molecular Hemopoiesis Workshop, Simultaneous Session
Disclosures: *No Affiliations*

Schroeder T
Molecular Hemopoiesis Workshop, EHA-ISEH Joint Symposium
Disclosures: *No Affiliations*

Schuurhuis GJ
Scientific Working Groups
Disclosures: *Becton Dickinson (Research Support)*

Schwaller J
Basic-Science-in-Focus, Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*

Sevilla J
Education Session
Disclosures: *Novartis (Advisory Board, Speaker's Bureau); Terumo BCT (Speaker's Bureau)*

Sexl V
Basic-Science-in-Focus, Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*

Shimamura A
Education Session, Hematology-in-Focus
Disclosures: *No Affiliations*

Shlush L
Basic-Science-in-Focus
Disclosures: *Affiliations Unknown*

Sierra J
Plenary Session 1, Simultaneous Session
Disclosures: *Pfizer (Honoraria, Speaker's Bureau); Amgen (Grant); Celgene (Grant, Honoraria, Speaker's Bureau); Janssen (Honoraria, Speaker's Bureau); Seattle Genetics (Honoraria, Speaker's Bureau);*

EHA-HST Joint Symposium
Disclosures: *Celgene (Research Support, Grant)*

Toh CH
Simultaneous Session
Disclosures: *Affiliations Unknown*

Traver D
EHA-ISEH Joint Symposium
Disclosures: *No Affiliations*

Treon S
Hematology-in-Focus
Disclosures: *Pharmacyclics Inc. Consultant (Research Funding); Janssen Pharmaceuticals (Consultant, Speaker, Research Funding)*

Trka J
Simultaneous Session
Disclosures: *Affiliations Unknown*

Turner D
Patient Advocacy Session 2
Disclosures: *No Affiliations*

Vago L
Poster Walk
Disclosures: *Affiliations Unknown*

van de Loosdrecht AA
Basic-Science-in-Focus
Disclosures: *Celgene (Advisory Board, Research Support); Novartis (Advisory Board); Amgen (Advisory Board); Janssen (Advisory Board); Alexion (Research Support)*

van den Brink M
Education Session, Basic-Science-in-Focus
Disclosures: *Seres (Research Support); Evelo (Consultant); Novartis (Consultant); Regeneron (Consultant); Flagship Ventures (Consultant); Boehringer Ingelheim (Consultant); Merck (Consultant)*

van den Heuvel-Eibrink MM
Meet-the-Expert, Simultaneous Session
Disclosures: *No Affiliations*

van Dijck P
EU Projects in Hematology
Disclosures: *Affiliations Unknown*

van Dongen JJM
Laboratory Diagnosis Workshop, Scientific Working Groups
Disclosures: *InVivoScribe (Patent Royalties; Royalties for the EuroClonality Consortium); Cytognos (Patent Royalties; Royalties for the EuroFlow Consortium); BD Biosciences (Patent Royalties; Royalties for the EuroFlow Consortium); BD Biosciences (Educational Services; Institutional Fee)*

Vannucchi AM
Education Session
Disclosures: *Novartis (Lectures, Advisory Board, Institutional Research Funding); Gilead (Lectures); Shire (Lectures)*

Vasconcelos A
EU Projects in Hematology
Disclosures: *Affiliations Unknown*

Vassiliou G
Basic-Science-in-Focus
Disclosures: *Kymab (Consultant); Celgene (Research Grant)*

Venditti A
Simultaneous Session
Disclosures: *Affiliations Unknown*

Vey N
Education Session
Disclosures: *Novartis (Advisory Board, Honoraria); Amgen (Advisory Board); Seattle Genetics (Advisory Board); Sunesis (Advisory Board); Roche (Advisory Board); Bioknesis (Consultant); Boerhinger (Advisory Board)*

Viprakasit V
Education Session
Disclosures: *Novartis Pharmaceuticals (Research Support, Honoraria); Genzyme-Sanofi (Research Support, Honoraria); Sebia (Research Support, Honoraria); Roche Diagnostics (Research Support, Honoraria); Shire (Research Support); Sideris (Research Support); Siriraj Hospital (Research Support)*

Visco C
Scientific Working Groups
Disclosures: *Mundipharma Italy (Research Funding); Janssen (Research Funding); Lundbeck Canada Inc. (Advisory Board, Advisor); Celgene (Advisory Board, Advisor); Mundipharma International (Advisory Board, Advisor); Gilead (Advisory Board, Advisor)*

von Lilienfeld-Toal M
Simultaneous Session
Disclosures: *Affiliations Unknown*

Vora A
Education Session
Disclosures: *Jazz (Advisory Board, Meeting Support); Pfizer (Advisory Board); Amgen (Advisory Board); Medac (Advisory Board, Meeting Support)*

Vyas P
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*

Waldmann A
Scientific Working Groups
Disclosures: *Affiliations Unknown*

Wallace WH
Education Session
Disclosures: *No Affiliations*

Wang J
EHA-CSH Joint Symposium
Disclosures: *No Affiliations*

Weisel K
Poster Walk
Disclosures: *Affiliations Unknown*

Weiss M
Education Session
Disclosures: *Glaxo SmithKline (Consultant); Biogen (Research Support); Rubius (Advisory Board); CRISPR therapeutics (Consultant); Editas (Consultant)*

Welte K
Scientific Working Groups
Disclosures: *No Affiliations*

Wendtner C
Education Session
Disclosures: *Hoffmann-La Roche (Research Support, Advisory Boards, Consultant); Celgene (Research Support, Advisory Boards, Consultant); Mundipharma (Research Support, Advisory Boards, Consultant); Janssen (Research Support, Advisory Boards, Consultant); Gilead (Research Support, Advisory Boards, Consultant); Morphosys (Research Support, Advisory Boards, Consultant); Abbvie (Research Support, Advisory Boards, Consultant)*

Windyga J
Hematology-in-Focus
Disclosures: *No Affiliations*

Wintrich S
Patient Advocacy Session 1
Disclosures: *Celgene (Grant); Novartis (Advisory Board, Grant); Janssen (Grant)*

Woermann B
Patient Advocacy Session 1
Disclosures: *No Affiliations*

Xu Y
Scientific Working Groups

Disclosures: *No Affiliations*

Younes A
Education Session
Disclosures: *Bayer (Honoraria); Celgene (Honoraria); Incyte (Honoraria); Janssen (Honoraria); Sanofi (Honoraria); Seattle Genetics (Honoraria); Takeda Millenium (Honoraria); Genentech (Honoraria); Merck (Honoraria); Novartis (Research Support); J&J (Research Support); Curis (Research Support); Roche (Research Support); BMS (Honoraria, Research Support)*

Zamagni E
Scientific Working Groups
Disclosures: *No Affiliations*

Zeiser R
Education Session
Disclosures: *No Affiliations*

Zijlstra J
Scientific Working Groups
Disclosures: Takeda (Advisory Board); BMS (Advisory Board); Roche (Advisory Board); Roche (Research Support); Gilead (Grant)

Zini G
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*

Zuber J
Molecular Hemopoiesis Workshop
Disclosures: *Mirimus Inc. (Advisory Board, Share Holder); Boehringer Ingelheim GmbH & Co KG (Research Support)*

Zwaan CM
Hematology-in-Focus
Disclosures: *Pzifer (Research Support/Grant); Karyopharm (Research Support); Novartis (Speaker's Bureau); Jazz pharmaceuticals (Travel Support)*

ABSTRACT AUTHORS INDEX

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.** Abstract author marked in **green** has won the Guiseppe Bigi grant award.

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

FLOOR PLANS

FLOOR PLAN CONGRESS CENTER





Ground floor

- Information Desk
- Internet Corner
- First Aid
- Cloakroom
- Charging Point
- Restaurant
- Coffee


N107
N108
N109
N111
N113
N115
N117
N118
To Room Colon
(2nd floor)
To Room Neptuno
(2nd floor)
N105
N104
N103
N101
A9.14
A9.13
EHA
Offices
A10.01
A10.02
A10.03
North
Convention
Centre
Praying
Room
Meeting Rooms
Meeting Rooms
Press
Center
Business
Center
Meeting Rooms
Meeting Rooms

First floor

FLOOR PLAN EXHIBITION

Hall 7 - Exhibition



FLOOR PLAN EXHIBITION

An extensive exhibition of pharmaceutical, technical and research products, equipment and services is organized in conjunction with the 22nd Congress of EHA. The scientific program will allow participants ample opportunity to visit the exhibits.

The exhibition will be open during the following hours:

Thursday, June 22	09:00-16:30
Friday, June 23	09:00-16:30
Saturday, June 24	09:00-16:30
Sunday, June 25	09:00-13:30

Company	Booth number
Abbvie	440
Adaptive Biotechnologies Corporation	660
Agios Pharmaceuticals	920
Alexion Pharma GmbH	910
American Society of Hematology	514
Amgen	430
ArcherDX	806
Argentinean Society of Hematology	210
AROG Pharmaceuticals	726
BD	770
Binding Site	860
Bio-Rad	664
Biotype Diagnostic GmbH	762
Bristol-Myers Squibb	930
Celgene	140
Celltrion Healthcare	250
Cepheid	764
CLL Advocates Network	560
CML Advocates Network	560
Cytognos SL	872
Daiichi Sankyo Europe GmbH	520
Erytech Pharma	100
ESLHO Foundation	560
EuroBloodNet	800
European School of Haematology	310
EWMn European Waldenstroem Network	560
F. Hoffmann-La Roche Ltd	230
Gilead Sciences	240
Harmony Alliance	800
Hematology Specialist Association	314
Illumina	214
Incyte Biosciences International Sàrl	640
Invivoscribe® Technologies, Inc.	720
International Society for Laboratory Hematology	812
ITP Support Association	560
Janssen Pharmaceutica	130
Japanese Society of Hematology	510
Jazz Pharmaceuticals	150
Karyopharm Therapeutics	110
Leukemia Patient Advocates Foundation	560
Lipomed AG	312
Lymphoma Coalition	560
Maco Pharma	302
MDS Alliance	560
MDS Foundation, Inc	316
MediCom Oncology	300
MorphoSys AG	360
MPN Advocates Network	560
MSD	650
Myeloma Patients Europe	560
NeoGenomics	722
Nordmedica	212
Novartis	940
Omeros Corporation	710
Otsuka Pharmaceutical Europe Ltd.	200
Oxford Gene Technology	662
Pfizer Oncology	750
Pharmacyclics, an AbbVie Company	900
PIVOTAL	102
PROFILE	800
Prothena Corporation	260
QIAGEN	970
Resonance Health	814
Sandoz	740
Sanofi Genzyme	960
Seattle Genetics	420
SEI Healthcare	804
SERVIER INTERNATIONAL	620
Shire	220
SkylineDx B.V.	760
Sunesis Pharmaceuticals, Inc.	810
Takeda Oncology	630+730
Turkish Society of Hematology	512
Verastem, Inc.	610
VIVIA BIOTECH	870
Wisepress Medical Bookshop	400
37th World Congress of the International Society of Hematology (ISH 2018)	244

EUROPEAN HEMATOLOGY ASSOCIATION



STOCKHOLM
23RD CONGRESS
JUNE 14 - 17 | 2018

European Hematology Association

January 1, 2018
Start abstract submission and congress registration

March 1, 2018
Deadline abstract submission

May 10, 2018
Deadline early registration fee

RAISING THE BAR

A Jazz Satellite Symposium

Thursday 22nd June 2017
10:45 – 12:45
Room N103

NEW MANAGEMENT AND TREATMENT IN ACUTE LEUKAEMIAS

AGENDA:

10:45–10:50	Welcome Prof Hartmut Döhner, University Hospital Ulm, Germany
10:50–11:20	The latest movement: What's new in the management and treatment of Acute Lymphoblastic Leukaemia? Prof Nicolas Boissel, Assitance Publique – Hôpitaux de Paris, France
11:20–11:50	New players in the treatment of Acute Myeloid Leukaemia: Are we improving treatment? Prof Nigel Russell, University of Nottingham, UK
11:50–12:40	Setting the tone: Managing challenging patients with Acute Myeloid Leukaemia – case study overview Prof Gail Roboz, Weill Medical College of Cornell University, USA, and Prof Hartmut Döhner, University Hospital Ulm, Germany
12:40–12:45	Close

A medical education symposium organised and funded by Jazz Pharmaceuticals

This symposium may contain information relating to drugs which do not have marketing authorisation

Jazz Pharmaceuticals

Date of preparation: April 2017
Job code: VYX-INT-015-0417-01



Introducing the first and only approved BCL-2 inhibitor[1,2]

AIM HIGH with VENCLYXTO™

VENCLYXTO demonstrated an ORR of 79% (95% CI: 70.5, 86.6, N=107, IRC assessed) or 77% (95% CI: 69.9, 83.5, N=158, investigator assessed) in a phase 2, single-arm, open-label, multicentre study (M13-982) in relapsed/refractory CLL harbouring del(17p).[1,3]

In a second, ongoing, phase 2, open-label, multicentre, non-randomised study (M14-032) evaluating CLL patients who had been previously treated with and failed ibrutinib or idelalisib therapy, VENCLYXTO demonstrated a combined ORR of 64% (95% CI: 51.1, 75.7, N=64, investigator assessed) at the time of data cut-off or 67% as determined after further evaluation by an IRC.[1]

Overall response rate (CR, CRi, PR, and nPR) was assessed using the 2008 International Workshop for Chronic Lymphocytic Leukemia updated National Cancer Institute–sponsored Working Group (iwCLL NCI-WG) guidelines.[1]

Select Safety Information
The most commonly occurring adverse reactions (≥20%) of any grade were neutropaenia/neutrophil count decreased, diarrhoea, nausea, anaemia, upper respiratory tract infection, fatigue, hyperphosphataemia, vomiting and constipation.

The most frequently occurring adverse reactions (≥2%) were pneumonia, febrile neutropaenia and TLS.

VENCLYXTO monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or *TP53* mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.

Study M13-982 description: A phase 2, single-arm, open-label, multicentre study evaluating the efficacy and safety of VENCLYXTO in relapsed or refractory subjects with CLL harbouring del(17p). Patients followed a dose-titration schedule starting at 20 mg and increasing up to 400 mg once daily and continued on 400 mg until disease progression or unacceptable toxicity; N=107 patients were enrolled in the main cohort with the data cut-off date of 30 April 2015. ORR, the primary efficacy endpoint, was evaluated by an Independent Review Committee (IRC) according to the iwCLL NCI-WG guidelines (2008). Secondary endpoints included CR, CRi, PR, nPR, DOR, PFS, and TTR. MRD was an exploratory endpoint. Fifty-one additional patients were enrolled in a safety expansion cohort. Investigator-assessed efficacy endpoints are presented for 158 patients (main + safety expansion cohorts) with a later data cut-off date of 10 June 2016.[1,3]

VENCLYXTO monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or *TP53* mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

Study M14-032 description: An ongoing phase 2, 2-arm, open-label, non-randomised study evaluating the efficacy and safety of VENCLYXTO in CLL patients who had been previously treated with and failed ibrutinib (n=43) or idelalisib (n=21) treatment. Patients followed a dose-titration schedule starting at 20 mg and increasing up to 400 mg once daily and continued on 400 mg until disease progression or unacceptable toxicity. Primary efficacy endpoint includes ORR. Secondary endpoints included PFS and DOR. MRD was an exploratory endpoint.[1,4]

ORR=overall response rate; IRC=independent review committee; CLL=chronic lymphocytic leukaemia; CR=complete remission; CRi=complete remission without complete marrow recovery; PR=partial remission; nPR=nodular partial remission; DOR=duration of response; MRD=minimal residual disease; PFS=progression-free survival; TTR=time to first response.

References: 1. VENCLYXTO [Summary of Product Characteristics]. AbbVie Ltd; Dec. 2016. **2.** European Medicines Agency. Assessment Report EMA/725631/2016: Venclyxto. London, UK: Committee for Medicinal Products for Human Use; 2017:1-132. Procedure No. EMEA/H/C/004106/0000. **3.** Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2016. http://dx.doi.org/10.1016/S1470-2045(16)30019-5. Accessed October 10, 2016. **4.** US National Institutes of Health. A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy. https://clinicaltrials.gov/ct2/show/NCT02141282?term=M14-032&rank=1. Accessed December 27, 2016.

SmPC included in the congress bag.

VENCLYXTO (venetoclax) may not be marketed in all EU countries.
VENCLYXTO (venetoclax) no se encuentra aún comercializado en España.
Está pendiente de la decisión de Precio y Reembolso.

▼ This product is subject to additional monitoring.
The report of the adverse events related to this medicine is a priority.

abbvie

▼VENCLYXTO™
venetoclax tablets